| Excerpt | Reference |
|---|
| "Prostate cancer is a major health problem for the aging male population." | ( Gormley, GJ, 1992) |
| "Prostate cancer is a disease mostly effecting aged men." | ( Yan, SQ, 1992) |
| "Prostate cancer is the most common cancer in American men today." | ( Blumenstein, BA; Crawford, ED; Dorr, FA; Eisenberger, MA; McLeod, DG, 1992) |
| "Immunodiagnosis of prostate cancer is at a more advanced stage than that of most other tumors." | ( Chu, TM, 1990) |
| "Prostate cancer is now the third commonest cancer in men." | ( Cooper, EH, 1991) |
| "Markers of human prostatic cancer are important diagnostic aids in the management of this most common tumor among US men." | ( Murphy, GP, 1991) |
| "Because prostatic cancer is common and compatible with prolonged survival, we surveyed other patients with stage D prostatic cancer." | ( Freeman, DA; Mirtsching, BC, 1992) |
| "Prostate cancer is the most frequently occurring non-skin cancer in men in the U." | ( Bosland, MC; Dreef-Van Der Meulen, HC; Han, X; Leav, I; Liehr, JG; Ofner, P; Sukumar, S, 1991) |
| "Prostate cancer is the most common malignancy in men and the second leading cause of cancer deaths." | ( Badalament, RA; Drago, JR, 1991) |
| "Prostatic cancer is a function of testosterone levels and shows increasing incidence from Mongoloids to Caucasoids to Negroids." | ( Lynn, R, 1990) |
| "Prostatic cancer is often locally advanced or metastatic when diagnosed, making surgical removal and radiotherapy ineffective treatments." | ( Bono, AV; Pozzi, E; Preti, P; Robustelli della Cuna, G, 1990) |
| "Hormonal therapy of prostate cancer is still the most effective systemic treatment." | ( Münch, D; Studer, UE, 1990) |
| "The diagnosis of prostatic cancer is usually made when the disease is no longer curable and it is important to find other means to discover the cancer at its earliest stage." | ( Mahler, C, 1989) |
| "As far as prostatic cancer is concerned, data coming from comparative trials show that MPA is less effective than diethylstilbestrol (DES), and therefore should not be considered the first choice for previously untreated patients." | ( Decensi, A; Pavesi, L; Prada, GA; Preti, P; Robustelli della Cuna, G; Zanon, P, 1986) |
| "Once a prostatic cancer is heterogeneously composed of both androgen-dependent and -independent cancer cells, androgen withdrawal therapy, no matter how complete, cannot be curative." | ( Isaacs, JT; Kyprianou, N, 1987) |
| "Prostate cancer is the most frequent malignancy in elderly men." | ( Guthrie, TH; Watson, P, 1987) |
| "Prostate cancer is a leading cause of cancer mortality in adult men." | ( Lyss, AP, 1987) |
| "Cancer of the prostate is usually represented by cellular groups that are more or less sensitive to the different kind of available treatments." | ( Bergerat, JP; Bollak, C; Jacquemin, D, 1986) |
| "Prostatic cancer is commonly manifested by obstructive uropathy, regional lymphatic metastases, and hematogenous metastases to the axial skeleton." | ( Aizawa, S; Furusato, M; Inomata, I; Matsumoto, I; Wada, T, 1986) |
| "Prostatic cancer is frequently associated with new bone formation although the tumor-derived factors responsible for changes in bone cell function have not been identified." | ( Eilon, G; Harrod, J; Jacobs, JW; Mundy, GR; Simpson, E, 1985) |
| "Prostatic cancer is one of the most frequent forms of malignancy in Western countries." | ( Rijnders, AW; Romijn, JC; Trapman, J; van der Korput, JA; van Steenbrugge, GJ, 1985) |
| "Their usefulness in prostatic cancer is at least comparable to that of acid phosphatase determinations by the enzymatic and radioimmunoassay methods, which were elevated in a smaller percentage of patients with prostate cancer than were the NANA or LSA concentrations." | ( Erbil, KM; Jones, JD; Sen, SE; Zincke, H, 1986) |
| "More than 80% of prostatic cancers are detected at stage C or D." | ( Cukier, J; Rivain, T, 1985) |
| "Prostate cancer is common among men in the United States." | ( Flanders, WD, 1984) |
| "The incidence of prostatic cancer is highly correlated with advanced age, and it has been suggested that changes in androgen binding may be important in age-associated alterations in growth regulatory mechanisms of prostatic epithelial cells." | ( Heidger, PM; Lubaroff, DM; Rowley, DR; Thompson, SA, 1984) |
| "Although prostatic cancer is evident late in life, pathological evidence suggests this disease is initiated earlier in life." | ( Garbaczewski, L; Hill, P; Walker, AR, 1984) |
| "The cause of prostatic cancer is unknown, and few specific environmental or viral agents have been linked with the tumor." | ( Elder, JS; Nyberg, LM; Scott, WW, 1980) |
| "Prostate cancer is an important problem of health care." | ( Droz, JP, 1995) |
| "Our knowledge of prostate cancer is less well-defined than our knowledge of cancers of other organs." | ( Guo, Y; Nagabhushan, M; Pretlow, TG; Pretlow, TP; Sy, M, 1994) |
| "Prostate cancer is amenable to control by intermittent androgen suppression." | ( Akakura, K; Bruchovsky, N; Gleave, ME; Goldenberg, SL; Sullivan, LD, 1995) |
| "Prostate cancer is the second cause of cancer death in men in the Western world; its medical and social impact is comparable to that of breast cancer in women." | ( Candas, B; Cusan, L; Diamond, P; Gomez, JL; Labrie, F, 1995) |
| "Prostate cancer is the second most common cause of death from cancer in U." | ( Eisenberger, MA; George, DJ; Hedican, SP; Nelson, JB; Piantadosi, S; Reddi, AH; Simons, JW, 1995) |
| "Since the growth of prostate cancer is testosterone-dependent (approximately 95% of testosterone is produced by the testes, with the remainder coming from the adrenals), hormonal manipulation has been the mainstay of palliative treatment." | ( Lynch, JH, 1993) |
| "Prostatic cancer is the second most frequent cancer in men in industrialised countries." | ( Costa, P; Le Pellec, L; Louis, JF; Mottet, N; Navratil, H, 1995) |
| "Metastatic prostate cancer is a leading cause of cancer-related death in men." | ( Balk, SP; Bubley, GJ; Frantz, ME; Keer, HN; Ogata, GK; Shuster, TD; Spooner, AE; Taplin, ME, 1995) |
| "Prostate cancer is the most common cancer diagnosed in U." | ( Akhtar, A; Donat, TL; Hogan, V; Lehr, J; Naik, H; Pienta, KJ; Raz, A; Replogle, TS; Tait, L; Yamazaki, K, 1995) |
| "Breast and prostate cancer are significant causes of morbidity and mortality and are very similar in etiology, epidemiology, and modalities of treatment." | ( Brawley, OW; Ford, LG; Johnson, KA; Kramer, BS; Nayfield, SG; Perlman, JA, 1994) |
| "Even if the risk of prostate cancer is marginally higher in vasectomized men, this risk in India has to be assessed against the immediate safety and other possible long-term benefits of this procedure." | ( Ramachandran, CR; Ramachandran, P; Tripathy, SP, 1994) |
| "Prostatic cancer is a common and frequently lethal malignant disease." | ( Rehm, S; Waalkes, MP, 1994) |
| "Prostate cancer is also associated with divorce, sexually transmitted diseases, and patronage of prostitutes, which factors are secondary to a causal association with high testosterone levels." | ( James, WH, 1994) |
| "As risk for prostate cancer is better defined, a number of interventions may eventually be tested." | ( Brawley, OW; Thompson, IM, 1994) |
| "Prostate cancer is one of the most common tumors in men." | ( Bos, SD, 1994) |
| "Prostate cancer is the most common malignancy among Swedish men." | ( Norberg, M, 1994) |
| "Because prostate cancer is known to show a high degree of heterogeneity of its sensitivity to androgens, we analyzed the effect of combined antiandrogen therapy on parameters more sensitive to androgens than ventral prostatic weight itself." | ( Labrie, F, 1993) |
| "Prostate cancer is the most frequent cancer diagnosed in American men today." | ( McLeod, DG, 1993) |
| "Chemoprevention of prostate cancer is an attractive idea that appeals to many struggling with the treatment of this disease." | ( Trachtenberg, J, 1996) |
| "Advanced prostate cancer is heterogeneous; therefore, the validity of PSA decline as a measurable end point was studied in advanced human prostate-cancer cell lines: androgen-sensitive LNCaP and androgen-insensitive PC3 cells." | ( Anthony, CT; Murphy, B; Seckin, B; Steiner, MS, 1996) |
| "Prostate cancer is the most common internal malignancy in men in the United States." | ( Chen, SH; Eastham, JA; Hall, SJ; Sehgal, I; Thompson, TC; Timme, TL; Woo, SL; Yang, G, 1996) |
| "Prostate cancer is the most commonly diagnosed cancer in the United States." | ( Altman, GB; Lee, CA, 1996) |
| "The growth of prostate cancer is androgen responsive, and androgen receptor (AR) is thought to play an important role in the development of this cancer." | ( Aida, S; Akakura, K; Akimoto, S; Komiya, A; Shimazaki, J; Suzuki, H, 1996) |
| "Cancer of the prostate is the most frequent cancer and the second leading cause of cancer death in men in North America." | ( Chen, C; Labrie, F; Poulin, R, 1996) |
| "Prostate cancer is a disease associated with aging." | ( Henry, WF; Rago, RP; Ripple, MO; Wilding, G, 1997) |
| "Prostate cancer is the most common cancer diagnosed in American men." | ( Esper, PS; Flaherty, LE; Krzeminski, R; Pienta, KJ; Zwas, F, 1997) |
| "Bone metastases in cancer of the prostate are diagnosed routinely by isotope bone scintigraphy and the measurement of alkaline phosphatase in serum and the calcium excretion in urine." | ( Delaere, KP; Westerhuis, LW, 1997) |
| "Prostate cancer is the most common serious cancer diagnosed in men in the United States." | ( Chang, L; Henderson, BE; Kolonel, LN; Makridakis, N; Pike, MC; Reichardt, JK; Ross, RK; Shi, CY; Stanczyk, FZ; Yu, MC, 1997) |
| "If advanced prostate cancer is defined either as a primary advanced-stage tumour (T3, T4, N0-N1), or a rising PSA level after primary and hopefully curative therapy, or the traditional patient presenting with small- or large-volume metastases with or without symptoms, then some 60% of all patients have advanced disease when first seen." | ( Newling, DW, 1997) |
| "Because prostate cancer is a hormonally responsive cancer, hormonal abnormalities from pituitary dysfunction may have played a role in its development." | ( Broderick, GA; Ebling, DW; Malkowicz, SB; Ruffer, J; Vanarsdalen, K; Wein, AJ; Whittington, R, 1997) |
| "Hormone-refractory prostate cancer is characterized by a low response rate following second-line therapy." | ( Colleoni, M; Graiff, C; Manente, P; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G, 1997) |
| "Cancer of the prostate is the leading cancer among American men, yet few risk factors are known." | ( Anderson, EE; Conaway, MR; Demark-Wahnefried, W; Mathias, BJ; Paulson, DF; Robertson, CN, 1997) |
| "Metastatic prostate cancer is a growing health problem and is the second leading cause of cancer death in men." | ( Dawson, NA; Waselenko, JK, 1997) |
| "While studies of prostate cancer are less advanced, the available data are in agreement with those designed to evaluate the associations between breast cancer and dietary fatty acids." | ( Rose, DP, 1997) |
| "Prostate cancer is the most common cancer among American men, with few established risk factors." | ( Breslow, RA; Weed, DL, 1998) |
| "Early stage prostate cancers are now commonly encountered because of widespread use of screening tools." | ( Idikio, HA, 1997) |
| "Prostate cancer is predominantly associated with osteoblastic bone metastases, but an increase in bone resorption has been demonstrated consistently, both histologically and biochemically." | ( Hamdy, NA; Lycklama à Nijeholt, AA; Papapoulos, SE; Pelger, RC; Zwinderman, AH, 1998) |
| "Prostate cancer is now the most common solid tumor in men in the United States." | ( Allerton, J; Coltman, CA; Higgins, B; Lovato, L; Optenberg, S; Seay, T; Thompson, I, 1998) |
| "Prostatic cancer is the second most common cause of cancer death in males." | ( Denis, L; Mahler, C; Verhelst, J, 1998) |
| "Prostate cancer is difficult to visualize using current techniques." | ( Hara, T; Kishi, H; Kosaka, N, 1998) |
| "Advanced prostate cancer is invariably lethal once it becomes androgen independent (AI)." | ( Both, GW; Daja, MM; Garcia-Aragon, J; Lockett, LJ; Martiniello-Wilks, R; Molloy, PL; Russell, P; Russell, PJ, 1998) |
| "When a prostate cancer is suspected, a new concept, the prostate specific antigen density related to the transition zone volume, has been demonstrated as a very effective mean for prostate cancer early detection in men with PSA levels below 10 ng/ml." | ( Schulman, CC; Zlotta, AR, 1998) |
| "Prostate cancer is a disease associated with androgens." | ( Cote, RJ; Henderson, BE; Mertes, SJ; Pike, MC; Ross, RK; Salem, CE; Skinner, EC; Stanczyk, FZ, 1998) |
| "Although prostatic cancer is often viewed as an androgen-dependent malignancy, a number of other hormones including 1alpha, 25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] are now recognized to modulate its growth and differentiated phenotype." | ( Hedlund, TE; Miller, GJ; Moffat, KA; Stapleton, GE, 1995) |
| "Hereditary prostate cancer is distinguished by early age at onset and autosomal dominant inheritance within families." | ( Casale, P; Di Chirio, C; Di Nicola, S; Di Silverio, F; Sciarra, A, 1998) |
| "Prostate cancer is the most common malignancy in men in the United States, with substantially higher rates among American blacks than whites." | ( Brown, LM; Fraumeni, JF; Greenberg, RS; Gridley, G; Hayes, RB; Hoover, RN; Liff, J; Pottern, LM; Schoenberg, JB; Schwartz, AG; Silverman, DT; Swanson, C; Swanson, GM; Ziegler, RG, 1999) |
| "Metastatic prostatic cancer is typically refractory to androgen ablation therapy due to the presence of androgen-independent clones in the neoplasia." | ( Aparicio, J; Larrán, J; López, A; Salido, M; Vilches, J, 1999) |
| "Metastatic prostate cancer is a leading cause of cancer-related death in men." | ( Lara, PN; Meyers, FJ, 1999) |
| "Since prostate cancer is hormone dependent, tumor androgen deprivation may enhance tumor eradication." | ( Bolla, M, 1999) |
| "Prostate cancer is a growing health problem with considerable economic consequences." | ( Carlsson, P; Pedersen, K; Varenhorst, E, 1994) |
| "Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in men in the United States." | ( Pienta, KJ; Smith, DC, 1999) |
| "Prostate cancer is the second leading cause of cancer deaths in men, therefore it is increasingly important to understand its biology and epidemiology." | ( Clark, LC; Jacobs, ET; Nelson, MA; Porterfield, BW, 1999) |
| "Cancer of the prostate is the second most commonly diagnosed cancer after skin cancer in the male population of the United States, and the second most common cause of death from cancer after that of the lung." | ( Denis, L; Griffiths, K; Morton, MS; Turkes, A, 1998) |
| "Prostate cancer is the most common malignancy in males and is the second most common cause of cancer mortality in American men." | ( Bell, DA; Lunn, RM; Mohler, JL; Taylor, JA, 1999) |
| "Prostate cancer is a rare disease before age 40; however, the prevalence increases quickly to 80% by the age of 80, and with increasing life expectancy, hormone-refractory prostate cancer (HRPC) will soon represent the most common cancer in the male population in the United States and other Western countries." | ( Beedassy, A; Cardi, G, 1999) |
| "Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists." | ( Bartsch, G; Culig, Z; Eder, IE; Erdel, M; Hittmair, A; Hobisch, A; Hoffmann, J; Klocker, H; Parczyk, K; Schneider, MR; Utermann, G, 1999) |
| "Prostate cancer is the most commonly diagnosed cancer among American men." | ( Pa-C, KB; Pienta, KJ, 1999) |
| "Prostate cancer is the most commonly diagnosed cancer in western men, and incidence is rising rapidly in most countries, including low-risk populations." | ( Devesa, SS; Hsing, AW; Tsao, L, 2000) |
| "Hormone-refractory prostate cancer is the terminal step in the natural history of prostate cancer." | ( Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C, 1999) |
| "Prostate cancer is the second leading cause of cancer-related deaths in men in the United States." | ( Davis, JN; Kucuk, O; Sarkar, FH, 1999) |
| "Prostate cancer is the most commonly diagnosed male malignancy and the second most common cause of male cancer death in the U." | ( Afrin, LB; Ergul, SM, 2000) |
| "Prostate cancer is one of the most common malignancies among men in Western countries." | ( Biàche, I; Cussenot, O; Fournier, G; Latil, A; Lidereau, R; Valéri, A; Vidaud, D; Vidaud, M, 2000) |
| "Prostate cancer is a significant health problem and one of the leading causes of cancer-related death among men." | ( Disis, ML; McNeel, DG, 2000) |
| "Cancer of the prostate is the most commonly diagnosed cancer in America." | ( Honn, KV; Li, L; Nie, D; Szekeres, K; Tang, K, 2000) |
| "Prostate cancer is the most commonly diagnosed malignancy in American men." | ( Pang, S, 2000) |
| "Chemoprevention of prostate cancer is the administration of agents to prevent, inhibit, or delay progression of prostate cancer." | ( Graefen, M; Hammerer, P; Huland, H; Steuber, T, 2000) |
| "The incidence of prostate cancer is increasing and, due to the use of PSA, more and more patients are diagnosed with localized disease." | ( Aus, G; Gunnarsson, G; Nodbrant, P, 2000) |
| "Patients with prostate cancer are treated with neoadjuvant, adjuvant and intermittent androgen deprivation therapy." | ( Bagiella, E; Benson, MC; Katz, AE; Nejat, RJ; Rashid, HH, 2000) |
| "Hormone refractory prostate cancer is dominated by osseous metastases leading to bone pain and pathological fractures." | ( Engelmann, UH; Heidenreich, A; Hofmann, R, 2001) |
| "Dog prostate cancer is usually considered to be highly relevant to human prostate cancer." | ( Anidjar, M; Barnoux, M; Berthon, P; Billotey, C; Cochand-Priollet, B; Copin, H; Cotard, JP; Cussenot, O; Delisle, F; Devauchelle, P; Fiet, J; Rain, JD; Teillac, P; Triballeau, S; Villette, JM, 2001) |
| "The progression of prostate cancer is accompanied by a marked suppression of the immune system, including the apoptotic death of dendritic cells (DC) responsible for the induction of antitumor immunity." | ( Aalamian, M; Esche, C; Huland, E; Huland, H; Nunez, A; Pirtskhalaishvili, G; Shurin, GV; Shurin, MR, 2001) |
| "Cancer of the prostate is the sixth most frequently found cancer in Singapore." | ( Aw, TC; Saw, S, 2000) |
| "Prostate cancer is a devastating disease that will be diagnosed in approximately 200,000 men in 2001." | ( DiPaola, RS; Hait, WN; Kumar, P; Weiss, RE, 2001) |
| "Death from prostate cancer is associated with objective and biochemical progression following hormonal manipulations often described as hormone refractory prostate cancer (HRPCA)." | ( Heidenreich, A; Hofmann, R; von Knobloch, R, 2001) |
| "Prostatic cancer is rarely diagnosed by detection of lung metastases." | ( Hashimoto, H; Inada, F; Ishida, H; Kawakami, N; Kitahara, K; Masui, N; Saga, Y; Tokumitsu, M; Yachiku, S, 2001) |
| "Prostate cancer is the second leading cause of cancer death in men." | ( Engedal, N; Saatcioglu, F, 2001) |
| "Hormone refractory prostate cancer is a disease that kills approximately 39,000 people per year." | ( Kamradt, JM; Pienta, KJ, 2000) |
| "The incidence of prostate cancer is low and occurs after a relatively long latency." | ( Dubey, P; Reiter, RE; Witte, ON; Wu, H, 2001) |
| "Prostate cancer is a major cause of male cancer death." | ( Brown, G; Campbell, MJ; Driver, PM; Edwards, CE; Engel, J; Moore, JS; Rashid, SF; Uskokovic, MR; Walker, E, 2001) |
| "Prostate cancer is the leading cause of cancer death in American males." | ( Chen, YQ; Feroze, F; Schober, M; Virgin, J; Waghray, A; Yao, F, 2001) |
| "Prostate cancer is the most frequently diagnosed malignancy in the Western world and changes in the ratio of testosterone and estrogens with advancing age is one of the potential risk factors in the development of this disease." | ( Lee, DT; Ouyang, XS; Tsao, SW; Wang, X; Wong, YC, 2001) |
| "Although prostate cancer is the most common incident cancer in men, not much is known about its etiology." | ( Babaian, RJ; Scardino, PT; Spitz, MR; Strom, SS; Wei, Q; Yamamura, Y, 2001) |
| "The diagnosis of prostate cancer is currently limited by the low sensitivity and specificity of systematic conventional grey-scale ultrasonography." | ( Bartsch, G; Frauscher, F; Halpern, EJ; Horninger, W; Klauser, A, 2001) |
| "Prostate cancer is one of the most common cancers in men and it is the second leading cause of cancer related death in men in the United States." | ( Chinni, SR; Koppolu, PK; Li, Y; Sarkar, FH; Upadhyay, S, 2001) |
| "Prostate cancer is dependent on the recruitment of new blood vessels to grow and metastasize." | ( Chen, CC; Dahut, W; Dixon, S; Duray, P; Figg, WD; Floeter, MK; Gubish, E; Hamilton, M; Jones, E; Kohler, DR; Krüger, EA; Linehan, WM; Pluda, JM; Premkumar, A; Reed, E; Steinberg, SM; Tompkins, A, 2001) |
| "Prostate cancer is a important tumor in which to evaluate vaccine strategies." | ( Slovin, SF, 2001) |
| "Prostate cancer is one of the most common male cancers in Western countries, yet the incidence of this fatal disease remains low in Asian populations." | ( Collins, AR; Duthie, SJ; Mitchell, JH, 2000) |
| "Prostate cancer is characterized by an early and near universal loss of expression of the phase 2 enzyme glutathione S-transferase (GST)-pi." | ( Brooks, JD; Paton, VG; Vidanes, G, 2001) |
| "Prostate cancer is perceived to be a disease of older men often diagnosed with widespread metastases that respond to hormonal ablation but for which there are few additional treatment options." | ( Haas, NB, 2001) |
| "Prostate cancer is the second most common cause of cancer deaths among men in the United States." | ( Brite, KH; Chatterjee, S; Matsumura, A, 2001) |
| "Prostate cancer is predominantly composed of luminal and neuroendocrine cells, while a minority of cells have a basal phenotype." | ( Aalders, TW; Hulsbergen-van de Kaa, CA; Ruiter, DJ; Schalken, JA; van Leenders, GJ, 2001) |
| "The risk of prostate cancer is lower in men reporting higher consumption of tomato products, which contain high levels of the antioxidant lycopene." | ( Ashton, D; Bowen, PE; Chen, L; Duncan, C; Ghosh, L; Sharifi, R; Stacewicz-Sapuntzakis, M; van Breemen, R, 2001) |
| "Prostate cancer is a worldwide significant health care problem, due to its high incidence and mortality." | ( Barni, T; Bonaccorsi, L; Crescioli, C; Ferruzzi, P; Forti, G; Luconi, M; Maggi, M; Salerno, R; Serio, M; Sinisi, AA; Vannelli, GB, 2002) |
| "Prostate cancer is the second leading cause of cancer mortality among men in Western countries." | ( Harris, KA; Reese, DM, 2001) |
| "Although prostate cancer is the most common non-cutaneous malignancy diagnosed in men in the United States, little is known about inherited factors that influence its genetic predisposition." | ( Baffoe-Bonnie, A; Bailey-Wilson, J; Brownstein, M; Bujnovszky, P; Burk, R; Carpten, J; Connors, T; De Marzo, A; Ewing, C; Faith, D; Faruque, M; Gildea, D; Gillanders, E; Grönberg, H; Hostetter, G; Hu, P; Isaacs, S; Isaacs, W; Jenkins, R; Kallioniemi, OP; Kelly, B; Klinger, K; Makalowska, I; Matikainen, M; Meltzer, P; Meyers, D; Moses, T; Nupponen, N; Papadopoulos, N; Robbins, C; Schleutker, J; Silverman, R; Smith, J; Sood, R; Stephan, D; Trent, J; Walsh, P; Wang, Z; Wiley, K; Xiang, Y; Xu, J, 2002) |
| "Prostate cancer is one of the leading causes of cancer-related death among men." | ( Carlsson, L; Larsson, A; Nilsson, BO; Ronquist, G, 2001) |
| "Prostate cancer is no more common in men with ED than in the normal male population." | ( Boustead, GB; Hanbury, DC; Kulinskaya, E; McNicholas, TA; Sairam, K, 2002) |
| "Prostate cancer is one of the most common malignancies and a leading cause of cancer-related death in men worldwide." | ( Hamdy, NA; Pelger, RC; Soerdjbalie-Maikoe, V, 2001) |
| "Advanced prostate cancer is treated initially by central suppression of androgen production by luteinizing hormone-releasing hormone (LHRH) agonists." | ( Bailey, KJ; Kassis, J; Solava, J; Souto, JC; Turner, T; Wells, A, 2002) |
| "Cancer of the prostate is one of the leading causes of cancer related deaths in men." | ( Prinsloo, SE; van Aswegen, CH, 2002) |
| "Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer related deaths in men in the United States." | ( Aranha, O; Aslam, N; El-Rayes, BF; Grignon, R; Sarkar, FH, 2002) |
| "Prostate cancer is the second leading cause of cancer-related deaths in menin the United States." | ( Li, Y; Sarkar, FH, 2002) |
| "Prostate cancer is 1 of the targets for the preventive role of genistein." | ( Fukabori, Y; Hasumi, M; Ito, K; Koike, H; Kurokawa, K; Matsui, H; Nakazato, H; Oki, K; Okugi, H; Ono, Y; Sekine, Y; Suzuki, K; Yamamoto, T; Yamanaka, H, 2002) |
| "Prostate cancer is one of the most common neoplasms in the USA and Europe." | ( Fujinami, K; Ishiguro, H; Kubota, Y; Uemura, H, 2002) |
| "Prostate cancer is a major health problem in men, causing significant morbidity and mortality." | ( Schellhammer, PF, 2002) |
| "Prostate cancer is the most common malignancy in American men, and as many as 70% of those initially treated for localized disease will ultimately progress and be considered candidates to receive therapy for metastatic cancer [Fuks et al." | ( Braun, TJ; Crawford, ED; Dakhil, SR; Hussain, MH; Klein, CE; Nichols, CR; Peereboom, DM; Rivkin, SE; Tangen, CM, 2002) |
| "Prostate cancer is the second leading cause of cancer related deaths in men in the United States and for many years the treatment results for metastatic prostate cancer have been disappointing." | ( Li, Y; Sarkar, FH, 2002) |
| "Prostate cancer is dependent on androgen stimulation mediated by the androgen receptor (AR), a member of the steroid hormone receptor family of ligand-dependent nuclear receptors." | ( Balk, SP, 2002) |
| "Prostate cancer is the most common cancer in American men." | ( Giovannucci, E, 2002) |
| "Many prostate cancers are quite indolent and may never cause a problem but it is impossible to identify such tumors with certainty." | ( Diamond, EJ; Droller, MJ; Lehrer, S; Stock, RG; Stone, NN, 2002) |
| "Cancer of the prostate is the most commonly diagnosed solid malignancy and the second leading cause of cancer-related death in men living in developed countries." | ( Mellon, JK; Pathak, SK; Sharma, RA, 2003) |
| "Prostate cancer is the fourth most common cancer in men worldwide and the most common cancer in men in the United States, with reported incidence rates for U." | ( Graubard, BI; Greenberg, RS; Hayes, RB; Mayne, ST; Schoenberg, JB; Swanson, CA; Swanson, GM; Vogt, TM; Ziegler, RG, 2003) |
| "Prostate cancer is a formidable disease and at current rates of diagnosis will affect one-in-six men living in the United States (Greenlee et al." | ( Nicholson, B; Theodorescu, D, 2003) |
| "Prostate cancer is the most common malignancy in men in the United States." | ( Benson, MC; Gilbert, SM; McKiernan, JM; Olsson, CA, 2003) |
| "Prostate cancer is known for its difficulties in preoperative staging of pelvic lymph nodes by conventional imaging techniques." | ( de Jong, IJ; Elsinga, PH; Mensink, HJ; Pruim, J; Vaalburg, W, 2003) |
| "Prostate cancer is the second cause of cancer death in men." | ( Apiou, F; Arvelo, F; Bara, J; Boye, K; de Pinieux, G; Dutrillaux, AM; Dutrillaux, B; Legrier, ME; Lidereau, R; Poirson-Bichat, F; Poupon, MF; Sihassen, A, 2003) |
| "Prostate cancer is one of the most frequently diagnosed cancers in males." | ( Di-Segni, A; Lupowitz, Z; Pinkas-Kramarski, R; Tal-Or, P, 2003) |
| "Prostate cancer is second only to lung and bronchial cancer as the leading cause of cancer death in men." | ( Mcleod, DG, 2003) |
| "Prostate cancer is known to be refractory to chemotherapy with only mitoxantrone showing some benefit." | ( Boyé, K; Bras-Gonçalves, R; De Cremoux, P; De Pinieux, G; Legrier, ME; Oudard, S; Poupon, MF, 2003) |
| "Prostate cancer is a common malignancy affecting men, which is often associated with skeletal metastases resulting in significant morbidity and mortality." | ( Arakelian, A; Garde, S; Kadhim, S; Rabbani, SA; Shukeir, N, 2003) |
| "Prostate cancer is one of the most common cancers in men and is the second leading cause of cancer-related deaths in the USA." | ( Bae, I; Cho, CH; Goldberg, ID; Jeon, KI; Kim, HJ; Lee, YJ; Rih, JK; Rosen, EM, 2003) |
| "Prostate cancer is initially dependent upon androgens for growth and development, but cells have the ability to escape androgen dependence and progress to an androgen independent state, which was evident in this study." | ( Bertrand, KP; de Avila, DM; Greenberg, NM; Hill, RE; Reeves, JJ, 2003) |
| "Prostate cancer is the leading internal malignancy in men with an age over 50." | ( Ebara, S; Nasu, Y, 2003) |
| "Breast and prostate cancer are leading causes of cancer death in the Western world." | ( Banwell, CM; Campbell, MJ; Singh, R; Stewart, PM; Uskokovic, MR, 2003) |
| "Prostate cancer is one of the leading causes of death among men in the United States, and acquisition of hormone resistance (androgen independence) by cancer cells is a fatal event during the natural history of prostate cancer." | ( Bub, JD; Iwamoto, Y; Onuma, M; Rummel, TL, 2003) |
| "Prostate cancer is the first neoplasia in the United States accounting the second in cancer deaths." | ( Berenguer Sánchez, A; Ferruelo Alonso, A; Romero Cagigal, I, 2003) |
| "Human prostate cancer is associated with a reactive stroma typified by an increase in the proportion of myofibroblast type cells and elevated synthesis of extracellular matrix proteins." | ( Dang, TD; Larsen, M; McAlhany, SJ; Ressler, SJ; Rowley, DR; Tuxhorn, JA; Yang, F, 2003) |
| "Prostate cancers are hormone-dependent malignancies that respond to drugs that reduce circulating testosterone levels or prevent binding of this ligand to the androgen receptor (AR)." | ( Rosen, N; Scher, HI; Solit, DB, 2003) |
| "Prostate cancer is the most common malignancy in men in the United States." | ( Clark, PE; Torti, FM, 2003) |
| "Advanced prostate cancer is resistant to current therapeutic strategies." | ( McConkey, DJ; Williams, SA, 2003) |
| "Prostate cancer is a major health threat for American men." | ( Du, J; Li, B; Liao, X; Thrasher, JB; Zhang, L, 2003) |
| "Prostate cancer is one of the most promising candidates for sodium iodide symporter (NIS)-mediated gene therapy." | ( Bergert, ER; Cheville, JC; Kakinuma, H; Lieber, MM; Morris, JC; Spitzweg, C, 2003) |
| "Prostate cancer is the most common male cancer, affecting one man in six." | ( Coltman, CA; Djavan, B; Klein, EA; Lippman, SM; Thompson, IM, 2003) |
| "Pathogenesis of prostate cancer is paralleled by aberrant transcriptional regulation which involves gene silencing by histone deacetylases." | ( Hemmerlein, B; Ringert, RH; Schweyer, S; Seseke, F; Thelen, P; Wuttke, W, 2004) |
| "Prostate cancer is the second leading cause of cancer deaths in American males, resulting in an estimated 37,000 deaths annually, typically the result of metastatic disease." | ( Bennett, ES; Harper, JM; Smith, BA, 2004) |
| "Prostate cancer is the most commonly diagnosed malignancy in men and is often associated with bone metastases." | ( Brown, LG; Brubaker, KD; Corey, E; Vessella, RL, 2004) |
| "Risk of developing prostate cancer is associated with advancing age, African American ethnicity, and a positive family history, and may be influenced by diet and other factors." | ( Crawford, ED, 2003) |
| "Chemoprevention of prostate cancer is currently being tested in a wide range of clinical trials." | ( Barqawi, A; Crawford, ED; Thompson, IM, 2004) |
| "Prostate cancer is an important healthcare issue in men worldwide." | ( Fradet, Y, 2004) |
| "Prostate cancer is the most common cancer diagnosed and the second leading cause of cancer-related deaths in men in the United States." | ( Goulet, AC; Kagey, J; Meuillet, E; Nelson, MA; Porterfield, B; Prasad Cherukuri, D; Stratton, S, 2004) |
| "Localized prostate cancer is characterized by marked hypoxia and significant heterogeneity in oxygenation, similar to other human tumors." | ( Bristow, R; Catton, C; Catton, P; Crook, J; Gospodarowicz, M; Hill, RP; McLean, M; Milosevic, M; Panzarella, T; Parker, C; Sweet, J; Toi, A; Warde, P, 2004) |
| "Prostate cancer is the most prevalent malignancy and the second leading cause of cancer mortality in men." | ( Cheville, JC; Lingle, WL; Mitchell, RF; Mora, GR; Olivier, KR; Tindall, DJ, 2004) |
| "Metastatic prostate cancer is one of the leading causes of cancer death in men." | ( Dahut, WL; Figg, WD; Retter, AS, 2003) |
| "Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in men, following lung cancer." | ( Culkin, DJ; Zimmerman, RA, 2003) |
| "Prostate cancer is currently the most-frequency malignancy in men, and the second cause of death from cancer in the Western world." | ( Ferrero, JM, 2004) |
| "Prostate cancer is one of the most common forms of cancer and understandably has received considerable recent attention as a potential target for chemoprevention." | ( Basler, JW; Hernandez, J; Mahal, K; Thompson, IM, 2004) |
| "Prostate cancer is considered a major health problem in western countries." | ( García Rodríguez, LA; González-Pérez, A, 2004) |
| "Although prostate cancer is traditionally considered a disease of old age, improved diagnostic techniques have resulted in early diagnosis, and many men are now treated while still physically and sexually active." | ( Davis, JW; Schellhammer, PF, 2004) |
| "Prostate cancer is the most common cancer diagnosed in American men and the second leading cause of cancer deaths." | ( Beebe-Dimmer, J; Bock, CH; Cassidy, AE; Cooney, KA; Ellis, L; Giri, VN; Smith, DC, 2004) |
| "Prostate cancer is the second most common cause of cancer death in men in the US." | ( Kyprianou, N; Rowland, RG; Tahmatzopoulos, A, 2004) |
| "Prostate cancer is the most commonly diagnosed malignancy in American men, yet treatment of its metastatic androgen-independent form remains inadequate." | ( Burch, PA; Croghan, GA; Gastineau, DA; Jones, LA; Kaur, JS; Kylstra, JW; Richardson, RL; Valone, FH; Vuk-Pavlović, S, 2004) |
| "Prostate cancer is the most frequently diagnosed non-cutaneous cancer and is the second leading cause of cancer death in American men." | ( Boileau, TW; Bray, TM; Ho, E, 2004) |
| "Prostate cancer is the second leading cause of cancer-related deaths in males in the United States." | ( Adhami, VM; Ahmad, N; Aziz, MH; Mukhtar, H; Nihal, M; Reagan-Shaw, SR, 2004) |
| "Prostate cancer is the most common malignancy and the second leading cause of male death in Western countries." | ( Fares, FA; Nachshon-Kedmi, M; Yannai, S, 2004) |
| "Prostate cancer is a leading killer of men in the industrialized world." | ( Buehrer, BM; Fletterick, RJ; Grøn, H; Hur, E; Payne, ES; Pfaff, SJ, 2004) |
| "Prostate cancer is the most common malignancy and the second leading cause of cancer death among men in the United States." | ( Dahiya, R; Li, LC; Okino, ST, 2004) |
| "Given that prostate cancer is generally a multiclonal disease representing different cell lineages, it is important to develop HDAC inhibitors that will be effective against all of these cell types." | ( Frønsdal, K; Saatcioglu, F, 2005) |
| "Prostate cancer is an important public health problem in the United States." | ( Ansell, PJ; Browning, JD; Lubahn, DB; Macdonald, RS; Sakla, MS; Shenouda, NS; Zhou, C, 2004) |
| "Proper staging of prostate cancer is particularly important in high-risk primary disease before embarking on radical prostatectomy or radiation therapy." | ( Larson, SM; Schöder, H, 2004) |
| "Prostate cancer is the second leading malignancy in men associated with an enormous research interest in all aspects of the disease." | ( Baltogiannis, D; Charalabopoulos, K; Giannakopoulos, X; Sofikitis, N, 2004) |
| "It appears that prostate cancer is not associated with increased body-iron stores." | ( Gauthier, T; Kuvibidila, S; Rayford, W; Warrier, RP, 2004) |
| "Prostate cancer is one of the most common cancers in men." | ( Kitamura, T; Miyazaki, H; Miyazono, K; Watabe, T, 2004) |
| "Prostate cancer is a heterogeneous disease." | ( Brendler, CB; Chung, LW; Rinker-Schaeffer, CW; Sokoloff, MH, 2004) |
| "Prostate cancer is the second leading cause of cancer related deaths in men in the United States." | ( Chinni, SR; Li, Y; Sarkar, FH, 2005) |
| "Prostate cancer is currently the most commonly diagnosed noncutaneous malignancy in American men." | ( Aizenberg, I; Eshhar, Z; Harmelin, A; Kanety, H; Kaufman-Francis, K; Malina, V; Pinthus, JH; Ramon, J; Waks, T, 2004) |
| "Prostate cancer is a leading cause of morbidity and mortality among males." | ( Hegeman, RB; Liu, G; McNeel, DG; Wilding, G, 2004) |
| "Prostate cancer is a significant health problem among American men." | ( El-Zawahry, A; McKillop, J; Voelkel-Johnson, C, 2005) |
| "Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express unique proteins which serve as highly specific targets." | ( Hershberg, RM; Schellhammer, PF, 2005) |
| "Prostate cancer is uniformly fatal once it has spread outside of the prostate gland." | ( Denmeade, SR; Isaacs, JT, 2005) |
| "Prostate cancer is one of the most common cancers among men and androgens are involved in controlling the growth of androgen-sensitive malignant prostatic cells." | ( Härkönen, P; Herrala, A; Isomaa, V; Kaija, H; Kurkela, R; Laiti, M; Li, Y; Patrikainen, L; Pulkka, A; Soronen, P; Törn, S; Vihko, P, 2004) |
| "Men with advanced prostate cancer are at high risk for developing bone metastases, which result in clinically significant skeletal morbidity." | ( Karakiewicz, P; Perrotte, P; Saad, F, 2005) |
| "Since advanced prostate cancer is difficult to treat, we have chosen a very different approach: the development of vaccines to prevent initial de novo tumor formation." | ( Pollard, M; Suckow, MA; Wolter, WR, 2005) |
| "Cancer of the prostate is an important and potentially fatal disease in humans but the etiology is yet undefined." | ( Goyer, RA; Liu, J; Waalkes, MP, 2004) |
| "Prostate cancer is often slowly progressive, and it can be difficult to treat with conventional cytotoxic drugs." | ( Bernasconi, M; Carson, DA; Corr, M; Cottam, HB; James, SY; Kolluri, SK; Leoni, LM; Liu, W; Lu, D; Zhang, XK, 2005) |
| "Prostate cancer is the second most common cause of death related to cancer in Western society." | ( Davoodpour, P; Landström, M, 2005) |
| "Prostate cancer is the second leading cause of cancer deaths among men in the United States." | ( Hantz, HL; Martin, KR; Young, LF, 2005) |
| "Prostate cancer is the second leading cause of death from cancer among US men." | ( Breeuwsma, AJ; de Jong, IJ; Jongen, MM; Nijman, RJ; Pruim, J; Suurmeijer, AJ; Vaalburg, W, 2005) |
| "Prostate cancer is the most common non-skin cancer affecting men in United States and the second leading cause of death after lung cancer." | ( Banerjee, SK; Kambhampati, S; Ray, G; Reddy, VP; Sengupta, K; Van Veldhuizen, PJ, 2005) |
| "Hormone refractory prostate cancer is dominated by osseous metastases." | ( Altan, A; Demir, C; Ozyuvaci, E, 2005) |
| "Prostate cancer is the most predominant cancer in men and prostate cancer related death increases every year." | ( Aruldhas, MM; Arunakaran, J; Arunkumar, A; Balasubramanian, K; Kanagaraj, P; Vijayababu, MR, 2005) |
| "Patients with prostate cancer are treated with neoadjuvant, adjuvant and intermittent therapy with gonadotropin-releasing hormone agonists (GnRH-A)." | ( Carter, J; Chatta, G; Dahut, WL; Figg, WD; Gulley, JL; Higano, CS; Hussain, MH; Petrylak, DP; Sartor, O; Steinberg, SM, 2005) |
| "Prostate cancer is a dynamic disease." | ( Fehér, M; Fél, P; Hazay, L; Holman, E; Kisbenedek, L; Kocsis, I; Lipták, J; Papp, G; Pintér, O; Streit, B; Szabó, Z; Tóth, C, 2005) |
| "Prostate cancer is the second leading cause of cancer deaths among men." | ( Chong, P; Rashid, P, 2005) |
| "Prostate cancer is one of the most common forms of cancer and understandably has received considerable recent attention as a potential target for chemoprevention." | ( Basler, JW; Hernandez, J; Mahal, K; Thompson, IM, 2005) |
| "Prostate cancer is considered to be hormone-dependent, and androgens appear to be important hormonal factors." | ( Asano, K; Hasegawa, N; Hasegawa, Y; Ikemoto, I; Ishikawa, T; Ohishi, Y; Onodera, S; Tomita, M, 2005) |
| "Men with prostate cancer are at high risk of developing bone metastases that can lead to clinically significant skeletal morbidity." | ( Saad, F, 2005) |
| "Prostate cancer is a heterogeneous disease and clinical outcomes vary considerably after failure of primary androgen ablation." | ( Bissada, NK; Chaudhary, UB; Onitilo, AA; Rashid, MH, 2005) |
| "With this approach, prostate cancer is detected 5-10 years before giving rise to symptoms and on average 17 years before causing the death of the patient." | ( Abrahamsson, PA; Aus, G; Bangma, C; Boccon-Gibod, L; Ekman, P; Hamdy, FC; Lilja, H; Stenman, UH, 2005) |
| "The suspicion of prostate cancer is an absolute contraindication for T use." | ( Morales, A, 2005) |
| "Prostate cancer is the major health problem and the leading cause of male cancer death." | ( Aruldhas, MM; Arunakaran, J; Arunkumar, A; Ilangovan, R; Kanagaraj, P; Vijayababu, MR, 2005) |
| "Prostate cancer is difficult to visualise in its early stages using current imaging technology." | ( Endou, H; Inoue, T; Kubota, Y; Lee, J; Oka, T; Sasaki, T; Shizukuishi, K; Takahashi, N; Uemura, H; Yamaguchi, T, 2005) |
| "Today, treatment of prostate cancer is done by inhibition of AR using antiandrogens such as flutamide (pro-drug of hydroxyflutamide), nilutamide, and bicalutamide." | ( Bechor, Y; Birman, A; Chisin, R; Even-Sapir, E; Fadeeva, L; Golan, E; Gozin, M; Gutman, M; Icar, A; Jacobson, O; Leibovitch, I; Marom, H; Mishani, E; Novak, N, 2005) |
| "Patients with prostate cancer are at risk for skeletal complications resulting from treatment-induced bone loss and for bone metastases." | ( Green, JR, 2005) |
| "Prostate cancer is poised to become the most prevalent male cancer in the Western world." | ( Gill, CI; McCann, MJ; McGlynn, H; Rowland, IR, 2005) |
| "Hormone-refractory prostate cancer is diagnosed with increasing incidence and has become a growing challenge for urologists." | ( Bierer, S; Bögemann, M; Hertle, L; Piechota, H; Wülfing, C, 2005) |
| "Prostate cancer is the most common cancer among men in the United States, and aberrant DNA methylation is known to be an early molecular event in its development." | ( Brooks, JD; Kaygusuz, G; Kim, H; Lapointe, J; Li, C; Ong, DE; Pollack, JR; van de Rijn, M, 2005) |
| "Breast and prostate cancer are the most well-characterized cancers of the type that have their development and growth controlled by the endocrine system." | ( Cha, TL; Hung, MC; Kang, HY; Miller, SA; Rau, KM, 2005) |
| "Prostate cancer is a relatively slow-growing disease compared to other cancers, and the patients tend to be older." | ( Akaza, H; Chodak, GW; Hirao, Y, 2005) |
| "Prostate cancer is unique in that bone is often the only clinically detectable site of metastasis." | ( Boustany, L; Ghilardi, JR; Halvorson, KG; Kubota, K; Lindsay, TH; Mantyh, PW; Rosol, TJ; Sevcik, MA; Shelton, DL; Sotillo, JE, 2005) |
| "Prostate cancer is a significant cause of cancer death, making it an attractive target for chemoprevention." | ( Canby-Hagino, ED; Thompson, IM, 2005) |
| "Prostate cancer is initially responsive to androgen ablation, but prostate cancer tumors invariably progress to an androgen-independent state that is ultimately lethal." | ( Hernandez, G; Hsieh, JT; Huang, CL; Tseng, CP; Tu, SW; Zhoul, J, 2005) |
| "Prostate cancer is a major cause of cancer death and morbidity in western countries." | ( Andoh, J; Bandyopadhyay, S; Fokum, FD; Furuta, E; Horvath, E; Iiizumi, M; Malafa, MP; Neitzel, LT; Watabe, K; Zhan, R, 2006) |
| "Prostate cancer is increasing in incidence, but current treatments including surgery and radiotherapy have significant side effects." | ( Bown, SG; Emberton, M; Freeman, A; Lees, WR; Moore, CM; Mosse, CA; Nathan, TR, 2006) |
| "Advanced prostate cancer is often treated with chemotherapy and most of these drugs exert their function by generating genotoxic stress such as DNA damage." | ( Garrett, MD; Mantoni, TS; Reid, G, 2006) |
| "The prevention of prostate cancer is conceivable." | ( Leisinger, HJ; Wisard, M, 2006) |
| "Prostate cancer is a leading cause of death from cancer in American men and metastasis the main cause of death." | ( Ablin, RJ; Mackenzie, CD; Rivette, AS; Tokar, EJ; Webber, MM; Williams, DE, 2005) |
| "Prostate cancer is an attractive and appropriate target for primary prevention because of its incidence, prevalence, and disease-related mortality; its long latency and molecular pathogenesis; and epidemiologic data indicating that modifiable environmental factors may decrease risk." | ( Klein, EA, 2005) |
| "Prostate cancer is the most common incident cancer and the second leading cause of cancer mortality in U." | ( Giovannucci, E; Liu, Y; Stampfer, MJ; Willett, WC, 2006) |
| "Prostate cancer is the most common type of cancer and the second leading cause of cancer-related deaths in American men." | ( Frazee, LA; Lowe, JF, 2006) |
| "Prostate cancer is one of the malignant tumors which exhibit resistance to anticancer drugs, at least in part due to enhanced antiapoptotic mechanisms." | ( Ellerhorst, J; Elsamman, E; Fukumori, T; Kanayama, HO; Kasai, T; Lotan, R; Nangia-Makker, P; Oka, N; Raz, A; Shono, M; Takenaka, Y, 2006) |
| "As advanced prostate cancers are resistant to currently available chemotherapies, we evaluated the cytotoxic effect of TNF-related apoptosis-inducing ligand (TRAIL) and characterized the involvement of its five receptors DR4, DR5, DcR1, DcR2, and osteoprotegerin (OPG) and of the death-inducing signaling complex (DISC)-forming proteins caspase 8 and c-FLIP in prostate cell lines." | ( Donaghy, L; Guillaudeux, T; Hesry, V; Jégou, B; Patard, JJ; Piquet-Pellorce, C; Travert, M, 2006) |
| "Prostatic cancer is the most common malignancy diagnosed in men." | ( Herman, ZS; Krysiak, R; Okopień, B; Szkróbka, W, 2005) |
| "Prostate cancer is largely an androgen-sensitive disease." | ( Carroll, PR; Cowan, JE; DuChane, J; Elkin, EP; Kawakami, J; Latini, DM, 2006) |
| "immunotherapy) of prostate cancer is essential." | ( Carlsson, L; Larsson, A; Nilsson, S; Ronquist, G; Ronquist, KG, 2006) |
| "Prostate cancer is more frequently being diagnosed at an earlier age, men are dying of prostate cancer at an older age, and men are now treated with androgen deprivation for biochemical relapse." | ( Higano, CS; Lin, DW; Wright, JL, 2006) |
| "Prostate cancer is a significant cause of disease and death, making it an attractive target for chemoprevention." | ( Brand, TC; Canby-Hagino, ED; Hernandez, J; Thompson, IM, 2006) |
| "Prostate cancer is the most predominant cancer in men and related death rate increases every year." | ( Aruldhas, MM; Arunakaran, J; Arunkumar, A; Srinivasan, N; Vijayababu, MR, 2006) |
| "Advanced prostate cancer is not curable by current treatment strategies indicating a significant need for new chemotherapeutic options." | ( Fitzpatrick, JM; Gill, C; O'Connor, K; Rehmann, FJ; Strohfeldt, K; Sweeney, N; Tacke, M; Watson, RW, 2006) |
| "Prostate cancer is the second leading cancer diagnosed in elderly males in the Western world." | ( Agarwal, C; Agarwal, R; Kaur, M, 2006) |
| "Prostate cancer is a major health problem in the U." | ( Ahmad, N; Aziz, MH; Fu, VX; Jarrard, DF; Nihal, M, 2006) |
| "Prostate cancer is the most frequently diagnosed cancer in the Western male population and the second leading cause of cancer mortality." | ( Geng, DJ; Liu, Y, 2006) |
| "Prostate cancer is one of the most frequent cancer types in Western societies and predominately occurs in the elderly male." | ( Magee, PJ; Pool-Zobel, BL; Raschke, M; Rowland, IR, 2006) |
| "Prostate cancer is one of the most frequently diagnosed cancers in human males." | ( Blum, R; Erlich, S; Karunagaran, D; Kloog, Y; Liebling, R; Pinkas-Kramarski, R; Tal-Or, P, 2006) |
| "Metastatic prostate cancer is characterized by the presence of osteoblastic bone metastases." | ( Kantoff, P; Kaufman, DS; Michaelson, MD; Oh, WK; Smith, MR, 2006) |
| "Prostate cancer is the most common type of cancer (other than skin cancer) among men in the United States." | ( Franc, BL; Hasegawa, BH; Hawkins, RA; Seo, Y; Wong, KH, 2006) |
| "Prostate cancer is one of the most common non-skin cancers in men." | ( Chang, HK; Kim, CJ; Kim, J; Kim, KH; Kim, YS; Lee, JW; Lee, MH; Shin, MS; Yang, HY, 2006) |
| "Prostate cancer is an important public health problem." | ( Fleshner, N; Kulkarni, G, 2006) |
| "The causes of prostate cancer are poorly understood, but genetic factors may be more important than for many other malignancies, and dietary phytoestrogens may be protective." | ( Adami, HO; Bälter, KA; Bellocco, R; Chang, ET; Grönberg, H; Hedelin, M; Johansson, JE; Klint, A; Thellenberg-Karlsson, C; Wiklund, F, 2006) |
| "Most prostate cancers are androgen dependent upon initial diagnosis." | ( Carlson, KE; Chisin, R; Elgavish, S; Even-Sapir, E; Gozin, M; Gutman, M; Jacobson, O; Katzenellenbogen, JA; Laky, D; Leibovitc, I; Mishani, E, 2006) |
| "Prostate cancer is the most common cancer and the second leading cause of cancer-related death in American men." | ( Bhagat, S; Cher, M; Chinni, SR; Deng, X; Dong, Z; Mullins, C, 2006) |
| "Prostate cancer is the most frequently occurring form of cancer in German men with an incidence of 49." | ( Theobald, S, 2006) |
| "Prostate cancer is one of the most commonly diagnosed malignant tumors in Western countries." | ( Fang, J; Jiang, BH; Shi, XL; Zhou, Q, 2007) |
| "Prostate cancer is a significant health concern for men worldwide." | ( Mancuso, A; Oudard, S; Sternberg, CN, 2007) |
| "Prostate cancer is an androgen-dependent disease; metastatic prostate cancer is typically treated by androgen receptor (AR) blockade." | ( Agoulnik, IU; Alvarado, M; Ayala, GE; Bingman, WE; Erdem, H; Frolov, A; Ittmann, MM; Nakka, M; Smith, CL; Vaid, A; Weigel, NL, 2006) |
| "Hormone-resistant prostate cancer is defined by disease progression despite of castration levels of serum testosterone." | ( Fosså, SD; Hernes, E; Lilleby, W; Raabe, N; Waehre, H, 2006) |
| "Prostate cancer is the most invasive and frequently occurred cancer in men." | ( Arunakaran, J; Arunkumar, A; Gunadharini, N; Krishnamoorthy, G; Vijayababu, MR, 2007) |
| "Prostate cancer is the second most common cancer that leads to death in elderly men." | ( Anbalagan, J; Aruldhas, MM; Arunakaran, J; Kanagaraj, P; Ravisankar, B; Vijayababu, MR, 2007) |
| "Prostate cancer is the most commonly diagnosed cancer in the majority of western countries." | ( Boothman, DA; Reichrath, J; Seifert, M; Shannan, B; Tilgen, W, 2007) |
| "Prostate cancer is a major health issue in westernized countries, being considered a prototypical age-related, androgen-dependent tumor." | ( Carruba, G, 2006) |
| "Prostate cancer is now recognized as one of the principal medical problems facing male population and the commonest cancer in males in delevoped countries." | ( Eis, V; Hampl, R; Heracek, J; Kuncova, J; Mandys, V; Sachova, J; Starka, L; Urban, M, 2007) |
| "The incidence of prostate cancer is much lower in Asian than Western populations." | ( Inoue, M; Iwasaki, M; Kurahashi, N; Otani, T; Sasazuki, S; Tsugane, S, 2007) |
| "Prostate cancer is one of the most common cancers in men, with more than 500,000 new worldwide cases reported annually, resulting in 200,000 deaths of mainly older men in developed countries." | ( Maru, Y; Sudo, H, 2007) |
| "Prostate cancer is the most common male cancer in developed countries and is increasing in the developing world." | ( Binns, CW; Jian, L; Lee, AH, 2007) |
| "Prostate cancer is an excellent target for chemoprevention strategies; given its late age of onset, any delay in carcinogenesis would lead to a reduction in its incidence." | ( Gescher, AJ; Jain, S; Marczylo, TH; Mellon, JK; Steward, WP; Thorpe, JF, 2007) |
| "Progression of prostate cancer is believed to be dependent on angiogenesis induced by tumor cells." | ( Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z, 2007) |
| "Prostate cancer is the most frequently diagnosed cancer and a leading cause of cancer deaths in American men." | ( Christensen, MJ; Eggett, DL; Parker, TL, 2007) |
| "Prostate cancer is the most common nonskin cancer in the United States, with more than 2 million men currently living with the disease (Prostate Cancer Foundation, 2005)." | ( Matthews, PA, 2007) |
| "Both obesity and prostate cancer are epidemic in Western society." | ( Freedland, SJ; Platz, EA, 2007) |
| "Prostate cancer is the most common non-skin cancer and the second leading cause of cancer deaths among men in most Western countries." | ( Chokkalingam, AP; Hsing, AW; Reichardt, JK; Stanczyk, FZ, 2007) |
| "Hormone-refractory prostate cancer is an advanced stage of the metastatic disease; it has a poor prognosis and a short median survival, about 9 to 18 months." | ( Alexandre, I; Rixe, O, 2007) |
| "Prostate cancer is the second-leading cause of cancer-related death among men and the seventh most common cause of death in the United States overall." | ( Beke, D; Kudlacek, S; Meran, JG, 2007) |
| "Prostate cancer is the most common malignant tumor in men." | ( Bastian, PJ; Biermann, K; Bollmann, D; Ellinger, J; Müller, SC; Schmidt, ME; Textor, J; Zhou, H, 2007) |
| "Prostate cancer is the most common type of cancer in men, however, therapeutic options are limited." | ( Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G, 2007) |
| "Prostate cancer is the most commonly diagnosed cancer and the second most common cause of cancer-related death in men, and benign prostatic hyperplasia is the most common benign condition known to occur in ageing men." | ( Ellem, SJ; Risbridger, GP, 2007) |
| "Prostate cancer is a public health problem of the elderly men." | ( Shiu, SY, 2007) |
| "Cancer of the prostate is the most common cancer in males accounting for 33% of newly diagnosed cases." | ( Gujral, SS; Mohammed, AA; Shergill, IS; Vandal, MT, 2007) |
| "Prostate cancer is the second most commonly diagnosed cancer and the third leading fatal cancer in American men." | ( Ni, J; Yeh, S, 2007) |
| "Prostate cancer is more frequently diagnosed in men from Western countries than from Asian societies." | ( Burfeind, P; Ringert, RH; Scharf, JG; Schweyer, S; Thelen, P; Wuttke, W, 2007) |
| "Prostate cancer is the most common malignancy in men." | ( Hung, H, 2007) |
| "Prostate cancer is an important public health problem." | ( Besch-Williford, C; Greenberg, NM; Lubahn, DB; MacDonald, RS; Newton, LG; Sakla, MS; Shenouda, NS, 2007) |
| "As prostate cancer care becomes increasingly focused on identifying the minority of patients who would benefit from aggressive systemic therapy, a reevaluation of the potential contribution of the prostatic acid phosphatase test seems timely." | ( Dattoli, M; Merrick, G; Taira, A; Wallner, K, 2007) |
| "Prostate cancer is the commonest non-skin cancer in men." | ( Carruba, G, 2007) |
| "Because prostate cancer is often treated with radiotherapy, and 2ME2 has shown efficacy as a single agent against human prostate carcinoma, we evaluated 2ME2 as a potential radiosensitizer in prostate cancer models." | ( Amorino, GP; Casarez, EV; Conaway, MR; Dunlap-Brown, ME, 2007) |
| "Prostate cancer is the most common type of cancer in men and ranks second only to lung cancer in cancer-related deaths." | ( Aziz, MH; Church, DR; Dreckschmidt, NE; Manoharan, HT; Oberley, TD; Verma, AK; Wilding, G; Zhong, W, 2007) |
| "Prostate cancer is a common cancer in men." | ( Arianayagam, M; Chang, J; Rashid, P, 2007) |
| "Prostate cancer is threatening human health heavily, for its causes are related to diet, genetic factors, and lifestyle." | ( Shen, SR; Yin, JJ; Yu, HN, 2007) |
| "Prostate cancer is the most common malignancy in men." | ( Baum, NH; Torti, DC, 2007) |
| "Prostate cancer is a common malignancy that disproportionately affects African-American men." | ( Ahaghotu, C; Akereyeni, F; Bonilla, C; Hooker, S; Kittles, RA, 2008) |
| "Prostate cancer is an attractive target for chemoprevention because of its ubiquity, treatment-related morbidity, long latency between premalignant lesions and clinically evident cancer, and defined molecular pathogenesis." | ( George, J; Kalra, N; Prasad, S; Shukla, Y; Singh, M; Tripathi, C, 2007) |
| "Prostate cancer is one of the most complex and enigmatic oncologic problems in medicine." | ( Hernandez, J; Hudak, SJ; Thompson, IM, 2006) |
| "Prostate cancer is the second leading cause of cancer mortality among men in the U." | ( Beer, TM; Bubley, GJ; Huang, J; Jacobus, S; Oh, WK; Ross, RW; Ryan, CW; Taplin, ME, 2008) |
| "Prostate cancer is a major health issue, and prevention of prostate cancer and/or its progression will yield benefits for men." | ( Ahlering, TE; Anton-Culver, H; Fujikawa-Brooks, S; Gerner, EW; Lieberman, R; McLaren, CE; Meyskens, FL; Nagle, R; Simoneau, AR; Yerushalmi, H; Ziogas, A, 2008) |
| "Metastatic prostate cancer is associated with a high morbidity and mortality but the spreading mechanisms are still poorly understood." | ( Härkönen, PL; Tuomela, JM; Väänänen, K; Valta, MP, 2008) |
| "Prostate cancer is a major cause of cancer mortality in American males." | ( Cai, LQ; Chen, GQ; Imperato-McGinley, J; Qiao, Y; Tan, C; Wu, W; Zhu, YS, 2009) |
| "Prostate cancer is initially responsive to hormonal therapy, but cancers inevitably progress in an androgen-independent fashion with virtually all tumors evolving into more aggressive androgen refractory disease." | ( Bao, BY; Cai, Y; Chang, C; Hsu, CL; Huang, J; Lee, YF; Li, G; Liu, S, 2008) |
| "High-grade prostate cancer is associated with low serum testosterone levels, which generally recover after radical prostatectomy." | ( Bieglmayer, C; Koller, A; Kratzik, C; Lackner, JE; Maerk, I; Marberger, M; Schatzl, G, 2008) |
| "Prostate cancer is the most commonly diagnosed and the second leading cause of cancer death in men." | ( Gao, X; Gong, H; Khadem, S; Lee, JH; Li, S; Lu, Y; Xie, W; Zhang, J, 2008) |
| "Prostate cancer is dependent on circulating testosterone in its early stages and is treatable with radiation and surgery." | ( Heber, D; Hong, MY; Seeram, NP, 2008) |
| "TMPRSS2-ERG fusion prostate cancer is a distinct molecular subclass." | ( Adami, HO; Andersson, SO; Andrén, O; Brown, M; Calza, S; Chinnaiyan, AM; Demichelis, F; Fall, K; Golub, TR; Hoshida, Y; Johansson, JE; Johnson, LA; Kantoff, PW; Lupien, M; Mertz, KD; Mucci, LA; Pawitan, Y; Perner, S; Rhodes, D; Rubin, MA; Sboner, A; Setlur, SR; Stampfer, MJ; Tang, J; Tomlins, S; Varenhorst, E, 2008) |
| "Prostate cancer is a hormonal sensitive disease with a response rate ranging from 80 to 90%; however, the majority of patients develop hormone resistance resulting in poor long term survival." | ( Azim, HA; Mok, T, 2008) |
| "Prostate cancer is a major cause of cancer death among men and the development of new biomarkers is important to augment current detection approaches." | ( Califano, JA; Henrique, R; Jeronimo, C; Kim, MS; Lee, J; Liu, JW; Moon, CS; Nagpal, JK; Ostrow, KL; Sidransky, D; Sun, W; Trink, B; Van Criekinge, W; Zhou, S, 2008) |
| "Prostate cancer is common around the world, but rates of advanced disease differ substantially by race and geography." | ( Gueye, SM; Jalloh, M; Malkowicz, SB; Mandhani, A; Mittal, B; Mittal, RD; Rebbeck, TR; Rennert, H; Sachdeva, R; Zeigler-Johnson, CM, 2008) |
| "Prostate cancer is the most frequent malignancy of the male population." | ( Becker, M; Börgermann, C; Hess, J; Rübben, H; Schenck, M; Vom Dorp, F, 2008) |
| "Prostate cancer is the most frequently diagnosed cancer in American men." | ( Bai, L; Chang, YM; Evans, CP; Kung, HJ; Liu, S; Yang, JC, 2008) |
| "Prostate cancer is a leading cause of cancer related death." | ( Krolewski, JJ; Nastiuk, KL, 2008) |
| "Prostate cancer is an age-related disease that is linked to the inability of prostate cells to accumulate zinc following transformation." | ( Abubakar, S; Wong, PF, 2008) |
| "Prostate cancer is a leading cause of death among the aging men." | ( Arunakaran, J; Arunkumar, A; Banudevi, S; Gayathri, R; Gunadharini, DN; Krishnamoorthy, G; Senthilkumar, K; Vignesh, RC, 2009) |
| "Advanced prostate cancer is first treated with androgen deprivation therapy." | ( Farrar, WL; Hurt, EM; Sharifi, N; Thomas, SB, 2008) |
| "Prostate cancer is thought to arise as a result of oxidative stresses and induction of antioxidant electrophile defense (phase 2) enzymes has been proposed as a prostate cancer prevention strategy." | ( Bhamre, S; Brooks, JD; Dill, DL; Sahoo, D; Tibshirani, R, 2009) |
| "Prostate cancer is the second most common cancer in men worldwide." | ( Hodge, A; Itsiopoulos, C; Kaimakamis, M, 2009) |
| "Prostate cancer is a highly heterogenous disease in which a patient-tailored care program is much desired." | ( Assinder, SJ; Dong, Q; Mangs, H; Richardson, DR, 2009) |
| "Prostate cancer is a highly heterogeneous disease in which a patient-tailored care program is a holy grail." | ( Assinder, SJ; Dong, Q; Kovacevic, Z; Richardson, DR, 2009) |
| "Prostate cancer is the second most frequently diagnosed cancer in men." | ( Cook, LM; Eltoum, IA; Harper, CE; Lamartiniere, CA; Patel, BB; Shirai, T; Wang, J, 2009) |
| "Prostate cancer is a common disease affecting males." | ( Deliveliotis, C; Mitsogiannis, IC; Skolarikos, A, 2009) |
| "Prostate cancer is one of the most prominent malignancies of elderly males." | ( Asim, M; Baniahmad, A; Eisold, M; Eskelinen, H; Linke, T, 2009) |
| "Prostate cancer is the most frequently diagnosed cancer in men." | ( Bonorden, MJ; Cleary, MP; Grambsch, PL; Grande, JP; Grossmann, ME; Kluczny, CM; Lokshin, A; Perkins, S; Rogozina, OP, 2009) |
| "The outcome of prostate cancer is highly unpredictable." | ( Arnholdt, H; Bertz, S; Blana, A; Harzmann, R; Klein, CA; Polzer, B; Ragg, T; Schlimok, G; Weckermann, D, 2009) |
| "Prostate cancer is among the most common causes of death from cancer in men, and accounts for 10% of all new male cancers worldwide." | ( Fitzpatrick, JM; Schröder, FH; Schulman, C; Zlotta, AR, 2009) |
| "Prostate cancer is the second cancer-related cause of death." | ( Flourakis, M; Prevarskaya, N, 2009) |
| "NED in prostate cancer is involved in the chemoresistance induced by EGF." | ( Bing Zu, X; Chen, HQ; Chen, MF; Dai, YQ; Li, Y; Liu, HZ; Lv, H; Qi, L, 2009) |
| "Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor." | ( Arora, V; Beer, TM; Chen, CD; Chen, Y; Clegg, NJ; Higano, CS; Hung, DT; Jung, ME; Kwon, A; Ouk, S; Sawyers, CL; Scher, HI; Smith-Jones, PM; Tran, C; Wasielewska, T; Watson, PA; Welsbie, D; Wongvipat, J; Yoo, D, 2009) |
| "Prostate cancer is third to lung and colon cancer as the cause of cancer-related deaths in American men." | ( Amling, CL; Colli, JL, 2009) |
| "Prostate cancer is a common disease in men and at present there is no effective therapy available due to its recurrence despite androgen deprivation therapy." | ( Bearss, D; Cooke, LS; Croce, KD; Mahadevan, D; Qi, W; Riley, C; Saldanha, JW; Stejskal, A, 2009) |
| "Prostate cancer is a leading cause of death among men due to the limited number of treatment strategies available for advanced disease." | ( Bologa, C; Curpan, RF; Edwards, BS; Haynes, MK; Leitao, A; Oprea, TI; Prossnitz, ER; Sklar, LA; Strouse, JJ; Thompson, TA; Waller, A, 2009) |
| "Prostate cancer is a major health problem, and the exploration of noninvasive imaging methods that have the potential to improve specificity while maintaining high sensitivity is still critically needed." | ( Jacobs, MA; Macura, KJ; Ouwerkerk, R; Petrowski, K, 2008) |
| "Prostate cancer is the most common tumour in men and there is a need to improve outcomes for men with hormone-sensitive, advanced disease as quickly as possible." | ( Clarke, NW; Dearnaley, DP; James, ND; Mason, MD; Morgan, RC; Parmar, MK; Royston, P; Sanders, K; Sydes, MR, 2009) |
| "Prostate cancer is one of the most commonly diagnosed cancers in Western men and one in three Australian men develops the cancer before the age of 75." | ( Ambrosini, GL; Fritschi, L; Girschik, J; Glass, D, 2010) |
| "Prostate cancer is the second leading cause of cancer-related deaths in men in the United States." | ( Markaverich, BM; Rodriguez, MA; Shoulars, K; Thompson, T, 2010) |
| "Metastatic prostate cancer is either inherently resistant to chemotherapy or rapidly acquires this phenotype after chemotherapy exposure." | ( Beer, TM; Garzotto, M; Higano, CS; Huang, CY; Myrthue, A; Nelson, PS; Pittsenbarger, J; Qian, DZ; Rademacher, BL, 2010) |
| "Prostate cancer is the most commonly diagnosed and second most lethal malignancy in men, due mainly to a lack of effective treatment for the metastatic disease." | ( Jajoo, S; Mukherjea, D; Ramkumar, V; Watabe, K, 2009) |
| "Prostate cancer is one of the most prevalent tumors." | ( Cheng, XD; Hao, X; Hu, XB; Su, MQ; Yang, L; Yin, Y; Yue, QH; Zhou, TC, 2009) |
| "Prostate cancer is the most common malignancy in men, and patients with metastatic disease have poor outcome even with the most advanced therapeutic approaches." | ( Marian, CO; Shay, JW; Wright, WE, 2010) |
| "Prostate cancer is one of the most frequently diagnosed cancers in men." | ( Arunakaran, J; Arunkumar, R; Banudevi, S; Senthilkumar, K; Sharmila, G; Vijayababu, MR, 2010) |
| "Prostate cancer is the most common neoplasm in men." | ( Azzouzi, AR; Bigot, P; Lebdai, S, 2010) |
| "Prostate cancer is the most prevalent cancer in the Western male population and the second leading cause of cancer death in men, affecting over 10 million individuals." | ( Naz, RK; Williams, RM, 2010) |
| "Prostate cancer is the second leading cause of cancer mortality among US men." | ( Clinton, SK; Cui, M; Fleet, JC; Kovalenko, PL; Zhang, Z, 2010) |
| "Prostate cancer is the leading cause of cancer-related death in men, incidences of which are increasing gradually in India." | ( Bhattacharya, RK; Mukherjee, S; Roy, M, 2009) |
| "Prostate cancer is the most commonly diagnosed cancer among men." | ( Steinberg, M, 2009) |
| "Recently, prostate cancer is one of the common cancer in Japanese men, with a high incidence of bone metastasis." | ( Endo, T; Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Suzuki, H; Takano, M; Yano, M, 2010) |
| "Prostate cancer is an appropriate target for primary chemoprevention because of its ubiquity, disease-related mortality, treatment-related morbidity, and long latency period." | ( Abouassaly, R; Klein, EA; Stephenson, AJ, 2010) |
| "In Malaysia, prostate cancer is ranked 6th among male cancer and expected to increase in the future." | ( Shah, SA; Subahir, MN; Zainuddin, ZM, 2009) |
| "Prostate cancer is the leading form of cancer in men." | ( Brenot, A; Gallo, E; Gordon, JI; Littlepage, LE; Phillips, J; Rougier, N; Sternlicht, MD; Werb, Z; Williams, K; Yu, Y, 2010) |
| "Prostate cancer is a common malignancy in the elderly population." | ( Gupta, NP; Nayyar, R; Sharma, N, 2010) |
| "Prostate cancer is one of the most prevalent cancers in men." | ( Antoszczyk, S; Buhrman, JS; Castelo-Branco, P; Marinelli, M; Martuza, RL; Passer, BJ; Rabkin, SD; Zaupa, C, 2010) |
| "Prostate cancer is characterized by a low rate of glycolysis and glucose uptake." | ( Ghesani, NV; Liu, Y; Zuckier, LS, 2010) |
| "Androgen refractory prostate cancer is a major clinical challenge." | ( Chen, IS; Chen, YC; Chou, TH; Guh, JH; Kung, FL; Tsai, IL, 2010) |
| "Prostate cancer is one of the most common types of cancer in men, and unfortunately many prostate tumours remain asymptomatic until they reach advanced stages." | ( Bellini, MH; Courrol, LC; de Oliveira Silva, FR; Schor, N; Tristão, VR; Vieira, ND, 2010) |
| "Prostate cancer is one of the most frequently diagnosed cancer in men." | ( Altieri, V; De Placido, S; Di Carlo, A; Di Lorenzo, G; Ferro, M; Giordano, A; Macchia, V; Mariano, A; Mazzarella, C; Terracciano, D, 2010) |
| "Prostate cancer is the most common non-cutaneous malignancy in males in the US." | ( Chaudhary, UB; Turner, JS, 2010) |
| "Of all cancers, prostate cancer is the most sensitive to hormones: it is thus very important to take advantage of this unique property and to always use optimal androgen blockade when hormone therapy is the appropriate treatment." | ( Labrie, F, 2010) |
| "Prostate cancer is the fifth most common neoplasm worldwide, and the second most common cancer among men." | ( Jin, F; Kondo, R; Liu, J; Shimizu, K; Yu, H; Zhang, C, 2010) |
| "The diagnosis of prostate cancer is based on the results of ultrasonography-guided needle biopsy of the prostate, but cancer foci are often not visible in conventional transrectal ultrasonography." | ( Hashiguchi, A; Kikuchi, E; Kono, H; Matsumoto, K; Miyajima, A; Nagata, H; Nakagawa, K; Oya, M, 2010) |
| "Prostate cancer is a major cause of mortality, largely as a consequence of metastases and transformation to androgen-independent growth." | ( Adeniji, OO; Buttle, DJ; Chandrasekharan, S; Hamdy, FC; Molokwu, CN, 2010) |
| "Human prostate cancer is androgen dependent." | ( Adler, S; Geier, R; Klein, A; Rashid, G, 2010) |
| "Prostate cancer is one of the most common cancers in the Western world, and it is believed that an individual's diet affects his risk of developing cancer." | ( Déziel, BA; Gottschall-Pass, K; Hurta, RA; Neto, C; Patel, K, 2010) |
| "Prostate cancer is the most common form of cancer in males in the United States, and the second leading cause of cancer death." | ( Hara, T; Kusaka, M; Yamaoka, M, 2010) |
| "Progression of prostate cancer is facilitated by growth factors that activate critical signaling cascades thereby promote prostate cancer cell growth, survival, and migration." | ( Arunakaran, J; Arunkumar, R; Banudevi, S; Elumalai, P; Gunadharini, ND; Selvakumar, K; Senthilkumar, K; Sharmila, G, 2010) |
| "Prostate cancer is one of the most commonly diagnosed cancers in men." | ( Chiao, JW; Wang, LG, 2010) |
| "Prostate cancer is a leading cause of cancer-related death in men worldwide." | ( Dong, Y; Gao, L; Gao, R; Liu, X; Zhang, H; Zhao, L; Zhao, X; Zhao, Y, 2010) |
| "Prostate cancer is the most common type of cancer among men." | ( Adaramoye, OA; Akinloye, O; Olatunji, IK, 2010) |
| "Prostate cancer is a major cause of mortality in men in developed countries." | ( Arai, H; Atkinson, J; Barnholtz-Sloan, J; Danielpour, D; Klein, E; Manor, D; Morley, S; Parker, R; Thakur, V, 2010) |
| "Prostate cancer is the mostly commonly diagnosed non-skin cancer in males." | ( Isaacs, JT, 2010) |
| "Prostate cancer is one of the first five leading site of cancers in Delhi." | ( Manoharan, N; Raina, V; Tyagi, B, 2010) |
| "Prostate cancer is a long latency type of tumor that usually develops in men older than 50 years of age." | ( Calvo, A; Nguewa, PA, 2010) |
| "Prostate cancer is the most commonly diagnosed malignancy in men and shows a predilection for metastasis to distant organs." | ( Hsu, HH; Huang, CY; Lai, TY; Su, CC; Tang, CH; Tsai, CH; Tsai, FJ; Wu, HC; Yeh, YL; Yu, HS, 2011) |
| "Prostate cancer is an interesting tumor for endocrine investigation." | ( Caruso, B; Comunale, L; Ghimenton, C; Lacola, V; Migliorini, F; Monaco, C; Petrozziello, A; Porcaro, AB; Romano, M; Rubilotta, E; Sava, T; Zecchini Antoniolli, S, 2010) |
| "Prostate cancer is the second most common cancer in men worldwide." | ( Lentini, A; Provenzano, B; Ricci, P; Tabolacci, C; Torricelli, P, 2011) |
| "Prostate cancer is the second leading cause of cancer-associated deaths among men in the western countries." | ( Balajee, AS; Bohr, VA; Calaf, GM; Meador, JA; Proietti De-Santis, L; Su, Y; Zhao, Y, 2010) |
| "Prostate cancer is the second-leading cause of cancer-associated death among men in the United States." | ( Al-Husein, B; Goc, A; Kochuparambil, ST; Soliman, S; Somanath, PR, 2011) |
| "Prostate cancer is a commonly diagnosed cancer in men, and dietary chemoprevention by pomegranate (Punica granatum) extracts has shown noticeable benefits." | ( Gasmi, J; Sanderson, JT, 2010) |
| "Prostate cancer is the second most frequently diagnosed cancer in men and the fifth most common cancer overall." | ( Figg, WD, 2010) |
| "Prostate cancer is the second leading cause of cancer-related death among the American male population, and the cost of treating prostate cancer patients is about $10 billion/year in the United States." | ( Khan, SA; Lu, W; Ray, PC; Senapati, D; Singh, AK; Yu, H, 2010) |
| "Prostate cancer is one of the most preventable cancers, yet effective therapeutics, especially targeted therapy, are still lacking." | ( An, JH; Kim, DH; Lee, KJ; Shin, JS, 2010) |
| "Prostate cancer is a disease with a complex etiology." | ( Agalliu, I; Kirsh, VA; Kreiger, N; Rohan, TE; Soskolne, CL, 2011) |
| "Prostate cancer is the most common cancer diagnosed in men." | ( Dotan, N; Mahajna, J; Wasser, SP, 2011) |
| "Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging." | ( Jadvar, H, 2011) |
| "Progression of prostate cancer is highly dependent upon the androgen receptor pathway, such that knowledge of androgen-regulated proteins is vital to understand and combat this disease." | ( Bevan, CL; Brooke, GN; Culley, RL; Dart, DA; Gamble, SC; Gaughan, L; Mann, DJ; McCracken, SR; Powell, SM; Robson, CN; Spencer-Dene, B; Wait, R; Walker, MM; Waxman, J, 2011) |
| "Prostate cancer is the most common malignancy among men in Western societies, and current therapeutic approaches are evolving to manage growth, recurrence, and mortality neoplasia." | ( Castanas, E; Kampa, M; Lagoudaki, ED; Mavromati, F; Morel-Salmi, C; Nifli, AP; Notas, G; Pelekanou, V; Stathopoulos, EN; Theodoropoulou, K; Vercauteren, J, 2011) |
| "Prostate cancer is the most common cancer, and the second leading cause of death from cancer, in males in most Western countries." | ( De-Bono, J; Massard, C; Zivi, A, 2010) |
| "Prostate cancer is a slowly developing but very common cancer in males that may be amenable to preventive strategies that are not toxic." | ( Heber, D; Henning, S; Hong, MY; Moro, A; Seeram, NP; Zhang, Y, 2011) |
| "Prostate cancer is the most common malignancy among men in the US." | ( Atkinson, BJ; Pagliaro, LC; Watkins, JL, 2011) |
| "Prostate cancer is considered the most common cancer form among males in Western countries." | ( Khanfar, M; Mudit, M; Sayed, KA; Shah, GV, 2011) |
| "Prostate cancer is the leading cause of cancer and second leading cause of death among men." | ( Goetz, D, 2011) |
| "Prostate cancer is among the more common and less lethal malignancies, yielding a large population of survivors." | ( Dorff, TB; Vogelzang, NJ, 2011) |
| "Advanced prostate cancers are known to acquire not only invasive capabilities but also significant resistance to chemotherapy-induced apoptosis." | ( Bhatnagar, N; Guo, B; Li, X; Padi, SK; Tang, MS; Zhang, Q, 2010) |
| "The progression of prostate cancer is associated with escape from cell cycle arrest and apoptosis under androgen-depleted conditions." | ( Bae, HC; Jeon, JH; Kim, BJ; Kim, SH; Kim, SJ; Kim, TW; Lee, CR; Lee, S; Park, EJ; Park, HH; So, I, 2011) |
| "Prostate cancer is a frequently diagnosed male cancer." | ( Braeckman, JG; Denis, L; Michielsen, DP, 2011) |
| "Prostate cancer is a major health threat for men." | ( Han, B; Pan, X; Qi, H; Xu, L; Zhu, H, 2012) |
| "Prostate cancer is rarely associated with leptomeningeal metastasis." | ( Akar, S; Kesari, S; Kim, RY; Mahta, A; Zhang, M, 2012) |
| "Prostate cancer is the most common cancer and the second leading cause of cancer deaths among males in most Western countries." | ( Graddis, TJ; McMahan, CJ; Page, KJ; Tamman, J; Trager, JB, 2011) |
| "Although prostate cancer is commonly diagnosed, few risk factors for high-grade prostate cancer are known and few prevention strategies exist." | ( D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE, 2011) |
| "Prostate cancer is one of the leading causes of cancer-related deaths among males." | ( Abdulah, R; Kobayashi, K; Koyama, H; Yamazaki, C, 2011) |
| "Prostate cancer is the most common malignancy and the second leading cause of cancer death in the male population in developing countries." | ( Govindaraj, S; Jagadeesan, A; Kalimuthu, S; Perumal, E; Ramachandran, A; Velayutham, S; Venkatesh, K, 2011) |
| "Prostate cancer is a worldwide public health problem and its treatment continues to be a therapeutic challenge especially in patients with metastatic androgen-independent cancer." | ( Baltazar-Rodriguez, LM; Delgado-Enciso, I; Espinoza-Gómez, F; Galvan-Salazar, HR; Gonzalez-Alvarez, R; Guzman-Esquivel, J; Martinez-Martinez, R; Montes-Galindo, DA; Ortiz-Lopez, R; Rodriguez-Hernandez, A; Rojas-Martinez, A; Soriano-Hernández, AD; Valdez-Velazquez, LL, 2012) |
| "Prostate cancer is the most commonly diagnosed cancer in men worldwide and is the second leading cause of cancer related mortality." | ( Berhane, N; Mahdi, SA; Sobti, RC, 2012) |
| "Prostate cancer is the second leading cause of cancer death among men in developed countries." | ( Kosa, JP; Lakatos, P; Majoros, A; Nyirady, P; Romics, I; Speer, G; Szendroi, A; Tabak, A, 2011) |
| "Prostate cancer is the most frequent male malignancy diagnosed in western countries and androgens are known to mediate key physiological processes in prostate tissue." | ( Schleutker, J, 2012) |
| "Prostate cancer is one of the most common malignancies in men." | ( Bo, JJ; Huang, YR; Li, Z; Liu, DM; Liu, P; Lv, JW; Sha, JJ; Zhang, C; Zhang, LH, 2011) |
| "Prostate cancer is the second leading cause of cancer related death in American men." | ( Byun, J; Creighton, CJ; Fischer, SM; Michailidis, G; Nalluri, S; Palapattu, GS; Pennathur, S; Putluri, N; Putluri, V; Sana, TR; Shojaie, A; Sreekumar, A; Vareed, SK; Vasu, VT; Vivekanandan-Giri, A, 2011) |
| "Prostate cancer is dependent on androgens for growth in the initial stages where apoptosis is simultaneously inhibited." | ( Arnoldussen, YJ; Saatcioglu, F; Wang, L, 2011) |
| "Prostate cancer is the most frequently diagnosed male malignancy." | ( Chen, MC; Chiang, MC; Hsu, FN; Huang, PH; Lee, GS; Lee, YT; Lin, E; Lin, H, 2011) |
| "Prostate cancer is an ideal disease for nutritional prevention." | ( Czuba, ZP; Krol, W; Mertas, A; Paradysz, A; Szliszka, E, 2013) |
| "Prostate cancer is known to be affected by the heavy metal levels and oxidative damage of the body, yet there are very few studies which look into the way it occurs." | ( Aksu, A; Alici, B; Ataus, S; Aydemir, B; Durak, H; Guzel, S; Kiziler, L, 2012) |
| "Prostate cancer is a leading cause of death among males in the United States." | ( Arnatt, CK; Gewirtz, DA; Haney, KM; Li, G; Ware, JL; Yuan, Y; Zhang, F; Zhang, Y, 2011) |
| "Prostate cancer is the most frequently diagnosed non-cutaneous tumor of men in Western countries." | ( Chuu, CP; Fukuchi, J; Hiipakka, RA; Huo, C; Kokontis, JM; Lin, CY; Lin, HP; Su, LC, 2011) |
| "Prostate cancer is no longer viewed predominantly as a disease of abnormally proliferating epithelial cells but rather as a disease of complex interactions between prostate cancer epithelial cells (epithelial compartment) and the surrounding tissues (stromal compartment) in which they reside." | ( Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ, 2011) |
| "Prostate cancer is frequently treated with radiotherapy." | ( Della Donna, L; Lagadec, C; Pajonk, F, 2012) |
| "Prostate cancer is one of the most common cancer types in men." | ( Gamagedara, S; Ma, Y, 2011) |
| "Prostate cancer is a common malignancy in men and although hormone ablation therapy is effective, men develop hormone resistance." | ( Attia, DM; Ederveen, AG, 2012) |
| "Prostate cancer is the most common noncutaneous cancer and the second leading cause of death from cancer in men in most western countries." | ( de Bono, JS; Massard, C; Michels, RM; Sartor, O, 2011) |
| "Advanced prostate cancer is initially treated with gonadal testosterone depletion, which suppresses this cascade of events and typically leads to a treatment response." | ( Sharifi, N, 2012) |
| "Prostate cancer is a polyfactorial molecular anomaly that is offering refractoriness against a broad range of therapeutic drugs." | ( Ahsan, Qu; Asif, H; Bhatti, S; Dilawar, BA; Farooqi, AA; Fayyaz, S; Javed, Z; Javeed, MK; Khanum, R; Mansoor, Q; Nisar, K; Rana, A; Riaz, AM, 2011) |
| "Prostate cancer is a common cause of death in developed countries, yet the benefits of screening for prostate cancer still remain controversial." | ( Forbes, KM; Hassed, C; Ilic, D, 2011) |
| "Prostate cancer is the most commonly diagnosed cancer and second most common cause of cancer deaths in American men." | ( Chornokur, G; Connors, SK; Kumar, NB, 2012) |
| "Prostate cancer is one of the most commonly diagnosed solid malignancies among US men." | ( Agharahimi, M; Badisa, RB; Goodman, CB; Mazzio, E; Millington, DJ; Russell, LH; Zhu, ZP, 2011) |
| "Prostate cancer is the second most diagnosed cancer in men next to skin cancer in the developed world." | ( Berhane, N; Gupta, L; Mahdi, SA; Melese, S; Singh, N; Sobti, RC; Thakur, H, 2012) |
| "Prostate cancer is the second leading cause of cancer deaths among men." | ( Bok, R; Costello, LC; Feng, P; Franklin, RB; Kurhanewicz, J; Swanson, MG; Zou, J, 2011) |
| "Advanced prostate cancer is currently treated with androgen deprivation therapy (ADT)." | ( Ai, J; Langmann, G; O'Malley, KJ; Ramos-Garcia, R; Vessella, RL; Wang, Z, 2012) |
| "Advanced prostate cancer is the second leading cause of cancer-related deaths among American men." | ( Sharifi, N; Thomas, R, 2012) |
| "Prostate cancer is associated with high mortality and new therapeutic strategies are necessary for improved patient outcome." | ( Cheng, WP; Ding, C; Gu, J; Guo, J; O'Driscoll, C; Qu, X; Yang, Z, 2012) |
| "Prostate cancer is the second leading cause of cancer mortality in men in developed countries." | ( Hilvo, M; Iljin, K; Kallioniemi, O; Lehtinen, L; Lundin, J; Mirtti, T; Nordling, S; Orešič, M; Rannikko, A; Sankila, A; Seppänen-Laakso, T; Vainio, P; Virtanen, J, 2011) |
| "Prostate cancer is the most common malignancy in men in Western countries." | ( Castelo, B; Espinosa, E; Merino, M; Pinto, A; Redondo, A; Zamora, P, 2012) |
| "Prostate cancer is the most common cancer in Western men and, for advanced disease, no curative agents are available." | ( Attard, G; Bahl, A; Bellmunt, J; Huland, H; Klotz, L; Kuban, D; Oudard, S; Watson, W, 2012) |
| "Prostate cancer is the most prevalent urogenital malignancy." | ( Arranz, JÁ; Cassinello, J; Climent, MA; García-Donas, J; González del Alba, A; León-Mateos, L; Mellado, B; Méndez-Vidal, MJ; Pérez-Valderrama, B; Piulats, JM; Sánchez-Hernández, A, 2012) |
| "Prostate cancer is the second leading cause of cancer death in men in the US and Europe." | ( Rehman, Y; Rosenberg, JE, 2012) |
| "Prostate cancer is the most common malignancy and the second leading cause of cancer related deaths among men in many countries." | ( Akadam-Teker, AB; İsbir, T; Küçükhüseyin, Ö; Kurnaz, Ö; Narter, F; Yılmaz-Aydoğan, H, 2011) |
| "Prostate cancer is the most common malignancy in men." | ( Chen, YA; Chiu, HW; Ho, SY; Wang, YJ, 2012) |
| "Prostate cancer is known to have a tissue tropism for bone." | ( Helo, S; Krupski, TL; Manger, JP, 2012) |
| "Prostate cancer is one of the most common cancers in the world, and its prevalence is expected to increase appreciably in the coming decades." | ( Catalli, A; Déziel, B; Gottschall-Pass, K; Hurta, R; Kulka, M; MacPhee, J; Neto, C; Patel, K, 2012) |
| "Prostate cancer is one of the most common malignancies in men." | ( Bianchini, F; Calorini, L; Chiarugi, P; Giannoni, E; Serni, S, 2012) |
| "Prostate cancer is one of the leading causes of cancer death among men worldwide." | ( Ho, PC; Hui, KM; Kumar, AP; Lun, CK; Ong, TH; Sethi, G; Shanmugam, MK; Wong, PT, 2012) |
| "Prostate cancer is one of the leading causes of death in men aged 40 to 55." | ( Durity, M; Hörmann, V; Kumi-Diaka, J; Rathinavelu, A, 2012) |
| "Among American men, prostate cancer is the most common, non-cutaneous malignancy that accounted for an estimated 241,000 new cases and 34,000 deaths in 2011." | ( Bilir, B; Cutler, DJ; Giardina, CK; Kucuk, O; Lai, YH; Moreno, CS; Phillip, CJ, 2012) |
| "Prostate cancer is the most common solid-organ cancer affecting the male population." | ( Beatty, J; Bell, R; Miller, M; Mohammed, A; Rawlinson, A, 2012) |
| "Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide." | ( Herchenhorn, D; Maluf, FC; Smaletz, O, 2012) |
| "Prostate cancer is the most commonly diagnosed cancer affecting 1 in 6 males in the US." | ( Chauhan, SC; Ebeling, M; Jaggi, M; Sundram, V, 2012) |
| "Prostate cancer is the most commonly diagnosed non-cutaneous cancer in American men." | ( Inokuchi, J; Itsumi, M; Kashiwagi, E; Naito, S; Shiota, M; Uchiumi, T; Yokomizo, A, 2012) |
| "Prostate cancer is detected with increasing frequency but has a highly variable natural history and prognosis and active surveillance of men with low-risk prostate cancer would benefit greatly from minimally invasive methods to identify progression." | ( Busch, R; Carroll, P; Chan, J; Hayes, GM; Hellerstein, MK; Holochwost, D; Kuchinsky, K; Misell, L; Murphy, EJ; Shinohara, K; Simko, J, 2012) |
| "Prostate cancer is the major cause of cancer death in men and the androgen receptor (AR) has been shown to play a critical role in the progression of the disease." | ( Berkland, C; Huang, Y; Li, B; Ling, M; Liu, J; Ran, Y; Thrasher, JB; Wang, Y; Xie, SX; Yang, J, 2012) |
| "Prostate cancer is the second most common cause of mortality." | ( Agharahimi, M; Badisa, RB; Goodman, CB; Mazzio, E; Oriaku, ET; Russell, LH; Zhu, ZP, 2012) |
| "Prostate cancer is a leading cancer affecting men worldwide." | ( Ilic, D; Misso, M, 2012) |
| "Prostate cancer is the most frequently diagnosed malignancy and the second-leading cause of cancer death in men." | ( Gallagher, PE; Krishnan, B; Tallant, EA; Torti, FM, 2013) |
| "Prostate cancer is a growing public health problem." | ( Aune, D; Beynon, R; Collings, R; Fairweather-Tait, SJ; Greenwood, DC; Harvey, LJ; Hooper, L; Hurst, R; Lau, R; Norat, T; Savović, J; Sterne, JA; Vieira, R, 2012) |
| "Prostate cancer is the most commonly diagnosed malignancy in men and shows a predilection for metastasis to the bone." | ( Lin, TH; Tang, CH; Yu, HS, 2013) |
| "Prostate cancer is one of the leading causes of cancer death in men in Western countries." | ( Fan, LL; Ho, CT; Lin, JN; Lin, VC; Pan, MH; Tsai, YC; Way, TD; Wu, JY, 2012) |
| "Prostate cancer is is the most common solid neoplasm and it is now recognized as one of the most important medical problems facing the male population." | ( Castelli, T; Cimino, S; Favilla, V; Madonia, M; Morgia, G; Russo, GI; Sansalone, S; Sortino, G, 2012) |
| "Bone metastases in prostate cancer are often the cause of significant morbidity in patients with castrate-resistant disease, and several studies have shown significant pain palliation with systemic radionuclide treatment." | ( O'Sullivan, JM; Parker, CC; Vengalil, S, 2012) |
| "Prostate cancer is the leading type of cancer diagnosed in men." | ( Adomat, H; Hosseini-Beheshti, E; Li, N; Pham, S; Tomlinson Guns, ES, 2012) |
| "Prostate cancer is the most commonly diagnosed cancer in men." | ( Edwards, A; Fan, W; Flemington, EK; Zhang, K; Zhang, W, 2012) |
| "Prostate cancer is the most commonly diagnosed cancer among men in the developed countries." | ( Austin, LA; Dreaden, EC; El-Sayed, MA; Gryder, BE; Hayden, SC; Oyelere, AK; Pi, M; Quarles, LD; Tene Defo, BA, 2012) |
| "Prostate cancer is a very common cancer among males." | ( Chen, YL; Chiu, HW; Fang, WH; Ho, SY; Wang, YJ; Wu, MD; Yuan, GF, 2012) |
| "Dyslipidemia and prostate cancer are two of the most common medical conditions affecting adult males in the USA." | ( Cheng, L; Koch, MO; Masterson, TA; Rice, KR, 2012) |
| "Prostate cancer is the second most common cancer worldwide and the sixth cause of cancer-related death in men." | ( de Carvalho, AL; Lopes, RP; Marques, MP; Matos, CS, 2012) |
| "Prostate cancer is the most common visceral malignancy in men." | ( Kudlacek, S; Puntus, T, 2012) |
| "Prostate cancer is the second leading cause of cancer death among United States men." | ( Berman, DM; Davicioni, E; Erho, N; Ghadessi, M; Gurel, B; Huang, Z; Hurley, PJ; Jenkins, RB; Marchionni, L; Miller, RM; Park, BH; Peskoe, SB; Platz, EA; Ross, AE; Schaeffer, EM; Simons, BW; Vergara, IA, 2012) |
| "Prostate cancer is the most frequently diagnosed malignancy and the second-leading cause of cancer death in men." | ( Acikelli, AH; Bardenheuer, W; Buehler, H; Díaz-Carballo, D; Ergun, S; Gustmann, S; Jastrow, H; Strumberg, D, 2012) |
| "As prostate cancer is the most prevalent form of cancer in men and constitutes the third most common cause of cancer associated deaths, early diagnosis of primary prostate cancer and accurate staging influencing the appropriate choice of therapy is crucial." | ( Farsad, M; Krause, BJ; Schwarzenböck, S, 2012) |
| "Prostate cancer is the most common malignancy in Western countries." | ( Cheng, JW; Deng, G; Gordon, JR; Li, F; Liu, X; Peng, J; Sun, W; Yang, S, 2012) |
| "Prostate cancer is the most common solid organ cancer affecting the male population." | ( Kunkler, R; Miller, M; Mohammed, A; Rawlinson, A, 2012) |
| "Prostate Cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related death in men in the Western World." | ( Bellmunt, J; Buonerba, C; De Placido, S; Di Lorenzo, G; Rescigno, P; Sonpavde, G, 2012) |
| "Prostate cancer is a bimodal disease with aggressive and indolent forms." | ( Allen, PD; Bong, CW; Chao, S; Das, PK; Lau, BE; Leong, WS; Liew, CC; Lim, CR; Liong, ML; Loh, CS; Nam, RK; Ooi, EJ; Richie, JP; Steele, GS; Wassmann, K; Yang, H; Yu, CG, 2012) |
| "The burden of prostate cancer is inversely related to the magnitude of HRQOL declines." | ( Penson, DF; Resnick, MJ, 2012) |
| "Prostate cancer is the most common male cancer and one of the top causes of male cancer-related death in Western countries." | ( Gleave, ME; Loriot, Y; Zoubeidi, A, 2012) |
| "In men, prostate cancer is the most common non-cutaneous malignancy and the second most common cause of cancer death." | ( Morgans, AK; Smith, MR, 2012) |
| "Prostate cancer is the second most commonly diagnosed cancer in men, and approximately one-third of those diagnosed succumb to the disease." | ( Abrams, SL; Chappell, WH; Lehmann, BD; McCubrey, JA; Steelman, LS; Terrian, DM, 2012) |
| "Prostate cancer is the second leading cause of cancer death in men in the United States." | ( Cheng, ML; Ryan, CJ, 2013) |
| "Prostate cancer is the product of dysregulated homeostasis within the aging prostate." | ( Bostwick, DG; Chiang, EC; Combs, GF; Kengeri, SS; Morris, JS; Shen, S; Waters, DJ, 2012) |
| "Since low-risk prostate cancers are monitored over time in an effort to determine which progress into clinically important, more aggressive cancers, they provide an excellent model in which to study, over an extended period of time, the effects of enhancing vitamin D status and related changes in tumor progression." | ( Garrett-Mayer, E; Gattoni-Celli, S; Hollis, BW; Kindy, MS; Marshall, DT; Savage, SJ, 2013) |
| "Prostate cancer is one of the most commonly occurring malignancies in men, and because existing treatments are not able to manage this neoplasm adequately, novel approaches are needed." | ( Park, JW; Shin, SW, 2013) |
| "Prostate cancer is an ideal target for chemoprevention." | ( Gao, X; Jia, S; Lee, SH; Loda, M; Maira, SM; Roberts, TM; Signoretti, S; Stack, EC; Wu, X; Zhao, JJ, 2013) |
| "Prostate cancer is the most common malignancy and second leading cause of cancer related deaths in American men supporting the study of prostate cancer chemoprevention." | ( Bailey, H; Cohen, MB; Gee, J; Havighurst, T; Jarrard, D; Kim, K; Kolesar, J; Levan, L; See, W; Street, N; Tutsch, KD; Wilding, G, 2013) |
| "Prostate cancer is a leading public health burden worldwide, and in New Zealand it is the most commonly registered cancer and the third leading cause of cancer deaths among males." | ( Bishop, K; Duan, H; Ferguson, LR; Goudie, M; Han, DY; Kan, ST; Karunasinghe, N; Ko, S; Lange, K; Masters, J; Medhora, R; Wang, A; Zhu, S, 2012) |
| "Prostate cancer is the most common malignancy among men." | ( Cha, YJ; Doo, SW; Kim, DH; Kim, JH; Kim, SU; Lee, HJ; Song, YS, 2013) |
| "Prostate cancer is the most common malignant tumor in men." | ( Baur, M; Daum, L; Franke, K; Schlosshauer, B; Sievert, KD; Vaegler, M, 2013) |
| "Prostate cancer is a major public health problem in developed countries." | ( Jadvar, H, 2013) |
| "Prostate cancer is the second most frequently diagnosed cancer of men." | ( Chuu, CP; Hsu, JM; Kuo, LK; Liu, CC, 2013) |
| "Globally prostate cancer is the second most frequently diagnosed cancer and sixth leading cause of cancer death in men." | ( Lalitha, K; Mathew, A; Murthy, NS; Pruthvish, S; Suman, G, 2012) |
| "Imaging of advanced prostate cancer is currently changing due to numerous technical innovations." | ( Graser, A; Kretschmer, A; Seitz, M; Stief, CG; Tilki, D, 2013) |
| "Prostate cancer is the most common type of cancer, and kallikreins play an important role in the establishment of this disease." | ( Andrade de Paula, CA; Diniz, PM; Ferreira, JG; Lobo, YA; Maza, PK; Nogueira-Pedro, A; Oliva, ML; Paredes-Gamero, EJ; Paschoalin, T; Suzuki, E; Toledo, MS, 2013) |
| "Recurrent prostate cancer is usually treated by combining radiotherapy and androgen deprivation therapy." | ( Breeuwsma, AJ; de Jong, IJ; Dost, RJ; Glaudemans, AW, 2013) |
| "Prostate cancer is one of the most prevalent cancers in males and ranks as the second most common cause of cancer-related deaths." | ( Chang, I; Chiyomaru, T; Dahiya, R; Deng, G; Fukuhara, S; Majid, S; Saini, S; Shahryari, V; Tanaka, Y; Yamamura, S; Zaman, MS, 2013) |
| "Prostate cancer is the second leading cause of cancer death in men worldwide." | ( Cho, SD; Choi, ES; Han, JH; Jeon, SJ; Kim, BY; Kim, DJ; Lee, J; Park, JH, 2013) |
| "Prostate cancer is the most commonly diagnosed cancer in males in many populations." | ( Avci, CB; Dodurga, Y; Gunduz, C; Harman, E; Susluer, SY, 2013) |
| "Prostate cancer is one of the most prevalent malignancies and is the second leading cause of cancer-related deaths in men." | ( Ho, CT; Lai, CS; Li, S; Miyauchi, Y; Pan, MH; Suzawa, M, 2013) |
| "Prostate cancer is the most common tumor in men." | ( Cortes Vizcaino, V; Gil Salom, M; Moratalla Charcos, LM; Osca Garcia, JM; Pastor Navarro, T, 2013) |
| "Prostate cancer is the most commonly diagnosed malignancy in men and shows a predilection for metastasis to the bone." | ( Chen, CC; Chen, WC; Hsieh, TF; Lee, SS; Lin, TH; Liu, HH; Tan, TW; Tang, CH; Tsai, TH, 2013) |
| "Prostate cancer is the most common malignancy in men in the United States." | ( Pascal, M; Wu, XH; Yang, L, 2013) |
| "Prostate cancer is common in elderly men, especially in western countries, and incidences are rising in low-risk populations as well." | ( Balasubramaniam, G; Mahantshetty, U; Saoba, S; Shrivastava, S; Talole, S, 2013) |
| "GVAX for prostate cancer is a cellular immunotherapy, composed of PC-3 cells (CG1940) and LNCaP cells (CG8711)." | ( Auerbach, E; Corman, JM; Dahl, K; Olgac, S; Porter, C; Vuky, J, 2013) |
| "Men with high-risk prostate cancer are often thought to have very poor outcomes in terms of disease control and survival even after definitive treatment." | ( Choi, SS; Frank, SJ; Hoffman, K; Kuban, DA; Lee, AK; Levy, LB; McGuire, S; Nguyen, QN; Pugh, TJ, 2013) |
| "Prostate cancer is the most commonly diagnosed malignancy in men and shows a predilection for metastasis to distant organs." | ( Lin, TH; Tang, CH; Yu, HS, 2013) |
| "Prostate cancer is a leading cause of morbidity and mortality in men and has significant treatment-associated complications." | ( Andriole, GL; Nepple, KG; Sandhu, GS; Tanagho, YS, 2013) |
| "Prostate cancer is a serious multidimensional disorder that arises because of misrepresentation of signaling cascades and acquired resistance against apoptosis." | ( Awan, M; Begum, A; Bhatti, S; Butt, G; Farooqi, AA; Mansoor, Q; Qadir, MI; Shaukat, U; Yousaf, G, 2013) |
| "Prostate cancer is the most common solid malignancy in men, with 32,000 deaths annually." | ( Bartik, MM; Chen, A; Dakshinamoorthy, G; Johnson, GL; Kalyanasundaram, R; Munirathinam, G; Samykutty, A; Shetty, AV; Webb, B; Zheng, G, 2013) |
| "Androgen-dependent prostate cancer is reliant on the function of AR for growth and progression." | ( Hu, GF; Hu, MG; Ibaragi, S; Kishimoto, K; Li, S; Sheng, J; Sun, G; Sun, Y; Yoshioka, N, 2013) |
| "Early diagnosis of cancer of the prostate is very important, because the sooner the cancer is detected, the better it is treated." | ( Adam, V; Babula, P; Cernei, N; Eckschlager, T; Gumulec, J; Heger, Z; Kizek, R; Masarik, M; Stiborova, M; Zitka, O, 2013) |
| "Prostate cancer is the most common non-skin cancer and the second leading cause of cancer-related death for men in the United States." | ( Farrell, J; McLeod, DG; Petrovics, G; Srivastava, S, 2013) |
| "Prostate cancer is the most common noncutaneous cancer in men in the United States." | ( Chun, OK; Fontham, ET; Koo, SI; Su, J; Vance, TM, 2013) |
| "Prostate cancer is a frequently diagnosed cancer in men with a high incidence." | ( Hachenberg, T; Strang, CM, 2013) |
| "Prostate cancer is responsible for major deaths globally after lung cancer." | ( Arunakaran, J; Arunkumar, R; Brindha Mercy, A; Elumalai, P; Raja Singh, P; Senthilkumar, K; Sharmila, G; Sivakamasundari, V; Suganthapriya, E, 2014) |
| "Prostate cancer is a lethal cancer for the invasion and metastasis in its earlier period." | ( Kong, CZ; Wang, Y; Zhang, YX; Zhang, Z; Zhu, YY, 2013) |
| "Prostate cancer is the most common non-cutaneous malignancy among men in the Western world, and continues to be a major health problem." | ( Kitajima, K; Murphy, RC; Nathan, MA; Sugimura, K, 2014) |
| "Prostate cancer is a major public health problem worldwide and, more specifically, new treatments for hormone-refractory cancers are highly sought by several research groups." | ( Asselin, É; Bérubé, G; Brasseur, K; Fortin, S; Morin, N, 2013) |
| "Prostate cancer is one of the most frequently diagnosed cancers among men." | ( Li, J; Li, X; Qin, H; Rasul, A; Yang, N; Zhao, B, 2013) |
| "Prostate cancer is the most common malignancy in men and the second leading cause of cancer-related mortality in men of the Western world." | ( Bianco, M; Borojevic, R; Ferreira, LB; Gimba, ER; Junior, AP; Junior, OS; Nasciutti, LE; Oliveira, FL; Santos, CA; Soares, Nda C; Takiya, CM; Teodoro, AJ, 2013) |
| "Prostate cancer is one of the frequently diagnosed cancers in men." | ( Arunakaran, J; Arunkumar, R; Bhat, FA; Elumalai, P; Raja Singh, P; Senthilkumar, K; Sharmila, G, 2014) |
| "Prostate cancer is the second leading cause of cancer death among men." | ( Bhalla, R; Bialkowska, AB; Botchkina, GI; Golub, LM; Johnson, F; Ojima, I; Park, R; Rowehl, RH; Shroyer, KR; Zhang, Y; Zuniga, ES, 2013) |
| "Prostate cancer is one of the most frequently diagnosed cancers in males, and PC-3 is a cell model popularly used for investigating the behavior of late stage prostate cancer." | ( Chen, JH; Huang, YL; Ju, TK; Lee, H; Lee, MS; Lin, CC; Lin, CE; Lin, YC, 2013) |
| "Prostate cancer is one of the most common types of cancer and it is the second most common cause of cancer-related death among men in the western world." | ( Saphier, O; Silberstein, E; Silberstein, T, 2013) |
| "Prostate cancer is the most commonly diagnosed noncutaneous malignancy in men, yet 100 years ago it was considered a rare disease." | ( Ciezki, JP; Klein, EA; Tendulkar, RD; Ward, MC, 2014) |
| "Prostate cancer is the most commonly diagnosed malignancy among men in industrialized countries, accounting for the second leading cause of cancer-related deaths." | ( Burns, AR; Frigo, DE; Han, JJ; Ilkayeva, OR; Ittmann, MM; Rick, FG; Schally, AV; Shi, Y; Tennakoon, JB; Tsouko, E; White, MA; Xia, X; Xin, L; Zhang, A, 2014) |
| "Prostate cancer is the most commonly diagnosed malignancy in men and shows a tendency for metastasis to distant organs." | ( Chang, AC; Lin, YM; Tai, HC; Tang, CH; Wang, SW; Yeh, HI; Yu, HS, 2014) |
| "Prostate cancer is an endocrine-dependent tumor which is still under-investigated for physiopathology factors related to its natural history." | ( Artibani, W; Caruso, B; Cavalleri, S; Ghimenton, C; Migliorini, F; Petrozziello, A; Porcaro, AB; Romano, M; Sava, T, 2014) |
| "Salvage surgery for prostate cancer is a fascinating but controversial approach." | ( Bianchi, L; Borghesi, M; Brunocilla, E; Cevenini, M; Concetti, S; Fanti, S; Gentile, G; Martorana, G; Molinaroli, E; Nanni, C; Schiavina, R, 2014) |
| "Prostate cancer is the most common cancer among American men and the second most common cause of cancer deaths among men." | ( Aragon-Ching, JB; El-Bahesh, E; Elkon, J; Gupta, K, 2016) |
| "Prostate cancer is the commonest, non-cutaneous cancer in men." | ( Carroll, JS; Neal, DE; Nelson, AW; Tilley, WD, 2014) |
| "Prostate cancer is the second most common cause of cancer death among men in the USA, and death results from the development of metastatic disease." | ( Bergan, RC; Krishna, SN, 2014) |
| "Prostate cancer is linked to the male sex hormone testosterone." | ( Drudge-Coates, L; Turner, B, 2014) |
| "prostate cancer is the most frequent solid malignant tumor in Western Countries." | ( Cózar-Olmo, JM; Gómez-Río, M; Llamas-Elvira, JM; Navarro-Pelayo Láinez, MM; Rodríguez-Fernández, A; Vázquez-Alonso, F, 2014) |
| "Metastatic prostate cancer is lethal and lacks effective strategies for prevention or treatment, requiring novel therapeutic approaches." | ( Abdulghani, J; Alanen, K; Gu, L; Hoang, DT; Huszar, D; Leiby, B; Liao, Z; Mirtti, T; Nevalainen, MT; Romero-Weaver, AL; Talati, P; Vogiatzi, P; Zinda, M, 2014) |
| "In Japan, prostate cancer is treated with non-steroidal anti-androgen (flutamide and bicalutamide)." | ( Ito, H; Kakehi, Y; Kitamura, Y; Manabe, Y; Masuda, N; Mishina, M; Okuno, H; Sakura, Y; Sugimoto, M; Taoka, R; Terai, A, 2014) |
| "Prostate cancer is the most common nonskin neoplasm and second leading cause of death in men." | ( Beltran, L; Blando, J; DiGiovanni, J; Saha, A; Sessler, J; Silver, E, 2014) |
| "Prostate cancer is the most common cancer of men in the Western world, and novel approaches for prostate cancer risk reduction are needed." | ( Aittokallio, T; Eckerman, C; Holmbom, B; Laajala, TD; Mäkelä, SI; Polari, L; Saarinen, NM; Smeds, A; Yatkin, E, 2014) |
| "Correct staging of prostate cancer is an unmet clinical need." | ( Eriksson, O; Estrada, S; Malmberg, J; Orlova, A; Tolmachev, V, 2014) |
| "Prostate cancer is one of the most prevalent malignant cancers in men." | ( Chen, QY; Li, YQ; Liu, XJ; Xiao, SJ; Zeng, SE, 2014) |
| "Prostate cancer is one of the most common malignancies affecting men worldwide, with bone being the most common site of metastasis in patients that progress beyond organ confinement." | ( Deng, X; Gao, Z; He, G; Keller, ET; Keller, JM; Lin, Q; Liu, J; Luo, F; Peng, X; Tang, S; Yang, T, 2014) |
| "Prostate cancer is common in men with very high mortality which is one of leading causes of cancer-related deaths in men." | ( Chen, J; Deng, YF; Kent, F; O'Donoghue, A; O'Hare, T; Zhang, B, 2014) |
| "Prostate cancer is the most common non-cutaneous malignancy in American men." | ( Behrman, SW; Chauhan, SC; Ganju, A; Jaggi, M; Khan, S; Yallapu, MM, 2014) |
| "Prostate cancer is one of the most common types of urological cancers." | ( Gurocak, S; Kiliccioglu, I; Konac, E; Varol, N; Yucel Bilen, C, 2014) |
| "Prostate cancer is an excellent target for prevention, to reduce both mortality and the burden of overdetection of potential inconsequential disease whose diagnosis increases cost, morbidity, and anxiety." | ( Kristal, A; Platz, EA; Thompson, I, 2014) |
| "Prostate cancer is the most prevalent cancer in males, and treatment options are limited for advanced forms of the disease." | ( Asara, JM; Cantley, LC; Chen, M; Clohessy, JG; Epping, MT; González-Billalabeitia, E; Hobbs, RM; Liu, XS; Loda, M; Lunardi, A; Nardella, C; Ng, C; Pandolfi, PP; Papa, A; Patnaik, A; Seitzer, N; Signoretti, S; Song, MS; Song, SJ; Webster, KA, 2014) |
| "Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men in the U." | ( Elbanna, M; Heemers, HV, 2014) |
| "Prostate cancer is common and may be treated immediately or managed conservatively by observation." | ( Bergen, N; Duchesne, G; Ferris, N; Frydenberg, M; Mills, J; Mitchell, C; Murphy, D; Pedersen, J; Styles, C, 2014) |
| "The prostate cancer is one of the leading causes of men's cancer mortality." | ( Gao, XH; Guo, F; Wu, YL; Zhang, LY, 2014) |
| "The incidence of prostate cancer is increasing worldwide and marks a significant health issue." | ( Gold, E; Ottley, E, 2014) |
| "Prostate cancer is a leading cause of cancer-related mortality in men worldwide and there is a lack of effective treatment options for advanced (metastatic) prostate cancer." | ( Chen, Q; Deng, R; Huang, J; Liu, X; Sun, Q; Wang, Y; Xu, M; Yan, J; Yu, J; Zhao, X; Zhu, M, 2014) |
| "Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer mortality among men in the United States." | ( Heo, SC; Jeong, GO; Kim, BR; Kim, JH; Kwon, YW; Seo, EJ; Shin, SH, 2014) |
| "Prostate cancer is the most commonly diagnosed cancer disease in men in the Unites States and its management remains a challenge in everyday oncology practice." | ( Balakrishna, S; Chauhan, N; Chauhan, SC; Ebeling, MC; Ganju, A; Gupta, BK; Jaggi, M; Khan, S; Maher, DM; Sundram, V; Yallapu, MM; Zafar, N, 2014) |
| "Prostate cancer is hormone-dependent and regulated by androgens as well as oestrogens." | ( Buchanan, G; Cawsey, B; Ellem, SJ; Frydenberg, M; Furic, L; Larsson, O; Need, E; Pedersen, J; Pook, D; Risbridger, GP; Taylor, RA; Trotta, A, 2014) |
| "Prostate cancer is the most common malignancy diagnosed in males, and bone metastases remain a significant source of morbidity and mortality in this population." | ( Ding, Y; Guo, S; Li, X; Shan, B; Shi, P; Shu, X; Wang, J; Wang, Z; Xing, L; Zhang, Y, 2014) |
| "Prostate cancer is the most frequently diagnosed cancer in Western men, and more men have been diagnosed at younger ages in recent years." | ( Abdelkader, TS; Chang, SN; Han, J; Kim, KS; Kim, TH; Lee, JM; Park, JH; Song, J, 2014) |
| "Prostate cancer is a commonly diagnosed and treated malignancy, although it rarely presents with cutaneous metastases." | ( Chin, M; De Souza, P; Mak, G; Nahar, N, 2014) |
| "Prostate cancer is the most commonly diagnosed malignancy among Western men and accounts for the second leading cause of cancer-related deaths." | ( Cimic, A; Cramer, SD; Eckel, RH; Gijón, MA; Glodé, LM; Pac, CT; Rider, L; Rodrigues, LU; Romero, L; Schlaepfer, IR; Sirintrapun, SJ, 2014) |
| "Prostate cancer is the most common fatal cancers in men, and exposure to toxic elements is the most important factor in the aetiology for prostate cancer." | ( Qayyum, MA; Shah, MH, 2014) |
| "Prostate cancer is an androgen receptor (AR)-dependent malignancy at initiation and progression, therefore hormone therapy is the primary line of systemic treatment." | ( Abroaf, A; Bevan, CL; Brooke, GN; Cano, LQ; de Rooij, J; Driouch, K; Gaughan, L; Heer, R; Lavery, DN; Mauri, F; Robson, CN; Sin, S; Spanjaard, E; Tilman, JD, 2015) |
| "Prostate cancer is the second most common cause of cancer-associated deaths in men, and signaling via a transcription factor called androgen receptor (AR) is an important driver of the disease." | ( Babaie, E; Engedal, N; Guldvik, IJ; Hohloch, J; Itkonen, HM; Luhr, M; Mills, IG; Minner, S; Schlomm, T; Tsourlakis, MC, 2015) |
| "Prostate cancer is one of the most common cancers in men." | ( Géczi, L; Sinkovics, I, 2014) |
| "Prostate cancer is the frequent non-cutaneous tumor with high mortality in men." | ( Alimoghaddam, K; Ghaffari, SH; Ghanizadeh-Vesali, S; Ghavamzadeh, A; Modarressi, MH; Salmaninejad, A; Yaghmaie, M; Zekri, A, 2015) |
| "Prostate cancer is the most common cause of cancer-related deaths in men." | ( Ji, H; Jiang, F; Li, Y; Shen, J; Wang, X; Yang, X; Zhang, J, 2014) |
| "Prostate cancer is the most commonly diagnosed type of cancer and the second leading cause of cancer‑associated mortality in males." | ( Chen, H; Cui, RJ; Li, D; Li, Y; Lin, F; Lin, P; Yu, XG; Zhao, LN; Zheng, XL; Zou, HF, 2014) |
| "Prostate cancer is the most common form of cancer in Danish men, and the incidence is rising." | ( Hayatzaki, K; Menne, S; Nielsen, K, 2014) |
| "Prostate cancer is the leading cause of cancer-related death in men in the United States." | ( Bansal, N; Bertino, JR; Farley, NJ; Lewis, J; Wu, L; Youssoufian, H, 2015) |
| "Prostate cancer is the most prevalent type of cancer in the United States." | ( Bao, BY; Chang, YS; Han, CK; Huang, CH; Huang, HC; Li, CY; Lu, TJ; Lu, TL; Wu, HY; Wu, TS, 2014) |
| "Prostate cancer is the second leading cause of male cancer death in developed countries." | ( Bernardini, M; Brossa, A; Bussolati, B; Fiorio Pla, A; Genova, T; Gkika, D; Grolez, G; Leroy, X; Prevarskaya, N; Villers, A, 2014) |
| "Prostate cancer is the second leading cause of cancer-related death in men in most Western countries." | ( Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Roviello, G, 2014) |
| "Prostate cancer is usually a disease of elderly men, however, over 40 years of age the tumor can appear at any times." | ( Kovács, GL, 2014) |
| "Prostate cancer is the most common malignancy in males and easily develops to be aggressive which is closely related to the chronic inflammatory tumor microenvironment in situ." | ( Jin, X; Kong, X; Liu, Y; Tan, J; Wei, X; Zhao, R, 2015) |
| "Prostate cancer is one of the most widespread types of tumor diseases in men." | ( Abdel-Rehim, A; Abdel-Rehim, M; Moein, MM, 2015) |
| "Prostate cancer is a leading cause of cancer-related death among men." | ( Guo, Z; Li, X; Su, B; Xie, F; Zhang, M; Zhang, X; Zhou, L, 2015) |
| "Prostate cancer is the second most common disease of the male reproductive system." | ( Du, S; Lu, W; Wang, J, 2015) |
| "Prostate cancer is a growing problem in New Zealand and worldwide, as populations adopt a Western style dietary pattern." | ( Bishop, KS; Erdrich, S; Ferguson, LR; Han, DY; Jesuthasan, A; Karunasinghe, N; Zhu, S, 2015) |
| "Prostate cancer is common in over-50s men and the sixth-leading cause of cancer-related death in men worldwide." | ( Adjakly, M; Bernard-Gallon, D; Bignon, YJ; Boiteux, JP; Dagdemir, A; Guy, L; Judes, G; Karsli-Ceppioglu, S; Ngollo, M; Pajon, A; Penault-Llorca, F, 2015) |
| "Prostate cancer is the second most common cancer with sexual history as a consistent risk factor." | ( Bharadwaj, M; Hussain, S; Kakkar, N; Singh, N; Singh, SK; Sobti, RC, 2015) |
| "Breast and prostate cancers are among the most common of all cancers." | ( Iwase, H; Omoto, Y, 2015) |
| "Prostate cancer is a leading cause of death among men due to the limited number of treatment strategies available for advanced disease." | ( Andrade, CM; Barbé-Tuana, FM; Guma, FT; Hirsch, GE; Martins, LA; Parisi, MM, 2015) |
| "Prostate cancer is the most common type of cancer affecting males." | ( Gao, L; Li, Y; Zhu, W, 2015) |
| "Nowadays prostate cancer is the most common solid tumor in men from industrialized countries and the second leading cause of death." | ( Celma, A; Colás, E; de Torres, I; Doll, A; Garcia, M; Montes, M; Morote, J; Olivan, M; Placer, J; Planas, J; Regis, L; Reventós, J; Rigau, M; Sequeiros, T, 2015) |
| "Prostate cancer is a worldwide health problem, and therapeutic resistance is a critical obstacle for the treatment of hormone-refractory prostate cancer patients." | ( Chang, YJ; Cheng, WL; Huang, CY; Huang, MT; Hung, CS; Kuo, LJ; Lin, FY; Wu, CT, 2015) |
| "Prostate cancer is the most common malignancy in males, for which chemotherapy is the usual treatment option in clinical practice." | ( An, Q; Hu, X; Huang, X; Yi, J; Zhan, W, 2015) |
| "Brain metastasis in prostate cancer is rare and not expected at initial presentation especially when the patient is asymptomatic for the same." | ( Bal, C; Chakraborty, PS; Das, CJ; Kumar, R; Tripathi, M, 2015) |
| "Prostate cancer is one of the main causes of cancer death, and drug resistance is the leading reason for therapy failure." | ( Jiao, YL; Liu, N; Liu, YQ; Liu, Z; Wang, Y; Zhang, BC; Zhang, GA; Zhao, YR, 2015) |
| "Prostate cancer is the second most common malignancy in men worldwide." | ( Dehghani, M; Kianpour, S; Mokarram, P; Monabati, A; Mostafavi-Pour, Z; Torabinejad, S, 2015) |
| "Prostate cancer is the most frequent non-cutaneous malignancy in men." | ( Amin, A; Boekelheide, K; Huse, SM; McDonnell-Clark, EV; Saffarini, CM, 2015) |
| "Causes of prostate cancer are not clear, but steroid hormones, particularly androgens and probably estrogens, may be involved." | ( Eriksen, KT; Halkjær, J; McElroy, JA; Meliker, JR; Raaschou-Nielsen, O; Sørensen, M; Tjønneland, A, 2015) |
| "Prostate cancer is one of the most common malignancies in men." | ( Chen, Z; Hann, SS; Li, J; Tang, Q; Wu, J; Xiang, S; Yang, L; Zhang, Q; Zhou, J, 2015) |
| "Prostate cancer is one of the most common cancer types worldwide." | ( Li, Z; Lin, Z; Lu, C; Peng, R; Shen, Y; Shi, G; Wang, J; Wang, Y, 2015) |
| "Metastatic prostate cancer is an incurable disease that is treated with a variety of hormonal therapies targeting various nodes of the androgen receptor (AR) pathway." | ( Antonarakis, ES; Maughan, BL, 2015) |
| "Prostate cancer is one of the leading causes of death among males in the world." | ( Raborg, TJ; Singh, S; Xu, GG; Yuan, Y; Zaidi, SA; Zhang, F; Zhang, Y, 2015) |
| "Prostate cancer is associated to a reactive stroma microenvironment characterized by angiogenic processes that are favorable for tumor progression." | ( Cagnon, VH; Kido, LA; Montico, F; Rowley, DR; San Martin, R, 2015) |
| "Prostate cancer is the second most frequently diagnosed cancer in the world." | ( Klotz, LH; Mayer, MJ; Venkateswaran, V, 2015) |
| "Prostate cancer is a heterogeneous disease ranging from indolent asymptomatic cases to very aggressive life threatening forms." | ( Baker, A; Booher, CL; Burch, TC; Isaac, G; Langridge, J; Nyalwidhe, JO; Rainville, P; Rhim, JS, 2015) |
| "Prostate cancer is the most common form of cancer in men in the Western world." | ( Benoist, GE; Gerritsen, WR; Kramers, C; Mulders, PF; Schers, HJ; van Erp, PH; Westdorp, H, 2015) |
| "Prostate cancer is one of the leading causes of death in American males." | ( Akinboye, E; Bakare, O; Bamji, ZD; Copeland, RL; Kanaan, YM; Washington, KN, 2015) |
| "Primary prostate cancers are infiltrated with programmed death-1 (PD-1) expressing CD8+ T-cells." | ( Anders, RA; DeMarzo, AM; Drake, CG; Francica, BJ; Kochel, CM; Lucia, MS; Martin, AM; Meeker, AK; Nirschl, CJ; Nirschl, TR; van Bokhoven, A, 2015) |
| "Human prostate cancers are highly heterogeneous, indicating a need for various novel biomarkers to predict their prognosis." | ( Goto, T; Inoue, T; Kamba, T; Kobayashi, T; Makino, Y; Miyazaki, Y; Nakayama, K; Ogawa, O; Okada, Y; Sumiyoshi, S; Terada, N; Uegaki, M; Utsunomiya, N; Yamasaki, T; Yoshikawa, T, 2015) |
| "Prostate cancer is initially responsive to androgen deprivation, but the effectiveness of androgen receptor (AR) inhibitors in recurrent disease is variable." | ( Arora, KS; Brannigan, BW; Broderick, KT; Dahl, DM; Desai, N; Desai, R; Fox, DB; Haber, DA; Kapur, R; Lee, RJ; Maheswaran, S; Miyamoto, DT; Ramaswamy, S; Sequist, LV; Shioda, T; Smith, MR; Ting, DT; Toner, M; Trautwein, J; Wittner, BS; Wu, CL; Zheng, Y; Zhu, H, 2015) |
| "Prostate cancer is a common malignant tumor in urinary system." | ( He, D; Ning, J; Peng, L; Yang, J, 2015) |
| "Risk assessment for prostate cancer is challenging due to its genetic heterogeneity." | ( Andrake, MD; Arora, S; Bodian, DL; Daly, MB; Dunbrack, RL; Egleston, BL; Giri, VN; Golemis, EA; Hall, MJ; Handorf, ED; Nicolas, E; Ross, EA; Serebriiskii, IG; Vockley, JG; Zhou, Y, 2015) |
| "Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification." | ( A'Hern, R; Ashworth, A; Attard, G; Bianchini, D; Boysen, G; Brough, R; Cao, X; Carreira, S; Chinnaiyan, AM; de Bono, JS; Ebbs, B; Eeles, R; Elliott, T; Feng, FY; Ferraldeschi, R; Figueiredo, I; Flohr, P; Fowler, G; Gillman, A; Goodall, J; Hall, E; Hussain, S; Jain, S; Jones, R; Knudsen, KE; Kunju, LP; Lord, CJ; Mateo, J; McGovern, U; Miranda, S; Mossop, H; Nava Rodrigues, D; Omlin, A; Paulding, C; Pemberton, H; Perez-Lopez, R; Porta, N; Protheroe, A; Ralph, C; Riisnaes, R; Robinson, D; Roda, D; Rubin, MA; Sandhu, S; Seed, G; Swain, A; Tunariu, N; Williamson, CT; Wu, YM; Yuan, W; Zafeiriou, Z, 2015) |
| "Prostate cancer is the most common non-cutaneous cancer and the second leading cause of cancer-related mortality among men in the USA." | ( Arab, L; Azabdaftari, G; Bensen, JT; Chen, MH; Chun, OK; Fontham, ET; Koo, SI; Lee, SG; Mohler, JL; Pop, EA; Steck, SE; Su, LJ; Vance, TM, 2016) |
| "Metastatic prostate cancer is still commonly a lethal condition." | ( Chowdhury, S; Gilson, C; Kirby, R; Manickavasagar, T, 2015) |
| "Prostate cancer is the most commonly diagnosed malignancy among men." | ( Chen, M; Chen, W; He, L; Ji, J; Kanchana, K; Liang, G; Weng, Q; Zhang, X; Zhong, P; Zhou, H; Zou, P, 2015) |
| "BACKGROUND Prostate cancer is a one of the most common malignant diseases in men worldwide." | ( Deng, QK; Fu, XL; Li, WP; Lin, YL; Ma, JG; Wang, YH, 2015) |
| "Prostate cancer is a leading cause of cancer-related death in men and RNA interference (RNAi) has emerged as a potential therapeutic option." | ( Darcy, R; Evans, JC; Fitzgerald, KA; Gooding, M; Malhotra, M; O'Driscoll, CM; Sallas, F, 2016) |
| "Prostate cancer is the most frequently diagnosed cancer and is one of the leading causes of male cancer death in the world." | ( Choi, KW; Lee, CH; Lee, J; Rhee, H; Ryou, C; Suh, H, 2016) |
| "Prostate cancer is the second most frequently diagnosed cancer in males worldwide and is commonly associated with metastasis." | ( Bi, D; Cui, M; Han, L; Jia, Y; Liu, S; Liu, Z; Niu, Z; Wang, X; Zhang, Y, 2016) |
| "Prostate cancer is one of the most frequently occurring cancers and often acquires the potential of androgen-independent growth as a malignant phenotype." | ( Sato, A; Sato, C; Shiozawa, S; Sugahara, R; Uchida, A; Virgona, N; Yano, T, 2015) |
| "BACKGROUND Prostate cancer is a heterogeneous malignancy with outcome difficult to predict." | ( Deng, QK; Lei, YG; Li, WP; Lin, YL; Ma, JG, 2016) |
| "Prostate cancer is the most common diagnosed invasive cancer in American men and is the second leading cause of cancer-related deaths." | ( Al-Jabban, SM; Chen, G; Chen, QH; Mekuria, EA; Rakotondraibe, LH; Zhang, X, 2015) |
| "Breast and prostate cancers are malignancies in which steroid hormones drive cellular proliferation." | ( Auchus, RJ; Capper, CP; Rae, JM, 2016) |
| "Prostate cancer is a common multiple malignant tumor occurring in males." | ( Liu, Y; Ma, T; Xiao, P; Xu, Y; Zhang, H; Zhou, C, 2016) |
| "Prostate cancer is considered as the major cause of death among men around the world." | ( Aghapour, M; Baradaran, B; Mansoori, B; Mohammadi, A, 2016) |
| "Prostate cancer is a leading cause of cancer-related mortality in men worldwide and there is a lack of effective treatment options for advanced (metastatic) prostate cancer." | ( Xie, JK; Yang, JK; Zhang, SR; Zhao, LC, 2016) |
| "Risk of prostate cancer is modifiable and chemoprevention of prostate cancer, particularly fatal/lethal cancer, is both needed and possible." | ( Bosland, MC, 2016) |
| "Given prostate cancer is driven, in part, by its responsiveness to androgens, treatments historically employ methods for their removal from circulation." | ( Abbott, DH; Bird, IM, 2016) |
| "Prostate cancer is the most commonly diagnosed tumor in men in the United States." | ( Fu, J; Keller, ET; Lu, Y; Mizokami, A; Wang, L; Yang, Y; Zhang, J, 2016) |
| "Prostate cancer is one of the leading causes of cancer death in men." | ( Asa, S; Gungor, S; Kupik, O, 2016) |
| "Prostate cancer is a prevalent public health problem worldwide." | ( Jadvar, H, 2016) |
| "Prostate cancer is the primary cancer in males, with increasing global incidence rates making this malignancy a significant healthcare burden." | ( Foster, PA; Hofland, J; Rahman, HP, 2016) |
| "Prostate cancer is the leading cause of cancer-related death among men in developed countries." | ( Castilla, C; Flores, ML; Gasca, J; Japón, MA; Medina, R; Pérez-Valderrama, B; Romero, F; Sáez, C, 2016) |
| "Prostate cancer is a major cause of male death worldwide and the identification of new and improved treatments is constantly required." | ( Bassetto, M; Brancale, A; Ferla, S; Kandil, S; McGuigan, C; Pertusati, F; Westwell, AD, 2016) |
| "Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe." | ( Borges Dos Reis, R; Botrel, TE; Clark, O; Ferreira, U; Horta Bretas, FF; Lima Pompeo, AC; Sadi, MV, 2016) |
| "Prostate cancer is prevalent with significant morbidity in the United States." | ( Erickson, SR; Hansen, RA; Huang, WT; Wu, CH, 2016) |
| "Prostate cancer is the second most common cancer in men worldwide." | ( Bahrami, AR; Hosseinymehr, M; Kaseb-Mojaver, N; Matin, MM; Sadeghian, H, 2016) |
| "Prostate cancer is one of the most common malignant tumors in males and it has become a major worldwide public health problem." | ( Barroso-Neto, IL; Caetano, EW; Cavalcanti, BC; Costa, MP; da Silva, EN; Di Fiore, S; Dias, GG; Feitosa, AC; Fischer, R; Freire, VN; Ladeira, LO; Oliveira, FC; Pessoa, C; Sales, FA; Sousa, BL, 2016) |
| "Prostate cancer is a disease of disrupted cell genomes." | ( Bakhtiari, A; Carraro, A; Guillaud, M; Keyes, M; Korbelik, J; MacAulay, C; Zarei, N, 2016) |
| "Prostate cancer is one of the most prevalent cancers in men worldwide." | ( Chang, MC; Chou, YW; Hung, HC; Sung, PJ; Tai, MH; Wang, CT; Wen, ZH; Wu, DC; Wu, JC; Wu, WJ, 2016) |
| "Prostate cancer is known to frequently recur in bone; however, how dormant cells switch its phenotype leading to recurrent tumor remains poorly understood." | ( Balaji, KC; Lin, HK; Liu, Y; Pochampally, R; Said, N; Sharma, S; Shiozawa, Y; Watabe, K; Wu, K; Xing, F, 2016) |
| "The development of prostate cancer is a complex biologic process potentially involving genetics,dietary, life style and hormonal factors." | ( Loughlin, KR, 2016) |
| "Prostate cancer is a common disease and, while detection and treatment have advanced, it remains a significant cause of morbidity and mortality in men." | ( Doersch, KM; Moses, KA; Zimmer, WE, 2016) |
| "Metastatic prostate cancer is incurable, and ultimately threatens the life of patients." | ( Chen, H; Chen, ZY; Guo, J; Liu, XH; Qiu, T; Wang, L; Weng, XD, 2016) |
| "Prostate cancer is one of the most common malignancies in adult males and metastasis is the leading cause of death cases without satisfactory treatment options." | ( Chen, L; Li, X; Song, Y; Sun, Y; Xiao, Y; Xing, Y; Zhang, P, 2016) |
| "Prostate cancer is the most common cancer in men and the second most common cause of cancer-related deaths in men." | ( Bazer, FW; Lim, W; Park, S; Song, G, 2017) |
| "Prostate cancer is the most prevalent cancer in men in the United States." | ( First, MR; Fitzsimmons, WE; Henning, AK, 2016) |
| "Progression of prostate cancer is associated with an increase in cellular level of interleukin-6 (IL-6)." | ( Ghatreh-Samani, K; Heidarian, E; Keloushadi, M; Valipour, P, 2016) |
| "However, prostate cancer is typically a slowly growing tumor suggesting that additional processes play a role in the response to taxanes." | ( Duensing, S; Heller, M; Hohenfellner, M; Li, J; Mang, J; Merkle, K; Schüler, J; Tolstov, Y, 2017) |
| "Recurrence of prostate cancer is suspected when an increase in the prostate-specific antigen level is detected after radical treatment; the recurrence could be local relapse, distant relapse, or both." | ( Castellucci, P; Ceci, F; Fanti, S; Incerti, E; Mapelli, P; Picchio, M, 2016) |
| "Prostate cancer is the most prominent cancer in men, experiencing a relapse in disease often express high serum TNF-α levels." | ( Arunakaran, J; Arunkumar, R; Balakrishnan, S; Priya, ES; Rajalakshmi, M; Sharmila, G; Singh, PR, 2016) |
| "Prostate cancer is the most frequent occurring malignancy in men in many Western countries." | ( Bandel, T; Bolt, HM; Bremicker, KD; Dickhut, S; Golka, K; Neugebauer, W; Reich, S; Sökeland, J; Urfer, W, 2016) |
| "Prostate cancer is the second leading cause of cancer related deaths in men in the United States." | ( Ganai, SA, 2017) |
| "Prostate cancer is a leading cause of cancer-related death in males worldwide." | ( Arioli, I; Bellone, M; Bongiovanni, L; Botti, L; Cancila, V; Chiodoni, C; Colombo, MP; Festinese, F; Jachetti, E; Parenza, M; Rigoni, A; Tardanico, R; Tripodo, C, 2017) |
| "Prostate cancer is a multistep and complicated cancer type that is regulated by androgens at the cellular level and remains the second commonest cause of death among men." | ( Demirci, S; Doğan, A; Rizvanov, AA; Şahin, F; Telci, D; Türkmen, NB, 2017) |
| "Prostate cancer is the second leading cause of death due to cancer in men." | ( Naderi-Manesh, H; Nazari, M; Tarokh, Z, 2017) |
| "Prostate cancer is most common malignancy among men in the world." | ( Arunakaran, J; Arunkumar, R; Balakrishnan, S; Raja Singh, P; Rajalakshmi, M; Sharmila, G; Sugantha Priya, E, 2017) |
| "Prostate cancer is one of the most common malignancies in men, and it urgently demands precise interventions that target the signaling pathways implicated in its initiation, progression, and metastasis." | ( Chen, X; Jia, Y; Kong, T; Wang, B; Wang, C; Yang, J; Zhang, Z, 2017) |
| "Prostate cancer is the most common cancer in the Western world." | ( Messina, CS; Schmidt-Wolf, IG; Weiher, H, 2017) |
| "Prostate cancer is one of the most common cancers among men in the United States." | ( Cheng, Y; Ding, X; Jia, X; Jiang, J; Li, Y; Sharma, A; Wang, G; Xie, G, 2017) |
| "Prostate cancer is driven by androgen stimulation of the androgen receptor (AR)." | ( Alyamani, M; Berk, M; Chang, KH; Courtney, K; Garcia, JA; Klein, EA; Li, J; Li, Z; Magi-Galluzzi, C; Petro, M; Sharifi, N; Taplin, ME; Zhang, A; Zhu, Z, 2017) |
| "Primary prostate cancer is readily identified on early dynamic and static delayed Ga-PSMA ligand PET images." | ( Bengel, FM; Christiansen, H; Derlin, T; Geworski, L; Henkenberens, C; Mamach, M; Ross, TL; Schmuck, S; Sohns, JM; Thackeray, JT; von Klot, CA; Wester, HJ; Wilke, F, 2017) |
| "Prostate cancer is the most common cancer and the second leading cause of cancer death in men in the United States." | ( Savir-Baruch, B; Schuster, DM; Zanoni, L, 2017) |
| "Prostate cancer is the second leading cause of cancer deaths among men in Western counties and has increased in incidence also in China in recent years." | ( Chen, H; Li, H; Liu, C; Qian, B; Yao, Y; Zhang, J, 2017) |
| "Prostate cancer is the most frequently diagnosed malignancy and the leading cause of cancer related death in men." | ( Chen, N; Kim, FJ; Lou, R; Oyer, HM; Salvino, JM; Srikanth, YVV, 2017) |
| "Prostate cancer is the most common male cancer and androgen receptor (AR) is the major driver of the disease." | ( Barfeld, S; Bloch, K; Brown, M; Clarke, N; Davicioni, E; Derua, R; Erho, N; Guldvik, IJ; Hart, C; Heemers, HV; Ho Lau, C; Itkonen, HM; Keun, HC; Mills, IG; Mohler, JL; Rekvig, OP; Swinnen, JV; Takhar, M; Tredwell, G; Urbanucci, A; Waelkens, E, 2017) |
| "Prostate cancer is one of the leading causes of cancer-related death in U." | ( Abnet, CC; Cook, MB; Daugherty, SE; Freedman, ND; Liao, LM; Pfeiffer, R; Zhou, CK, 2017) |
| "Prostate cancer is the second most common cancer among men and the leading cause of death after lung cancer." | ( Başak Türkmen, N; Beker, MÇ; Çağlayan, AB; Dede, B; Demirci, S; Doğan, A; Kiliç, E; Özkan, F; Şahin, F; Telci, D, 2017) |
| "Aim of study - prostate cancer is second most common cancer in men worldwide, and fifth leading cause of death from cancer in men (6." | ( Guruli, G; Matchavariani, K; Mchedlishvili, K; Mitskevich, N; Tsertsvadze, T, 2017) |
| "Prostate cancer is the most common tumor in men." | ( Anastasi, E; Cilli, M; Cipriani, C; Colangelo, L; Diacinti, D; Fassino, V; Longo, F; Minisola, F; Minisola, S; Nieddu, L; Pascone, R; Pepe, J; Sciarra, A; Von Heland, M, 2018) |
| "Prostate cancer is the second most common cancer in men in the world." | ( Fidan, E; Fidan, S; Kocak, G, 2016) |
| "Prostate cancer is the first cancer in men and has a specific tropism to bones." | ( Aupee, O; Bertolaso, P; Cazeau, AL; Gross-Goupil, M; Le Moulec, S; Leroy, L; Ravaud, A; Roubaud, G, 2017) |
| "Prostate cancer is the second most common type of cancer in men in Iowa, surpassed only by non-melanotic skin cancer." | ( Kelly, KM; Ludewig, G; Lynch, CF; Roh, T; Wang, K; Weyer, P, 2017) |
| "Metastatic prostate cancer is initially treated with androgen deprivation therapy (ADT)." | ( Brown, JS; Cunningham, JJ; Gatenby, RA; Staňková, K; Thuijsman, F; You, L; Zhang, J, 2017) |
| "Prostate cancer is the most commonly diagnosed cancer in men in developed countries." | ( Dalla Via, J; Daly, RM; Fraser, SF; Livingston, PM; Millar, JL; Mundell, NL; Owen, PJ, 2017) |
| "Metastatic prostate cancer is a disease of older men, a population with an increased incidence of medical comorbidities warranting anticoagulation." | ( Beer, TM; Daughety, MM; DeLoughery, TG; Olson, SR; Shatzel, JJ, 2017) |
| "Prostate cancer is one of the most common cancers among men and can in its later stages cause serious medical problems." | ( Balzerová, A; Bařinková, J; Beneš, P; Chaloupková, Z; Konvalinka, J; Medříková, Z; Ranc, V; Šácha, P; Zbořil, R, 2018) |
| "Functions of Cap in prostate cancer are not clear." | ( Chang, YL; Feng, TH; Hou, CP; Juang, HH; Lee, BW; Lin, YH; Tsui, KH; Yang, PS, 2018) |
| "Prostate cancer is one of the most difficult cancers to treat especially when it becomes hormone resistant such as castrate resistant prostate cancer (CRPC) and subsequent metastatic CRPC." | ( Bimonte, S; Boccellino, M; Botti, G; Capunzo, M; Caraglia, M; Ciliberto, G; Crispo, A; D'Arena, G; Facchini, G; Giudice, A; Montella, M; Quagliuolo, L, 2017) |
| "Prostate cancer is one of the leading causes of cancer-related mortality among men living in developed countries, making the development of safe, practical approaches to prostate cancer risk reduction a high research priority." | ( Chiang, EC; Waters, DJ, 2018) |
| "Prostate cancer is a widespread problem among men, with >160 000 new cases in 2017 alone." | ( Anastos, H; Begemann, D; Kyprianou, N, 2018) |
| "Background Prostate cancer is one of the leading causes of cancer death in men." | ( Assinger, A; Basílio, J; Dikorman, B; Hell, L; Hoesel, B; Mackman, N; Moser, B; Mussbacher, M; Paar, H; Resch, U; Salzmann, M; Schmid, JA; Thaler, J, 2018) |
| "Prostate cancer is the most prevalent type of cancer in men around the world." | ( Alves, LF; Cagnon, VHA; da Silva, RF, 2018) |
| "Prostate cancer is impacting many men globally." | ( Hantash, J, 2018) |
| "Obesity and prostate cancer are related, but the causal relationship remains unknown." | ( Borowski, A; Kajdaniuk, D; Kos-Kudła, B; Marek, B; Nowak, M; Siemińska, L; Warakomski, J, 2018) |
| "Prostate cancer is a typical malignant disease with a high incidence and a poor prognosis." | ( Fu, X; Tang, Z; Wang, G; Wang, Y; Yang, S; Zhang, D, 2018) |
| "Prostate cancer is the second most frequently diagnosed cancer worldwide." | ( Chen, N; Chen, W; Qian, J; Shen, S, 2018) |
| "Prostate cancer is the second most diagnosed cancer in the world, and alternative methods to prevent and treat different lesion grades need to be evaluated." | ( Cagnon, VHA; Kido, LA; Montico, F; Pilli, RA; Silva, RS; Vendramini-Costa, DB, 2018) |
| "Prostate cancer is known as the most common malignancy in men." | ( Afkham, A; Afkham, NM; Aghebati-Maleki, L; Ahmadi, M; Akbarzadeh, P; Dolati, S; Jadidi-Niaragh, F; Sadreddini, S; Siahmansouri, H; Younesi, V; Yousefi, M, 2018) |
| "Prostate cancer is one of the most common cancers and among the leading causes of cancer deaths in the United States." | ( Basilion, JP; Burda, C; Escamilla, M; Govande, M; Mangadlao, JD; McCleese, C; Ramamurthy, G; Wang, X; Wang, Z, 2018) |
| "Prostate cancer is the most common male reproductive system cancer." | ( Chung, JG; Funayama, S; Kuo, CL; Lin, CH; Peng, SF, 2018) |
| "Prostate cancer is the most commonly diagnosed malignancy among men, but few genetic factors that drive prostate cancer initiation have been identified." | ( O'Bryant, D; Wang, Z, 2018) |
| "Prostate cancer is associated with the overexpression of prostate-specific membrane antigen (PSMA) in a majority of cases, predominantly in advanced tumors, increasing with the grade or Gleason's score." | ( Baum, RP; Kulkarni, HR; Langbein, T; Lehmann, C; Mueller, D; Schuchardt, C; Singh, A; Zhang, J, 2018) |
| "Prostate cancer is the most common cancer in men, and before it progresses and metastasizes, the anticancer drug bicalutamide is often administered to patients." | ( Heun Cha, B; Kang, HG; Kim, D; Lee, J; Mun, S; Park, A, 2018) |
| "Prostate cancer is a widespread malignancy characterized by a comparative ease of primary diagnosis and difficulty in choosing the individualized course of treatment." | ( Hofmann, WA; Maly, IV, 2018) |
| "Prostate cancer is one of the most common cancers affecting men worldwide with a high recurrence rate following therapy." | ( Behnia, F; Sannananja, B; Shah, HU, 2018) |
| "Prostate cancer is one of the leading causes of cancer related deaths in males worldwide." | ( Bahrami, AR; Matin, MM; Orafaie, A; Saboormaleki, S; Sadeghian, H, 2018) |
| "Though prostate cancers are better known for their responsiveness to androgen deprivation, ∼17% of late stage tumors regress in response to high dose natural or pharmaceutical Es; however, the mechanisms at the cellular level are not understood." | ( Jeng, YJ; Koong, L; Vinas, R; Watson, CS, 2019) |
| "Prostate cancer is the most common cancer and the second leading cause of cancer death in men in the United States." | ( Savir-Baruch, B; Schuster, DM; Zanoni, L, 2018) |
| "Prostate cancer is one of the most commonly diagnosed malignancies among men in Western populations." | ( Baszuk, P; Białkowska, K; Cybulski, C; Dębniak, T; Durda, K; Gromowski, T; Gronwald, J; Gupta, S; Huzarski, T; Jakubowska, A; Jaworska-Bieniek, K; Lubiński, J; Marciniak, W; Muszyńska, M; Prajzendanc, K; Scott, RJ; Sukiennicki, G, 2018) |
| "Prostate cancer is one of the most common types of cancer in men and the leading cause of death in developed countries." | ( Albayrak, G; Bilen, CY; Konac, E; Ugras Dikmen, A, 2018) |
| "Prostate cancer is an androgen-dependent disease subject to interactions between the tumor epithelium and its microenvironment." | ( Agarwal, P; Angara, B; Bhowmick, NA; Duong, F; Gottlieb, RA; Haldar, S; Liu, Z; Madhav, A; Mishra, R; Placencio, V; Posadas, EM; Rohena-Rivera, K; Tripathi, M; Wagner, S, 2018) |
| "Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide." | ( Chen, X; Jacobson, O; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Szajek, LP; Tian, R; Wang, Z, 2018) |
| "Prostate cancer is one of the most commonly diagnosed cancers in man." | ( Deng, F; Geng, S; Huang, C; Li, X; Liang, Z; Ma, X; Wu, J; Wu, R; Xie, C; Zhong, C; Zhu, M; Zhu, W, 2018) |
| "Prostate cancer is a heterogenous disease and the mechanisms that drive it to behave differently are not well understood." | ( Lim, J; Ong, DBL; Ong, KC; Razack, A; Rhodes, A; Sundram, M; Tan, JSJ; Yunus, R, 2018) |
| "Prostate cancer is the second leading cause of cancer death in men and about one in nine will be diagnosed in his lifetime." | ( Asal, R; Bhagat, S; Singh, S, 2018) |
| "The lethality of prostate cancer is mainly due to metastasis." | ( Fan, G; Kong, D; Liu, J; Tan, X; Xing, X; Zhang, P; Zhang, Z; Zhao, W; Zhong, Y, 2019) |
| "Progression of prostate cancer is accompanied by Golgi scattering, translocation of GSK3β from the Golgi to the cytoplasm, and the cytoplasmic shift in HDAC6 localization." | ( Casey, CA; Frisbie, CP; LaGrange, CA; Manca, S; Petrosyan, A; Riethoven, JM, 2019) |
| "Prostate cancer is one of the most frequent malignancies affecting men." | ( Li, N; Li, XX; Liu, JY; Long, B; Wu, ZH; Xu, XJ; Xu, XX, 2018) |
| "Prostate cancer is the most common non-skin cancer among men." | ( El-Sherbiny, IM; Khalil, IA; Sedki, M, 2018) |
| "Prostate cancer is a serious affliction worldwide." | ( Adlat, S; Han, T; Jiang, N; Nasser, MI; Tian, Y, 2019) |
| "Prostate cancer is the third leading cause of cancer death in the United States." | ( Banks, KP; McConathy, JE; Molchanova-Cook, OP; Parent, EE; Savir-Baruch, B; Schuster, DM; Subramaniam, RM; Takalkar, A; Tulchinsky, M; Yu, JQ, 2018) |
| "Metastases from prostate cancer are best detected at DWI or gadolinium-enhanced T1-weighted VIBE sequences." | ( Chan, R; Ghai, S; Metser, U; Tau, N; Veit-Haibach, P, 2019) |
| "Prostate cancer is the most frequent cancer type in men in industrialized countries." | ( Knoll, P; Mirzaei, S; Zandieh, S, 2019) |
| "Prostate cancer is one of the most common tumors in the world and the fifth leading cause of male cancer death." | ( Cui, L; Duan, Y; Ji, J; Luan, M; Meng, X; Si, H; Song, F; Zhai, H, 2020) |
| "Prostate cancer is known as a common malignant tumor in clinics and moreover, traditional chemotherapeutic drugs have great toxic side effects and drug resistance." | ( Li, XN; Liu, L; Liu, SB; Qiu, S; Sun, H; Wang, XJ; Zhang, AH; Zhang, TL, 2018) |
| "Prostate cancer is still the one of the leading threats to males." | ( Lv, Q; Wang, D; Wang, M; Wang, Y; Yang, J; Yang, X; Yang, Z; Zhang, R, 2018) |
| "Prostate cancer is one of the most common cancers in the world." | ( Chun, S; Chung, HJ; Jeong, BH; Kim, HK; Kwon, YD; La, MT; Lee, SH; Lee, SJ; Oh, JM, 2019) |
| "Prostate cancer is highly prevalent with a high mortality among males worldwide." | ( Chen, KM; Chen, PN; Chen, WJ; Han, KY; Hong, MC; Hseu, YC; Hsu, LS, 2018) |
| "Prostate cancer is one of the major causes of cancer-related deaths in men and there is a growing interest in identifying natural compounds for its management." | ( Akhtar, N; Dilshad, E; Haq, IU; Keefover-Ring, K; Khan, MI; Mirza, B; Rehman, S, 2019) |
| "Prostate cancer is one of the most commonly diagnosed cancers in men worldwide." | ( Chen, W; Huang, H; Li, P; Liu, Y; Yang, Y; Ye, X; Zhang, F, 2018) |
| "Prostate cancer is the most common illness affecting men worldwide." | ( Adlat, S; Gao, L; Jiang, N; Ming Jiang, M; Nasser, MI; Wang, J, 2018) |
| "Although prostate cancer is one of the most common cancers in the male population, its basic biological function at a cellular level remains to be fully understood." | ( Aracil, C; Cabello, M; Estrela, P; Ge, H; I Pascu, S; Manuel Quero, J; Moschou, D; R F Rocha, P, 2019) |
| "Prostate cancer is the second common cancer in men with high morbidity and mortality." | ( Dai, X; Guo, K; Liang, Z; Liu, L; Wang, H; Xu, S, 2019) |
| "Prostate cancer is among the major malignancies that affect men around the world." | ( Battastini, AMO; Cappellari, AR; da Silva, BT; de Souza, JB; Engroff, P; Figueiró, F; Gardani, CFF; Moritz, CEJ; Morrone, FB; Scholl, JN, 2019) |
| "Prostate cancer is the sixth leading cause of death, among all cancer deaths By 2030, this burden is expected to increase with 1." | ( Chhabra, M; Rashid, M; Shamshavali, K, 2019) |
| "Metastatic prostate cancer is a source of great morbidity and mortality especially due to osseous involvement that gives rise to significant symptoms of pain or pathologic fractures or cord compression." | ( Aragon-Ching, JB; Finianos, A, 2019) |
| "Prostate cancer is the most common malignant cancer in men worldwide and after lung cancer, it is the second leading cause of cancer mortality in men." | ( Dehkordi, AH; Ghiasi, B; Motedayen, M; Najafi, F; Sarokhani, D, 2019) |
| "Background Prostate cancer is an extremely common disease in males, and the mortality of prostate cancer has been rising year by year." | ( Cao, X; Li, Q; Wang, Z; Xu, F, 2019) |
| "Prostate cancer is a common type of malignancy." | ( Chen, P; Jin, J; Wang, J; Yang, C; Zhang, W, 2019) |
| "Prostate cancer is most frequently diagnosed cancer of men and bone is the most common site of metastasis." | ( Ghori, HU; Lal, N; Pareek, A; Redhu, P; Singh, OP; Yogi, V, 2019) |
| "Prostate cancer is the second leading cause of cancer death among men in the United States." | ( Ahmad, N; Cheng, L; Farah, E; Kong, Y; Lanman, NA; Li, C; Li, L; Liu, X; Lorenz, GR; Pascuzzi, P; Ratliff, T; Zhang, Y, 2019) |
| "Prostate cancer is one of the most frequent types of cancer." | ( Popov, SV; Rogovskii, VS; Shimanovskii, NL; Sturov, NV, 2019) |
| "Breast and prostate cancers are frequently treated with chemotherapy." | ( Almeida Paz, FA; Bachari, K; Bentarzi, Y; Helguero, LA; Nedjar-Kolli, B; Rocha, DHA; Saidi, L; Silva, AMS; Talhi, O, 2019) |
| "BACKGROUND Prostate cancer is a common malignant tumor in males." | ( Cao, Y; Chen, X; Geng, H; Han, F; Tong, W; Zhu, K, 2019) |
| "Prostate cancer is one of the most common cancers in the male population." | ( Fraile, B; Martínez-Onsurbe, P; Paniagua, R; Royuela, M; Torrealba, N; Vera, R, 2020) |
| "Prostate cancer is among the types of cancer with high mortality in men." | ( Hacioglu, C; Kacar, S; Kanbak, G; Kar, F; Sahinturk, V, 2020) |
| "Prostate cancer is among the most prevalent malignancies in men." | ( Bang, SI; Kim, JY; Lee, SD, 2020) |
| "Prostate cancer is still one of the serious causes of mortality and morbidity in men." | ( Bayer, B; Bekçi, H; Cumaoğlu, A; Küçükgüzel, ŞG; Uba, AI; Yelekçi, K; Yılmaz, Ö, 2020) |
| "Breast and prostate cancers are typical examples of hormone-dependent cancers, showing remarkable similarities at the hormone-related signaling pathways level, and exhibiting a high tropism to bone." | ( Casimiro, S; Lopes, MB; Vinga, S, 2019) |
| "Prostate cancer is one of the main causes of male cancer-related deaths worldwide and the suppression of androgen receptor signalling is established as an effective strategy for the treatment." | ( Bazgier, V; Berka, K; Jorda, R; Kiełczewska, U; Maj, J; Morzycki, JW; Rárová, L; Řezníčková, E; Siergiejczyk, L; Wojtkielewicz, A, 2019) |
| "Prostate cancer is the most diagnosed type of cancer in men in Canada." | ( Bérubé, G; Côté, MF; Gaudreault, RC; Ouellette, V; Tajmir-Riahi, HA, 2019) |
| "Prostate cancer care in the Middle East is highly variable and access to specialist multidisciplinary management is limited." | ( Abbas, F; Al Dousari, S; Al Hallaq, Y; Al Hamdani, N; Alameh, W; Ashou, R; Assaf, G; Bachir, B; Bitar, N; Bulbul, M; Dagher, C; Dbouk, H; El Khoury, C; El-Hajj, A; Faddoul, S; Farha, G; Farhat, F; Geara, F; Ghazal, H; Gillessen, S; Haidar, M; Hussain, HK; Ibrahim, K; Jabbour, M; Khauli, R; Mukherji, D; Nasr, R; Nemer, E; Omlin, A; Rabah, D; Said, R; Sakr, G; Sayyid, K; Shamseddine, A; Temraz, S; Wazzan, W; Youssef, B; Zouain, N, 2020) |
| "Prostate cancer is the second leading cause of cancer-related deaths among men in developed countries." | ( Bajo, AM; Carmena, MJ; Muñoz-Moreno, L; Prieto, JC; Schally, AV, 2020) |
| "Prostate cancer is the main cause of cancer-related mortality in men around the world and an important health problem." | ( Hacioglu, C; Kacar, S; Kanbak, G; Kar, F; Sahinturk, V, 2019) |
| "Prostate cancer is the second leading cause of cancer death in men in the US." | ( Beck, JR; Correa, AF; Geynisman, DM; Handorf, EA; Ramamurthy, C, 2019) |
| "Prostate cancer is a very heterogeneous disease, and contemporary management is focused on identification and treatment of the prognostically adverse high-risk tumors while minimizing overtreatment of indolent, low-risk tumors." | ( Burger, IA; Ghafoor, S; Vargas, AH, 2019) |
| "Prostate cancer is one of the most prevalent cancers in men." | ( Chia, SE; Geok, PP; Lee, J; Lim, JT; Ong, CN; Seow, WJ; Tan, YQ; Valeri, L, 2019) |
| "Prostate cancer is the most common cancer and leading cause of cancer death for males." | ( Barlaz Us, S; Comelekoglu, U; Sogut, F; Yalin, S; Yetkin, D; Yildirim, M; Yilmaz, SN, 2019) |
| "Breast and prostate cancer are two of the most common malignancies worldwide." | ( Berindan-Neagoe, I; Gurzau, E; Manda, G; Schitcu, V; Stavaru, C; Szedlacsek, S; Zimta, AA, 2019) |
| "Prostate cancer is one of the most commonly diagnosed cancers in men, leading to a high mortality rate due to a lack of effective anticancer treatment." | ( Chen, J; Gu, T; Jiang, Q; Lu, Q; Meng, X; Ning, X; Shan, X; Zhang, J; Zhang, L, 2019) |
| "Patients with prostate cancer are monitored by prostate-specific antigen (PSA) evaluation and PET [PET/computed tomography (CT)]." | ( Cholewiński, W; Czepczyński, R; Miechowicz, I; Ruchała, M; Siminiak, N; Wojciechowska, K, 2019) |
| "Prostate cancer is fourth most abundant cancer type around the globe." | ( Bhukya, B; Chanda, D; Dubey, P; Fatima, K; Khan, F; Kumar, S; Kumar, Y; Lakshmi, V; Luqman, S; Nagar, A; Negi, AS; Shanker, K; Tandon, S, 2020) |
| "Prostate cancer is the most highly diagnosed cancer in men worldwide." | ( Abdelkafi-Koubaa, Z; BenAissa, R; Essafi-Benkhadir, K; Luis, J; Marrakchi, N; Mlayah-Bellalouna, S; Othman, H; Peigneur, S; Srairi-Abid, N; Tytgat, J; Villard, C, 2020) |
| "Radio-recurrent prostate cancer is typically detected by a rising prostate-specific antigen and may reflect local or distant disease." | ( Archer, S; Bauman, G; Berlin, A; Boylan, C; Chung, HT; Chung, P; Emmett, L; Helou, J; Kapoor, A; Liu, W; Loblaw, A; Lock, M; Metser, U; Morton, G; Pond, GR; Rachinsky, I; Sexton, T; Wolfson, R; Zukotynski, K, 2020) |
| "Prostate cancer is a leading cause of death in men and despite improved surgical procedures that aid tumor resection, the risk of recurrence after surgery as a result of positive resection margins remains significant." | ( Ahmed, H; Day, RM; Di Maggio, F; Ho, HMK; Paliashvili, K; Sathasivam, S, 2019) |
| "Prostate cancer is primarily fatal after it becomes metastatic and castration-resistant despite novel combined hormonal and chemotherapeutic regimens." | ( Artemov, D; Bařinka, C; Donnelly, MC; Hapuarachchige, S; Huang, CT; Lupold, SE; Pomper, MG, 2020) |
| "Prostate cancer is the second cause of death in men worldwide." | ( Ebrahimi, M; Khoei, S; Mahdavi, SR; Mahdavian, A; Rajaee, Z; Shirvalilou, S, 2020) |
| "Prostate cancer is the second most commonly diagnosed cancer in men, and metastatic prostate cancer is currently incurable." | ( Asay, S; Barnes, B; Graham, A; Hollingsworth, S; Kenealey, JD; Michaelis, DJ; Oblad, RV, 2020) |
| "Prostate cancer is a candidate for immunotherapy because cancer cells express tissue-specific proteins that can be therapeutic targets." | ( Cannella, F; Rowley, DT; Simons, BW; Viscidi, RP, 2020) |
| "Prostate cancer is difficult to treat if it metastasizes to other organs." | ( Lim, W; Song, G; Yang, C, 2020) |
| "Accurate staging of prostate cancer is required for optimal treatment planning." | ( Choyke, PL; Lim, I; Lindenberg, L; Mena, E; Turkbey, B; Walker, SM, 2020) |
| "Metastatic prostate cancer is a heterogeneous disease entity." | ( Cookson, MS; Parker, DC, 2020) |
| "Cancer of the prostate are cancers in which most incidences are slow-growing, and in the U." | ( Bartzatt, R, 2020) |
| "Prostate cancer is one of the forcing sources of cancer-relevant deaths among men." | ( Abdel Moaty, SA; El-Shahawy, AA; Farghali, AA; GadelHak, Y; Mahmoud, RK; Mohamed, NA; Zaki, AH, 2020) |
| "Prostate cancer is the second most common cause of male cancer death after lung cancer in the US." | ( Man, L; Xu, X, 2021) |
| "Prostate cancer is a major worldwide health concern with up to 60% of patients experiencing biochemical relapse after radical treatment." | ( Akbarian, R; Fattahi, K; Ghodsirad, MA; Javanmard, B; Kaghazchi, F; Pirayesh, E; Tavakoli, M, 2020) |
| "Prostate cancer is initially dependent on the androgen, gradually evolves into an androgen-independent form of the disease, also known as castration-resistant prostate cancer (CRPC)." | ( Lombardi, APG; Porto, CS; Vicente, CM, 2020) |
| "Prostate cancer is one of the most common cancers in men and can progress to metastatic castration-resistant prostate cancer (CRPC) which possesses resistance to androgen deprivation therapy." | ( Lee, SY; Son, J, 2020) |
| "Prostate cancer is the second most common tumor and the fifth cause of cancer-related death among men worldwide." | ( Astobiza, I; Blanco, FJ; Bruzzone, C; Cannet, C; Carracedo, A; Cortazar, AR; Diercks, T; Embade, N; Gil-Redondo, R; Loizaga-Iriarte, A; Mato, JM; Millet, O; Sánchez-Mosquera, P; Schäfer, H; Spraul, M; Ugalde-Olano, A; Unda, M, 2020) |
| "Prostate cancer is the second most common cancer in men and the second leading cause of male cancer deaths." | ( Butler, L; Chan, KM; Gleadle, JM; Li, J; MacGregor, M; McNicholas, K; Ostrikov, K; Rouget, J; Shirazi, HS; Vasilev, K, 2020) |
| "Prostate cancer is one of the leading causes of cancer-related death in men." | ( Bridges, HR; Hirst, J; Kidd, SL; Mateu, N; Osberger, TJ; Russell, DA; Serreli, R; Sore, HF; Spring, DR, 2020) |
| "Prostate cancer is characterized by stiff tissue properties and reduced water diffusion, whereas, at the same time, tissue fluidity is increased, suggesting greater mechanical friction inside the lesion." | ( Aldoj, N; Asbach, P; Braun, J; Guo, J; Haas, M; Hamm, B; Köhlitz, T; Lenk, J; Reiter, R; Ro, SR; Sack, I; Snellings, J, 2020) |
| "Prostate cancer is the most common carcinoma of the male urinary system in developed countries." | ( Bian, J; Li, Z; Luan, H; Meng, Y; Xu, P, 2020) |
| "Prostate cancer is the most commonly diagnosed malignancy in men." | ( Alaterre, E; Balaguer, P; Boulahtouf, A; Bourguet, W; Cuenant, A; Dellal, H; Gongora, C; Grimaldi, M; Pourquier, P, 2020) |
| "Prostate cancer is the second cause of cancer death in men worldwide." | ( Al-Jamal, WT; Borges, JC; Chorilli, M; de Lima, FT; de Oliveira, CS; Eloy, JO; Marchetti, JM; Nogueira, KAB; Petrilli, R; Raspantini, G; Ruiz, A; Santos, E, 2020) |
| "Prostate cancer is a major health issue with an incidence of 1,100,000 worldwide." | ( Bedke, J; Lawaczeck, L; Norz, V; Rausch, S; Stenzl, A, 2020) |
| "Prostate Cancer is the second cause of cancer-related death in men and development of metastatic castration-resistant prostate cancer (mCRPC) is the major reason for its high mortality rate." | ( Alishahi, Z; Esmaeili, F; Ghaffari, SH; Hamzehlou, S; Karimi, B; Kashani, B; Momeny, M; Mousavi, SA; Mousavipak, SH; Nasrollahzadeh, A; Sabourinejad, Z; Sankanian, G; Shamsaiegahkani, S; Yousefi, H; Zandi, Z, 2020) |
| "Prostate cancer is the most common malignant tumour and represents the third cause of cancer-mortality in men." | ( Abecassis, JP; Ghazzar, N; Giraud, P; Peyromaure, M, 2020) |
| "Prostate cancer is the second most common cause of cancer-related deaths in men, representing a major source of morbidity and mortality." | ( Abrahamsson, PA; Van Poppel, H, 2020) |
| "Prostate cancer is an important cause of death in the male population and for which there is no satisfactory chemotherapy." | ( Carneiro, JWM; Filho, EV; Fiorot, RG; Freitas, MCR; Greco, SJ; Guimarães, ARA; Loureiro, LB; Muri, EMF; Pessôa, JC; Pinheiro, EMC; Pinheiro, S; Rocha-Brito, KJP; Rotamiro, KM; Silva Junior, CMD, 2020) |
| "Studying prostate cancer is important due to its high annual incidences and mortality rates in the world." | ( Azimi-Hashemi, S; Hadizadeh, F; Kamali, H; Mirahmadi, M; Pishbin, M; Saburi, E, 2020) |
| "Prostate cancer is one of the most common types of cancer in many industrialized countries and is among the leading causes of death." | ( Afable, A; Bruno, DM; Persaud, H; Yuan, J, 2021) |
| "Although prostate cancer is a leading cause of cancer death, its aetiology is not well understood." | ( Allen, NE; Andrews, C; Fensom, GK; Key, TJ; Martin, RM; Perez-Cornago, A; Travis, RC; Van Hemelrijck, M; Watts, EL, 2020) |
| "Bone metastatic prostate cancer is one of the most common malignancies in developed countries and the second leading cause of cancer-related death in men." | ( Murata, T; Ramos, JW; Yamaguchi, M, 2021) |
| "Prostate cancer is one of the most prevalent cancers among men, and the principal reason of death due to this cancer is the inappropriate detecting tools." | ( Farshchi, F; Hasanzadeh, M, 2020) |
| "Worldwide, prostate cancer is considered to be one of the three most commonly occurring cancers amongst the male population." | ( Akl, MA; El-Gharkawy, ER; El-Mahdy, NA; El-Sheikh, SM; Sheta, SM, 2020) |
| "Prostate cancer is the most common malignant tumor with bone metastasis, and there is still no ideal treatment for bone metastasis of prostate cancer." | ( Cheng, Y; Ji, QF; Liu, DZ; Liu, M; Mei, QB; Yang, Q; Zhou, SY, 2021) |
| "Prostate cancer is the most common malignancy in men in developed countries." | ( Ding, G; Fan, C; Li, K; Lu, W; Sun, J; Wang, F; Wang, J; Zhao, C; Zhou, H, 2020) |
| "Prostate cancer is the most common cancer, which is about 15-20% among male cancers worldwide." | ( Bolat, ZB; Bozkir, A; Gulyuz, S; Kocak, P; Oz, UC; Ozkose, UU; Sahin, F; Tasdelen, MA; Telci, D; Yilmaz, O, 2021) |
| "Prostate cancer is an epithelial malignant tumor of the prostate, and it is one of the malignant tumors with a high incidence of urogenital system in men." | ( Fan, Y; Li, H; Liu, J; Luo, C; Quan, Z; Sun, W; Wu, X; Xiao, F; Zheng, Y, 2021) |
| "Prostate cancer is currently one of the most common fatal tumor types in men." | ( Ding, Y; He, S; Huang, Z; Jia, Z; Li, X; Liu, B; Sheng, H, 2020) |
| "Prostate cancer is one of the most common cancer in males." | ( Chen, CY; Liao, KM; Wang, YL, 2020) |
| "Prostate cancer is a heterogeneous disease and considered to be the most commonly diagnosed cancer." | ( Damodaran, M; Natarajan, A; Sudha Bandla, S; Sundaram, S; Venkatesan, V, 2020) |
| "Prostate cancer is the fifth cause of tumor-related deaths in man worldwide." | ( Beretta, GL; Zaffaroni, N, 2021) |
| "Prostate cancers are reliant on androgens for growth and survival." | ( Elgehama, A; Guo, W; Sun, L; Xu, Q; Yu, B, 2021) |
| "Prostate cancer is the most common cancer in men." | ( Avcı, S; Kırca, M; Ozpolat, B; Soylu, H; Ustunel, I, 2021) |
| "In males, prostate cancer is ranked second as leading cause of death out of more than 200 different cancer types1." | ( Arkan, E; Behbood, L; Darvishi, E; Ehzari, H; Shahlaei, M, 2021) |
| "Prostate cancer is the most prevalent oncological disease among men in industrialised countries." | ( Araujo, N; Braga, R; Carneiro, AF; Costa, AR; Cruz, VT; Figueiredo, LP; Lunet, N; Morais, S; Oliveira, J; Pereira, S; Ruano, L, 2021) |
| "Prostate cancer are the most common, malignant and lethal tumors in men, and the complexity of prostate cancer (CaP) is also due to the diverse metastasis profile." | ( Chen, C; Li, Y; Liao, G; Ma, H; Sheng, Y, 2021) |
| "Prostate cancer is one of the prominent causes of cancer mortality in men all over the world and a challenge to treat." | ( Akanda, M; Douroumis, D; Getti, G; Mithu, MS; Nandi, U, 2021) |
| "Prostate cancer is one of the most common cancers in men." | ( Abu-Dahab, R; Aqabani, H; Hikmat, S; Mahmoud, NN, 2021) |
| "Prostate cancer is one of the most frequently diagnosed types of cancers worldwide." | ( Bravo-Cuellar, A; Cancino-Marentes, ME; Cruz-Gálvez, CC; Hernández-Flores, G; Orozco-Alonso, E; Ortiz-Lazareno, PC; Sierra-Díaz, E; Solís-Martínez, RA; Villaseñor-García, MM, 2021) |
| "Prostate cancer is one of the most prevalent neoplasms in male patients, and surgery is the main treatment." | ( Auler, JOC; Carmona, MJC; Coelho, RF; Cordeiro, MD; Nahas, WC; Rangel, FP; Simões, CM, 2021) |
| "Nowadays, prostate cancer is the most widespread tumour in worldwide male population." | ( Ambrosio, L; Caporali, M; Fasolino, I; Peruzzini, M; Raucci, MG; Serrano-Ruiz, M; Soriente, A, 2021) |
| "Prostate cancer is among the most common cancer diagnoses in men, and the best treatment for patients with metastatic disease in advanced stages is still unclear." | ( Amaral, SS; Lobo, MM; Saffi, J; Silva Dos Santos, M; Viau, CM; Zanatta, N, 2021) |
| "Prostate cancer is the most frequently diagnosed cancer among elderly men in the United States." | ( Andreana, S; Manuballa, S; Vaddi, A, 2021) |
| "Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer." | ( Addison, D; Baliga, R; Calaway, AC; Campbell, CM; Challa, AA; Cullen, J; Desai, N; Deswal, A; Garcia, J; Guha, A; Kutty, S; Vallakati, A; Weintraub, NL, 2021) |
| "Prostate cancer is the second leading cause of cancer-related death in men." | ( Bazylianska, V; Brunzelle, JS; Chowdhury, DD; Edwards, BFP; Heath, EI; Hüttemann, M; Kalpage, HA; Kim, K; Lee, I; Mahapatra, G; Marcus, K; Morse, PT; Podgorski, I; Polin, L; Subedi, P; Turner, AA; Vaishnav, A; Wan, J, 2021) |
| "Prostate cancer is a major health concern in males worldwide, owing to its high incidence." | ( Hu, J; Liu, S; Shi, C; Song, Y; Sun, L; Yan, W, 2021) |
| "Most men who die of prostate cancer are older than 70 years." | ( Greer, JA; Lage, DE; Lee, RJ; Michaelson, MD; Sweeney, CJ; Temel, JS, 2021) |
| "Prostate cancer is one of the most common cancers in men." | ( Badawi, JK, 2021) |
| "Prostate cancer is a heterogeneous, slow growing asymptomatic cancer that predominantly affects man." | ( Kandhavelu, M; Konda Mani, S; Le, HTT; Murugesan, A; Ramesh, T; Yli-Harja, O, 2021) |
| "Prostate cancer is heterogeneous and patients would benefit from methods that stratify those who are likely to respond to systemic therapy." | ( Attard, G; Bläuer, M; Cao, S; Claessens, F; Cremaschi, P; Devlies, W; Engedal, N; Erickson, A; Granberg, KJ; Häkkinen, T; Handle, F; Henttinen, S; Kaarijärvi, R; Kaljunen, H; Ketola, K; Kiviaho, A; Lahnalampi, M; Lamb, AD; Mills, IG; Murtola, T; Nätkin, R; Nowakowska, K; Nykter, M; Prekovic, S; Syvälä, H; Taavitsainen, S; Tammela, TLJ; Tolonen, T; Urbanucci, A; Visakorpi, T; Vuorinen, EM; Wang, W; Wetterskog, D, 2021) |
| "Although prostate cancer is a very common form of malignancy in men, the clinical significance of androgen deprivation therapy (ADT) with abiraterone acetate versus the nonsteroidal antiandrogen bicalutamide has not yet been verified in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)." | ( Egawa, S; Enei, Y; Fukuokaya, W; Hata, K; Iwamoto, Y; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Obayashi, K; Onuma, H; Otsuka, T; Sakanaka, K; Sano, T; Shimomura, T; Suzuki, H; Tsuzuki, S; Yanagisawa, T, 2022) |
| "Prostate cancer is the second leading cause of cancer related death in American men." | ( Goodman, O; Gorjala, P; Mitra, R; Vetrichelvan, O, 2021) |
| "Prostate cancer is the third most common cancer in Malaysia with the lifetime risk of 1 in 117 men." | ( Akaza, H; Chui, BJT; Jr, S; Khoo, SC; Koh, WJ; Lee, SB; Lim, J; Malek, R; Nasuha, NA; Ngu, IS; Omar, S; Ong, TA; Sundram, M; Teh, GC; Teoh, BW; Tham, TM; Thevarajah, S; Toh, CC; Woo, SYY; Yusoff, NAM; Zainal, R, 2021) |
| "Prostate cancer is a clinically and molecularly heterogeneous disease, with highest incidence and mortality among men of African ancestry." | ( Allen, T; Armstrong, AJ; Chen, X; Foo, WC; Freedman, JA; George, DJ; Gregory, S; Gupta, S; Hsu, DS; Huang, J; Inman, BA; Kittles, RA; Li, Y; McCall, SJ; Owzar, K; Patierno, BM; Patierno, SR; Qin, X; Somarelli, JA; Ware, KE; Wise, JP; Wise, S; Xu, L; Zhang, D, 2022) |
| "Prostate cancer is one of the most frequent causes of cancer death in men worldwide, and novel drugs for prostate cancer therapies are still being developed." | ( Hou, L; Jiao, W; Kong, D; Li, H; Shao, J; Wang, R; Xu, Y; Zhang, X; Zhu, S, 2021) |
| "Prostate cancer is the second most frequently diagnosed cancer among men worldwide in 2020." | ( Ajay, K; Al Armashi, AR; Bawwab, A; Patell, K; Ravakhah, K, 2022) |
| "Prostate cancer is the second most common form of cancer in men." | ( Glass, AD; Grossfeld, DJ; Katz, AE; Pinkhasov, A; Reiss, AB; Saeedullah, U, 2022) |
| "Prostate cancer is a highly heterogeneous disease, understanding the crosstalk between complex genomic and epigenomic alterations will aid in developing targeted therapeutics." | ( Chinni, SR; Feng, FY; Gerke, TA; Ghale, R; Govindarajan, B; Jehane, LE; Kantoff, PW; Lee, GM; Liao, Y; Luo, JH; Mazzu, YZ; Mucci, LA; Nandakumar, S; Sjöström, M, 2022) |
| "Prostate cancer is the second most common type of cancer among men." | ( Beloglazkina, EK; Ber, AP; Borisova, YA; Chepikova, OE; Erofeev, A; Gorelkin, P; Khazanova, ES; Khudyakov, AD; Kolmogorov, VS; Kovalev, S; Machulkin, AE; Majouga, AG; Nimenko, EA; Pankratov, AA; Petrov, SA; Plotnikova, EA; Pokrovsky, VS; Polshakov, VI; Shafikov, RR; Skvortsov, DA; Smirnova, GB; Uspenskaya, AA; Vaneev, AN; Zamyatnin, AA; Zyk, NU; Zyk, NV, 2021) |
| "Prostate cancer is the most common cancer in males worldwide." | ( Chen, L; Chen, S; Ding, X; Ge, W; Guo, T; Liang, S; Lyu, M; Sun, R; Wang, Y; Zhang, C; Zhou, Y, 2022) |
| "Prostate cancer is a common condition with limited treatment efficacy in castration-resistant metastatic disease, including with immune checkpoint inhibitors." | ( Babbage, A; Barrett, T; Berry, B; Clatworthy, MR; Coupland, P; Field, S; George, A; Gnanapragasam, V; Grenfell, R; Hori, S; Jones, J; Kania, K; Loudon, KW; Lynch, AG; Massie, C; Nguyen, Q; Richoz, N; Tan, X; Tuong, ZK; Warren, AY, 2021) |
| "Prostate cancer is the most common malignancy and the second leading cause of cancer-induced death among men." | ( Li, H; Liu, F; Sun, Q; Sun, S; Wen, Z; Xia, J; Xu, Y, 2022) |
| "Prostate cancer is a major malignancy, affecting men, worldwide." | ( Clark, CCT; Malekahmadi, M; Rezavand, L; Sharifi-Zahabi, E; Shidfar, F; Soltani, S, 2022) |
| "Prostate cancer is the most common cancer diagnosis among men." | ( Belzile, E; Culos-Reed, SN; De Raad, M; Duncan, LR; Ellis, J; Hallward, L; Higano, CS; Ibberson, C; Katz, A; Korman, MB; Lambert, SD; Loban, E; McTaggart-Cowan, H; Peacock, S; Saha-Chaudhuri, P; Sears, C; Walker, L, 2022) |
| "Prostate cancer is one of the most frequently diagnosed malignancies in men worldwide and the life expectancy for men with prostate cancer is improving due to advancements in diagnostics and treatment." | ( Chen, R; Rajan, P; Tharakan, T, 2022) |
| "Death caused by prostate cancer is increased by 13% in men between 1980 and 2005." | ( Özler, S; Pazarci, P, 2022) |
| "The role of BTAs in prostate cancer is pivotal throughout many stages of the disease, but several toxicities should be quickly recognized and treated." | ( Errani, C; Marchetti, A; Massari, F; Mollica, V; Nigro, MC; Nuvola, G; Rizzo, A; Rosellini, M; Tassinari, E, 2022) |
| "Prostate cancer is one of the most common types of cancer found to occur in males and is ranked as the second-highest cause of cancer-associated deaths among male patients." | ( Cheng, L; Qin, H; Tao, L; Wang, J; Wang, Y; Zhu, G, 2022) |
| "Canine prostate cancer is classified into adenocarcinoma, transitional cell carcinoma with prostatic involvement, and mixed forms." | ( Granados-Soler, JL; Hewicker-Trautwein, M; Klose, K; Murua Escobar, H; Nolte, I; Packeiser, EM, 2022) |
| "Prostate cancer is one of the most frequently diagnosed cancer in men and ranks as the second most common cause of cancer-related deaths in developed countries." | ( Varisli, L, 2022) |
| "Prostate cancer is a common cause of cancer death in men." | ( Axcrona, K; Bjerknes, C; Currie, C; Framroze, B; Hermansen, E; Pettersen, CHH, 2022) |
| "Prostate cancer is the most common cancer in men." | ( Arslan, E; Beyhan, E; Çermik, TF; Erol Fenercioğlu, Ö; Leblebici, C, 2022) |
| "Prostate cancer is the second most harmful malignant tumor in men because of its insidious onset, easy metastasis, and easy development into castration-resistant prostate cancer even after treatment." | ( Gao, L; Ge, B; Li, L; Shi, H; Xu, H; Zhou, B, 2022) |
| "Animal models of prostate cancer are essential to identify chemopreventive treatments against this major male malignancy." | ( Bosland, MC; Horton, L; McCormick, DL; Schlicht, MJ, 2022) |
| "Cancer of the prostate is an indicated type that is often recorded as a kind of cancer in men and the second critical cause of mortality through cancer cases." | ( Afshari, JT; Alwan, AM, 2022) |
| "Prostate cancer is the most common malignancy of the male genitourinary system and is one of the leading causes of male cancer death." | ( Li, Q; Peng, X; Qiao, C; Tang, Y; Zhao, R; Zhu, X, 2022) |
| "Prostate cancer is the most common noncutaneous cancer in American males." | ( Fraser, GE; Jaceldo-Siegl, K; Knutsen, SF; Mashchak, AD; Orlich, MJ; Sveen, LE; Utt, JT, 2022) |
| "Prostate cancer is the second most common cause of cancer mortality in men worldwide." | ( Fleming, J; Ford, CA; Leung, HY; Lynch, V; Mackay, G; Mui, E; Patel, R; Rodgers, L; Rushworth, LK; Sansom, OJ; Sumpton, D; Vande Voorde, J; Watson, D; Zhang, T, 2022) |
| "Prostate cancer is a common cancer in elderly males." | ( Fang, G; Feng, X; Gan, X; Li, X; Liu, P; Liu, Y; Wang, X; Zhou, Q, 2022) |
| "Prostate cancer is a disease that often occurs in elderly men." | ( Fang, G; Gan, X; Huang, H; Li, X; Liu, K; Liu, Y; Wang, X; Wen, J; Yang, Y, 2022) |
| "Prostate cancer is one of the most common cancers worldwide." | ( Ben Rhouma, S; Bibi, M; Chaker, K; Mrad Dali, K; Nouira, Y; Ouanes, Y; Rahoui, M; Sellami, A, 2022) |
| "Since prostate cancer is the most commonly diagnosed malignancy in men, the theranostic approach has become very attractive since the discovery of urea-based PSMA inhibitors." | ( Boschi, S; Cuni, C; Di Iorio, V; Masini, C; Monti, M; Paganelli, G; Severi, S, 2022) |
| "Prostate cancer is the second most frequently malignancy in men worldwide." | ( Alves, VS; Cardoso, TC; Monteiro, MMLV; Rocha, MA; Savio, LEB; Silva, CLM, 2022) |
| "Prostate cancer is a leading cause of cancer death in men." | ( Burke, AJ; Glynn, SA; McAuliffe, JD; Natoni, A; Ridge, S; Sullivan, FJ, 2022) |
| "Neuroendocrine prostate cancer is a histological variant of prostate cancer that is characterized by aggressiveness, poor clinical outcomes, and expression of neuroendocrine markers." | ( Alabi, BR; Liu, S; Stoyanova, T, 2022) |
| "Prostate cancer is one of the most frequently diagnosed cancers in men." | ( Xu, Y; Ye, ZY; Zheng, J, 2022) |
| "Prostate cancer is the second most frequent type of cancer that affects men." | ( Ahn, KS; Alharbi, SA; Chinnathambi, A; Deivasigamani, A; Hui, KM; Jung, YY; Mohan, CD; Rangappa, KS; Sethi, G; Zhang, J, 2022) |
| "Prostate cancer is the second-deadliest tumor in men all over the world." | ( Baker, A; Khalid, M; Khan, MS; Uddin, I, 2022) |
| "Prostate cancer is the leading cause of cancer in men, and its incidence increases with age." | ( Juárez-López, D; Schcolnik-Cabrera, A, 2022) |
| "Prostate cancer is the most common type of cancer among men, and there is still no definitively effective drug treatment." | ( Akpinar, G; Kanli, A; Kasap, M; Saglam, BS; Yanar, S, 2022) |
| "Prostate cancer is the most inheritable cancer with approximately 42% of disease risk attributed to inherited factors by studies of twins, indicating the importance of additional genetic screening to identify predisposition variants." | ( Cao, Q; Chiu, PK; Liang, Y; Ng, CF; Teoh, JY; Tsui, SK; Wang, L; Wei, Y; Wong, CY; Xiong, Q; Ye, DW; Zhu, Y, 2022) |
| "Prostate cancer is one of the most common health hazards for men worldwide, specifically in Western countries." | ( Aljabali, AAA; Arshad, F; Birkett, M; Haggag, Y; Hassan, IU; Khan, R; Mishra, V; Mishra, Y; Naikoo, GA; Pedram, MZ; Pourfarzad, H; Serrano-Aroca, Á; Tambuwala, MM; Zedegan, MS, 2022) |
| "Prostate cancer is the second cause of cancer-related deaths in men worldwide, and new agents for curing the disease are still needed." | ( Han, R; Li, Y; Ling, C; Lu, L; Yang, H, 2022) |
| "Prostate cancer is a clinically heterogeneous disease with a subset of patients rapidly progressing to lethal-metastatic prostate cancer." | ( Clark, SJ; Daly, RJ; Horvath, LG; Kench, JG; Korbie, D; Lam, D; Luu, PL; Peters, TJ; Pidsley, R; Qu, W; Stirzaker, C; Stricker, P, 2022) |
| "Prostate cancer is one of the most common malignancies in men." | ( Chen, B; Daba, M; Gao, X; Li, Q; Liu, B; Liu, J; Miao, J; Song, G; Wang, Z; Wu, B; Yuan, X; Zeng, K, 2022) |
| "Prostate cancer is one of the most frequently diagnosed male malignancies and can be detected by prostate-specific antigen (PSA) as a biomarker." | ( Adiraju, A; Al-Hamry, A; Alnaimi, A; Kanoun, O; Makableh, Y, 2022) |
| "Prostate cancer is highly dependent on androgens and the androgen receptor (AR)." | ( Alyamani, M; Berk, M; Chung, YM; Goins, C; Klein, E; Li, X; Patel, M; Rathi, N; Sharifi, N; Stauffer, S; Wang, C; Willard, B; Zhu, Z, 2023) |
| "Prostate cancer is the most commonly diagnosed tumor disease in men, and its treatment is still a big challenge in standard oncology therapy." | ( Balvan, J; Kratochvilova, M; Masarik, M; Mayorga-Martinez, CC; Navratil, J; Pumera, M; Urso, M; Ussia, M; Vyskocil, J, 2023) |
| "Prostate cancer is among most malignant tumors around the world and this urological tumor can be developed as result of genomic mutations and their accumulation during progression towards advanced stage." | ( Abkenar, ZO; Babaei, R; Entezari, M; Hashemi, M; Hushmandi, K; Khorrami, R; Nabavi, N; Nejad, MM; Rahmanian, P; Rajabi, R; Rashidi, M; Ren, J; Rezaei, S; Sadi, FH; Shafiee, SS; Taheriazam, A; Talebi, Y; Zandieh, MA, 2023) |
| "Prostate cancer is the second most frequently occurring carcinoma in males worldwide and one of the leading causes of death in men around the world." | ( Jantjies, ZE; Moleya, B; Motadi, LR, 2023) |
| "Prostate cancer is the most common cancer in American men, aside from skin cancer." | ( Botelho, FV; de Melo Gomes, LC; de Oliveira Cunha, AB; de Paoli, F; Góes, RM; Peixoto, LFF; Pinto-Fochi, ME; Ribeiro, DL; Silva, MJB; Zanon, RG, 2023) |
| "Prostate cancer is a disease with a high incidence and mortality rate in men worldwide." | ( Angnes, L; Felici, E; Fernández-Baldo, MA; Messina, GA; Ortega, FG; Pereira, SV; Regiart, MD, 2023) |
| "Prostate cancer is the most common cancer in men in the developed world, with most deaths caused by advanced and metastatic disease which has no curative options." | ( Ahmad, I; Galbraith, L; Hartley, A; Leung, HY; Mui, E; Shaw, R; Tibbo, AJ; Vasan, R, 2023) |
| "Prostate cancer is the second-leading cause of cancer death in men." | ( An, L; Chen, CY; Chen, H; Chen, X; Lin, Y; Liu, CM; Liu, X; OuYang, AJ; Shao, Z; Su, M; Wu, Z, 2023) |
| "Currently, prostate cancer is one of the major malignant tumors in males." | ( Xie, Y; Yang, P; Yeasmin Khusbu, F; Zhou, X, 2023) |
| "Prostate cancer is the second most diagnosed form of cancer in men worldwide and accounted for roughly 1." | ( Beloukas, A; Gioti, K; Klentrou, P; Kornel, A; Nadile, M; Retsidou, MI; Sakellakis, M; Sze, NSK; Tsiani, E, 2023) |
| "Prostate cancer is the second most common cause of cancer-related deaths in men and is common in most developed countries." | ( Dou, T; Gao, L; Lai, KP; Li, J; Li, R; Li, X; Li, Z; Lin, X; Liu, J; Xu, H, 2023) |
| "Prostate cancer is the second most prevalent cancer among men." | ( Bahrami, AR; Goftari, SN; Maleki, F; Matin, MM; Sadeghian, H, 2023) |
| "Prostate cancer is dependent on the action of steroid hormones on the receptors." | ( Hodolic, M; Kairemo, K, 2023) |
| "Prostate cancer is the second prevalent cancer in men." | ( Akbari, S; Assaran Darban, R; Esparham, A; Hashemy, SI; Javid, H, 2023) |
| "Prostate cancer is one of the most common cancers among men." | ( Benedicto, A; Hernandez-Unzueta, I; Márquez, J; Sanz, E; Telleria, U, 2023) |
| "Prostate cancer is the second most commonly diagnosed cancer in males." | ( Mahdavi, A; Mofid, B; Taghizadeh-Hesary, F, 2023) |
| "Metastases from prostate cancer are more frequently seen in the brain, liver, lungs, and lymph nodes." | ( Bulan, OK; Dagsuyu, E; Gul, IB; Koroglu, P; Yanardag, R, 2023) |
| "Prostate cancer is one of the most prevalent lethal diseases among men globally." | ( Bai, L; Tao, N; Zhang, W, 2023) |
| "Prostate cancer is the second leading cause of cancer-related deaths in men in the United States." | ( Behr, S; Houshmand, S; Lawhn-Heath, C, 2023) |
| "Prostate cancer is a major cause of cancer morbidity and mortality in men worldwide." | ( Blandino, G; Gentile, E; Gorgoulis, VG; Havaki, S; Kletsas, D; Lagopati, N; Logothetis, CJ; Mourkioti, I; Panaretakis, T; Papaspyropoulos, A; Petty, R; Polyzou, A; Stellas, D; Stravokefalou, V; Thanos, DF; Theocharous, G; Veroutis, D, 2023) |
| "Prostate cancer is the second and fourth most diagnosed cancer in the USA and Europe, respectively." | ( Lee, A, 2023) |
| "Prostate cancer is a common cancer in men in older age groups." | ( Dzik, R; Jasik, K; Kabała-Dzik, A; Kleczka, A; Stojko, J; Woźniak, P, 2023) |
| "Prostate cancer is the second most common cancer for men and a major health issue." | ( Carrion, C; Gallardo-Villagrán, M; Léger, DY; Liagre, B; Martin, F; Ouk, C; Paulus, L; Therrien, B, 2023) |
| "Prostate cancer is the fifth leading cause of cancer death in men, responsible for over 375,000 deaths in 2020." | ( Azam, H; Cosgrave, J; Gallagher, WM; Khalifa, K; O'Reilly, E; Perry, AS; Prencipe, M; Simpson, JC, 2023) |
| "Men with prostate cancer are likely to have CV risk factors and use CV-related concomitant medications." | ( Brown, B; Cookson, MS; Fallick, M; Hanson, S; Lu, S; Mehlhaff, BA; Saad, F; Saltzstein, DR; Shore, ND; Tutrone, R, 2023) |
| "Prostate cancer is a leading cause of cancer-related deaths in men in the United States." | ( Bialkowska, A; Gordon, C; Hillowe, A; Kaczocha, M; Ojima, I; Rizzo, RC; Trotman, LC; Wang, L, 2023) |
| "Prostate cancer is the second most frequent cancer diagnosed in men in the world today." | ( Gu, T; Hu, S; Jin, B; Li, J, 2023) |
| "Prostate cancer is one of the most common cancers in men and one of the top causes of death in men worldwide." | ( Baillie, GS; Hoffmann, R; Parsons, EC, 2023) |
| "Prostate cancer is the most common malignancy in men, and its incidence is increasing year by year." | ( An, H; Duan, Y; Gao, Y; Li, C; Li, T; Tao, N; Wang, J; Xiao, S; Zhou, Y, 2023) |
| "Prostate cancer is generally considered an immunologically "cold" tumor type that is insensitive to immunotherapy." | ( Bosco, EE; Breen, S; Carrasco, RA; Chain, D; Chang, CY; Cheung, CS; Chu, NJ; Clark, B; Cobbold, M; Damschroder, M; Endlich-Frazier, A; Fazenbaker, C; Gilbreth, RN; Harder, N; Hoover, CE; Kim, YJ; Luo, W; Martin, PL; McGlinchey, K; Meekin, J; Moody, G; Pezold, JM; Phipps, S; Riley, K; Sweet, SM; Tu, E; van Dyk, D; Vantellini, A; Zanvit, P, 2023) |
| Excerpt | Reference |
|---|
| "Endocrine therapy in prostatic cancer is palliative but there is no evidence that is increases survival." | ( Stoll, BA, 1979) |
| "We studied 38 patients with prostatic cancer who received breast irradiation before oral estrogen administration." | ( Gagnon, JD; Moss, WT; Stevens, KR, 1979) |
| "There were 13 patients with prostatic cancer who received estrogen therapy with daily doses of 30 mg." | ( Fukutani, K; Ishida, H; Isurugi, K; Yokoyama, M, 1979) |
| "In the treatment of advanced prostatic cancer, hormonal therapy has been only palliative." | ( Scott, WW, 1976) |
| "In 36 men with prostatic cancer, the following findings were obtained: intravenous administration of 12." | ( Dörner, G; Mebel, M; Rohde, W; Schnorr, D; Stahl, F, 1976) |
| "Patients with prostatic cancer, receiving oestrogen therapy were found to have elevated serum cortisol levels and lymphopenia." | ( Bruce, AW; Kraus, AS; Morales, A, 1975) |
| "The National Prostatic Cancer Project has randomized this study for endocrine-resistant prostatic cancer patients for treatment with standard hormonal or other therapies compared to 5-fluorouracil and cyclophosphamide." | ( Gibbons, RP; Johnson, DE; Joiner, JR; Murphy, GP; Prout, GR; Saroff, J; Schmidt, JE; Scott, WW, 1975) |
| "Hormonal manipulation of prostate cancer is an effective therapy for metastatic disease." | ( Dubin, A; Guinan, PD; McKiel, CF; Rubenstein, M; Shaw, M; Targonski, P, 1992) |
| "Inasmuch as treatments for advanced prostate cancer may have identical clinical outcomes but very different meanings to patients, we sought to compare the impact of surgical and medical castration (orchiectomy versus injected goserelin acetate Zoladex) on quality of life and psychosocial status." | ( Cassileth, BR; Chou, JM; Kennealey, GT; Schellhammer, PD; Seidmon, EJ; Soloway, MS; Vogelzang, NJ, 1992) |
| "The finding of prostatic cancer in cadmium-treated rats clearly supports a possible role for exposure to cadmium in human prostatic cancer." | ( Coogan, TP; Perantoni, AO; Rehm, S; Waalkes, MP, 1992) |
| "The methods for treatment of advanced prostate cancer, based on the agonistic analogs of LH-RH were reviewed." | ( Comaru-Schally, AM; Gonzalez-Barcena, D; Schally, AV, 1992) |
| "The standard therapy for advanced prostate cancer is androgen ablation." | ( Bang, YJ; Danielpour, D; Kim, KY; Kim, SJ; Myers, CE; O'Reilly, MA; Trepel, JB, 1992) |
| "Almost all patients with prostatic cancer will eventually escape the control of the first-line endocrine therapy and relapse." | ( Denis, L; Mahler, C, 1992) |
| "As a clinical trial, 14 cases of prostatic cancer were treated with local hyperthermia after the administration of anticancer agents." | ( Hirai, M, 1992) |
| "Theoretically the mortality rate of prostate cancer can be reduced by the prevention programs and by the improvements of treatment methods, but the 'earlier' diagnosis is certainly an easier and less expensive strategy to achieve the same objective." | ( Broggini, P; Campo, B; Corrada, P; Derenzini, M; Lardennois, B; Marandola, P; Ploton, D; Roggia, A; Treré, D; Valentino, V, 1992) |
| "A 66-year-old man with metastatic prostate cancer was treated with bilateral orchiectomy and 750 mg." | ( Dankoff, JS, 1992) |
| "Thirty five cases with stage B prostate cancer underwent radiotherapy to the primary lesion from 1965 to 1989 in our hospital." | ( Aizawa, T; Kawai, T; Kobayashi, T; Tachibana, Y; Yamauchi, T, 1992) |
| "Although current hormonal therapy of prostate cancer may not appear to have altered survival appreciably, there have been considerable changes that may significantly affect the future management of this disease." | ( Venner, P, 1992) |
| "Human prostatic cancer cell lines LNCaP and DU 145 were studied to examine the effects of heat shock treatment (HST), androgen (5 alpha-dihydrotestosterone: 5 alpha DHT) and antiandrogen (hydroxyflutamide: OH-Flut) on cell growth and survival." | ( Chalmers, D; Kirk, D; Leake, RE; Lloyd, SN, 1992) |
| "Seventy-seven patients with prostatic cancer were treated at our department in the last 5 years." | ( Aizawa, T; Itoh, T; Miki, M; Namiki, K; Tsujino, S, 1992) |
| "Twenty-nine patients with metastatic prostate cancer that had progressed following orchiectomy were treated with intravenous epirubicin 90 mg/m2 every 28 days." | ( Delaere, KP; Leliefeld, H; Peulen, F; Smeets, J; Stapper, EW; Wils, J, 1992) |
| "Until now, patients with a progressive prostatic cancer, in whom all therapies failed and the disease spread locally and distally, was considered "a lost patient"; because it did not exist an effective therapy easily to be used." | ( Bertana, F; Castellani, R; Dormia, G; Gonnella, G; Luongo, P; Malagola, G; Mantovani, F; Mazza, L; Minervini, S, 1992) |
| "Because 20% of all advanced prostate cancers do not respond to hormonal treatment even when given as primary therapy, hormone-resistant cells may have been present from the beginning." | ( Janknegt, RA, 1992) |
| "In clinical studies of prostatic cancer, use of the depot formulation has effectively reduced the dose required to as low as one-eighth of that needed for administration by daily injection." | ( Toguchi, H, 1992) |
| "Twenty-five patients with advanced prostatic cancer progressing after one course of endocrine treatment entered a phase II study of weekly administration of 30 mg Idarubicin orally." | ( Bastholt, L; Bertelsen, K; Gadeberg, CC; Madsen, EL; Nielsen, ES; Rose, C, 1992) |
| "Because it is well known that prostatic cancer is dependent on testosterone, and that dihydrotestosterone is the active mediator of the androgen action in the prostatic cell, we studied serum concentrations of testosterone and dihydrotestosterone in 84 patients with prostatic cancer, 40 of whom were treated by orchidectomy, and 44 who were not treated." | ( Beuke, HP; Røhl, HF, 1992) |
| "By contrast, the rat R-3327 H prostatic cancer has a much higher level of tissue 5 alpha-reductase activity, and neither tumor DHT content nor growth of the tumor was inhibited by treatment with SK&F 105657." | ( Isaacs, JT; Johnson, RK; Lamb, JC; Levy, MA, 1992) |
| "Seven patients with metastatic prostatic cancer were treated with biodegradable implants of the GnRH analogue buserelin and six were treated with buserelin intranasally." | ( Blom, JH; De Jong, FH; Kwekkeboom, DJ; Lamberts, SW; Schroeder, FH, 1990) |
| "In 9 cases of prostate cancer treated by endocrine therapy, tumor markers (PAP." | ( Murao, T; Namba, K; Tanahashi, T, 1990) |
| "The authors found that prostate cancer contains AR-positive and AR-negative malignant cells before androgen withdrawal therapy, but the percentage of AR-positive cells did not predict the time to tumor progression after therapy." | ( Barrack, ER; Sadi, MV; Walsh, PC, 1991) |
| "Of 91 patients with prostatic cancer treated at our Department of Urology, from January 1976 through December 1987, 42 cases of stage D2 cancer treated with endocrine therapy were evaluated retrospectively with regard to clinical parameters and prognoses." | ( Chino, I; Hayashi, N; Imamura, H; Kimura, M; Kudo, K; Matsuyama, K; Mimura, H; Nagata, M; Shishido, S, 1991) |
| "The treatment of advanced prostatic cancer with CPA is found to be a valuable alternative to orchiectomy." | ( Bonnesen, T; Frimodt-Møller, C; Nilsson, T; Ostri, P, 1991) |
| "Rare cases of remission of prostatic cancer on androgen treatment have been reported." | ( Fittler, F; Schulz, P; Wolf, DA, 1991) |
| "Ten to twenty percent of advanced prostate cancer do not respond to the initial endocrine therapy." | ( Imai, K; Masimo, T; Suzuki, T; Yamanaka, H, 1991) |
| "As a result of the treatment, the prostate cancer was stabilized." | ( Kawada, Y; Kobayashi, S; Kuriyama, M; Nagatani, Y; Shinoda, I; Takahashi, Y; Takeuchi, T, 1991) |
| "In the therapy of localized prostatic cancer the radical prostatectomy shows good results within a five-year interval with no evidence of disease in nearly 90%." | ( Braun, J; Hofmann, R; Kneschaurek, P; Lindner, A; Lukas, P; Schwarzer, JU, 1992) |
| "Eight patients with recurrent prostate cancer were treated with Etoposide and CDDP or Etoposide alone." | ( Imai, K; Kato, N; Kurita, M; Nakamura, T; Nakazawa, Y; Suzuki, K; Suzuki, T; Yamanaka, H, 1991) |
| "Patients with stages C, D1 or D2 prostatic cancer who received Buserelin as monotherapy and had a known treatment duration were eligible for efficacy analysis." | ( Adenauer, H; de Voogt, HJ; Widdra, WG, 1991) |
| "Sixty one men, with advanced prostatic cancer, were entered on a trial using a nasally administered gonadotropin-releasing hormone analogue agonist, buserelin, as first line treatment." | ( Falkson, CI; Falkson, G; Falkson, HC, 1991) |
| "GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation." | ( Dubin, A; Guinan, P; McKiel, CF; Rubenstein, M; Shaw, M; Targonski, P, 1991) |
| "Twenty patients with metastatic prostatic cancer were treated on an ambulatory basis with continuous 5-fluorouracil (5-FU) infusion 250-300 mg/M2 per day through a chronic indwelling central venous catheter." | ( Anderson, T; Beatty, P; Hansen, R; Libnoch, J; Moynihan, T; Quebbeman, E; Schulte, W, 1991) |
| "It is held that estrogen therapy for prostatic cancer should be preceded and monitored by therapeutic evaluation responsible for optimal conditions to prevent and early diagnose cardiovascular complications." | ( Begunov, AV; Gembitskiĭ, EV; Portnoĭ, AS, 1990) |
| "Twenty-six patients with prostate cancer being treated with leuprolide acetate underwent serial bone scans at three-month intervals." | ( Garnick, MB; Johns, WD; Kaplan, WD, 1990) |
| "GnRH agonist therapy in prostate cancer patients was associated with a significant reduction in serum testosterone, dihydrotestosterone (DHT), luteinizing hormone (LH), and cortisol, and significant increases in triiodothyronine (T3) and free triiodothyronine (free T3)." | ( Byerley, LO; Heber, D; Rajfer, J; Steiner, B; Swerdloff, RS; Tayek, JA, 1990) |
| "The follow-up time is rather short for prostatic cancer, but on the basis of this preliminary study the dose of PEP seems to be insufficient in the treatment of advanced prostatic cancer." | ( Alfthan, O; Haapiainen, R; Rannikko, S, 1990) |
| "In our therapeutic protocol for prostate cancer, those included between categories 7 and 9 are submitted to antidrogen therapy, regardless of the type of surgical procedure indicated in each case." | ( Abad Menor, F; Arnaiz Esteban, F; Espuela Orgaz, R; Martínez Pérez, E; Nogueras Gimeno, MA; Pérez Arbej, JA, 1990) |
| "A total of 59 patients with advanced prostate cancer relapsed from or refractory to castration plus oestrogen were treated in a randomised trial comparing 1000 to 1250 mg aminoglutethimide + 40 mg hydrocortisone (AG + HC) with 500 mg medroxyprogesterone acetate + 40 mg hydrocortisone (MPA + HC)." | ( Bezwoda, WR, 1990) |
| "A total of 327 patients with metastatic prostatic cancer were randomized to either bilateral orchiectomy or treatment with zoladex depot supplemented by flutamide 250 mg 3 qid." | ( Bond, A; Carvalho, AP; De Pauw, M; Denis, L; Keuppens, F; Newling, D; Ongena, P; Smith, P; Sylvester, R; Vermeylen, K, 1990) |
| "A total of 591 patients with advanced prostatic cancer have been randomized to either orchiectomy or treatment with zoladex 3." | ( Christensen, I; Denis, L; Iversen, P; Suciu, S; Sylvester, R, 1990) |
| "A total of 327 patients with metastatic prostate cancer have been randomized to either orchidectomy or treatment with goserelin (Zoladez) 3." | ( Bono, A; De Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Smith, P; Sylvester, R, 1990) |
| "Fifty-one patients with stage D prostate cancer, who had failed primary hormone treatment, were treated with diethylstilbestrol diphosphate (DES-DP) 1." | ( Araujo, CE; Cervellino, JC; Morera, E; Pirisi, C; Podskubka, O, 1990) |
| "Hormonal therapy of prostate cancer is still the most effective systemic treatment." | ( Münch, D; Studer, UE, 1990) |
| "Clinical studies in prostate cancer patients have demonstrated efficacy with flutamide monotherapy in patients who had received no prior treatment, in untreated patients with combined androgen blockade concomitantly with a luteinizing hormone-releasing hormone (LHRH)-agonist, and in relapsed patients." | ( Goldspiel, BR; Kohler, DR, 1990) |
| "Twenty-nine patients with metastatic prostate cancer progressing after hormonal therapy (orchiectomy 19, diethylstilbestrol 10) and who had never received cytotoxic therapy were treated with carboplatin." | ( Citrin, D; Davis, TE; Hahn, RG; Kvols, LK; Marsh, JC; Trump, DL; Vogl, SE, 1990) |
| "Eight patients with hormone resistant prostate cancer were treated with 30 mg/m2 etoposide every two or three weeks." | ( Kondoh, I; Moriyama, M; Murai, T, 1990) |
| "Fourteen patients with advanced prostate cancer were treated." | ( Butler, K; Hermansen, D; Marshall, ME, 1990) |
| "Ten patients with reactivated stage D prostatic cancer were treated with the combination therapy of vincristine, ifosfamide and peplomycin (VIP therapy)." | ( Akiya, T; Katayama, T; Kazama, T; Nakada, T; Umeda, K, 1986) |
| "The patient material consisted of 92 prostate cancer patients (59 untreated, and 33 previously treated), 106 patients with benign hyperplasia and 66 patients with non-prostatic urological diseases." | ( Frederichsen, P; Haffner, F; Johannessen, NB; Strømme, JH; Talseth, T; Theodorsen, L, 1986) |
| "Twenty patients with advanced prostate cancer have been treated with an intermittent endocrine therapy schedule." | ( Herr, HW; Klotz, LH; Morse, MJ; Whitmore, WF, 1986) |
| "Abnormal values of PAP in untreated prostatic cancer were found in 0, 0, 50, 50, 0, 73% of stage A1, A2, CpN0, CNX, D1 and D2 cases, respectively, and those of PA were found in 25, 0, 50, 100, 100, 100% of the same stages, respectively." | ( Akimoto, S; Fuse, H; Shimazaki, J, 1986) |
| "In the treatment of prostatic cancer, prostatic acid phosphatase (PAP), prostatic-specific antigen (PA) and gamma-seminoprotein (gamma-Sm) are important serum markers, and the RIA method has improved their specificity and sensitivity." | ( Akaza, H; Aso, Y; Kameyama, S, 1987) |
| "The population consisted of 140 prostate cancer patients (34 newly diagnosed and 106 under treatment) and 101 patients with benign prostatic hypertrophy (BPH)." | ( Brombacher, PJ; Delaere, KP; Gijzen, AH; Van Dieijen-Visser, MP, 1988) |
| "Response of prostatic cancer bone metastases to therapy (androgen withdrawal and Estracyt) was studied in 43 patients by applying scintiscanning and radioimmunodetective measurement of serum osteocalcin (OC) values." | ( Kovaćić, K; Strelkov-Alfirević, A; Tarle, M, 1989) |
| "A case of prostatic cancer treated with an LH-RH analogue depo-preparation was found to have a mediastinal thymoma which was later removed by surgery." | ( Hirasawa, K; Honma, Y; Isurugi, K; Kondo, Y; Masuda, S; Oyamatsu, T; Yakumaru, K; Yoshino, S, 1989) |
| "However, the value of these agents in prostate cancer therapy continues to be hotly debated." | ( Crawford, ED, 1989) |
| "Six patients with advanced prostatic cancer who had been treated by long-term administration of LH-RH agonistic preparations (Buserelin or Leupron) were tested for their pituitary-testicular endocrine functions." | ( Hirasawa, K; Honma, Y; Isurugi, K; Kondo, Y; Oyamatsu, T, 1989) |
| "In summary, patients with prostatic cancer during long-term oestrogen treatment were found to have increased levels of factor VII, factor VIII:C and fibrinogen." | ( Blombäck, M; Bratt, G; Edhag, O; Eriksson, A; Henriksson, P; Vesterqvist, O, 1989) |
| "In the treatment of advanced prostate cancer, luteinising hormone-releasing hormone analogue monotherapy is a valuable alternative to standard treatment such as oestrogen therapy or surgical castration." | ( Debruyne, F, 1989) |
| "Treatment of advanced prostate cancer with a combination of luteinising hormone-releasing hormone analogues and anti-androgens is advisable for the initial 2 weeks, in patients with newly diagnosed, extensive disease." | ( Denis, L, 1989) |
| "Treatment of patients with prostatic cancer with a combination of 1-2 mg depot-estrogen (ethinylestradiol sulfonate = Turisteron) per week and 1 mg dexamethasone per day suppressed the mean testosterone (T) level to 2." | ( Bär, CM; Dörner, G; Fröhlich, G; Schnorr, D; Stahl, F, 1989) |
| "Oral estrogen therapy for prostatic cancer is clinically effective but also accompanied by severe cardiovascular side effects." | ( Carlström, K; Collste, L; Eriksson, A; Henriksson, P; Pousette, A; Stege, R; von Schoultz, B, 1989) |
| "Treatment of newly diagnosed advanced prostatic cancer with flutamide plus a luteinising hormone releasing hormone (LHRH) agonist has produced very promising results, and appears to prolong survival relative to that achieved with leuprolide alone." | ( Brogden, RN; Clissold, SP, 1989) |
| "Treatment of 17 patients with prostatic cancer with 320 mg polyestradiol phosphate (PEP) as intramuscular injections every fourth week suppressed serum testosterone (T) values to orchidectomy levels within 1 month, and serum estradiol-17 beta (E2) rose to a mean level of 2,456 pmol/liter after 6 months." | ( Carlström, K; Collste, L; Eriksson, A; Henriksson, P; Pousette, A; Stege, R; von Schoultz, B, 1989) |
| "Patients with advanced prostate cancer (n = 7) were treated with the potent GnRH agonist analogue buserelin (Bu, Hoechst), 600 micrograms X 3/day intranasally." | ( Huhtaniemi, I; Nikula, H; Parvinen, M; Rannikko, S, 1988) |
| "Forty-one patients with prostatic cancer were treated with DTrp6 LH-RH, a luteinizing hormone releasing hormone agonist." | ( Boccon-Gibod, L; Chiche, R; Debré, B; Steg, A, 1985) |
| "in 1941, hormonal treatment of advanced prostatic cancer has been directed primarily at neutralizing testicular androgens by orchiectomy or estrogen therapy." | ( Bélanger, A; Dupont, A; Labrie, F; Lacourcière, Y; Monfette, G; Monfette, JE, 1986) |
| "As far as prostatic cancer is concerned, data coming from comparative trials show that MPA is less effective than diethylstilbestrol (DES), and therefore should not be considered the first choice for previously untreated patients." | ( Decensi, A; Pavesi, L; Prada, GA; Preti, P; Robustelli della Cuna, G; Zanon, P, 1986) |
| "Seventeen patients with advanced prostatic cancer were treated with the gonadotrophin-releasing hormone analogue DSer (tBU)6 AzaGly 10 GnRH (ICI 118630), either as a constant SC infusion, or in the form of a monthly SC slowrelease depot formulation, in which case patients were randomised to receive one of three doses." | ( Arkell, DG; Bailey, LC; Blackledge, G; Clayton, RN; Cottam, J; Farrar, D; Holder, G; Lynch, SS; Perren, TJ; Young, CH, 1986) |
| "Twenty-four patients with advanced prostatic cancer were treated with daily injections of the LHRH analogue ICI 118630 (Zoladex) for up to 2 1/2 years." | ( Ahmed, SR; Blacklock, NJ; Costello, CB; Grant, JB; Howell, A; Shalet, SM; Weatherson, T, 1986) |
| "Thirteen patients with untreated prostate cancer were treated initially with subcutaneous 0." | ( Bertermann, H; Saerbeck, C; Seppelt, U, 1986) |
| "Patients (154) with clinical stage D2 prostate cancer with no previous endocrine therapy or chemotherapy received the combination therapy with the pure antiandrogen Flutamide and the LHRH agonist [D-Trp6]LHRH ethylamide for an average of 22 months (3-49 months)." | ( Belanger, A; Borsanyi, JP; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lachance, R; Lacourciere, Y; Monfette, G, 1987) |
| "Ten castrated patients with prostatic cancer received flutamide (FLU) alone for 2 months and, afterwards, the combined therapy of FLU and AG for 2 months." | ( Bélanger, A; Brochu, M; Cusan, L; Dupont, A; Labrie, F, 1987) |
| "45 patients with recently detected prostatic cancer were treated with cyproterone acetate (CPA) at a dosage of 100 mg/die." | ( Maier, U, 1988) |
| "Second, in groups of prostate cancer patients with far advanced disease treated with palliative intention, only true subjective or objective remission should be considered a positive treatment response." | ( Ehrenthal, W; Hohenfellner, R; Jacobi, GH; Spindler, HW; von Wallenberg, H; Wenderoth, UK, 1988) |
| "The National Prostatic Cancer Project from 1982 to 1985 evaluated several treatments for metastatic prostatic cancer patients who had a history of prior radiotherapy and were refractory to hormone manipulation." | ( McLeod, DG; Murphy, GP; Priore, R, 1988) |
| "Thirty-six patients with advanced prostatic cancer were treated by monthly depot injections of a luteinizing-hormone releasing hormone analogue (LHRH-a)." | ( Hjertberg, H; Kågedal, B; Nordenskjöld, B; Svensson, M; Varenhorst, E, 1988) |
| "Seven patients suffering from prostatic cancer were treated with a depot form of D-Trp-6-luteinizing hormone-releasing hormone (LH-RH), a LH-RH agonist analogue (3 mg i." | ( Barreca, T; Franceschini, R; Giberti, C; Giuliani, L; Martorana, G; Rolandi, E; Truini, M, 1988) |
| "Seven patients suffering from prostatic cancer were treated with a slow-release D-Trp-6-LHRH preparation for a period of 24-32 months." | ( Barreca, T; Brancadoro, T; Franceschini, R; Giberti, C; Martorana, G; Rolandi, E, 1988) |
| "Eighty patients with prostatic cancer have been treated with an LH-RH analogue (Zoladex)." | ( Bonichon, F; Coste, P; Lamarche, P; Mage, P; Mauriac, L; Richaud, P, 1988) |
| "trials of the treatment of advanced prostate cancer are outlined." | ( Peeling, WB; Ryan, PG, 1988) |
| "Six patients with advanced prostatic cancer were treated with a potent GnRH agonist analog (buserelin, Hoechst; 600 micrograms, intranasally, three times a day) for 6 months." | ( Huhtaniemi, I; Nikula, H; Rannikko, S, 1985) |
| "For men with prostate cancer, current issues in sexual rehabilitation include the debate on nerve-sparing radical prostatectomy, the role of vascular damage in causing erectile dysfunction after radiotherapy, and the need for a better understanding of hormonal effects on central and peripheral mechanisms of sexual function." | ( Schover, LR, 1987) |
| "Eighty-five men with progressive prostate cancer refractory to orchiectomy were treated continuously with aminoglutethimide and hydrocortisone to lower adrenal androgen secretion and were administered cyclic intravenous (IV) chemotherapy." | ( Bartholomew, M; Boucher, A; Caplan, R; Gordon, R; Harvey, H; Lipton, A; Manni, A; Santen, R; Simmonds, M; White-Hershey, D, 1988) |
| "151 patients with locally advanced prostatic cancer (T3-4 M0), representing 38% of the 404 cancer patients in a Finnish multicenter study, were randomly assigned to one of three treatment arms: orchiectomy, estrogens or radiotherapy." | ( Alfthan, O; Aro, J; Haapiainen, R; Kajanti, M; Rannikko, S, 1988) |
| "Patients with metastatic prostatic cancer were treated by means of an LHRH agonist, Buserelin, by nasal administration." | ( Jacobi, GH; Wenderoth, UK, 1986) |
| "Thirty-five patients with advanced prostatic cancer were entered in a trial of nasally administered gonadotropin-releasing hormone analogue agonist (GnRHA) buserelin." | ( Falkson, G; Vorobiof, DA, 1987) |
| "They state that care of prostatic cancer patients is highly important because only observation of the course of the disease may ensure the evaluation of treatment results and the indication of the adequate therapeutic method." | ( Frang, D; Hübler, J, 1987) |
| "45 patients with prostatic cancer were treated conservatively with Turisteron at a dosage of 2 mg per week." | ( Dörner, G; Guddat, HM; Rohde, W; Schnorr, D; Stahl, F, 1987) |
| "A 77-year-old man with prostate cancer was serially evaluated for bone metastases using Tc-99m methylene disphosphonate (Tc-99m MDP) both on and off treatment with etidronate disodium (EHDP)." | ( Collier, BD; Ewey, D; Hellman, RS; Isitman, AT; Krasnow, AZ, 1988) |
| "According to the National Prostatic Cancer Project Criteria, 2 of the untreated cases showed a partial response and 3 of the untreated ones showed a stable response, one of which underwent transurethral resection later." | ( Akakura, K; Akimoto, S; Fuse, H; Murakami, S; Shimazaki, J, 1988) |
| "The therapy for the treatment of prostate cancer and other sex-steroid-dependent tumors based on agonists of LH-RH has been made more practical and efficacious by the development of a long-acting formulation of microcapsules of D-Trp-6-LH-RH for controlled release." | ( Redding, TW; Schally, AV, 1985) |
| "Treatment of LNCaP human prostatic cancer cells with 0." | ( Bolt, J; Mulder, E; Schuurmans, AL, 1988) |
| "From 1982 to 1985, the National Prostatic Cancer Treatment Group conducted a randomized prospective trial of single-agent or combination chemotherapy in 180 patients with metastatic prostatic disease refractory to hormonal therapy." | ( Murphy, GP; Priore, RL; Scardino, PT, 1988) |
| "Since more than half of stage A-C prostatic cancers show pelvic lymph node metastasis (D1, pN1-3), a staging operation is required at the start of treatment." | ( Akakura, K; Akimoto, S; Fuse, H; Shimazaki, J, 1988) |
| "Brachytherapy in the treatment of prostate cancer is an accepted modality." | ( Pocha, JS; Porter, AT; Scrimger, JW, 1988) |
| "Ten men with prostatic cancer, stage T3M0 Nx or more, who were anxious to maintain sexual potency, were treated with flutamide." | ( Johansson, JE; Schnürer, LB; Stegmayr, B, 1988) |
| "One problem in the management of prostatic cancer is that about half of the patients with this disease have metastatic lesions at first diagnosis and therefore tend to be given palliative rather than radical therapy." | ( Hata, M, 1988) |
| "Effect of chemotherapy for relapse of prostatic cancer was evaluated with new response criteria, in which four objective parameters including the prostate, bone metastasis, soft tissue metastasis and the serum acid phosphatase level estimated by radioimmunoassay or enzyme immunoassay were judged separately and then summarized to evaluate the response as complete response (CR), partial response (PR), stable and progressive disease (PD)." | ( Akaza, H; Fuse, H; Imai, K; Isaka, S; Kotake, T; Matsumoto, K; Matsumura, Y; Moriyama, N; Usami, M; Yamanaka, H, 1987) |
| "Briefly stated, if patients with prostatic cancer are examined by means of exercise stress tests and blood tests for luteinizing hormone, cholesterol, and follicle-stimulating hormone prior to treatment, the discriminant function enables the authors to identify an extremely high-risk group for cardiovascular complications if estrogen therapy is commenced." | ( Henriksson, P; Johansson, SE, 1987) |
| "Groups of prostate cancer-susceptible male L-W rats (age 3 months) were treated with subcutaneous depots of testosterone or of DHT." | ( Luckert, PH; Pollard, M; Snyder, DL, 1987) |
| "Conventional antiandrogen therapy for prostatic cancer generally results in the death of androgen-dependent cells, resulting in shrinkage of the tumor, followed by regrowth of the tumor as androgen-insensitive cells take over." | ( Amerongen, HM; Buzzell, GR; Hennes, SC; McBlain, WA; O'Brien, MG; Toma, JG, 1987) |
| "Seventy-five patients with stage D-2 prostate cancer refractory to orchiectomy have been entered in a controlled trial to test whether androgen priming enhances the efficacy of chemotherapy." | ( Boucher, AE; Drago, J; Gordon, R; Harvey, H; Lipton, A; Manni, A; Rohner, T; Santen, RJ; Simmonds, M; Wettlaufer, J, 1987) |
| "Approximately 65% of patients with prostatic cancer treated by the combination therapy using a gonadorelin (LHRH) agonist or orchidectomy in association with the antiandrogen Anandron complained of a delay in recovering vision after bright illumination (sun, television, bright light)." | ( Dupont, A; Harnois, C; Labrie, F; Malenfant, M, 1986) |
| "The responsiveness of prostate cancer to treatment with estrogen has been recognized for over 40 years, but whether the effect is mediated by diminished tumor growth or reduction in metastatic spread is not known." | ( de la Monte, SM; Hutchins, GM; Moore, GW, 1986) |
| "A patient with brain metastases from prostatic cancer received chemotherapy using CDDP alone." | ( Kobayashi, H; Miyaji, N; Nakajo, M; Niimura, K; Onohara, S; Shinohara, S; Ueki, K, 1986) |
| "A patient with metastatic prostate cancer is described where treatment with Adriamycin (doxorubicin) and estramustine produced severe hypophosphatemia (serum phosphate level, 1." | ( Citrin, DL; Geiger, C; Hauck, W; Kaplan, EH; Nadler, R; Tuttle, K; Wallemark, CB, 1986) |
| "The treatment of prostatic cancer with oestrogen has been reported to be associated with cardiovascular side effects." | ( Blombäck, M; Bratt, G; Edhag, O; Eriksson, A; Henriksson, P, 1986) |
| "Progressive prostatic cancer in hormone treated patients was associated with increased CL as compared to patients with stable or regressive disease." | ( Bauer, S; Braun, J; Hofmann, R; Lehmer, A, 1986) |
| "In 93 patients suffering from prostatic cancer, serum levels of neopterin, a pteridine reflecting activation of the immune defence system, were measured at the time of diagnosis and 6 and 12 months after treatment with orchidectomy or estrogens." | ( Ekman, P; Eneroth, P; Eriksson, A; Lewenhaupt, A; Nilsson, B; Nordström, L, 1986) |
| "Hormonal therapy for metastatic prostate cancer blocks the androgen-mediated action that stimulates the hormone-dependent clone of tumor cells." | ( Geller, J, 1985) |
| "In men with prostatic cancer, weekly administration of 2 mg Turisteron resulted in a striking decrease of the biologically active free testosterone level to less than 2% of the basal level; i." | ( Dörner, G; Rohde, W; Schnorr, D; Stahl, F, 1985) |
| "Twenty-two patients with prostatic cancer were treated for 12 to 52 weeks with the luteinizing hormone-releasing hormone agonist, (D-Leu6)-des Gly-NH2 10-LHRH ethylamide (leuprolide)." | ( Makino, T; Saruki, K; Shida, K; Yajima, H; Yamanaka, H, 1985) |
| "Twenty-six patients treated for prostate cancer are excluded because of their short follow-up." | ( Cox, RS; Edmundson, GK; Gunderson, LL; Howes, AE; Martinez, A, 1985) |
| "Compared to a control group of prostatic cancer patients undergoing orchiectomy as primary therapy, the testes in the hormonally treated group showed marked spermatogenic suppression, peritubular membrane thickening and decreased numbers of Leydig cells." | ( Smith, JA; Urry, RL, 1985) |
| "We studied 32 patients with prostatic cancer before, and after 1 and 6 months of treatment with orchiectomy, estramustine phosphate or conventional estrogens (polyestradiol phosphate plus ethinyl estradiol)." | ( Hedlund, PO; Jogestrand, T; Rössner, S; Säwe, U, 1985) |
| "In 24 untreated stage D2 prostate cancer patients with prostate DHT levels greater than 2." | ( Albert, JD; Geller, J, 1985) |
| "Androgen-insensitive cells: Advanced prostate cancer does not respond to endocrine therapy but is temporarily controlled by the cytotoxic steroid estramustine." | ( Marts, SA; Mukherji, S; Padilla, GM; Petrow, V, 1985) |
| "The majority of patients with advanced prostatic cancer respond either to castration or estrogen therapy." | ( Anderson, K; Block, M; Bonomi, P; Bunting, N; Harris, J; Pessis, D; Rossof, A; Slayton, R; Wolter, J, 1985) |
| "Twenty-five patients with metastatic prostate cancer resistant to primary hormone therapy, received high-dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES-P) in a Phase II study using established response criteria." | ( Camacho, F; Citrin, DL; Kaplan, E; Khandekar, J; Kies, MS; Lind, R; Wallemark, CB, 1985) |
| "Human prostatic cancer (HONDA) serially transplanted in nude mice grew well in male mice but not at all in untreated female mice or in castrated male mice." | ( Ito, YZ; Mashimo, S; Nakazato, Y; Takikawa, H, 1985) |
| "When in a patient with metastatic prostatic cancer progression of tumour growth occurs during first-line endocrine therapy the prognosis appears to be poor." | ( Alexieva-Figusch, J; Klijn, JG; Nielander, AJ; van Putten, WL, 1985) |
| "In men with diagnosed prostatic cancer undergoing radiation or chemotherapy, the assays were useful in distinguishing between those with active and inactive disease." | ( Bracken, B; Chen, IW; Kaplan, LA; Sperling, M; Stein, EA, 1985) |
| "Response rate of prostatic cancer to endocrine therapy is approximately 80%, but more than half of responders show relapse by five years." | ( Fuse, H; Shimazaki, J; Zama, S, 1985) |
| "Twenty-three patients with advanced prostatic cancer refractory to hormonal therapy were entered into a phase II study of cytotoxic chemotherapy combined with androgen priming." | ( Case, D; Cooper, MR; Muss, HB; Nelson, EC; Pope, E; Puckett, JB; Resnick, MI; Richards, F; Spurr, CL; Zekan, P, 1985) |
| "Standard initial therapy for metastatic prostatic cancer involves surgical or chemically induced castration." | ( Ellis, WJ; Isaacs, JT, 1985) |
| "O 40 patients with untreated prostatic cancer, 34 patients (85%) gave positive results (1/3 33% of stage A, 3/4 75% B, 10/11 90% C, 20/22 90% D)." | ( Ando, K; Masukagami, T; Shimazaki, J, 1984) |
| "Examining the case for prostatic cancer, the authors indicate that there is a good correlation between the predictive assay and the clinical evolution of the treated prostatic carcinoma employing the determination of cell receptors for 5-alpha-dihydrotestosterone (DHT) by exchange at 15 degrees C with the synthetic steroid methyltrienolone." | ( Calvo, MA; Castellanos, JM; Galán, A; Schwartz, S, 1984) |
| "Fifteen patients with biopsy-proven prostate cancer were treated with ketoconazole 400 mg every 8 h." | ( Pont, A; Trachtenberg, J, 1984) |
| "The HPr levels were higher in prostatic cancer patients, in BPH patients, and in subjects on estrogen therapy." | ( Chu, TM; Kirdani, RY; Murphy, GP; Saroff, J; Wajsman, Z, 1980) |
| "23 patients with prostatic cancer were treated with (Estracyt) estramustine phosphate disodium, (Hexron) hexestrol, and (Honvah) diethylstilbestrol 4, 4-diphosphoric ester." | ( Shimada, M; Yoshida, H, 1980) |
| "Estrogen treated prostatic cancer patients had significantly higher platelet EPM." | ( Isohisa, I; Jung, SM; Kinoshita, K; Tanoue, K; Yamazaki, H, 1982) |
| "Patients with prostate cancer demonstrate a significant change in thyroid hormones when treated with estrogens after orchiectomy." | ( Dunzendorfer, U; Schulz, H, 1982) |
| "The goals of hormonal therapy for prostatic cancer are to decrease circulating plasma testosterone to castration levels; prevent a rise in or reduce circulating prolactin; and block residual androgen at the cell level." | ( Albert, JD; Geller, J, 1983) |
| "These results indicate neither that prostatic cancers which do not regress or cease growing following antiandrogen therapy can necessarily be considered hormonally unresponsive nor that antiandrogen therapy of such tumors has been completely ineffective, since, as shown in the present study, such progression can be of either a hormonally unresponsive or a responsive type." | ( Isaacs, JT, 1982) |
| "The national Prostatic Cancer Project has evaluated single and combination chemotherapeutic agents for the treatment of patients with advanced prostatic cancer that has been unresponsive to hormonal therapy." | ( deKernion, JB; Lindner, A, 1984) |
| "Thirty patients with advanced prostatic cancers (8 stage C, and 22 stage D) were treated for at least three months with D Trp6 LH-RH, a powerful LH-RH agonist." | ( Boccon-Gibod, L; Chiche, R; Debré, B; Duchier, J; Schally, AV; Steg, A, 1984) |
| "Since the polyclonal theory of prostatic cancer is attractive, its logical extension is the evaluation of combinations of treatments including both endocrine manipulation and cytotoxic agents." | ( Schmidt, JD, 1983) |
| "The efficacy of chemotherapy for prostatic cancer is difficult to evaluate owing to the low incidence of measurable indicator lesions and the resulting need for indirect response criteria." | ( Könyves, I; Müntzing, J; Rozencweig, M, 1984) |
| "In May 1978, the National Prostatic Cancer Project Treatment Subgroup activated its first clinical trial evaluating adjuvant chemotherapy (Protocol 900)." | ( Schmidt, JD, 1984) |
| "Metastatic prostatic cancer generally is treated by either castration or the administration of exogenous estrogens, both of which have significant clinical disadvantages." | ( Trachtenberg, J, 1983) |
| "The data suggest that for some prostatic cancers gonadotropin releasing hormone agonist administration must reduce serum testosterone levels to those achieved by orchiectomy for maximal growth rate inhibition." | ( Block, NL; Fuentes, MP; Irvin, GL; Pollack, A; Stover, BJ, 1984) |
| "Estracyt is a new drug for treatment of prostatic cancer, which is a molecule combining estradiol and nornitrogen mustard by a carbamate link." | ( Shida, K; Yamanaka, H, 1984) |
| "Three patients with metastatic prostatic cancer were treated for 10, 6 and 2 months with the potent LHRH-agonist Buserelin (Hoe 766) as a first-line agent." | ( Blankenstein, MA; de Jong, FH; Klijn, JG; Lamberts, SW, 1984) |
| "The treatment of early stage prostatic cancer with retropubic radical prostatectomy, pelvic lymphadenectomy and antiandrogenic therapy is reported." | ( Giuliani, L, 1980) |
| "Model systems for prostate cancer in rats have been developed and used for investigations on tumor biology and therapy." | ( Luckert, PH; Pollard, M, 1984) |
| "Thirty-seven patients with metastatic prostate cancer refractory to endocrine therapy were treated in a phase II trial of mitoxantrone." | ( Crawford, ED; Drelichman, A; Osborne, CK; Von Hoff, DD, 1983) |
| "The treatment of prostate cancer has been mainly conservative as it is in most parts of Europe." | ( Andersson, L; Könyves, I, 1984) |
| "Patients with bulky prostate cancer have usually been treated by palliative measures because the likelihood of tumor control with definitive irradiation has been low and the development of distant metastases high." | ( Bodner, H; Broth, E; Chiang, C; Garrett, J; Goldberg, H; Goldstein, A; Gray, R; Green, N; Gualtieri, V; Jaffe, J, 1984) |
| "Data from trials of the National Prostatic Cancer Project (NPCP) and a series from Roswell Park Memorial Institute (RPMI) were divided into short-term (up to twenty weeks and up to fifty-two weeks in adjuvant trials) and long-term therapy." | ( Brady, MF; Murphy, GP; Slack, NH, 1982) |
| "Thirty-two men with stage D2 prostatic cancer were monitored by bone scan, acid and alkaline phosphatase values, and urinary hydroxyproline, beginning from 4 to 36 months after initiation of hormonal manipulation and/or systemic chemotherapy." | ( Hopkins, SC; Ikard, M; Moinuddin, M; Nissenkorn, I; Palmieri, GM; Soloway, MS, 1983) |
| "Improvement of chemotherapy for the prostatic cancer will provide better results." | ( Kawai, T; Kihara, K; Kusuyama, H; Washizuka, M, 1983) |
| "Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone." | ( Ablin, RJ; Baumgartner, G; Guinan, PD; John, T; Sundar, B, 1982) |
| "Twenty-three patients with advanced prostate cancer who had failed previous hormone therapy were treated with cyclophosphamide, doxorubicin, and methotrexate on a 3-week course." | ( Engelking, C; Fleit, JP; Straus, MJ, 1982) |
| "Although patients with metastatic prostatic cancer may benefit from chemotherapy, impressive clinical responses are uncommon." | ( Brodkin, R; Cooper, MR; Howard, V; Jackson, DV; Muss, HB; Resnick, MI; Richards, F; Spurr, CL; Stuart, JJ; White, DR, 1981) |
| "Twenty-five patients with metastatic prostate cancer were treated with a combination of Adriamycin 50 mg/m2 and cis-platinum (CDDP) 50 mg/m2 every three weeks." | ( Citrin, DL; Hogan, TF, 1982) |
| "Longitudinal and vertical studies on prostatic cancer have confirmed that many forms of oestrogen therapy have a profound effect on the levels of several acute phase reactant proteins (APRP)." | ( Cooper, EH; Haworth, S; Trautner, K; Ward, AM, 1980) |
| "Plasma samples from patients with prostatic cancer under oral treatment with estramustine phosphate (Estracyt) were quantitatively analyzed for the presence of the parent drug and some of its possible metabolites." | ( Andersson, SB; Forshell, GP; Gunnarsson, PO; Nilsson, T, 1981) |
| "Based on the Response Criteria for Prostate cancer Treatment, one of 9 patients with bony metastasis had partial response, 2 patients with nodal disease on the CT scan obtained partial response." | ( Demura, T; Harabayashi, T; Koyanagi, T; Matsuda, H; Matsumara, K; Nagomori, S; Nonomura, K; Nounaka, O; Ohmuro, H; Shinohara, N, 1995) |
| "Twenty-nine patients with metastatic prostate cancer were treated with simultaneous flutamide withdrawal and aminoglutethimide (250 mg given orally four times daily)." | ( Cooper, M; Figg, WD; Headlee, D; Linehan, WM; Myers, CE; Sartor, O; Steinberg, S; Thibault, A; Tompkins, A; Weinberger, M, 1994) |
| "In patients with prostate cancer, after the first week of therapy with SB-75, we observed a significant decrease in bone pain, relief in urinary outflow obstruction, and reversal of the signs of prostatism." | ( Cardenas-Cornejo, I; Comaru-Schally, AM; Fuentes Garcia, M; Gomez-Orta, F; Gonzalez-Barcena, D; Graef-Sanchez, A; Schally, AV; Vadillo-Buenfil, M, 1994) |
| "This correlation makes prostate cancer a candidate for potentially achieving improved cure rates following local tumor sterilization by combining cisplatin with radiation therapy." | ( Coughlin, CT; Page, RL; Richmond, RC, 1994) |
| "During the study period 32 cases of prostate cancer were diagnosed: 12 were detected during the 12 months of the controlled study and were evenly distributed among the treatment groups (4 on placebo, and 3 on 1 mg and 5 on 5 mg finasteride) and 20 cases were detected in the extension study." | ( Ferguson, D; Gormley, GJ; Round, E; Stoner, E, 1994) |
| "The treatment of locally advanced prostatic cancer is controversial, as there are several possible treatment options." | ( Schulman, CC, 1994) |
| "From 1988 to 1991, 284 patients with prostatic cancer and painful bone metastases were treated with either radiotherapy or strontium-89 (200 MBq)." | ( Bolger, JJ; Dearnaley, DP; Kirk, D; Lewington, VJ; Mason, MD; Quilty, PM; Reed, NS; Russell, JM; Yardley, J, 1994) |
| "Metastatic prostate cancer remains a disease with no effective therapy." | ( Dreicer, R; Forest, PK; Williams, RD, 1994) |
| "Patients with node-positive prostate cancer that is regionally localized (T1-4, N1-3, M0) have a relatively poor prognosis when a single-treatment modality such as radical surgery, definitive radiotherapy, or androgen ablation is used." | ( Pollack, A; Sands, ME; Zagars, GK, 1995) |
| "Node-positive prostate cancer patients with regionally localized disease fared significantly better when combined local radiotherapy and early androgen ablation were used, as compared to early androgen ablation alone." | ( Pollack, A; Sands, ME; Zagars, GK, 1995) |
| "Two cases with prostate cancer had been treated with surgical castration and the steroidal antiandrogen chlormadinone acetate (CMA), and, on disease progression, the administration of CMA was terminated." | ( Akakura, K; Akimoto, S; Ohki, T; Shimazaki, J, 1995) |
| "The present open study included 16 prostate cancer patients who had painful bone metastases and who had failed hormonal therapy." | ( Kylmälä, T; Lindholm, TS; Seppänen, J; Tammela, TL, 1994) |
| "In patients with metastatic prostate cancer, bicalutamide plus LHRH-A is well tolerated and provides superior efficacy to flutamide plus LHRH-A with respect to time to treatment failure." | ( Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N, 1995) |
| "These data show that PSA synthesis by prostate cancer is reduced after androgen deprivation but that the PSA nadir and PSA doubling time following treatment provide important prognostic information." | ( Braswell, NT; Feliz, TP; Fowler, JE; Pandey, P; Seaver, LE, 1995) |
| "To estimate the growth rate of prostate cancer, the doubling times of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) were determined in 51 patients: 44 were refractory to endocrine therapy, and 7 were in an untreated state." | ( Akakura, K; Akimoto, S; Masai, M; Shimazaki, J, 1995) |
| "Enhanced detection of prostate cancer achieved with modern technology can lead to undesirable treatment of clinically insignificant tumors." | ( Egawa, S; Kawakami, T; Koshiba, K; Kuwao, S; Ohori, M; Soh, S; Uchida, T; Yokoyama, E, 1995) |
| "We report a case of advanced prostate cancer in which an initial response to hormonal therapy with surgical castration and estramustine phosphate (EMP) was followed by disease progression, as shown by sequential elevations in serum prostate specific antigen (PSA) and prostate acid phosphatase (PAP) and the development of new symptoms, during maintenance endocrine and anti-cancer chemotherapy." | ( Nishiyama, T; Terunuma, M, 1994) |
| "To improve results for locally advanced prostate cancer, a prospective clinical trial of concurrent external beam irradiation and fractionated iridium-192 (Ir-192) high dose rate (HDR) conformal boost brachytherapy was initiated." | ( Edmundson, G; Gonzalez, J; Gustafson, G; Hollander, J; Martinez, A; Ohanian, N; Spencer, W; Stromberg, J; Vicini, F; Yan, Di, 1995) |
| "Between 1986 and 1993, 40 patients with prostate cancer were given endocrine therapy before radical prostatectomy." | ( Kinouchi, T; Kotake, T; Kuroda, M; Maeda, O; Meguro, N; Saiki, S; Usami, M, 1995) |
| "Hormonal treatment of advanced prostatic cancer patients generally results in an initially beneficial response, but the treated patients develop hormonally resistant disease in which no curative therapy is currently available." | ( Belldegrun, A; Bonavida, B; Borsellino, N, 1995) |
| "Two additional patients with prostate cancer have been treated with the estramustine/paclitaxel combination, one achieving a major response and the other stable disease." | ( Chapman, A; Gallo, J; Greenberg, R; Hudes, GR; McAleer, C; Obasaju, C, 1995) |
| "Patients with advanced prostate cancer have a beneficial effect from maximal androgen blockade in terms of the subjective and objective delay of progression and median duration of survival, although side effects do occur more often in the combination treatment than in testicular suppression alone." | ( Debruyne, FM; Dijkman, GA; Fernandez del Moral, P; Janknegt, RA, 1995) |
| "In men with untreated advanced prostate cancer, monthly goserelin 3." | ( Brogden, RN; Faulds, D, 1995) |
| "Hormonal treatment of prostate cancer has advanced little in the past 20 years." | ( Smith, PH, 1995) |
| "Stimulation of prostate cancer growth by androgens is well established with androgen withdrawal therapy being the most effective therapy in men with prostate cancer." | ( Wilding, G, 1995) |
| "Its ultimate role in prostate cancer remains to be determined, but 1,25-D may prove useful in chemoprevention and/or differentiation therapy." | ( Feldman, D; Peehl, DM; Skowronski, RJ, 1995) |
| "This reversion of prostate cancer cells to an apparently nontumorigenic phenotype points to a potentially significant therapeutic role for azatyrosine in the treatment of advanced prostate cancer." | ( Benoit, RM; Eiseman, J; Jacobs, SC; Kyprianou, N, 1995) |
| "Three cohorts of patients with advanced prostate cancer that progressed despite castrate levels of testosterone received oral hydrocortisone plus suramin administered in the following manners: (1) a loading dose of suramin followed by a continuous infusion using an adaptive control program (cohort A); (2) an intermittent schedule using a simplified adaptive control schedule (cohort B); and (3) an empiric dosing regimen (cohort C)." | ( Cohen, L; Curley, T; Dnistrian, A; Kelly, WK; Leibertz, C; Mazumdar, M; Pfister, D; Scher, HI; Schwartz, M; Vlamis, V, 1995) |
| "The TP53 gene mutation pattern in prostatic cancer was examined in relation to progression and survival, using archival formalin-fixed pre- and post-treatment tumour specimens from 84 prostatic cancer patients." | ( Berner, A; Børresen, AL; Fosså, SD; Geitvik, G; Karlsen, F; Nesland, JM, 1995) |
| "Neoadjuvant hormonal therapy in prostatic cancer, although definitely not standard therapy, bears investigation." | ( Aprikian, A; Fair, WR; Reuter, V; Sogani, P; Whitmore, WF, 1993) |
| "The major focus in prostate cancer therapy currently is the role of the adrenal androgens." | ( Geller, J, 1993) |
| "The patients with prostatic cancer were treated with VIP (vincristine, ifosfamide, peplomycin) chemotherapy and the patients with urothelial cancer were treated with MP (methotrexate, cisplatinum) or MEP (methotrexate, Etoposide, cisplatinum) combination chemotherapy." | ( Kitamura, Y; Komatsubara, S; Sakata, Y; Watanabe, M, 1993) |
| "A multivariate analysis of 874 cases of prostate cancer treated between 1966 and 1988 was conducted." | ( Ayala, AG; von Eschenbach, AC; Zagars, GK, 1993) |
| "Optimal treatment of prostate cancer depends on accurate staging." | ( Grzonka, R; Heal, A; Helal, M; Persky, L; Sanford, E; Tyson, I, 1994) |
| "We describe an in vitro model for prostate cancer treatment that suggests a potential benefit for combined androgen ablation and cytotoxic chemotherapy." | ( Berchem, GJ; Bosseler, M; Gelmann, EP; Sugars, LY; Voeller, HJ; Zeitlin, S, 1995) |
| "57 patients with advanced prostate cancer and a failure of prior hormonal treatment were selected for a double-blind placebo-controlled trial, in which they were randomly allocated to receive either clodronate (C) or placebo concomitantly with the basic cancer treatment, estramustine phosphate (E) (560 mg daily)." | ( Elomaa, I; Kylmälä, T; Lamberg-Allardt, C; Tammela, TL; Taube, T, 1994) |
| "In men treated for prostate cancer, established general and cancer specific health related quality of life instruments may be combined with newly developed measures that assess the prostate related sexual, urinary and bowel domains in terms of degree of dysfunction and level of bother from that dysfunction." | ( Litwin, MS, 1994) |
| "Breast and prostate cancer are significant causes of morbidity and mortality and are very similar in etiology, epidemiology, and modalities of treatment." | ( Brawley, OW; Ford, LG; Johnson, KA; Kramer, BS; Nayfield, SG; Perlman, JA, 1994) |
| "Treatment of androgen-independent prostate cancer cells of both rat and human origin with TG inhibits their endoplasmic reticulum Ca(2+)-dependent ATPase activity, resulting in a 3-4-fold elevation in the level of intracellular free Ca2+ (Cai) within minutes of exposure." | ( Furuya, Y; Gill, DL; Isaacs, JT; Lundmo, P; Short, AD, 1994) |
| "Those involved in prostate cancer treatment are often frustrated by the surfeit of careful comparative studies." | ( Crawford, ED; Mayer, FJ, 1994) |
| "The treatment against hormone relapsing prostate cancer was examined clinically, experimentally and by a review of the literature." | ( Akino, H; Aoki, Y; Fujita, T; Iwaoka, K; Miwa, Y; Okada, K; Saikawa, S; Suzuki, Y, 1994) |
| "Hormone-refractory prostate cancer generally remains a chemotherapy-resistant tumor and therefore warrants the continued evaluation of promising agents." | ( Cummings, GD; Flaherty, LE; Hussain, MH; Pienta, KJ; Redman, BG, 1994) |
| "Although the only opportunity to cure prostate cancer is treatment at an early stage, radical prostatectomy has remained relatively unpopular because 40-50% of prostate cancers estimated at diagnosis as confined to the prostate are found to be at a more advanced stage following histopathological analysis of the surgical specimen." | ( Cusan, L; Diamond, P; Dupont, A; Fradet, Y; Gomez, J; Koutsilieris, M; Labrie, F; Lemay, M; Suburu, R; Têtu, B, 1993) |
| "The response of advanced prostatic cancer with metastatic chest wall tumor to high-dose diethylstilbestrol diphosphate (DESP) therapy was monitored by in vivo 31P magnetic resonance spectroscopy (31P MRS) study." | ( Kaneko, H; Kawakami, M; Kumakawa, T; Mashima, Y; Nakauchi, K, 1994) |
| "Nineteen patients with metastatic prostate cancer were treated with orchiectomy plus six cycles of epirubicin in a dose of 90 mg/m2, intravenously, every 28 days." | ( Leliefeld, H; Peulen, G; Smeets, J; Wils, J, 1994) |
| "Twenty-two patients with bulky prostatic cancers were treated with a 3 month course of neoadjuvant leuprolide acetate and eulexin prior to three-dimensional (3-D) conformal radiotherapy." | ( Burman, CM; Fuks, Z; Happersett, L; Harrison, A; Kutcher, GJ; Leibel, SA; Zelefsky, MJ, 1994) |
| "Thus far, 39 prostatic cancer patients with multiple painful bone metastases were treated." | ( Blijham, GH; de Klerk, JM; Han, SH; Stokkel, MP; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1994) |
| "Sera from 40 patients with prostatic cancer, stored prior to and after 6 and 12 months' treatment with a gonadotrophin-releasing hormone agonist and an anti-androgen were analysed." | ( Baker, T; Docherty, A; Isenberg, D; Tickle, S; Wasan, H; Waxman, J, 1994) |
| "We can not treat prostatic cancer patients leading to better outcomes without hormonal therapy." | ( Oishi, K, 1994) |
| "The treatment of advanced metastatic prostate cancer by hormone manipulation or orchiectomy is frequently followed by the appearance of hormone-insensitive and highly chemoresistant tumor cells." | ( Baumgartner, G; Hamilton, G; Schirmböck, M; Sherwood, ER; Thalhammer, T; Theyer, G, 1993) |
| "Eight patients with locally advanced prostate cancer were treated with the LHRH analogue, leuprorelin acetate." | ( Dearnaley, DP; Fisher, C; Muir, GH; Shearer, RJ, 1994) |
| "Fourty-eight patients with stage D2 prostate cancer, initially treated with endocrine therapy at the University of Tokyo between 1981 and 1990, were followed up and analysed." | ( Aso, Y; Higashihara, E; Hirasawa, K; Homma, Y; Kasuya, Y; Kawabe, K; Tanaka, Y; Yoshida, M, 1994) |
| "The endocrine treatment of metastatic prostate cancer includes castration which reliably lowers the serum testosterone (T); however, the effect on intratumor levels of T and dihydrotestosterone (DHT) is less predictable." | ( Jones, RE; Loop, S; Meikle, AW; Ostenson, RC; Plymate, SR; Tuttle, RM, 1994) |
| "Sixteen patients with hormone-resistant prostate cancer were treated by continuous infusion of high-dose fosfestrol according to two schedules: 10 patients were included in a phase I trial of a daily escalating dose from 1." | ( Culine, S; Droz, JP; Kattan, J, 1993) |
| "Twenty-nine men with stage D2 prostate cancer who were treated at the National Cancer Institute, Bethesda, Md, in 1992." | ( Calis, KA; Cooper, MR; Figg, WD; Headlee, D; Mays, D; Sartor, AO; Thibault, A, 1994) |
| "In recent years immunotherapy of prostate cancer has developed into an innovative field of investigation." | ( Schulze, H; Sommerfeld, HJ, 1993) |
| "In the two patients with metastatic prostatic cancer, the level of alpha 2-plasmin inhibitor gradually increased with the reduction of tumor size by treatment." | ( Binder, BR; Kohno, I; Okabe, H; Okajima, K; Soe, G; Takatsuki, K, 1994) |
| "Because prostate cancer is known to show a high degree of heterogeneity of its sensitivity to androgens, we analyzed the effect of combined antiandrogen therapy on parameters more sensitive to androgens than ventral prostatic weight itself." | ( Labrie, F, 1993) |
| "A total of 327 patients with metastatic prostate cancer were randomized to receive bilateral orchiectomy or treatment with Zoladex and flutamide." | ( Bono, A; Carneiro de Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Sylvester, R; Whelan, P, 1993) |
| "The treatment of advanced prostate cancer is based on hormone manipulation to eliminate the trophic effect of testosterone on sensitive androgen tissue of the tumor." | ( Castagnetti, G; Dotti, A; Ferrari, G; Ferrari, P; Pollastri, CA; Tavoni, F, 1993) |
| "They reported that a group of prostate cancer patients who underwent estrogen therapy showed the same survival as a no treatment group." | ( Oishi, K; Yoshida, O, 1993) |
| "A 65-year-old man with advanced prostate cancer was treated with a luteinizing hormone-releasing hormone (LH-RH) analogue." | ( Satoh, J; Shibata, Y; Shimizu, T; Uchida, T, 1993) |
| "Until now, patients with a progressive prostatic cancer, in whom all therapies failed and the disease spread locally and distally, was considered "a lost patient"; because it did not exist an effective therapy easily to be used." | ( Bertana, F; Castellani, R; Dormia, E; Dormia, G; Gonnella, G; Luongo, P; Malagola, G; Mantovani, F; Mazza, L; Minervini, S, 1993) |
| "Eleven patients with prostate cancer were treated by intra-arterial infusion chemotherapy and radiotherapy combined with hormone therapy." | ( Akiyama, M; Hashine, K; Inoue, Y; Sumiyoshi, Y, 1993) |
| "Radiotherapy for the treatment of prostate cancer has long been known as an alternative medical therapeutic approach, but the molecular mechanism involved in radiation-induced toxicity in prostatic tumors is poorly defined." | ( Eddy, HA; Jacobs, SC; Kyprianou, N; Sklar, GN, 1993) |
| "In 1978, the National Prostatic Cancer Project launched two protocols evaluating adjuvant therapy after surgery (Protocol 900) or irradiation (Protocol 1000) for clinically localized prostate cancer." | ( Bartolucci, A; Gibbons, RP; Murphy, GP; Schmidt, JD, 1993) |
| "The initial treatment of advanced-stage prostate cancer is total androgen deprivation." | ( Bekradda, M; Bonnay, M; Chraibi, Y; Culine, S; Droz, JP; Kattan, J, 1993) |
| "Twenty-six patients with prostatic cancer were treated with courses of epirubicin at 3-week intervals, starting at an initial intravenous dose of 75 mg/m2." | ( Erwin, TJ; Fontaine, B; Gupta, S; Stewart, DJ; Tannock, IF, 1993) |
| "Patients with Stage D2 prostate cancer relapsing on endocrine treatment have a grim prognosis." | ( Matzkin, H; Rangel, MC; Soloway, MS, 1993) |
| "Metastatic prostate cancer which is refractory to hormone therapy remains an incurable disease for which there is no effective therapy." | ( Lehr, JE; Pienta, KJ, 1993) |
| "Neoadjuvant therapy for prostatic cancer might be important to increase cure rates of the disease and preservability of the organs." | ( Kinouchi, T; Kotake, T; Kuroda, M; Maeda, O; Miki, T; Saiki, S; Usami, M, 1993) |
| "To develop an improved model of human prostate cancer, 16-wk-old Wistar rats were treated orally for 18 days with the antiandrogen, flutamide (50 mg/kg body weight [BW]/day), followed by 3 days of s." | ( Austin, GE; Collins, DC; Dillehay, DL; Fallon, MT; Schleicher, RL; Zhang, M; Zheng, M, 1996) |
| "In 1978 the National Prostate Cancer Project launched two protocols evaluating adjuvant therapy following surgery (Protocol 900) or irradiation (Protocol 1,000) for clinically localized prostate cancer." | ( Bartolucci, A; Gibbons, RP; Murphy, GP; Schmidt, JD, 1996) |
| "A total of 48 patients with untreated prostate cancer of different stages and 16 with histologically confirmed benign prostatic hyperplasia (BPH) underwent static PET after intravenous injection of 150 to 300 MBq." | ( Bares, R; Büll, U; Effert, PJ; Handt, S; Jakse, G; Wolff, JM, 1996) |
| "The role of inhibition of aromatase in prostate cancer therapy, which was postulated for aminoglutethimide, could not be confirmed by the use of more selective aromatase inhibitors, such as formestane." | ( Bruynseels, J; De Coster, R; Wouters, W, 1996) |
| "Eighteen patients had prostate cancer (all hormone-refractory cancer), seven patients had breast cancer, and three patients had lung cancer, all previously treated with either radiation, chemotherapy, or a combination of the two." | ( Aeppli, DM; Boudreau, RJ; Lee, CK; Levitt, SH; Unger, J, 1996) |
| "Treatment of prostate cancer cell lines expressing bcl-2 with taxol induces bcl-2 phosphorylation and programmed cell death, whereas treatment of bcl-2-negative prostate cancer cells with taxol does not induce apoptosis." | ( Chintapalli, J; Croce, CM; Haldar, S, 1996) |
| "The objective was to investigate how prostate cancer and its treatment affects sexual, urinary and bowel functions and to what extent eventual complications cause distress." | ( Adolfsson, J; Arver, S; Dickman, P; Fredrikson, M; Helgason, AR; Steineck, G, 1996) |
| "Among the patients with prostate cancer and bone metastases, 15 were new or reactivated cases and the 11 others were well controlled by hormonal therapy." | ( Ikeda, I; Kondo, I; Miura, T, 1996) |
| "Patient with new or reactivated prostate cancer with bone metastases had a higher urinary excretion of Py and dPy than did the patients with BPH, patients with prostate cancer and no bone metastases and patients with prostate cancer and bone metastases well controlled with hormonal therapy." | ( Ikeda, I; Kondo, I; Miura, T, 1996) |
| "Of 102 patients with metastatic prostate cancer, 52 were treated with orchidectomy and 50 with CHB; 22 of these received a LHRH analog + Flutamide and 28 orchidectomy + Flutamide." | ( de Torres, JA; Encabo, G; López Pacios, MA; Lorente, JA; Morote, J; Soler Roselló, A; Vallejo, C, 1995) |
| "There is interest in treating prostate cancer with induction androgen deprivation prior to radical prostatectomy." | ( Corn, BW; Gomella, LG; Hyslop, T; Liberman, SN; Mulholland, SG; Petersen, RO, 1996) |
| "To determine, in patients with prostate cancer treated with cryosurgery, whether levels of choline and citrate measured at magnetic resonance (MR) spectroscopy can help discriminate regions of residual tumor from other prostatic tissues and necrosis." | ( Carroll, PR; Hricak, H; Kurhanewicz, J; Nelson, SJ; Parivar, F; Shinohara, K; Vigneron, DB, 1996) |
| "Chemoprevention of prostate cancer is an attractive idea that appeals to many struggling with the treatment of this disease." | ( Trachtenberg, J, 1996) |
| "Patients with metastatic prostate cancer treated with CAB can be stratified on the basis of clinical prognostic parameters such as performance status, the presence or absence of pain, the levels of alkaline phosphatase, and the levels of prostate-specific antigen (PSA) during the first months of CAB: for combined androgen deprivation, if they fall in the good prognostic category (+/- 30-35% of the patients); for surgical castration and palliative treatment or (experimental) cytotoxic therapy if they belong to the poor prognostic category (+/- 20% of the patients), and, for initial CAB during the first 3-6 months of therapy, followed by an evaluation of the regression of PSA under therapy." | ( Debruyne, FM, 1996) |
| "Twelve patients with hormone-refractory prostate cancer were treated with combination chemotherapy of etoposide, epirubicin and carboplatin (EEC)." | ( Fujishiro, Y; Fuse, H; Katayama, T; Muraishi, Y, 1996) |
| "The ability of human prostate cancer cells to metabolize androgens was assessed through administration of physiological concentration (0." | ( Bue, AL; Cannella, S; Carruba, G; Castagnetta, LA; Farruggio, R; Granata, OM; Leake, RE; Pavone-Macaluso, M, 1996) |
| "Of 111 surgically treated patients with prostate cancer (T1b-T3a, N0, M0, G1-3), 55 were randomised to immediate radical prostatectomy and 56 to 3 months of neo-adjuvant treatment with triptorelin (3." | ( Abrahamsson, PA; Ahlgren, G; Aus, G; Hugosson, J; Lundberg, S; Pedersen, K; Schain, M; Schelin, S, 1996) |
| "In most patients with prostate cancer, continuous androgen suppression (CAS) therapy causes tumour regression and an accompanying decrease in serum prostate specific antigen (PSA)." | ( Bruchovsky, N; Gleave, ME; Goldenberg, SL; Lange, PH; Rennie, PS; Sato, N; Sullivan, LD, 1996) |
| "In endocrine-therapy-refractory prostate cancer, the early requirement for analgesics suggests poor prognosis, and the onset of pain may be attributable not to the extent of the disease but rather to the rapid expansion of bone metastasis." | ( Akakura, K; Akimoto, S; Shimazaki, J, 1996) |
| "The definitive treatment of prostate cancer remains controversial although certainly radical prostatectomy is the standard all other treatments must be compared against." | ( Hargis, R; Zachow, SE, 1996) |
| "over 4 (range 2-152 months) years for prostatic cancer treatment were retrospectively evaluated." | ( Berges, RR; Hinkel, A; Pannek, J; Schulze, H; Senge, T, 1996) |
| "The treatment of hormonally resistant prostate cancer is therefore palliative." | ( Moore, MJ; Tannock, IF, 1996) |
| "Seventeen men with various stages of prostate cancer, all of whom were candidates for androgen deprivation therapy, were treated with finasteride plus flutamide and were followed for a mean of 13." | ( Fair, WR; Fleshner, NE, 1996) |
| "Treatment decisions for metastatic prostate cancer require the consideration of factors such as survival, quality of life, costs of care, and toxicities." | ( Bennett, CL; Matchar, DB; McCrory, DC, 1997) |
| "Seven hundred twelve consecutive prostate cancer patients treated at this institution between 1986 and 1994 (inclusive) with conformal or conventional techniques were included in the analysis." | ( Hanks, GE; Hanlon, AL; Hunt, MA; Lee, WR; Peter, RS; Schultheiss, TE, 1997) |
| "The palliative therapy of advanced prostate cancer still remains a perplexing problem." | ( Newling, DW, 1997) |
| "The interval to the development of prostate cancer, stage at diagnosis, prostate-specific antigen level, Gleason score, treatment, and treatment outcome were also investigated." | ( Broderick, GA; Ebling, DW; Malkowicz, SB; Ruffer, J; Vanarsdalen, K; Wein, AJ; Whittington, R, 1997) |
| "Two cases of metastatic prostate cancer demonstrating decrease in PSA of 92% and 56% on discontinuation of nilutamide therapy are reported." | ( Gerridzen, RG; Huan, SD; Stewart, DJ; Yau, JC, 1997) |
| "For patients with stage D2 prostate cancer and disease progression or an increasing PSA concentration, withdrawal of antiandrogen therapy with bicalutamide or flutamide may result in a PSA response." | ( Chen, Y; Furr, B; Haas, GP; Klein, E; Kolvenbag, GJ; Nieh, PT; Patterson, AL; Schellhammer, PF; Seabaugh, DR; Small, EJ; Venner, P; Wajsman, Z, 1997) |
| "Metastatic prostate cancer has been traditionally treated with androgen ablation using surgical orchiectomy or estrogens." | ( Gomella, LG; Ismail, M, 1997) |
| "Apoptosis in prostate cancer was evaluated after three months of combined endocrine therapy to investigate the association with tumour grade, tumour stage, and the immunohistochemical detection of p53 and bcl-2 in tumour cells before and after therapy." | ( Colecchia, M; Colloi, D; Del Boca, C; Frigo, B; Guardamagna, A; Leopardi, O; Zucchi, A, 1997) |
| "Patients with progressive prostate cancer were treated with bicalutamide 200 mg daily." | ( Brett, C; Kelly, WK; Kolvenbag, G; Liebertz, C; Mazumdar, M; Scher, HI; Schwartz, L; Schwartz, M; Shapiro, L, 1997) |
| "Hormone-refractory prostate cancer is characterized by a low response rate following second-line therapy." | ( Colleoni, M; Graiff, C; Manente, P; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G, 1997) |
| "We describe a patient with metastatic prostate cancer who developed nonoliguric renal failure during treatment with suramin." | ( Harbour, D; Liebmann, J; Smith, A, 1997) |
| "In patients of 70 years and under with prostate cancer resistant to androgen-deprivation therapy and who still have good performance status, ECF chemotherapy can achieve useful remissions." | ( Chao, D; Harland, SJ; von Schlippe, M, 1997) |
| "In conclusion, in patients with prostate cancer without bone metastases at the time of diagnosis, pretreatment PSA and tumour stage can be used for the assessment of risk of development of metastases during follow-up and survival." | ( Pauwels, E; Stokkel, M; van Eck-Smit, B; Zwartendijk, J; Zwinderman, A, 1997) |
| "Fifty-seven patients with advanced prostate cancer resistant to first-line hormonal therapy were treated with estramustine and additionally randomized for treatment with clodronate or placebo." | ( Elomaa, I; Kylmälä, T; Risteli, J; Risteli, L; Tammela, TL; Taube, T, 1997) |
| "To improve the therapeutic results in prostatic cancer, radical prostatectomy or total cystoprostatectomy were performed with chemohormonal therapy before operation." | ( Hamano, K; Maruoka, M; Nagayama, T; Nishikawa, Y, 1997) |
| "A patient with advanced prostate cancer with progressive symptomatology was treated with DHEA after other treatment regimens failed." | ( Jones, JA; Leidich, RB; Nguyen, A; Straub, M; Veech, RL; Wolf, S, 1997) |
| "Localized prostate cancer was treated with combined external beam radiotherapy and high dose rate Ir-192 brachytherapy with the purpose of a high dose." | ( Borghede, G; Hedelin, H; Holmäng, S; Johansson, KA; Mercke, C; Sernbo, G, 1997) |
| "Up to stage B1 or prostate cancer with N0-1 positive lymph node may be curable by monotherapy of either radical prostatectomy or irradiation." | ( Akakura, K; Akimoto, S; Isaka, S; Morita, S; Shimazaki, J, 1997) |
| "A total of 144 patients with Stage D2 prostate cancer who received androgen deprivation therapy were studied." | ( Falkson, G; Ribeiro, M; Ruff, P, 1997) |
| "practically all well differentiated prostatic cancers, regardless of their stage, responded remarkably well to first-line treatment with sufficient doses of DES, as, when correctly monitored, practically none of these cancers escaped and early stages of escape can be salvaged." | ( Reziciner, S, 1997) |
| "67 patients referred for prostate cancer not suitable for surgery were randomly allocated to two treatment regimens: 33 patients received 3." | ( Abourachid, H; Blumberg, J; Brucher, P; Doutres, JC; Dufour-Esquerré, F; Fretin, J; Jaupitre, A; Jorest, R; Kuhn, JM; Lambert, D; Petit, J; Pin, J, 1997) |
| "Treatment of prostatic cancer with GnRH agonist is a medical alternative to surgical castration, although hyperstimulation of the tumor can occur." | ( Chapon, F; Deboucher, N; Lahlou, N; Mahoudeau, J; Reznik, Y, 1997) |
| "Their density in prostatic cancer increases following hormonal therapy and varies in relation to the tumoral degree or histological evaluation, suggesting a role of neuroendocrine cells in human prostatic cancer." | ( del Valle, M; Escaf, S; Guate, JL; Menendez, CL; Vega, JA, 1997) |
| "A total of 390 patients with advanced prostate cancer were treated for a minimum of 12 weeks with a daily monotherapy dose of Casodex." | ( Channer, K; Cockshott, ID; Denis, L; Newling, D; Soloway, M; Tyrrell, CJ, 1998) |
| "A 69-year-old man with advanced prostate cancer was receiving antiandrogen therapy (bicalutamide [Casodex])." | ( DiFabrizio, L; Macris, N; Seriff, NS; Wong, PW, 1998) |
| "Hormonally insensitive prostate cancer is a relatively slow-growing, but usually fatal, disease with no long-term treatment options." | ( Campbell, MJ; Dawson, M; Koeffler, HP, 1998) |
| "Management of prostate cancer progression after failure of initial hormonal therapy is controversial." | ( Bergan, R; Brawley, OW; Cooper, MR; Dawson, N; Figg, WD; Headlee, D; Linehan, WM; Patronas, N; Reed, E; Sartor, O; Sausville, E; Senderowicz, A; Steinberg, SM; Sutherland, M, 1998) |
| "Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen independence is frequently observed." | ( Akakura, K; Akimoto, S; Furuya, Y; Igarashi, T; Ito, H; Murakami, S; Shimazaki, J, 1998) |
| "In treating hormone-refractory advanced prostate cancer, the first pharmacologic manipulation should be withdrawal of the oral component of combined hormonal therapy." | ( Nishiyama, T; Terunuma, M, 1998) |
| "To provide appropriate therapy for prostate cancer, accurate staging of the patient's disease is essential." | ( Barth, RF; Burgers, JK; Hinkle, GH; Lamatrice, RA; Maguire, RT; Olsen, JO; Rogers, B; Williams, BS, 1998) |
| "The basis for the medical treatment of prostate cancer is inhibition of the influence of testosterone on the prostate." | ( Debruyne, FM; Witjes, JA, 1997) |
| "Downstaging of prostate cancer by hormone ablative therapy remains a controversial issue at this time, but the use of androgen ablation decreases the size of the prostate gland which facilitates cryosurgery and improves the results." | ( Derakhshani, P; Engelmann, U; Neubauer, S; Zumbé, J, 1998) |
| "In patients with untreated prostate cancer at high risk for pelvic lymph node metastases, capromab pendetide imaging had respective sensitivities and specificities of 52 and 96% in 1 study and 62 and 72% in another, as confirmed by pelvic lymph node dissection biopsy results." | ( Faulds, D; Lamb, HM, 1998) |
| "In the past 20 years, 3,500 prostate cancer patients have been recruited in 16 phase III trials in untreated and advanced disease and in seven phase II trials in hormone-refractory, metastatic disease." | ( Denis, L, 1998) |
| "Endocrine therapy for prostate cancer has been changing rapidly." | ( Usami, M, 1998) |
| "There were 13 prostate cancer cases in the selenium-treated group and 35 cases in the placebo group (relative risk, RR=0." | ( Borosso, C; Carpenter, D; Clark, LC; Combs, GF; Dalkin, B; Falk, S; Herlong, JH; Janosko, E; Krongrad, A; Rounder, J; Slate, EH; Turnbull, BW; Witherington, R, 1998) |
| "A total of 321 patients with metastatic prostate cancer in relapse after first-line endocrine therapy entered a Phase III international multicenter study (recruitment from February 1992 to August 1994) comparing liarozole (300 mg two times daily) with CPA (100 mg two times daily)." | ( Boccardo, F; Brune, D; Bruynseels, J; De Porre, P; Debruyne, FJ; Denis, L; Fradet, Y; Janssens, M; Johansson, JE; Marberger, JM; Murray, R; Rassweiler, J; Tyrrell, C; Vangeneugden, T, 1998) |
| "Treatment options for advanced prostate cancer are very limited, and there is a need to develop new therapies." | ( Bartsch, G; Culig, Z; Hittmair, A; Hobisch, A; Klocker, H; Pai, LH; Pastan, I, 1998) |
| "To evaluate prostate cancer detection and prostate-specific antigen (PSA) among men with benign prostatic hyperplasia treated with finasteride." | ( Andriole, GL; Cook, TJ; Crawford, ED; Epstein, JI; Guess, HA; Hudson, P; Jackson, CL; Kadmon, D; Patterson, L; Romas, NA; Waldstreicher, J; Wise, H, 1998) |
| "Then, 23 cases with local relapsed prostate cancer and two cases with endocrine-resistant prostate cancer received chemotherapy." | ( Deguchi, T; Kawada, Y; Kuriyama, M; Nakano, M; Shinoda, I; Takahashi, Y; Takeuchi, T; Yamamoto, N; Yasuda, M; Yoh, M, 1998) |
| "In patients with progressive prostate cancer who have been treated with surgical or medical castration plus an antiandrogen, antiandrogen withdrawal can result in a significant decline in serum prostate-specific antigen (PSA)." | ( Akakura, K; Akimoto, S; Furuya, Y; Ito, H, 1998) |
| "Clinical records of 68 prostate cancer patients who had been treated with surgical castration plus the administration of chlormadinone acetate, ethynylestradiol or estramustine phosphate, and who had shown clinical progression associated with a steady increase in serum PSA, were investigated." | ( Akakura, K; Akimoto, S; Furuya, Y; Ito, H, 1998) |
| "In regressed and therapy-resistant prostate cancers, an increase in cytokeratin 5-positive tumor cells was noted when compared with untreated carcinomas." | ( Abbou, CC; Bellot, J; Chopin, DK; Colombel, M; Gil-Diez de Medina, S; Radvanyi, F; Salomon, L; Thiery, JP; Van der Kwast, TH, 1998) |
| "For the endocrine therapy of prostate cancer, chlormadinone acetate, flutamide and bicalutamide are or will be available in Japan." | ( Akakura, K; Furuya, Y; Ito, H, 1998) |
| "For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels." | ( Blumenstein, BA; Crawford, ED; Eisenberger, M; Higgins, B; Lovato, LC; Meyskens, FL; Moinpour, CM; Savage, MJ; Skeel, R; Troxel, A; Veith, RW; Yee, M, 1998) |
| "Exposure of BIS-treated PC-3 prostate cancer cells to gamma-irradiation resulted in a significant increase in the number of cells undergoing apoptosis and a subsequent decrease in the IC50." | ( Callery, PS; Eiseman, JL; Guo, Y; Kauffman, J; Klinger, MF; Kyprianou, N; Rogers, FA; Sentz, DL, 1998) |
| "Immunotherapy against prostate cancer is an alternative approach in overcoming hormonal/drug-resistant prostate cancer." | ( Belldegrun, A; Bonavida, B; Borsellino, N; Frost, P; Gárban, H; Mizutani, Y; Ng, CP; Uslu, R, 1997) |
| "However, as most patients who die from prostate cancer have hormone refractory disease, fine tuning of antiandrogen treatment by combined androgen blockade (CAB) can not be expected to improve survival significantly." | ( Mills, RD; Studer, UE, 1998) |
| "Clinical data suggest that prostate cancer is amenable to control by IAS and offers clinicians an opportunity to improve patients' quality of life by balancing the benefits of immediate androgen ablation (delayed progression and prolonged survival) while reducing treatment-related side effects and expense." | ( Bruchovsky, N; Gleave, M; Goldenberg, SL; Rennie, P, 1998) |
| "In human prostate cancer, the constitutive production of VEGF by the glandular epithelium was suppressed as a consequence of androgen-ablation therapy." | ( Benjamin, LE; Golijanin, D; Itin, A; Keshet, E; Pode, D, 1999) |
| "Metastatic prostatic cancer is typically refractory to androgen ablation therapy due to the presence of androgen-independent clones in the neoplasia." | ( Aparicio, J; Larrán, J; López, A; Salido, M; Vilches, J, 1999) |
| "Thirty patients with hormone-refractory prostate cancer were treated with cycles of oral cyclophosphamide (100 mg/m2/day for 14 days, with a 14-day gap)." | ( Coates, AS; Coorey, GJ; Cox, K; Grygiel, JJ; McNeil, E; Pearson, BS; Raghavan, D; Rogers, J; Watt, WH, 1993) |
| "Intermittent hormonal treatment of prostate cancer was first developed based upon experimental study results." | ( Rambeaud, JJ, 1999) |
| "Most prostate cancers eventually develop resistance to hormonal therapy and chemotherapies." | ( Aisner, J; DiPaola, RS, 1999) |
| "For treatment of prostate cancer, we now administer only adjuvant intra-arterial chemotherapy plus irradiation for patients after radical prostatectomy." | ( Hashine, K; Nakatsuji, H; Sumiyoshi, Y, 1999) |
| "Then, 23 cases of local relapsed prostate cancer and two cases of endpocrine-resistant prostate cancer were administered the chemotherapy." | ( Deguchi, T; Kawada, Y; Kuriyama, M; Nakano, M; Shinoda, I; Takahashi, Y; Takeuchi, T; Yamamoto, N; Yasuda, M; Yoh, M, 1999) |
| "Causing prostate cancer cells to express functionally active sodium iodide symporter (NIS) would enable those cells to concentrate iodide from plasma and might offer the ability to treat prostate cancer with radioiodine." | ( Bergert, ER; Castro, MR; Heufelder, AE; McIver, B; Morris, JC; Spitzweg, C; Tindall, DJ; Young, CY; Zhang, S, 1999) |
| "The magnitude of the problem of prostate cancer, and the failure of conventional chemotherapy and surgery to effect a marked diminution in the total number of deaths from this disease, now indicate that chemoprevention of prostatic carcinogenesis must be seriously considered." | ( Sporn, MB, 1999) |
| "Current approaches to the management of prostate cancer include surgery, radiation therapy, or hormonal manipulation either individually or in combination." | ( Getzenberg, RH; Johnson, CS; Konety, BR; Trump, DL, 1999) |
| "For patients with local recurrence of prostate cancer after definitive irradiation therapy there is no treatment widely considered safe and effective." | ( Adler, HL; Aguilar-Cordova, E; Herman, JR; Rojas-Martinez, A; Scardino, PT; Thompson, TC; Timme, TL; Wheeler, TM; Woo, S, 1999) |
| "Androgen-independent (AI) prostate cancer (CaP) resulting from progression of disease is untreatable." | ( Bennett, S; Berry, J; Downing, SR; Hill, MA; Joshua, A; Kingsley, EA; Mason, RS; Russell, PJ; Yu, Y, 1999) |
| "Stage A2, B or C prostate cancers were randomized to one of two groups: (i) group I (n=90), who received androgen deprivation (leuploride and chlormadinone acetate) for 3 months preoperatively followed by radical prostatectomy and adjuvant endocrine therapy (leuploride only); and (ii) group II (n=86), who underwent the surgery followed by 3 month androgen deprivation and subsequent adjuvant endocrine therapy." | ( Akaza, H; Aso, Y; Hirao, Y; Homma, Y; Moriyama, N; Ohashi, Y; Okada, K; Sakamoto, A; Tsushima, T; Usami, M; Yokoyama, M, 1999) |
| "TSU-Pr1 prostate cancer cells treated with okadaic acid demonstrated activation of caspase-3, PARP cleavage, and nuclear fragmentation by 24 h and apoptosis by 72 h." | ( Bowen, C; Gelmann, EP; Kikly, K; Voeller, HJ, 1999) |
| "We found that the androgen-independent prostate cancer cell line PC-3 undergoes terminal differentiation and apoptosis after treatment with sodium butyrate (NaBu)." | ( Huang, H; Reed, CP; Shridhar, V; Smith, DI; Wang, L; Zhang, JS, 1999) |
| "A seventy-three year-old patient with prostate cancer underwent radical prostatectomy, followed by total androgen brocking therapy using flutamide and LH-RH agonist." | ( Kinebuchi, Y; Murata, Y; Okaneya, T, 1999) |
| "Three human prostate cancer cell lines PC-3, DU145 and LNCaP were treated with one of the phosphodiesterase inhibitors, papaverine, 3-isobutyl-1-methylxanthine (IBMX) or theophylline, for 6 days." | ( Goto, T; Hida, A; Hosaka, Y; Kasuya, Y; Kawabe, K; Kitamura, T; Matsushima, H; Ohta, Y; Simizu, T; Takeda, K, 1999) |
| "At 12 different hospitals, 52 prostate cancer patients were treated, whereby 25 patients received a s." | ( Gulati, A; Jocham, D; Klippel, KF; Möser, B; Rübben, H; Winkler, CJ, 1999) |
| "Biopsies were taken from 16 men with prostate cancer (T1-3,Nx,M0) before the start (START) of androgen deprivation with LHRH analogue, during the following pelvic lymph node dissection (PLND), and twice after radiotherapy (POSTRAD and FINAL)." | ( Berner, A; Dahl, O; Fosså, SD; Ogreid, P; Rettedal, E, 1999) |
| "Of the 136 patients with prostate cancer enrolled in this study from April 1990 to December 1992, 69 received endocrine plus UFT therapy and the remaining 67 received endocrine-only therapy." | ( Kawada, Y; Kuriyama, M; Ohshima, S; Ono, Y; Shimizu, H; Takahashi, Y, 1999) |
| "We retrospectively reviewed 121 prostate cancer patients who received long-term antiandrogen, either flutamide (n = 56) or cyproterone acetate (n = 65), and had normal pretreatment serum alanine aminotransferase (ALT) levels." | ( Chen, J; Kao, JH; Lai, MK; Liu, CM; Pu, YS, 1999) |
| "Brachytherapy is widely used for prostate cancer in the USA." | ( Inoue, T, 1999) |
| "The localized prostate cancer can be treated curatively by radiation therapy." | ( Andreopoulos, D; Krenkel, B; Piatkowiak, M; Schleicher, UM; Wolff, JM, 1999) |
| "Patients with clinically localized prostate cancer with poor prognostic features (pretreatment PSA > or = 10 ng/ml, Gleason score > or = 7, and/or T2c or greater palpation stage) show improved rates of bNED control and a trend towards improved DMFS when treated with 3DCRT and short-term adjuvant hormones compared with 3DCRT alone." | ( Hanks, GE; Hanlon, AL; Horwitz, EM; Pinover, WH, 1999) |
| "Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists." | ( Bartsch, G; Culig, Z; Eder, IE; Erdel, M; Hittmair, A; Hobisch, A; Hoffmann, J; Klocker, H; Parczyk, K; Schneider, MR; Utermann, G, 1999) |
| "A total of 201 patients with metastatic prostate cancer, progressive after hormonal therapy and antiandrogen withdrawal (if prior antiandrogen treatment), were randomized to receive vinblastine (V) 4 mg/m(2) by intravenous bolus weekly for 6 weeks followed by 2 weeks off, either alone or together with estramustine phosphate (EM-V) 600 mg/m(2) PO days 1 through 42, repeated every 8 weeks." | ( Ansari, R; Balsham, A; Dugan, W; Einhorn, L; Entmacher, M; Hanna, M; Hudes, G; Loehrer, P; Monaco, F; Ramsey, H; Ross, E; Roth, B; Sprandio, J, 1999) |
| "Endocrine treatments for prostate cancer, such as castration, combined androgen blockade and non-steroidal antiandrogen monotherapy, have shown similar results in terms of time to progression and survival." | ( Iversen, P, 1999) |
| "Following treatment of human prostatic cancer DU-145 cells with the varying concentrations of NH(4)Cl for 3 days, cell growth was inhibited by approximately 50% at 5 mM NH(4)Cl and almost completely inhibited at 10 mM NH(4)Cl." | ( Choudhury, MS; Davidson, SD; Konno, S; Luddy, JS; Mallouh, C; Parekattil, SJ; Tazaki, H; Won, JH, 1999) |
| "Twenty-two patients with prostate cancer or other advanced malignancies were treated with CRA/IFNalpha and escalating doses of TAX." | ( DiPaola, RS; Goodin, S; Gupta, E; Hait, WN; Medina, M; Medina, P; Patel, J; Rafi, MM; Rubin, E; Toppmeyer, D; Vyas, V; White, E; Zamek, R; Zhang, C, 1999) |
| "These results suggest that prostate cancer patients with bone metastases in whom ALP flare is observed in response to hormonal therapy tend to have more extensive bone metastases, high pretreatment PSA levels, to be resistant to PSA normalization and more likely to experience biochemical failure." | ( Kagawa, S; Kanayama, H; Taue, R, 1999) |
| "The cause of death was prostate cancer in 3 men in the immediate-treatment group and in 16 men in the observation group (P<0." | ( Crawford, ED; Manola, J; Messing, EM; Sarosdy, M; Trump, D; Wilding, G, 1999) |
| "In summary, prostate cancers developing during finasteride therapy may have distinct biological properties, such as a low number of chromosomal alterations and frequent involvement of the AR gene." | ( Ehren-van Eekelen, C; Helin, H; Kallioniemi, OP; Koivisto, PA; Schleutker, J; Trapman, J, 1999) |
| "A given prostate cancer patient's response to therapy may be predicted by following apoptotic and mitotic activity, as well as Ki-67 and p53 expression in repeated biopsies." | ( Bély, M; Lovász, S; Romics, I; Szegedi, Z; Szende, B; Torda, I, 1999) |
| "Treatment of androgen responsive prostate cancer cells with dihydrotestosterone leads to a rapid and reversible activation of mitogen-activated protein kinases MAPKs (also called extracellular signal-regulated kinases or Erks)." | ( Becker, M; Cato, AC; Klocker, H; Mink, S; Peterziel, H; Schonert, A, 1999) |
| "Treatment of hormone-refractory prostate cancer (HRPC) historically has shown limited efficacy." | ( Kantoff, PW; Oh, WK, 1999) |
| "The treatment of advanced prostate cancer has evolved rapidly in the last several years." | ( Reese, DM; Small, EJ; Vogelzang, NJ, 1999) |
| "Patients with prostate cancer and their physicians need knowledge of treatment options and their potential complications, but limited data on complications are available in unselected population-based cohorts of patients." | ( Albertsen, PC; Eley, JW; Feng, Z; Gilliland, FD; Hamilton, AS; Harlan, LC; Potosky, AL; Stanford, JL; Stephenson, RA, 2000) |
| "Severe hepatotoxicity occurred in a prostate cancer patient treated with 375 mg of flutamide per day, 125 mg three times a day, for 11 weeks." | ( Koyama, M; Matsumoto, M; Nakagawa, Y, 1999) |
| "Patients with advanced prostate cancer (n = 371) were randomized to treatment with goserelin acetate alone or a combination of goserelin acetate plus either long-term or short-term antiandrogen (chlormadinone acetate) or short-term estrogen (diethylstilbestrol diphosphate)." | ( Akaza, H; Aso, Y; Hirao, Y; Homma, Y; Isaka, S; Kanetake, H; Kawabe, K; Koiso, K; Kotake, T; Kumazawa, J; Naito, S; Ohashi, Y; Ohi, Y; Okajima, E; Orikasa, S; Saito, Y; Shimazaki, J; Usami, M; Yoshida, O, 1999) |
| "Limited options for the treatment of prostate cancer have spurred the search for new therapies." | ( Blutt, SE; Kattan, MW; Polek, TC; Stewart, LV; Weigel, NL, 2000) |
| "Patients with Stage D2 prostate cancer were treated with surgical or medical (LHRH analog) castration combined with either estrogen, chlormadinone acetate or flutamide as initial therapy." | ( Hamano, S; Kinsui, H; Murakami, S; Oikawa, T; Shimazaki, J; Suzuki, N; Tanaka, M, 2000) |
| "Patients with metastatic prostate cancer progressing on androgen ablation therapy without demonstrable antiandrogen withdrawal response were treated with losoxantrone 50 mg/m2 i." | ( Finizio, M; Huan, SD; Natale, RB; Roberts, JD; Sartiano, GP; Stella, PJ; Stewart, DJ; Symes, AL, 2000) |
| "Human prostate cancer PC-3 cells were treated with various concentrations of the highly purified beta-glucan preparation Grifron-D(R) (GD), and viability was determined at 24 h." | ( Choudhury, MS; Fullerton, SA; Konno, S; Mallouh, C; Samadi, AA; Tazaki, H; Tortorelis, DG, 2000) |
| "The detection and treatment of prostate cancer has been markedly improved by the use of Prostate-Specific Antigen (PSA) as a serological biomarker for disease." | ( Jakobovits, A; Reiter, RE; Saffran, DC; Witte, ON, 1999) |
| "The anatomic extent of prostate cancer has long served the role of providing prognostic information to assist in therapeutic decision-making, evaluating treatment outcomes, facilitating information exchange between medical centers, and promoting cancer research." | ( Davis, BJ; Pisansky, TM, 2000) |
| "Historically, hormone-refractory prostate cancer has not been routinely treated with chemotherapy, based on perceptions that single agents were not all that active, this patient population was too fragile to receive such therapy, responses were virtually impossible to verify given the rarity of bidimensionally measurable disease, and, if seen, responses were not clinically meaningful." | ( Roth, BJ, 1999) |
| "Developing gene therapy for prostate cancer is important, because there is no effective treatment for patients in the advanced stages of this disease." | ( Pang, S, 2000) |
| "We attempted to establish a new prostate cancer therapy by controlling the malignancy of tumor cells through the induction of differentiation in vitro." | ( Shimizu, T; Takahashi, N; Takeda, K, 2000) |
| "Chemoprevention of prostate cancer is the administration of agents to prevent, inhibit, or delay progression of prostate cancer." | ( Graefen, M; Hammerer, P; Huland, H; Steuber, T, 2000) |
| "PC-3 and LNCaP prostate cancer cells were heat-shocked and then treated with or without diethyl-maleate, etoposide, cycloheximide, or 3 Gray irradiation." | ( Brady, HP; Coffey, RN; Fitzpatrick, JM; Gibbons, NB; Watson, RW, 2000) |
| "Nude mice bearing PSA-producing human prostate cancer xenografts were treated either intraperitoneally (IP) or by continuous infusion with the Dox prodrug." | ( Denmeade, SR; Khan, SR, 2000) |
| "LNCaP, PC-3 and DU 145 prostatic cancer cell lines were induced to undergo apoptosis after treatment with etoposide alone or plus androgen ablation." | ( López, A; Salido, M; Vilches, J, 2000) |
| "Our results indicate that treatment of prostate cancer cells with doxazosin or terazosin results in a significant loss of cell viability, via induction of apoptosis in a dose-dependent manner, whereas tamsulosin had no effect on prostate cell growth." | ( Benning, CM; Kyprianou, N, 2000) |
| "In men with locally advanced prostate cancer, bicalutamide 150 mg monotherapy provides a similar disease outcome to medical or surgical castration." | ( Anderson, J, 2000) |
| "Seven patients with hormone-resistant prostate cancer were entered into the study, one at 15 mg/m2, four at 20 mg/m2 and two at 23 mg/m2 of carboplatin, and received a median of four cycles of treatment." | ( Olver, IN; Schulze, D; Stephenson, J, 2000) |
| "Endocrine treatment of prostate cancer has been established for more than 5 decades." | ( Stege, R, 2000) |
| "Patients with prostate cancer are treated with neoadjuvant, adjuvant and intermittent androgen deprivation therapy." | ( Bagiella, E; Benson, MC; Katz, AE; Nejat, RJ; Rashid, HH, 2000) |
| "In the treatment of prostate cancer, radiation therapy currently is being evaluated in combination with androgen deprivation (AD)." | ( Garzotto, M, 2000) |
| "Patients with localized prostate cancer receiving adjuvant chemotherapy had a higher initial objective response rate (95% vs 53%, P = 0." | ( Halford, S; Lynch, M; Rigg, A; Roylance, R; Wang, J; Waxman, J, 2000) |
| "All four of the doxorubicin-selected prostate cancer cell lines exhibited a multidrug resistance phenotype; administration of verapamil restored doxorubicin sensitivity for each of the drug resistant sublines." | ( Campbell, PA; David-Beabes, GL; de Marzo, AM; Nelson, WG; Overman, MJ; Petrofski, JA, 2000) |
| "A 59-year-old man with prostate cancer and pain from multiple bone metastases was treated with 1,424 MBq (38." | ( Franke, WG; Hliscs, R; Kropp, J; Liepe, K, 2000) |
| "Human leukaemic HL-60 and prostate cancer LNCaP and JCA-1 cells were treated with Onc in the absence and presence of several inducers of differentiation and frequency of apoptosis was assessed using three different cytometric methods and confirmed by analysis of cell morphology." | ( Darzynkiewicz, Z; Halicka, HD; Mikulski, SM; Mittelman, A; Murakami, T; Papageorgio, CN; Shogen, K, 2000) |
| "These data suggest that prostate cancer is not as resistant to chemotherapy as it was once thought to be." | ( Kelly, WK; Slovin, SF, 2000) |
| "Ninety-five patients with prostate cancer were divided into one of three groups: 26 patients with bone metastasis (BM(+)), 35 patients without bone metastasis on nonhormonal therapy (BM(-)HT(-)) and 34 patients without bone metastasis on hormonal therapy (BM(-)HT(+))." | ( Fukunaga, M; Jo, Y; Sone, T; Tamada, T; Tanaka, H; Tomomitsu, T, 2001) |
| "Current therapy for locally advanced prostate cancer is suboptimal." | ( Ben-Josef, E; Chuba, P; Fontana, J; Han, S; Hussain, M; Mertens, W; Porter, AT, 2001) |
| "These findings suggest that some prostate cancer patients who appear to become hormone-independent may have tumors which are stimulated by P(5) via a mutated AR and that these patients could benefit from treatment with antiestrogens, antiprogestins, or with some of our novel androgen synthesis inhibitors." | ( Brodie, AH; Grigoryev, DN; Long, BJ; Njar, VC, 2000) |
| "Evidence from studies in patients with prostate cancer of intermittent hormone therapy combined with results from rechallenge of hormone resistant patients with testosterone demonstrate that the majority of prostate cancers retain a similar degree of dependence on male sex hormone milieu as normal prostate cells." | ( Oliver, RT; Slater, S, 2000) |
| "The benefit of adjuvant hormones in prostate cancer patients receiving definitive radiation therapy (RT) in RTOG 85-31 and 86-10 has previously been reported." | ( Hanks, GE; Horwitz, EM; Lawton, CA; Machtay, M; Russell, AH; Winter, K, 2001) |
| "The most common treatment of prostate cancer is androgen ablation therapy which leads to regression of the tumor due to increased cell death." | ( Engedal, N; Saatcioglu, F, 2001) |
| "One of the mechanisms through which prostate cancers relapse during anti-androgen therapy may involve adaptation to low concentrations of androgen induced by anti-androgen therapies." | ( Fujimoto, N; Harada, S; Keller, ET; Koshida, K; Matsumoto, T; Mizokami, A; Namiki, M, 2001) |
| "Although prostate cancer initially responds well to endocrine therapy, it becomes resistant to the therapy a few years later, and is called hormone-refractory cancer." | ( Fujimoto, N; Harada, S; Hida, T; Matsumoto, T, 2001) |
| "In men receiving 3DCRT for prostate cancer, these data indicate that sildenafil citrate is effective for restoring SF and associated satisfaction back to baseline before treatment." | ( Chen, C; Choi, E; Gomella, LG; Hirsch, IH; Lu, JD; Mulholland, GS; Valicenti, RK, 2001) |
| "We reported previously that human prostate cancer cell line TSU-Pr1 can differentiate into microglia-like cells by 12-O-tetra-decanoylphorbol-13-acetate (TPA) treatment." | ( Hamada, H; Shimizu, T; Sugibayashi, R; Suzuki, T; Takeda, K; Yamamoto, N, 2001) |
| "Treatment of hormone refractory prostate cancer requires new treatment strategies." | ( Dalgleish, AG; Eaton, JD; Griffiths, JR; Kirby, RS; Mazucco, RA; Perry, MJ; Todryk, SM, 2001) |
| "Interstitial brachytherapy for prostate cancer leads to a high incidence of acute urinary toxicity, most of which is mild to moderate in severity." | ( Anscher, MS; Bowen, MG; Buckley, NJ; Chou, RH; Clough, RW; Das, SK; Dodge, RK; Ingram, SS; Joyner, RE; Kang, HL; Kang, SK; Kim, JH; Montana, GS; Sarmina, I; Steffey, BA; Whitehurst, AW; Zhou, SM, 2001) |
| "The implications for possibly treating prostatic cancer using fewer and larger fractions are important." | ( Chappell, R; Fowler, J; Ritter, M, 2001) |
| "In this study, brachytherapy for prostate cancer was preceded by using low-dose rate Ir-192." | ( Dokiya, T; Momma, T; Murai, M; Saito, S, 2001) |
| "Four cultured human prostate cancer cell lines (LnCap, DU145, DuPro, and PC-3) were treated with the new tetramines to examine their effects on cell growth with a MTT assay." | ( Basu, HS; Frydman, B; Marton, LJ; Reddy, VK; Sarkar, A; Valasinas, A, 2001) |
| "We report the clinical evolution of a prostate cancer, metastasizing to lungs and bones, recurring locally, and escaping from anti-androgen therapy." | ( Bras-Gonçalves, R; Broqua, P; Courty, Y; de Pinieux, G; Dutrillaux, AM; Dutrillaux, B; Junien, JL; Legrier, ME; Lidereau, R; Némati, F; Oudard, S; Poirson-Bichat, F; Poupon, MF, 2001) |
| "Treating prostate cancer in the D0 stage or in the neoadjuvant setting will result in biochemical evidence of testosterone surge, but these patients are at very little risk for clinical flare responses." | ( Bubley, GJ, 2001) |
| "Although the large, phase-3 Prostate Cancer Prevention Trial (PCPT) of finasteride versus placebo has established the feasibility and role of ADT for primary prevention, nevertheless, limitations of the anticipated treatment-effect size (eg, 25% reduction) and the potential for selection of androgen resistance provide incentive for finding other effective chemopreventive agents." | ( Lieberman, R, 2001) |
| "The high rate of progression of prostate cancer after androgen deprivation therapy mandates that new strategies be developed." | ( Feldman, D; Peehl, DM; Seto, E, 2001) |
| "Although their ultimate value in prostate cancer therapy remains to be defined in randomized trials, docetaxel and paclitaxel are active agents in HRPC." | ( Hudes, GR; Obasaju, C, 2001) |
| "The human prostate cancer cell lines LNCaP, MDA PCa 2a, MDA PCa 2b, PC-3, and TSU-Pr1 were treated with 0." | ( Brooks, JD; Paton, VG; Vidanes, G, 2001) |
| "LNCaP human prostate cancer cells were treated with IL-6 at a concentration of 5 ng/ml." | ( Bartsch, G; Culig, Z; Fuchs, D; Godoy-Tundidor, S; Hobisch, A; Klocker, H; Ramoner, R, 2001) |
| "Long-term treatment of LNCaP human prostate cancer cells with IL-6 leads to abolishment of inhibitory growth response." | ( Bartsch, G; Culig, Z; Fuchs, D; Godoy-Tundidor, S; Hobisch, A; Klocker, H; Ramoner, R, 2001) |
| "Still, treatment of prostate cancer lags behind treatment of other malignancies." | ( Haas, NB, 2001) |
| "Forty-two men with prostate cancer and indications for androgen ablation were treated with one, two, or four implants." | ( Bardin, CW; Chertin, B; Farkas, A; Frick, J; Gomahr, A; Jungwirth, A; King, P; Kuzma, P; Mack, D; Moo-Young, A; Nash, H; Schlegel, PN; Spitz, I, 2001) |
| "Approximately 2-10% of prostate cancer patients treated with 125I or 103Pd brachytherapy will develop radiation proctitis." | ( Billingsley, K; Dominitz, JA; Han, B; Smith, S; Sutlief, S; True, L; Wallner, K, 2001) |
| "No effect on the development of the prostate cancer precursor lesions (prostate intraepithelial neoplasia) was observed when mice were treated with DHEA, DFMO, tocopherol acetate, selenomethionine, or 9-cis-retinoic acid, although the effects on late-stage prostate cancer development were not determined." | ( Anver, MR; Green, JE; Kelloff, G; Lubet, R; Moon, RC; Shibata, E; Shibata, MA, 2001) |
| "Over the past 10 years, men with prostate cancer have received earlier diagnoses and are undergoing prostatectomy and/or radiation therapy with curative intent; however, many men have increasing prostate-specific antigen (PSA) levels without evidence of local progression or metastatic disease during the first 2 years after definitive local therapy." | ( Bubley, GJ; Ko, YJ; Morganstern, DE; Rajeshkumar, B; Shuster, T; Taplin, ME, 2001) |
| "The trend toward earlier diagnosis of prostate cancer and technological advances in radiotherapeutics (eg, imaging enhancement, planning optimization, refinement of calculation algorithms, and computerized delivery systems) have led to increased use of radiation therapy (RT) as primary treatment for presumed localized disease." | ( Senzer, NN, 2001) |
| "A common therapy for nonorgan-confined prostate cancer involves androgen deprivation." | ( Chen, YQ; Feroze, F; Hanash, S; Krause, M; Puravs, E; Schober, MS; Waghray, A; Wood, C; Yao, F, 2001) |
| "Twenty-one patients with metastatic prostate cancer received two monthly vaccinations of xenoantigen-loaded dendritic cells with minimal treatment-associated side effects." | ( Benike, C; Breen, JK; Brockstedt, D; Engleman, EG; Fong, L; Ruegg, CL; Strang, G, 2001) |
| "The 2 androgen independent prostate cancer cell lines PC-3 and DU 145 were treated with docetaxel or paclitaxel." | ( Frenkel, EP; Hsieh, JT; Li, Y; Lombardi, DP; Okegawa, T, 2002) |
| "A human prostate cancer cell (PC-3) model was exposed to 5-fluorouracil (5-FU) for 2 and 4 days (prefreeze), freezing (-5 to -100 degrees C), or a combination of the two treatments, and each was assessed for effectiveness over a 2-week posttreatment period." | ( Baust, JG; Baust, JM; Clarke, DM; Van Buskirk, RG, 2001) |
| "The identification in many prostate cancer specimens of a mutant androgen receptor, T877A, with altered ligand specificity has provided an explanation for some treatment failures." | ( Chang, CY; McDonnell, DP; Walther, PJ, 2001) |
| "Treatment of human prostate cancer cells, LNCaP, with cadmium stimulated cell growth." | ( Danielsen, M; Gelmann, EP; Hebert, EJ; Lu, J; Martin, MB; Pentecost, E; Reiter, R; Singh, B; Stoica, A; Stoica, EG; Voeller, HJ, 2002) |
| "Four human prostate cancer cell lines (LNCap, JCA-1, DU-145 and PC-3) and 24 pairs of untreated prostate cancer tissue and noncancerous tissue from resected prostate glands were subjected to RT-PCR testing." | ( Ito, T; Murai, M; Nakashima, J; Tachibana, M; Yamamoto, S, 2001) |
| "Therapy for prostate cancer in the PC3 tumor-nude mouse model with 90yttrium-(90Y)-DOTA-peptide-ChL6 (5." | ( DeNardo, GL; DeNardo, SJ; Kukis, DL; Lamborn, KR; Meyers, FJ; Miers, LA; O'Donnell, RT, 2002) |
| "Nude mice bearing human prostate cancer PC3 xenografts were treated with 90Y-DOTA-peptide-ChL6 (2." | ( DeNardo, GL; DeNardo, SJ; Kukis, DL; Lamborn, KR; Meyers, FJ; Miers, LA; O'Donnell, RT, 2002) |
| "One hundred and two cases of advanced prostate cancer were treated either with Leuplin alone (group I), Leuplin and Estracyt (group II) or Estracyt alone (group III)." | ( Aoki, S; Fujioka, T; Hasegawa, S; Hata, M; Hayakawa, M; Ikeuchi, K; Izawa, A; Kimura, S; Matsunaga, J; Murai, M; Nagakura, K; Naide, Y; Nakajima, Y; Nakamura, S; Nakashima, J; Nakazono, M; Oda, T; Ogawa, Y; Saito, S; Shibayama, T; Suzuki, K; Tanoguchi, H; Tazaki, H; Yamamoto, Y, 2001) |
| "The initial treatment of advanced prostate cancer is suppression of testicular androgen production by medical or surgical castration, but nearly all men with metastases will develop disease progression." | ( Harris, KA; Reese, DM, 2001) |
| "Four weeks later, PC3 human prostate cancer cells were injected directly into some of the implants, and daily treatment was begun with batimastat (a broad-spectrum MMP inhibitor)." | ( Bhagat, S; Che, M; Cher, ML; Fridman, R; Herzog, M; Mullins, C; Nemeth, JA; Shekarriz, B; Upadhyay, J; Yousif, R, 2002) |
| "Earlier estimates of alpha/beta for prostate cancer have relied on comparing results from external beam radiotherapy (EBRT) and brachytherapy, an approach with significant pitfalls due to the many differences between the treatments." | ( Armour, EP; Brenner, DJ; Edmundson, GK; Martinez, AA; Mitchell, C; Thames, HD, 2002) |
| "All patients with prostate cancer were either treated with external beam radiotherapy without androgen deprivation or were started on androgen deprivation therapy." | ( Pitts, WR; Scherr, D; Vaughn, ED, 2002) |
| "For metastatic prostatic cancer presenting with an emergency oncologic condition, the treatment of choice is surgical orchiectomy, but surgery may not be possible in the presence of severe DIC." | ( Amornpichetkul, K; Chakrapee-Sirisuk, S; Sangruchi, T; Sinlarat, P; Srimuninnimit, V; Visudhiphan, S, 2001) |
| "The models are extended to accommodate prostate cancer as a survival endpoint; this is compared to treating it as a binary endpoint." | ( Lin, H; McCulloch, CE; Slate, EH; Turnbull, BW, 2002) |
| "PC-SPES is a herbal mixture used by prostate cancer patients as an alternative form of treatment." | ( Hsieh, TC; Wu, JM, 2002) |
| "Twenty-two patients with prostate cancer underwent PET after intravenous administration of 740 MBq (11)C-acetate." | ( Akino, H; Kanamaru, H; Muramoto, S; Okada, K; Oyama, N; Sadato, N; Suzuki, Y; Yamamoto, K; Yonekura, Y, 2002) |
| "In early, androgen dependent stages of prostate cancer, androgen withdrawal, the major course of therapy in prostate cancer, leads to a rapid regression of the tumor as a result of apoptosis." | ( Engedal, N; Korkmaz, CG; Saatcioglu, F, 2002) |
| "Despite the high frequency of prostate cancer, therapeutic options for advanced disease are limited to chemotherapy, radiation or hormonal therapy and eventually fail in all patients." | ( Kongkanand, A; Matsumiya, K; Nishimura, K; Nonomura, N; Okuyama, A; Permpongkosol, S; Takahara, S; Tsujimura, A; Wang, JD, 2002) |
| "Patients with Stage T1b-T3bN0 prostate cancer, and Gleason score > or = 7 or prostate-specific antigen (PSA) level >10 ng/mL were treated with seed implantation with or without HTx." | ( Lee, LN; Stock, RG; Stone, NN, 2002) |
| "In our study, LNCaP prostate cancer cells were treated with GA for 30 minutes or 24 hours, in the presence of mibolerone, a synthetic androgen." | ( Mitchell, SH; Toft, DO; Vanaja, DK; Young, CY, 2002) |
| "Advanced prostate cancer is treated initially by central suppression of androgen production by luteinizing hormone-releasing hormone (LHRH) agonists." | ( Bailey, KJ; Kassis, J; Solava, J; Souto, JC; Turner, T; Wells, A, 2002) |
| "MRI is a valuable staging procedure for prostate cancer patients treated by SI." | ( Able, AM; Artiles, C; Banks, SJ; Blair, DN; Clarke, DH; Hindle, WV; Houk, RR; Klousia, JW; Lissy, JM; Miller, M; Sheridan, MJ; Wiederhorn, AR, 2002) |
| "Hormone refractory metastatic prostate cancer has been treated with circadian-timed FUDR chemotherapy; however, without objective response." | ( Hrushesky, WJ; Kobayashi, M; Wood, PA, 2002) |
| "Here, we show that treatment of prostate cancer PC-3 and LNCaP cells with the benzoquinone ansamycin geldanamycin, an Hsp90-specific inhibitor, induced degradation of HIF-1alpha protein in a dose- and time-dependent manner under both normoxia and hypoxia." | ( Kaur, B; Mabjeesh, NJ; Post, DE; Simons, JW; Van Meir, EG; Willard, MT; Zhong, H, 2002) |
| "To improve the therapy of advanced prostate cancer (CaP), it is critical to develop animal models that mimic CaP bone metastases." | ( Bladou, F; Brown, JM; Brown, LG; Buhler, KR; Corey, E; Quinn, JE; Roudier, MP; Vessella, RL, 2002) |
| "We have demonstrated the utility of two prostate cancer-specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer." | ( Chung, LW; Gardner, TA; Gotoh, A; Kamidono, S; Kao, C; Ko, SC; Shirakawa, T; Wada, Y, 2000) |
| "One hundred thirty-four patients with prostate cancer treated with transperineal brachytherapy from 1997 to 1999 had rectal toxicity data available for analysis." | ( Anscher, MS; Buckley, NJ; Chou, RH; Clough, RW; Dodge, RK; Hahn, CA; Ingram, SS; Joyner, RE; Kang, HS; Kang, SK; Kim, JH; Montana, GS; Whitehurst, AW, 2002) |
| "Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen-independence is frequently observed later." | ( Furuya, Y; Fuse, H; Nagakawa, O; Nozaki, T, 2002) |
| "Moreover, selenomethionine (SM), a prostate cancer treatment adjuvant, shows an inhibitory effect on LNCaP cell growth, yet has no effect on the AR/PSA pathway." | ( Chang, E; Messing, EM; Ni, J; Yang, CR; Yeh, S; Zhang, Y, 2002) |
| "An important role in the development of prostate cancer is played by androgens and androgen ablation is therefore currently used in cancer treatment." | ( Prinsloo, SE; van Aswegen, CH, 2002) |
| "Conformal therapy of prostate cancer is based on high-dose irradiation to the entire prostate gland." | ( Cellini, N; Digesu', C; Dinapoli, N; Leone, M; Luzi, S; Manfredi, R; Mattiucci, GC; Morganti, AG; Smaniotto, D; Valentini, V, 2002) |
| "A hormone-refractory human prostate cancer cell line, PC-3, was treated with ATS alone at 10 pg/ml, PYY or BA-129 alone at doses of 75 and 500 pmol/ml, or a combination of the two agents." | ( Balsubramaniam, A; McFadden, DW; Rose, AT; Somasundar, P; Vona-Davis, L; Yu, A, 2002) |
| "Twenty patients with Stage B2/T2 prostate cancer who were treated for a median duration of 7." | ( Candas, B; Cusan, L; Gomez, JL; Labrie, F, 2002) |
| "Nutritional prevention of prostate cancer is very different from the use of dietary or nutritional treatments for established prostate cancer." | ( Bahnson, R; Clinton, SK; Erdman, JW; Giovannucci, E; Miller, EC; Schwartz, SJ, 2002) |
| "Current approaches to the management of prostate cancer include surgery, radiation therapy or hormonal manipulation either individually or in combination." | ( Getzenberg, RH; Konety, BR, 2002) |
| "A 75-year-old man with metastatic prostate cancer had been treated with goserelin acetate, and prostate specific antigen (PSA) had decreased, but 11/2 years after beginning the treatment of goserelin acetate, PSA was markedly elevated and serum testosterone was at normal level." | ( Kinouchi, T; Kuroda, M; Maeda, O; Meguro, N; Ono, Y; Usami, M, 2002) |
| "Because of the high prevalence of prostatic cancer and the limitations of its treatment, enormous effort has been put into the development of new therapeutic modalities." | ( Hajdúch, M; Hlobilková, A; Kolár, Z; Lenobel, R; Lukesová, M; Mad'arová, J; Murray, PG; Perera, S; Strnad, M; Vojtesek, B, 2002) |
| "We reported previously that human prostate cancer cell line TSU-Pr1 can differentiate into neuronal cells by staurosporine treatment." | ( Shimizu, T; Tachibana, K; Takeda, K; Tonami, K, 2002) |
| "Current therapy for advanced prostate cancer is largely based on androgen deprivation and is mostly palliative because all patients eventually relapse with androgen-independent disease." | ( Hsieh, JT; Logothetis, CJ; Martinez, LA; Navone, NM; Olive, M; Rodriguez-Vargas, Mdel C; Vazquez, ES; Yang, J, 2002) |
| "A total of 57 patients with localized prostate cancer were treated with interstitial hyperthermia using cobalt-palladium thermoseeds and conformal radiation between July 1997 and December 2000." | ( Boehmer, D; Budach, V; Deger, S; Loening, SA; Roigas, J; Türk, I, 2002) |
| "Metastatic prostate cancer, which is the precursor of most deaths from the disease, is treated most commonly with hormonal therapy." | ( Basler, J; Crawford, ED; Tangen, C; Thompson, IM, 2002) |
| "While men with metastatic prostate cancer frequently show a good initial response to androgen ablation, few options have been available for progressive hormone-refractory prostate cancer, and survival following chemotherapy has not exceeded 9 to 12 months." | ( Petrylak, DP, 2002) |
| "The indication is local recurrence of prostate cancer after definitive radiation therapy." | ( Aguilar-Cordova, E; Barton, K; Brown, S; DePeralta-Venturina, M; Freytag, SO; Khil, M; Kim, JH; Lu, M; Menon, M; Nafziger, D; Paielli, D; Peabody, J; Pegg, J; Stricker, H, 2002) |
| "Treatment for prostate cancer other than surgery included radiotherapy in eight patients, administration of estramustine phosphate sodium in nine patients, and LH-RH analogues in six patients." | ( Fukasawa, R; Imao, S; Mikata, N, 2002) |
| "Patients with hormone relapsed prostate cancer (HRPC) are often treated with flutamide or diethylstilboestrol." | ( Basketter, V; Burns-Cox, N; Higgins, B; Holmes, S, 2002) |
| "Patients with locally advanced prostate cancer (TNM clinical stage T3, T4) who were treated using external-beam radiotherapy (EBRT) and 3 years of androgen deprivation therapy (ADT) were compared with patients treated with EBRT alone and were shown to have a survival benefit." | ( D'Amico, AV, 2002) |
| "Many patients with prostate cancer for whom hormonal therapy is indicated are still physically and sexually active; quality of life is therefore a vital issue when considering treatment options." | ( Iversen, P, 2002) |
| "Because the three prostate cancer cell lines demonstrated similar morphological changes after the raloxifene treatment, PC3 (ER-alpha/ER-beta+) and DU145 (ER-beta+ only) cells were selected to further characterize the raloxifene-induced cell death." | ( Hong, YJ; Kim, BC; Kim, HT; Kim, IY; Kim, SJ; Lee, DK; Morton, RA; Seo, JM; Seong, DH, 2002) |
| "Under the diagnosis of prostatic cancer with multiple pulmonary metastasis, we performed total androgen blockade (TAB) consisting of luteinizing hormone releasing hormone agonist and flutamide following dietylstilbestrol (DES) intravenous injection therapy." | ( Fukuda, M; Fuse, H; Hirano, S; Takashima, H, 2002) |
| "We analyzed whether classifying bone prostate cancer metastases correlates with survival in patients treated primarily with androgen deprivation." | ( Bouchot, O; Buzelin, JM; Glemain, P; Karam, G; Le Normand, L; Rigaud, J; Tiguert, R, 2002) |
| "Patients with hormone-refractory prostate cancer and a history of bone metastases were randomly assigned to a double-blind treatment regimen of intravenous zoledronic acid at 4 mg (N = 214), zoledronic acid at 8 mg (subsequently reduced to 4 mg; 8/4) (N = 221), or placebo (N = 208) every 3 weeks for 15 months." | ( Chen, B; Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ, 2002) |
| "Chemotherapy of prostate cancer with antimitotic agents such as vinblastine and doxorubicin is only marginally effective, due to dose-limiting systemic toxicity." | ( Brady, SF; DeFeo-Jones, D; Feng, DM; Freidinger, RM; Garsky, VM; Jones, R; Lin, JH; Lumma, PK; Miller-Stein, C; Oliff, A; Pawluczyk, JM; Wai, JM; Wong, BK, 2002) |
| "Twenty selected patients with prostate cancer, who were treated with hormonal therapy and demonstrated biochemical downstaging by reduction of PSA prior to RP and bilateral pelvic node dissection at the Tohsei National Hospital between January 1997 and August 2001, are reported on." | ( Kiriyama, I; Nishimura, T; Ogaki, K; Ohba, S, 2002) |
| "Treatment of leukemic Jurkat T or prostate cancer LNCaP cells with either (+)-EGCG or (+)-GCG accumulated p27 and IkappaB-alpha proteins, associated with an increased G(1) population." | ( Chan, TH; Dou, QP; Kazi, A; Li, LH; Smith, DM; Wang, Z, 2002) |
| "Treatment of the hormone refractory prostate cancer cell line DU 145 with sublethal concentrations of chemotherapeutic drugs has been reported to sensitise these cells to Fas mediated apoptosis." | ( Cotter, TG; Curtin, JF, 2002) |
| "We treated three human prostate cancer cell lines with etoposide, a toposiomerase II inhibitor with activity against various tumors including prostate cancer." | ( Ishida, E; Kishi, M; Konishi, N; Nakamura, M; Shimada, K; Yonehara, S, 2002) |
| "A 73-year-old man with metastatic prostate cancer treated with weekly docetaxel chemotherapy for 5 months developed an acute nail dystrophy restricted to the fingernails." | ( Howard, A; Nicolopoulos, J, 2002) |
| "LNCaP-C4 prostate cancer cells were treated with Mifepristone and/or Tamoxifen." | ( Eid, MA; El Etreby, F; Kumar, MV; Lewis, RW; Liang, Y, 2002) |
| "Patients with hormone refractory prostate cancer who are asymptomatic but had progressive disease had a significantly higher response rate when treated with mitoxantrone and prednisone as demonstrated by the 50% or greater decrease in prostate specific antigen compared to treatment with prednisone alone." | ( Asmar, L; Berry, W; Dakhil, S; Gregurich, M; Modiano, M, 2002) |
| "A total of 128 patients with prostate cancer underwent 3-D conformal radiation therapy (median dose 70." | ( Bissonette, EA; Chen, C; Theodorescu, D; Valicenti, RK, 2002) |
| "Recently, chemotherapy for prostate cancer has been primarily reserved for the palliation of symptoms secondary to prostate cancer." | ( Carducci, MA; Walczak, JR, 2002) |
| "The first Conference on Asian Trends in Prostate Cancer Hormone Therapy was held in September 2001 to serve as a forum for Asian urologists to compare data on prostate cancer and discuss issues regarding the use of hormone therapy." | ( Akaza, H; Chang, SJ; Cheng, C; Esuvaranathan, K; Gu, FL; Hirao, Y; Hong, SJ; Huang, CH; Kaisary, A; Kim, WJ; Lee, SE; Murai, M; Naito, S; Rim, JS; Soebadi, DM; Song, JM; Tsukamoto, T; Umbas, R; Usami, M; Yang, CR; Yoon, JH; Zhou, L, 2002) |
| "In a prostate cancer cell line, PC3, mevastatin treatment led to elevated levels of p21 and caused a small increase in the p21 associated with cdk2." | ( Dutta, A; Ukomadu, C, 2003) |
| "goserelin in patients with prostate cancer on androgen suppression therapy." | ( Oefelein, M, 2003) |
| "For patients with advanced prostate cancer, hormonal manipulation including castration and antiandrogen therapy is a well-established mode of treatment." | ( Chiang, YJ; Chu, SH; Chuang, CK; Lin, MH; Lin, SJ; Wei, TY; Wu, CT, 2002) |
| "Treatment of DU-145 prostatic cancer cells with genistein led to a time- and dose-dependent inhibition of CYP24." | ( Cross, HS; Farhan, H, 2002) |
| "The progression of prostate cancer from androgen-responsive to an androgen-unresponsive state remains the greatest obstacle in the treatment of this disease." | ( Kondrikov, D; Lin, MF; Rothermund, CA; Vishwanatha, JK, 2002) |
| "Increased insight into the biology of prostate cancer and the emergence of new therapeutic strategies and chemotherapeutic agents has changed approaches in treating patients with advanced prostate cancer." | ( Sternberg, CN, 2003) |
| "Most prostate cancers (PCs) become resistant to combined androgen blockade therapy with surgical or medical castration and antiandrogens after several years." | ( Araki, H; Hara, T; Kanzaki, N; Kusaka, M; Miyamoto, M; Miyazaki, J; Yamaoka, M, 2003) |
| "The exact staging of prostate cancer is mandatory to allow selection of the appropriate primary therapy." | ( Ackermann, R; Coenen, HH; Hautzel, H; Herzog, H; Krause, BJ; Müller-Gärtner, HW; Müller-Mattheis, V; Roden, W, 2002) |
| "If detected at an early stage, prostate cancer is highly treatable." | ( Nelson, PS, 2002) |
| "The progression of prostate cancer during androgen deprivation therapy is a serious clinical problem." | ( Härkönen, P; Isomaa, V; Kurkela, R; Lindfors, A; Porvari, K; Pulkka, A; Törn, S; Vihko, P, 2003) |
| "The mainstay of hormonal therapy in prostate cancer has been medical or surgical castration, both of which are associated with loss of libido and impotence, and may not always be acceptable to the patient." | ( Anderson, J, 2003) |
| "Patients with stage T1b-T3 prostate cancer who were not scheduled for radical prostatectomy were allocated into two groups: group 1 (73 men) received luteinizing hormone-releasing hormone (LHRH) agonist monotherapy and group 2 (78 men) received LHRH agonist and chlormadinone acetate." | ( Akaza, H; Aso, Y; Hirao, Y; Homma, Y; Ohashi, Y; Okada, K; Tsushima, T; Usami, M; Yokoyama, M, 2003) |
| "For hormone resistant prostate cancer (HRPC), chemotherapy is used but the mortality is 100% with a mean survival time of 7-8 months." | ( Aranha, O; Fernandes, N; Grignon, R; McDonnell, TJ; Sarkar, FH; Wood, DP, 2003) |
| "When prostate cancer cell lines were treated with hypomethylating agent, 5-aza-2(')-deoxycytidine (DNMT inhibitor), HDAC1 and HDAC2 expression was decreased." | ( Carroll, P; Dahiya, R; Patra, A; Patra, SK; Zhao, H, 2003) |
| "In LNCaP prostate cancer cells, the natural ligand 5alpha-dihydrotestosterone (DHT) activates transiently transfected AR-responsive promoter constructs; concurrent treatment with the protein kinase A activator forskolin enhanced AR stimulation induced by DHT." | ( Clark, PE; Coetzee, GA; Jia, L; Kim, J; Shen, H; Tilley, WD, 2003) |
| "Twenty patients with prostate cancer were treated with 300 mg genistein/d for 28 d and then with 600 mg/d for another 56 d." | ( Craciunescu, CN; Crowell, J; Fischer, L; Jeffcoat, RA; Koch, MA; Lopaczynski, W; Mahoney, C; Miltyk, W; Paglieri, J; Zeisel, SH, 2003) |
| "Androgen deprivation as a treatment for prostate cancer has evolved since the pioneering studies of Huggins and Hodges 60 years ago using surgical castration or estrogen treatments." | ( Sartor, O, 2003) |
| "In most cases, however, prostate cancer cells eventually lose androgen dependency and become refractory to the conventional endocrine therapy." | ( Aoki, K; Furuhata, S; Ide, H; Miura, Y; Yoshida, T, 2003) |
| "Patients with non-organ confined prostate cancer (pT3-T4) showed significantly lower pretreatment total testosterone levels than those with organ confined cancer (pT1-T2) (nonparametric p = 0." | ( Amling, C; Chung, A; Donahue, T; Foley, J; Kusuda, L; Lance, R; Massengill, JC; McLeod, DG; Moul, JW; Sexton, W; Soderdahl, D; Sun, L; Wu, H, 2003) |
| "A total of 20 patients with prostate cancer progression during Gn-RH agonist therapy received 100 mg." | ( Beer, TM; Eilers, KM; Garzotto, M; Lemmon, D, 2003) |
| "Treatment of androgen independent prostate cancer with abarelix decreases circulating FSH and maintains anorchid testosterone but does not result in clinical responses." | ( Beer, TM; Eilers, KM; Garzotto, M; Lemmon, D, 2003) |
| "The results of Stage B2/C prostate cancer treated with this method were analyzed." | ( Igaki, H; Kaizu, T; Karasawa, K; Matsuda, T; Niibe, Y; Shinohara, M; Tanaka, Y, 2003) |
| "Between 1987 and 1997, 33 cases of prostate cancer were definitively treated with this method: 9 Stage B2 tumors and 24 Stage C tumors." | ( Igaki, H; Kaizu, T; Karasawa, K; Matsuda, T; Niibe, Y; Shinohara, M; Tanaka, Y, 2003) |
| "We herein present two cases of prostate cancer associated with acute myeloid leukemia (AML) presenting as thrombocytopenia during endocrine therapy." | ( Arima, K; Matsuura, H; Sakurai, M, 2003) |
| "Progression of prostate cancer ultimately results in a disease that is refractory to hormone ablation therapy but nevertheless continues to require the androgen receptor." | ( Bakin, RE; Bissonette, EA; Gioeli, D; Sikes, RA; Weber, MJ, 2003) |
| "Long-term pamidronate treatment of prostate cancer bone metastases does not generally affect the ability to detect bone metastases with Tc99 MDP bone scintigraphy." | ( Higano, CS; King, SH; Ott, SM; Roudier, MP; True, LD; Vessella, RL; Vesselle, H, 2003) |
| "Study 1 employed 99 patients with prostate cancer: 39 were untreated, 25 were treated with LH-RH agonist therapy alone, and 35 were treated with oral diethylstilbestrol diphosphate (DESdP) 300 mg per day." | ( Hayashi, N; Ikemoto, I; Oishi, Y; Suzuki, H; Ueda, M; Wada, T, 2003) |
| "Androgen-sensitive prostate cancer cell line (LNCaP) cells plated on sterile glass coverslips were treated with 10(-8) M dihydrotestosterone (DHT) or epidermal growth factor (EGF) (10 ng/ml) for periods ranging from 1 min to 96 h." | ( Bell, WC; Grizzle, WE; Hosein, TO; Myers, RB; Oelschlager, DK, 2003) |
| "A total of 373 patients with T1-T2 prostate cancer underwent radioactive seed implant using 125I (n = 337) or 103Pd (n = 36) without hormonal therapy or external beam RT." | ( Cesaretti, JA; Stock, RG; Stone, NN, 2003) |
| "Twenty five patients with prostate cancer treated by androgen ablation and showing a steady increase in serum prostate specific antigen (PSA) were treated with low-dose dexamethasone." | ( Akakura, K; Ichikawa, T; Igarashi, T; Ito, H; Komiya, A; Suzuki, H; Ueda, T, 2003) |
| "The role of chemotherapy in prostate cancer continues to evolve." | ( Lau, YK; Trump, D, 2003) |
| "CAM is used by almost 1/3 of prostate cancer patients in Austria, particularly by those with disease progression, impaired quality of life and treatment satisfaction." | ( Madersbacher, S; Ponholzer, A; Struhal, G, 2003) |
| "Men with M0 (no distant metastases) prostate cancer beginning androgen deprivation therapy were randomly assigned to receive 4 mg." | ( Eastham, J; Gleason, DM; Shasha, D; Smith, MR; Tchekmedyian, S; Zinner, N, 2003) |
| "A greater understanding of prostate cancer metastasis is required if new treatment strategies are to be developed." | ( Coleman, RE; Eaton, CL, 2003) |
| "Patients with localized prostate cancer frequently seek alternatives to radical surgery and external beam radiation therapy." | ( Ahmed, SN; Eichling, J; Michalski, J; Mutic, S, 2003) |
| "Androgen-independent prostate cancer is resistant to therapy and is often metastatic." | ( Fu, X; Fu, YM; Ge, X; Li, YQ; Meadows, GG; Sanchez, PJ; Yu, ZX, 2003) |
| "Thirteen prostate cancer patients with skeletal involvement were treated with 2,700-3,459 MBq (mean dose, 3,120 MBq) (188)Re-HEDP." | ( Franke, WG; Hliscs, R; Knapp, FF; Kropp, J; Liepe, K; Runge, R, 2003) |
| "However, patients with metastatic prostate cancer are usually treated with LHRH analogue." | ( Awakura, Y; Fujikawa, K; Nishimura, S; Okabe, T; Watanabe, R, 2003) |
| "Patients with advanced prostate cancer (castrate and noncastrate) were administered escalating doses of weekly 1-h infusion of i." | ( Curley, T; Fallon, M; Hartley-Asp, B; Kelly, WK; Larson, S; Pellizzoni, C; Rocchetti, M; Scher, H; Schwartz, L; Slovin, S; Tong, W; Zhu, AX, 2003) |
| "Patients with clinical T3 or T4 prostate cancer or with elevated serum prostate-specific antigen (PSA) levels greater than 40 ng/ml are at high risk of failure with primary treatment." | ( Febbo, P; Kantoff, PW; Kaplan, ID; Kaufman, DS; Manola, J; Oh, WK; Prisby, J, 2003) |
| "New approaches to treat prostate cancer (PCA) are utilizing gene therapy and aim to correct the disease at the genetic level." | ( Alken, P; Knoll, T; Michel, MS; Sagi, S; Schaaf, A; Trojan, L, 2003) |
| "Thirty-six patients with localized prostate cancer, treated by either radical prostatectomy (n=20) or by external beam radiotherapy (n=16) were studied with 11C-choline PET." | ( de Jong, IJ; Elsinga, PH; Mensink, HJ; Pruim, J; Vaalburg, W, 2003) |
| "The treatment of hormone resistant prostate cancer) with epirubicin 25 mg/m(2)(Epi25) on a weekly intravenous regimen may be better in terms of health related quality of life (HRQOL) than with 100 mg/m(2)(Epi100) on a 4-weekly regimen." | ( Caris, CT; Carpentier, P; de Bruin, MJ; Debruyne, FM; Fernandez de Moral, P; van Andel, G; Wils, J; Witjes, JA; Witjes, WP, 2003) |
| "Staging of advanced prostate cancer may be enhanced by FDG-PET imaging in patients who are untreated, who have had an incomplete response to therapy, or who have a rising PSA level despite treatment." | ( Espiritu, JI; Segall, GM; Sung, J; Terris, MK, 2003) |
| "In patients with localized prostate cancer the combination of neo-adjuvant hormonal therapy and radiotherapy has been associated with improved survival compared to radiotherapy alone." | ( Widmark, A, 2003) |
| "This offers the potential to treat prostate cancer with radioiodine." | ( Bergert, ER; Göke, B; Morris, JC; Scholz, IV; Spitzweg, C; Tindall, DJ; Young, CY, 2003) |
| "For good prognosis metastatic prostate cancer patients under anti-androgen treatment, PSA response at 6 months with cut-off levels of < or = 1 ng/ml and < or = 10 ng/ml is prognostic for survival." | ( Collette, L; de Reijke, TM; Schröder, FH, 2003) |
| "The alarmingly high rate of prostate cancer (PCA) mortality as well as the limited success in the treatment of advanced PCA suggest that additional approaches are needed to control PCA growth and its metastatic potential." | ( Agarwal, C; Agarwal, R; Dhanalakshmi, S, 2003) |
| "Patients with local recurrent prostate cancer following initial brachytherapy including those with seminal vesicle invasion can be successfully treated with pararectal stereotactic CT-guided reimplantation." | ( Bondy, H; Gil-Montero, G; Hendricks, F; Katz, S; Khawand, N; Koutrouvelis, P; Lailas, N; Sehn, J, 2003) |
| "LNCaP-derived C4-2 human prostate cancer cells are quite resistant to treatment with Apo2 ligand (Apo2L) or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), when using a nontagged, Zn-bound recombinant trimeric version that is devoid of any exogeneous sequences and therefore least likely to be immunogenic in human patients and that has been optimized for maximum efficacy and minimum toxicity." | ( Almasan, A; Ray, S, 2003) |
| "Thirty-nine patients (30 of whom had prostate cancer) were treated in cohorts of three patients each with escalating atrasentan doses (2." | ( Carr, RA; Groenewegen, G; Humerickhouse, RA; Isaacson, JD; Janus, TJ; Leahy, TW; Voest, E; Zonnenberg, BA, 2003) |
| "Several preoperative prostate cancer nomograms have been developed that predict risk of progression using pretreatment prostate-specific antigen (PSA) level, clinical stage, and biopsy Gleason grade." | ( Andrews, B; Canto, E; Kattan, MW; Matsumoto, K; Muramoto, M; Ohori, M; Scardino, PT; Shariat, SF; Slawin, KM; Wheeler, TM; Zhu, K, 2003) |
| "Hypoxia is also associated with human prostate cancers, which are highly resistant to chemotherapy." | ( Adams, MA; Frederiksen, LJ; Graham, CH; Heaton, JP; Maxwell, LR; Siemens, DR, 2003) |
| "Human prostate cancer PC3 cells were treated in vitro with psychosomatic power emitted by a Buddhist-Zen Master." | ( Hwang, ML; Tsai, HL; Yu, T, 2003) |
| "The Bicalutamide Early Prostate Cancer Program is the largest study under way to define the role of adjuvant treatment in early prostate cancer and identify subgroups of patients likely to benefit from immediate hormonal therapy." | ( Froehner, M; Wirth, MP, 2003) |
| "In patients with hormone-refractory prostate cancer, BPs might be administered for analgesic purposes." | ( Heidenreich, A, 2003) |
| "Hormonal treatment of advanced prostate cancer should be considered for patients who have stages C and D1 disease, a high risk of recurrence after local therapy, or prostate-specific antigen-measured recurrence after local treatment." | ( Crawford, ED; Oottamasathien, S, 2003) |
| "Participants are men with biopsy-proven prostate cancer who have elected to forgo therapy and be closely followed by 'watchful waiting' that includes quarterly prostate-specific antigen (PSA) screening." | ( Ahmann, FR; Alberts, DS; Marshall, JR; Minter, FE; Monroe, BK; Reid, ME; Schwartzberg, G; Stratton, MS, 2003) |
| "Ten men with conservatively treated prostate cancer were randomised to a daily supplement of 295 g of rye bran bread and eight men to 275 g of wheat bread (control) with similar fibre content for three weeks." | ( Adlercreutz, H; Aman, P; Bergh, A; Bylund, A; Hallmans, G; Kaaks, R; Lundin, E; Nilsson, TK; Nordin, A; Stattin, P; Stenman, UH; Zhang, JX, 2003) |
| "As the prognosis of HG prostate cancer is poor, these tumours should be analysed by immunohistochemical staining to identify specific tumour features for an appropriate selection of adjuvant therapy." | ( Augustin, H; Daghofer, F; Erbersdobler, A; Graefen, M; Hammerer, PG; Huland, H; Palisaar, J, 2003) |
| "Growth of human prostate cancer cells, LNCaP and PC-3 cells, was suppressed by zinc or cadmium treatment in a dose-dependent manner." | ( Hasumi, M; Ito, K; Koike, H; Matsui, H; Suzuki, K; Yamanaka, H, 2003) |
| "Identified proteins expressed in prostate cancer, including prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), and prostate-specific membrane antigen (PSMA), have been used as immunologic targets for immunotherapy." | ( Fong, L; Small, EJ, 2003) |
| "The bicalutamide 150mg Early Prostate Cancer (EPC) programme is the largest clinical trial programme in the treatment of prostate cancer to date." | ( Garside, L; Iversen, P; McLeod, D; Morris, T; See, W; Wirth, M, 2003) |
| "Patients with prostate cancer being treated with combined androgen block would develop a significant degree of anemia." | ( Cheng, SG; Hua, LX; Sui, YG; Wu, HF; Xu, ZQ; Zhang, W, 2003) |
| "Although treatment of PC3 prostate cancer cells with G3139, which contains two CpG motifs, causes a dramatic decrease in bcl-2 protein expression after 3 days, it did not result in significant cellular apoptosis, as it does in many other cell lines." | ( Benimetskaya, L; Lai, JC; Miller, PS; Santella, RM; Stein, CA; Wang, Q, 2003) |
| "The standard of care in advanced prostate cancer is androgen deprivation therapy." | ( Clark, PE; Torti, FM, 2003) |
| "Patients with prostate cancer at high risk for recurrence despite local therapy include those with clinical stage T3 disease, biopsy Gleason scores of 8 to 10 or serum prostate specific antigen greater than 20 ng/ml." | ( Oh, WK, 2003) |
| "Systemic therapy for advanced prostate cancer is improving." | ( Oh, WK, 2003) |
| "Androgen refractory prostate cancer continues to evade effective treatment." | ( Nelson, JB, 2003) |
| "Patients with prostate cancer and other solid tumors are also at high risk for skeletal complications, and, until recently, no effective treatment had been identified." | ( Hohneker, J; Lacerna, L, 2003) |
| "We report a first case of prostate cancer in a patient with Klinefelter syndrome who had undergone long-term testosterone replacement therapy since childhood for chronically depressed levels of testosterone." | ( Dharmawardana, PG; Hwang, JJ; Phillips, JL; Uchio, EM; Wynberg, J, 2003) |
| "Models for human prostate cancer can facilitate the study of resistance to endocrine therapy, aid drug discovery, and pre-clinical assessment." | ( Goddard, L; Harper, ME; Nicholson, RI; Smith, C, 2004) |
| "The failure of prostate cancer treatment is largely due to the development of androgen independence, since the androgen depletion therapy remains the front-line option for this cancer." | ( Lee, DT; Ling, MT; Tam, PC; Tsao, SW; Wang, X; Wong, YC, 2004) |
| "In DHT-treated androgen-sensitive prostate cancer LNCaP C-33 cells, the protein level of p66(Shc) was elevated by approximately 3-fold, correlating with increased cell growth." | ( Chen, SJ; Christman, JK; Igawa, T; Johansson, SL; Lee, MS; Lin, FF; Lin, JS; Lin, MF; Van Bemmel, D, 2004) |
| "A total of 57 patients with metastatic prostate cancer aged 59-80 years (median 74 years) were entered in the study and were randomized to the treatment of estramustine phosphate (560 mg/day) plus LHRH agonist (estramustine group) or flutamide (375 mg/day) plus LHRH agonist (flutamide group) with stratification for the degree of performance status, histological differentiation and bone metastasis." | ( Itoh, K; Noda, S; Noguchi, M; Shiraishi, T; Ueda, S; Yoshida, M, 2004) |
| "Bioluminescent PC-3M-luc-C6 human prostate cancer cells were implanted subcutaneously into SCID-beige mice and were monitored for tumor growth and response to 5-FU and mitomycin C treatments." | ( Contag, PR; Dusich, J; Hornig, YS; Jenkins, DE; Oei, Y; Purchio, T; Yu, SF, 2003) |
| "A new anti-prostate cancer MAb, BLCA-38, was radioiodinated (I125) and assessed for its ability to target subcutaneous human prostate cancer (DU-145) xenografts after systemic intraperitoneal administration." | ( Carter, T; Doughty, L; Hattarki, M; Hewish, D; Kortt, AA; Ow, K; Russell, PJ; Shapira, D; Sterling-Levis, K, 2004) |
| "For 96 patients with T1b-T3 prostate cancer, three carbon ion beams were used to irradiate the prostate and seminal vesicles (20 times/5 weeks) with or without endocrine therapy." | ( Akakura, K; Akaza, H; Fujime, M; Harada, M; Hata, M; Isaka, S; Ito, H; Morita, S; Shimazaki, J; Tsuji, H; Tsujii, H; Yagishita, T, 2004) |
| "To develop molecular targets for prostate cancer treatment, JAK kinase and STAT3 inhibition of two prostate cancer lines were compared." | ( Barton, A; Barton, BE; Huang, HF; Karras, JG; Murphy, TF, 2004) |
| "Recurrent prostate cancer specimens from 22 men whose prostate cancer recurred locally during androgen deprivation therapy and benign prostate specimens from 48 men who had received no prior treatment were studied." | ( Ford, OH; French, FS; Gregory, CW; Kim, D; Mohler, JL; Petrusz, P; Weaver, CM; Wilson, EM, 2004) |
| "HDR monotherapy as prostate cancer treatment resulted in the same biochemical control with much lower toxicity." | ( Chen, PY; Goldman, K; Grills, IS; Gustafson, GS; Hollander, M; Huang, R; Martinez, AA, 2004) |
| "In locally advanced M0 prostate cancer bicalutamide 150 mg monotherapy seems equivalent to castration in terms of overall survival and time to progression." | ( Cardi, A; Di Silverio, F; Sciarra, A, 2004) |
| "The majority of men with advanced prostate cancer (PCa) respond to androgen deprivation therapy (ADT) with objective evidence of tumor regression." | ( Conaway, MC; Gregory, CW; McPherson, RA; Santen, RJ; Yue, W, 2004) |
| "Men participating in the 2001 and 2002 Prostate Cancer Awareness Week screening for prostate cancer were given a self-administered questionnaire." | ( Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C, 2004) |
| "Pretreatment of prostate cancer cells harboring wild-type or mutant androgen receptor with the GSK-3beta inhibitors, lithium chloride (LiCl), RO318220, or GF109203X, inhibited R1881-stimulated androgen-responsive reporter activity in a dose- and time-dependent manner." | ( Holzbeierlein, J; Li, B; Liao, X; Stanley, S; Thrasher, JB, 2004) |
| "Standard therapy of metastatic prostate cancer consists of androgen deprivation, which is a palliative therapy yielding a clinical response of limited duration." | ( Johannsen, M; Loening, SA; Schnorr, D; Wilke, K, 2004) |
| "We report on two patients with prostatic cancer who received a therapy with flutamide." | ( Haupt, R; Lübbert, C; Ruf, BR; Wiese, M, 2004) |
| "This offers the potential to treat prostate cancer with radioiodine." | ( Cengic, N; Göke, B; Morris, JC; Scholz, IV; Spitzweg, C, 2004) |
| "In Japanese patients with advanced prostate cancer, first-line treatment with bicalutamide 80 mg in combination with an LHRH agonist is superior to LHRH agonist monotherapy in terms of the antitumor response at 12 weeks, and also time to treatment failure and progression, and does not compromise treatment safety." | ( Akaza, H; Arai, Y; Igawa, M; Kanetake, H; Kumon, H; Matsuda, T; Naito, S; Ohashi, Y; Soeda, A; Usami, M; Yamaguchi, A, 2004) |
| "LNCaP prostate cancer cells express the aryl hydrocarbon receptor (AhR), and treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 protein and an Ah-responsive reporter gene." | ( Morrow, D; Qin, C; Safe, S; Smith, R, 2004) |
| "Forty-eight patients with pT3pN0M0 prostate cancer and biochemical (prostate-specific antigen) progression after RRP were randomized to bicalutamide monotherapy or pharmacologic castration." | ( Di Silverio, F; Sciarra, A, 2004) |
| "Once metastatic, prostate cancer was regarded as a systemic disease that is not amenable to surgical therapy." | ( Brooks, JD; Chao, DH; Higgins, JP, 2004) |
| "Altogether, 40 patients with advanced prostate cancer received the LH-RH analog, Decapeptyl (D), as monotherapy for 1 month." | ( Farid, P; Lovász, S; Romics, I; Szende, B, 2003) |
| "We treated 5 patients diagnosed with prostate cancer between September and November 2002." | ( Fujisawa, Y; Harano, M; Hida, T; Kano, M, 2004) |
| "The hormonal treatment of advanced prostate cancer involves life disruptive side-effects, such as impotence, libido loss and bodily feminisation." | ( Morag, A; Navon, L, 2004) |
| "Treatment of prostate cancer (CaP) cell lines (DU145, PC-3, CL-1, and LNCaP) with nitric oxide donors (e." | ( Bonavida, B; Cheng, G; Garban, H; Hongo, F; Huerta-Yepez, S; Jazirehi, A; Vega, M, 2004) |
| "To report outcomes for prostate cancer patients treated with external beam radiation therapy (EBRT) and permanent prostate brachytherapy utilizing radioimmunoguided targeting of biological tumor volumes (BTVs)." | ( Colussi, V; Dinchman, KH; Ellis, RJ; Fu, P; Kim, E; Resnick, MI; Sodee, B; Spirnak, JP; Vertocnik, A; Young, B; Zhou, H, 2003) |
| "Seventy-seven patients with T1-T3 prostate cancer received an ultrasound-guided permanent seed implant (36 received (125)I, 7 (103)Pd, and 34 a partial (103)Pd implant plus external beam radiation therapy)." | ( Hong, S; Howard, V; Lo, YC; Stock, RG; Stone, NN, 2003) |
| "(125)I permanent seed brachytherapy for prostate cancer produces good clinical outcomes and limits radiation exposure to medical staff and patients' families." | ( Dogan, N; Glasgow, GP; Mohideen, N, 2002) |
| "Although prostate cancer is traditionally considered a disease of old age, improved diagnostic techniques have resulted in early diagnosis, and many men are now treated while still physically and sexually active." | ( Davis, JW; Schellhammer, PF, 2004) |
| "Sixteen patients with metastasis prostate cancer received hormone therapy with strontium-89 chloride (89Sr), and 4 of them received radiotherapy." | ( Jiang, Y; Ren, X; Yao, D; Ye, C; Ying, J, 2004) |
| "Squamous differentiation in prostate cancer is uncommon, often but not necessarily arising in the setting of prior hormone or radiation therapy, and is associated with a poor prognosis." | ( Chang, S; Epstein, JI; Gaudin, P; Genega, EM; Kronz, JD; Parwani, AV, 2004) |
| "Although many prostate cancer cases relapse to a hormone-insensitive state, endocrine therapy involving androgen depletion by orchiectomy or by treatment with LHRH-analogue as well as blockade of the androgen receptor (AR) with anti-androgens remains a primary treatment option." | ( Ferrari, AC; McCarron, JP; Mencher, SK; Wang, LG, 2004) |
| "Men with prostate cancer were randomly assigned to one of four treatment arms: leuprorelin, goserelin, cyproterone acetate (CPA), or close clinical monitoring." | ( Gardiner, RA; Green, HJ; Headley, BC; Mactaggart, PN; Nicol, DL; Pakenham, KI; Swanson, CE; Watson, RB; Yaxley, J, 2004) |
| "Patients with stage A(2), B or C prostate cancers were randomized to one of two groups: group I (n = 90), who received androgen deprivation (leuprolide and chlormadinone acetate) for 3 months followed by radical prostatectomy and subsequent adjuvant endocrine therapy (leuprolide alone), and group II (n = 86), who underwent the surgery followed by 3-month androgen deprivation (leuprolide and chlormadinone acetate) and subsequent adjuvant endocrine therapy (leuprolide alone)." | ( Akaza, H; Aso, Y; Hirao, Y; Homma, Y; Moriyama, N; Ohashi, Y; Okada, K; Sakamoto, A; Tsushima, T; Usami, M; Yokoyama, M, 2004) |
| "Patients with prostate cancer are initially treated with surgical resection, radiation or antiandrogen therapy." | ( Kyprianou, N; Rowland, RG; Tahmatzopoulos, A, 2004) |
| "Once metastatic, prostate cancer (CaP) treatment options are limited to androgen withdrawal." | ( Busby, JE; Evans, CP; Kung, HJ; Shih, SJ; Yang, JC, 2003) |
| "Two PSA secreting prostate cancer cell lines (LAPC4 and LNCaP) were treated with atrasentan and an ETB receptor antagonist (A192621) in varying concentrations (10(-6)-10(-10) M) and PSA levels were measured in the culture media." | ( Brink, AK; Nelson, JB; Pecher, S; Pflug, BR, 2004) |
| "LNCaP prostate cancer cells were treated with either etoposide or neuropeptides." | ( Roomans, GM; Salido, M; Vilches, J, 2004) |
| "Limited options for the treatment of prostate cancer have spurred the search for new therapies." | ( Allen, BJ; Bander, NH; Li, Y; Rizvi, SM; Tian, Z, 2002) |
| "Once prostate cancer metastasizes to bone, conventional chemotherapy is largely ineffective." | ( Fan, D; Fidler, IJ; He, J; Killion, JJ; Kim, SJ; Langley, RR; Tsan, R; Uehara, H; Yazici, S, 2004) |
| "DU145 and PC-3 prostate cancer cell lines were used; cells were treated with zoledronic acid, with or without several other reagents, to investigate its mechanism of action." | ( Colston, KW; Coxon, JP; Kirby, RS; Oades, GM, 2004) |
| "human prostate cancer (PC3 or 22Rv1) xenografts were treated with the analogs at their maximum tolerated doses." | ( Eger, K; Figg, WD; Gütschow, M; MacPherson, GR; Ng, SS, 2004) |
| "Forty men with prostate cancer were clinically treated with androgen blockade therapy (flutamide and leuprolide) for 36 weeks and subsequently followed up for another 18 weeks after treatment was discontinued." | ( Almeida, OP; Flicker, L; Martins, RN; Spry, N; Waterreus, A, 2004) |
| "In men with prostate cancer, bicalutamide monotherapy increases bone mineral density, lessens fat accumulation, and has fewer bothersome side effects than treatment with a gonadotropin-releasing hormone agonist." | ( Finkelstein, JS; Goode, M; Lee, H; McGovern, FJ; Smith, MR; Zietman, AL, 2004) |
| "In men with prostate cancer, relatively minor side effects of chronic isoflavone treatment were observed including some estrogenic effects (breast changes, increased frequency of hot flashes)." | ( Boan, J; Crowell, JA; Fischer, L; Jeffcoat, AR; Koch, MA; Mahoney, C; Stinchcombe, T; Thomas, BE; Valentine, JL; Zeisel, SH, 2004) |
| "Androgen ablation-refractory prostate cancer patients (stage D3) develop painful bone metastases and limited responsiveness to conventional therapies, hence the lack of universally accepted "gold standard" treatment for this poor prognosis clinical setting." | ( Bogdanos, J; Dimopoulos, T; Karamanolakis, D; Koutsilieris, M; Milathianakis, C; Mitsiades, CS; Tsintavis, A, 2004) |
| "A total of 97 patients with prostate cancer who underwent radiotherapy were retrospectively reviewed to analyze the protective efficacy of Cepharanthin for acute or late toxicity to the bladder/urethra and rectum." | ( Imada, H; Kato, F; Korogi, Y; Morioka, T; Nomoto, S; Ohguri, T; Yahara, K, 2004) |
| "Eligible patients had progressive prostate cancer after androgen deprivation therapy (with documented castration levels of testosterone), an Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate hematologic, renal, and hepatic function." | ( Barrier, RC; George, SL; Gilligan, TD; Halabi, S; Small, EJ; Vogelzang, NJ, 2004) |
| "Treatment of prostate cancer with GnRH agonists results in an initial flare of symptoms that may be prevented by co-administration of a steroidal or non-steroidal antiandrogen." | ( Harzmann, R; Weckermann, D, 2004) |
| "The timing of endocrine treatment for prostate cancer remains controversial." | ( Collette, L; Debois, M; Fosså, SD; Hoekstra, W; Karthaus, PP; Kurth, KH; Schröder, FH, 2004) |
| "In LNCaP human prostate cancer cells, treatment with E7389 also led to generation of hypodiploid cells, activation of caspase-3 and -9, and appearance of cleaved PARP, indicating that E7389 can activate cellular apoptosis pathways under anchorage-independent and -dependent cell culture conditions." | ( Cheng, H; Kawamura, T; Kishi, Y; Kuznetsov, G; Littlefield, BA; Liu, D; TenDyke, K; Towle, MJ; Yu, MJ, 2004) |
| "Using both the human PC3 and rat PAII prostate cancer cell lines have gone on to identify a subset of one hundred and fifty-four genes that demonstrate a similar level of differential expression to Selenium treatment in both species." | ( Brodzeller, T; Datta, MW; Dhir, R; Hessner, MJ; Liu, H; Matysiak, B; Pollard, M; Schlicht, M; Suckow, M; Tonellato, P; Wen, X; Zhou, G, 2004) |
| "He had prostate cancer treated with orchiectomy and hormone therapy 2 years previously." | ( Chau, T; Chen, YH; Cheng, CJ; Lin, SH, 2004) |
| "The treatment of prostate cancer cells with pharmacological concentrations of melatonin influences not only androgen-sensitive but also androgen-insensitive epithelial prostate cancer cells." | ( León, J; Manchester, L; Mayo, JC; Reiter, RJ; Sainz, RM; Tan, DX, 2005) |
| "We surveyed patients with prostate cancer treated with androgen deprivation therapy to examine the influence of hot flashes on quality of life (QOL)." | ( Kanazawa, S; Nishiyama, T; Takahashi, K; Terunuma, M; Watanabe, R, 2004) |
| "Fifty-five outpatients with prostate cancer (M0, 39; M1, 16) treated with androgen deprivation therapy (castration, 15; castration and antiandrogen, 40) were enrolled in this study." | ( Kanazawa, S; Nishiyama, T; Takahashi, K; Terunuma, M; Watanabe, R, 2004) |
| "A 88-year-old man with prostate cancer was receiving non-steroidal anti-androgen therapy (flutamide, 375 mg/day)." | ( Fujimoto, N; Matsumoto, T; Nomura, M; Sato, H, 2004) |
| "Male BALB/C-nu mice bearing PC-3 prostate cancer were treated with docetaxol and retinoic acid singly or synergistically, followed by measurement of the body weight and immunohistochemical examination of serum prostate specific antigen (PSA) and PSA expression in the implanted tumors." | ( Chen, YR; Li, H; Lu, YP; Sun, M; Wang, ZP; Wei, Q; Yang, YR; Yue, ZJ, 2004) |
| "Breast and prostate cancer cells were treated with zoledronic acid alone, doxorubicin alone, or drugs in sequence (doxorubicin before, after, or with zoledronic acid), and the levels of apoptotic death were determined by evaluation of nuclear morphology." | ( Coleman, RE; Evans, CA; Holen, I; Neville-Webbe, HL; Rostami-Hodjegan, A, 2005) |
| "Metastatic prostate cancer-associated antigens recognized by multiple monoclonal antibodies are potential targets for alpha-therapy." | ( Abbas Rizvi, SM; Allen, BJ; Blair nee Brown, JM; Cozzi, PJ; Li, Y; Ow, KT; Perkins, AC; Qu, CF; Russell, PJ; Tam, PN, 2004) |
| "Six patients with hormone refractory prostate cancer were orally administered 560 mg of Estramustine daily in 2 equally divided doses for four or five days." | ( Kanno, T; Shibasaki, N; Takeuchi, H; Taki, Y; Tsuji, Y, 2004) |
| "Forty-eight osteoporotic patients with prostate cancer, treated with 3-month depot triptorelina, were enrolled and randomly assigned to two different treatment groups: group A (n = 24) was treated with a daily calcium and cholecalciferol supplement (500 mg of elemental calcium and 400 IU cholecalciferol), and group B (n = 24) received in addition to the same daily calcium and cholecalciferol supplement, 25 mg of neridronate given intramuscularly every month." | ( Anastasi, G; Atteritano, M; Catalano, A; Frisina, N; Gaudio, A; Lasco, A; Melloni, D; Morabito, N; Trifiletti, A, 2004) |
| "Development in the management of prostate cancer has placed increased attention on patient quality of life after treatment, particularly sexual function." | ( Hellstrom, WJ; Kendirci, M, 2004) |
| "During the course of therapy for prostate cancer, abnormal blood counts and subsequent bone marrow biopsy led to a diagnosis of acute lymphoblastic leukemia." | ( Gandhok, N; Sartor, O, 2004) |
| "Unfortunately, every treatment for prostate cancer has adverse effects with negative impact in health-related quality of life." | ( Baltogiannis, D; Charalabopoulos, K; Giannakopoulos, X; Sofikitis, N, 2004) |
| "Treatment of human prostate cancer LNCaP cell lines with the synthetic liver X receptor agonist T0901317 decreased the percentage of S-phase cells in a dose-dependent manner and increased the expression of cyclin-dependent kinase inhibitor p27(Kip-1) (p27)." | ( Chuu, CP; Fukuchi, J; Hiipakka, RA; Kokontis, JM; Liao, S, 2004) |
| "In 30 of the patients with prostate cancer, dihydrotestosterone levels in prostatic tissue were determined by performing rebiopsy or with prostate tissues excised after 6 months on androgen deprivation therapy with castration and flutamide." | ( Hashimoto, Y; Nishiyama, T; Takahashi, K, 2004) |
| "Stool samples from 15 patients with prostate cancer scheduled for radiation therapy were examined." | ( Dahl, O; Fagerhol, MK; Hovdenak, N; Karlsdottir, A; Larsen, A; Wentzel-Larsen, T, 2004) |
| "Forty-nine men with prostate cancer were treated with ADT before beginning radical therapy for 6 months." | ( Anraku, T; Ishizaki, F; Nishiyama, T; Shimura, H; Takahashi, K, 2005) |
| "Male BALB/C-nu mice with PC-3 prostate cancer cell lines were treated by docetaxol and retinoic acid singly or synergistically in vivo." | ( Li, DJ; Li, H; Li, X; Lu, YP; Sun, M; Wei, Q; Yang, YR, 2004) |
| "A 76-year-old man with prostate cancer T3N0M0 and increasing PSA was treated with goserelin three times in a half year." | ( Berg, P; Ernst, G; Gericke, A, 2004) |
| "The significance of COX-2 in prostate cancer growth and response to chemotherapy was investigated in an androgen-refractory prostate cancer cell line using a Tet-inducible antisense COX-2 expression system." | ( Dandekar, DS; Lokeshwar, BL, 2004) |
| "A total of 17 patients with prostate cancer who had not yet received treatment for the disease underwent whole body PET following intravenous administration of 3." | ( Coel, MN; Ko, JP; Kwee, SA; Lim, J, 2005) |
| "Men with prostate cancer for whom hormonal therapy was indicated were randomized to open-label goserelin 3." | ( Bidair, M; Centeno, A; Tomera, K; Zinner, NR, 2004) |
| "Human prostate cancer cells were evaluated for growth after photodynamic therapy, radiotherapy, and combined treatment." | ( Colasanti, A; Kisslinger, A; Quarto, M; Riccio, P, 2004) |
| "EGCG was incubated with prostate cancer cells, LNCaP, pretreated with or without Cu2+." | ( Shen, SR; Xiong, YK; Yu, HN, 2005) |
| "High dose radiation treatment of prostate cancer cell lines inhibits integrin expression." | ( Fitzgerald, TJ; Goel, HL; Languino, LR; Simon, EL; Teider, N; Wang, T, 2005) |
| "Functional Assessment of Cancer Therapy Prostate Cancer Subscale (FACT-P) quality-of-life questionnaires were completed at baseline and during treatment." | ( Baetz, T; Berry, S; Brundage, M; Canil, CM; Chi, KN; Douglas, L; Ernst, DS; Fisher, B; McKenna, A; Moore, MJ; Pollak, M; Seymour, L; Winquist, E, 2005) |
| "Intratesticular models of prostate cancer appear to be suitable for studying the mechanisms of metastasis and for evaluating various treatment strategies." | ( Egawa, M; Imao, T; Konaka, H; Koshida, K; Mizokami, A; Namiki, M, 2004) |
| "The endocrine therapy used to treat prostate cancer aims to eliminate androgenic activity from the prostatic tissue." | ( Härkönen, P; Herrala, A; Isomaa, V; Kaija, H; Kurkela, R; Laiti, M; Li, Y; Patrikainen, L; Pulkka, A; Soronen, P; Törn, S; Vihko, P, 2004) |
| "IM-9 myeloma cells and C4-2 prostate cancer cells were treated with up to 200 microM concentrations of zoledronic acid, irradiated with single doses of up to 1,000 cGy, or exposed to combinations of both treatments." | ( Algur, E; Häfeli, UO; Macklis, RM, 2005) |
| "Even in the cases of localized prostate cancer, there are a substantial number of patients who undergo endocrine therapy, and their prognosis is affected by the treatment." | ( Kameoka, H; Katayose, K; Kumakawa, K; Shiraiwa, Y; Takahashi, Y; Uchida, H; Yamaguchi, O; Yazaki, J, 2005) |
| "Seventy-seven cases with localized prostate cancer who underwent maximal androgen blockade (MAB) therapy 1 year or longer were pathologically evaluated using repeat biopsy specimens from November 1994 to October 2001." | ( Kameoka, H; Katayose, K; Kumakawa, K; Shiraiwa, Y; Takahashi, Y; Uchida, H; Yamaguchi, O; Yazaki, J, 2005) |
| "Since advanced prostate cancer is difficult to treat, we have chosen a very different approach: the development of vaccines to prevent initial de novo tumor formation." | ( Pollard, M; Suckow, MA; Wolter, WR, 2005) |
| "Cultured prostate cancer cell lines (Du145, DuPro, LNCaP, and PC-3) with and without 5'-aza-2-deoxycytidine treatment, 177 prostate cancer samples, and 69 benign prostatic hyperplasia (BPH) samples were used." | ( Bassett, WW; Breault, JE; Dahiya, R; Enokida, H; Fujime, M; Igawa, M; Kawakami, T; Li, LC; Ogishima, T; Ribeiro-Filho, LA; Shiina, H; Tabatabai, L; Terashima, M; Urakami, S, 2005) |
| "The majority of human prostate cancers overexpress the important antiapoptotic proteins Bcl-2 and/or Bcl-xL, which render tumors resistant to radiation therapy." | ( Chen, J; Davis, M; Lawrence, T; Lippman, ME; Liu, M; Rae, JM; Tang, W; Wang, S; Xu, L; Yang, D, 2005) |
| "Human prostate cancer cell line DU145 was treated with different concentration of baicalin in vitro." | ( Gu, ZQ; Liu, Y; Sun, YH; Xu, CL, 2005) |
| "To establish heavy ion therapy for prostate cancer, three trials have been conducted." | ( Akakura, K, 2005) |
| "Although prostate cancer patients with metastatic lesion initially respond to androgen ablation therapy, almost patients develop to hormone-refractory states." | ( Kubota, Y; Miyoshi, Y; Uemura, H, 2005) |
| "This therapy's purpose is downstaging prostate cancer at radical prostatectomy and thereby improving the prognosis of prostate cancer." | ( Miyakita, H, 2005) |
| "Several clinical trials of prostate cancer gene therapy are currently underway, using therapeutic genes which include suicide genes, immunomodulatory genes, tumor suppressor genes and anti-oncogenes." | ( Kumon, H; Nasu, Y, 2005) |
| "However, PC3, an androgen-insensitive prostate cancer cell line with deletion of p53 showed an appreciable post-transcriptional induction of p21 expression after treatment with pioglitazone." | ( Gartel, AL; Radhakrishnan, SK, 2005) |
| "When local treatments for prostate cancer have failed, and prostate-specific antigen (PSA) rises in the absence of symptoms, there is little consensus as to the best management strategy." | ( Chander, S; Choo, R; Jamieson, M; Vieth, R; Woo, TC, 2005) |
| "Treatment of hormone refractory prostate cancer (HRPC) has generally aimed at increasing symptom free survival in asymptomatic patients and improving quality of life in symptomatic patients." | ( Van Poppel, H, 2005) |
| "Most prostate cancer patients develop androgen-independent recurrent prostate tumors a few years after androgen ablation therapy." | ( Chuu, CP; Fukuchi, J; Hiipakka, RA; Kokontis, JM; Liao, S, 2005) |
| "We examined the relationship between prostate cancer and the MnSOD polymorphism and its interactions with baseline plasma antioxidant levels (selenium, lycopene, and alpha-tocopherol) and beta-carotene treatment among 567 cases and 764 controls nested in the prospective Physicians' Health Study." | ( Gaziano, JM; Giovannucci, E; Kantoff, PW; Leitzmann, MF; Li, H; Ma, J; Stampfer, MJ, 2005) |
| "Twenty patients with prostate cancer were treated with extracorporeal HIFU device( model FEP-BY01 ) and androgen ablation, of whom 15 received orchiectomy and 5 LHRH-a." | ( Hua, LX; Qian, LX; Song, NH; Sui, YG; Wu, HF; Zhang, JX; Zhang, W, 2005) |
| "However, once prostate cancer metastasizes, radiotherapy cannot be used due to the distribution of multiple metastases to lymph nodes and bones." | ( Alicke, B; Biroc, SL; Dinter, H; Müller-Tiemann, B; Parry, G; Parry, R; Sakamoto, C; Schneider, D; Schulze, M; Toy, P; Wada, K; Xuan, JA; Zhao, XY, 2005) |
| "This review highlights developments in prostate cancer imaging that may improve staging and treatment planning for prostate cancer patients." | ( Brassell, SA; McLeod, DG; Rosner, IL, 2005) |
| "Patients with prostate cancer are treated with neoadjuvant, adjuvant and intermittent therapy with gonadotropin-releasing hormone agonists (GnRH-A)." | ( Carter, J; Chatta, G; Dahut, WL; Figg, WD; Gulley, JL; Higano, CS; Hussain, MH; Petrylak, DP; Sartor, O; Steinberg, SM, 2005) |
| "Sixty patients with prostate cancer and osteoporosis were enrolled and randomly assigned to 2 different treatment regimes: group A (30 patients) treated with maximum androgenic blockage (MAB), and group B (30 patients) treated with bicalutamide 150 mg." | ( Anastasi, G; Franchina, F; Frisina, N; Galì, A; Gaudio, A; Magno, C; Maisano, D; Melloni, D; Morabito, N, 2005) |
| "Advanced prostate cancer invariably recurs despite androgen deprivation therapy." | ( Earp, HS; Gregory, CW; Liu, Y; Majumder, S; McCall, W; Mohler, JL; Sartor, CI; Whang, YE, 2005) |
| "However, in androgen-independent prostate cancer patients, who are already orchiectomised, the administration of DES improves symptoms and decreases prostate-specific antigen (PSA)." | ( Ito, K; Koike, H; Oyama, T; Suzuki, K; Takezawa, Y; Yamanaka, H, 2005) |
| "The treatment of advanced prostate cancer remains unsolved; it is a well-known fact that a hormone-resistant state develops after the primary treatment forms (androgen withdrawal)." | ( Fehér, M; Fél, P; Hazay, L; Holman, E; Kisbenedek, L; Kocsis, I; Lipták, J; Papp, G; Pintér, O; Streit, B; Szabó, Z; Tóth, C, 2005) |
| "Men with nonmetastatic prostate cancer and rising PSA despite androgen deprivation therapy have a relatively indolent natural history." | ( Bilhartz, DL; Cook, R; Gittelman, MC; Goessl, C; Hei, YJ; Higano, CS; Hussain, A; Kabbinavar, F; Linnartz, R; Murray, R; Saad, F; Schulman, C; Small, EJ; Smith, MR; Wynne, C; Zheng, M; Zinner, NR, 2005) |
| "The annual mortality rate from prostate cancer appears to remain stable after 15 years from diagnosis, which does not support aggressive treatment for localized low-grade prostate cancer." | ( Albertsen, PC; Fine, J; Hanley, JA, 2005) |
| "In patients with prostate cancer, myelotoxicity after treatment with (177)Lu-J591 can be predicted on the basis of the amount of radioactive dose administered or the BMrad." | ( Bander, NH; Goldsmith, SJ; Hamacher, KA; Konishi, S; Kostakoglu, L; Milowski, MI; Nanus, DM; Vallabhajosula, S, 2005) |
| "Many patients with localised prostate cancer present with symptoms of benign prostatic hypertrophy (BPH) and require neoadjuvant hormone therapy to shrink the gland before brachytherapy." | ( Al-Qaisieh, B; Ash, D; Bottomley, D; Carey, B; Joseph, J, 2005) |
| "For targeted gene delivery to human prostate cancer LNCaP and PC-3 cells and nasopharyngeal cancer KB cells, we developed a folate-linked nanoparticle (NP-F), and evaluated the potential of NP-F-mediated suicide gene therapy in the cells and xenografts with herpes simplex virus thymidine kinase (HSV-tk) and connexin 43 (Cx43)." | ( Hattori, Y; Maitani, Y, 2005) |
| "Progression of human prostate cancer to a malignancy that is refractory to androgen-ablation therapy renders the disease resistant to available treatment options and accounts for the high prostate cancer mortality rate." | ( O'Brian, CA; Stewart, JR, 2005) |
| "In this study, human prostatic cancer cell line LNCaP was found to be resistant to TRAIL-induced apoptosis while it could be restored to TRAIL sensitivity with combination treatment of low concentration of doxorubicin." | ( Bu, J; Chen, F; Hao, Y; Kang, J, 2005) |
| "Endocrine therapy of prostate cancer (PCa) relies on agents which disrupt the biosynthesis of testosterone in the testis and/or by direct antagonism of active hormone on the androgen receptor (AR) in non-gonadal target tissues of hormone action such as the prostate." | ( Attar, RM; Fink, BE; Gottardis, MM; Kick, EK; Lawrence, RM; Lorenzi, MV; Rizzo, CA; Ruan, Z; Salvati, ME; Spires, TE; Takenaka, I; Vite, GD; Weinmann, R; You, D, 2005) |
| "Human prostate cancer xenografts were treated with DES and docetaxel to assess the effects of combining estrogens and taxane in vivo." | ( Bonham, M; Grim, J; Makary, E; Montgomery, RB; Nelson, PS; Stahl, WL; Vessella, R, 2005) |
| "Androgen-independent metastatic prostate cancer is the main obstacle in the treatment of this cancer." | ( Chan, FL; Chan, KW; Chua, CW; Glackin, C; Kwok, WK; Lau, TC; Lee, TW; Ling, MT; Wang, X; Wong, YC; Zhang, X; Zhou, C, 2005) |
| "Thirty-two patients with localized prostate cancer had cognitive assessments at baseline (T1) before the start of drug treatment, at 3 months (T2) or on completing drug treatment but before radiotherapy, and 9 months later (T3)." | ( Bloomfield, DJ; Edginton, TL; Jenkins, VA; Shilling, VM, 2005) |
| "Although patients with prostate cancer with metastatic lesions initially respond to androgen ablation therapy, most patients ultimately develop a hormone-refractory state." | ( Hasumi, H; Kishida, T; Kubota, Y; Makiyama, K; Miyoshi, Y; Nakaigawa, N; Nakamura, M; Ogawa, T; Sugiura, S; Uemura, H; Yao, M, 2005) |
| "Recurrent prostate cancer specimens from 18 men whose cancer recurred locally during androgen deprivation therapy and androgen-stimulated benign prostate specimens from 18 men receiving no hormonal treatments were studied." | ( Lih, FB; Mohler, JL; Schell, MJ; Titus, MA; Tomer, KB, 2005) |
| "In laboratory models of prostate cancer, simultaneous androgen deprivation plus paclitaxel is more effective than sequential treatments." | ( Baybik, J; Chi, KN; Eggener, SE; Eigl, BJ; Ettinger, S; Gleave, ME; Nelson, C; Wang, Z, 2005) |
| "Human prostate cancers express high levels of receptors for BN/gastrin releasing peptide (GRP) that can be used for targeted chemotherapy." | ( Corey, E; Halmos, G; Kanashiro, CA; Letsch, M; Nagy, A; Schally, AV; Stangelberger, A; Szepeshazi, K; Vessella, R, 2006) |
| "However, concomitant treatment of the prostate cancer cells with EGCG and ferrous ions abolished the increase in HIF-1-mediated transcription that was seen with EGCG treatment alone, suggesting that EGCG may act as a ferrous ion chelator." | ( Kim, MH; Thomas, R, 2005) |
| "A total of 20 men were diagnosed with prostate cancer after initiation of testosterone therapy." | ( Amling, CL; Cosgrove, DJ; Gaylis, FD; Ignatoff, JM; Lin, DW; Tutrone, RF, 2005) |
| "A sample of 1,977 men with localized prostate cancer who received external beam radiation therapy or radical prostatectomy in 1994 to 1995 were surveyed for 5 outcome measures of ED treatment, namely treatment, perceived helpfulness, erectile sufficiency, sexual activity frequency and erection maintenance." | ( Beer, TM; Gilliland, FD; Hoffman, RM; Hsieh, YC; Mori, M; Potosky, AL; Stanford, JL; Stephenson, RA, 2005) |
| "Maspin overexpression in prostate cancer cells resulted in an increased ability to attach to ECM-coated plates, and doxazosin treatment considerably antagonized this effect by decreasing the attachment potential to collagen and fibronectin." | ( Kyprianou, N; Sheng, S; Tahmatzopoulos, A, 2005) |
| "Men with advanced prostate cancer now have many treatment options which include first and second-line hormonal therapy, chemotherapy, radiation therapy, (either directed external beam or systemic radio-istotope), and investigational agents on protocols." | ( Higano, CS, 2005) |
| "Specific immunotherapy of prostate cancer may be an alternative or be complementary to other approaches for treatment of recurrent or metastasized disease." | ( Bar Haim, E; Cytron, S; Eisenbach, L; Finkel, E; Goldberger, O; Lemonnier, F; Lugassy, G; Machlenkin, A; Paz, A; Tirosh, B; Tzehoval, E; Vadai, E; Volovitz, I, 2005) |
| "Patients with prostate cancer are at risk for skeletal complications resulting from treatment-induced bone loss and for bone metastases." | ( Green, JR, 2005) |
| "In this trial, prostate cancer prevalence was reduced by 25%; however, an increase in the number of high-grade tumors among the treatment group necessitates the long-term projection of the likely benefits and costs." | ( Etzioni, RD; Penson, DF; Ramsey, SD; Thompson, IM; Zeliadt, SB, 2005) |
| "The treatment of prostate cancer by endocrine therapy induces histological changes of benign or malignant prostate glands." | ( Allory, Y; Cochand Priollet, B; de la Taille, A; Leroy, X; Molinié, V; Paraf, F; Ruffion, A, 2005) |
| "Eligible patients included prostate cancer patients, American Joint Committee on Cancer Stage T1-3, M0 being treated with external beam radiotherapy in the University of Kentucky Department of Radiation Medicine." | ( Bettenhausen, D; Jahraus, CD; Malik, U; Sellitti, M; St Clair, WH, 2005) |
| "ASCENT, the Androgen-Independent Prostate Cancer (AIPC) Study of Calcitriol Enhancing Taxotere, is a double-blind, placebo-controlled randomized clinical trial designed to determine if DN-101, a high-dose oral formulation of calcitriol designed for cancer therapy, significantly increases the proportion of patients who have > 50% reduction in serum prostate-specific antigen (PSA) levels in response to docetaxel." | ( Beer, TM, 2005) |
| "Patients with recurrent or metastic prostate cancer received cyclical periods of treatment with leuprolide acetate and nilutamide for 8 months, and rest periods." | ( Crook, J; Dahrouge, S; Malone, S; Perry, G; Segal, R, 2005) |
| "Changes in a prostate cancer patient's systematic and random setup characteristics during the course of therapy often violate the gaussian assumptions of adaptive and off-line correction models." | ( Balter, JM; Lam, KL; Litzenberg, DW; Sandler, HM; Ten Haken, RK, 2005) |
| "Three prostate cancer patients treated with radioimmunotherapy alone had no grade 3 or 4 toxicity." | ( Chew, HK; DeNardo, GL; Denardo, SJ; Goldstein, DS; Kukis, DL; Lamborn, KR; Lara, PN; Meares, CF; Natarajan, A; O'Donnell, RT; Richman, CM; Shen, S; Tuscano, JM; Wun, T; Yuan, A, 2005) |
| "The human prostatic cancer cells, DU-145, have been treated with pro-apoptotic substances like puromycin (1 microg/ml for 4 and 6 h) and oxygen peroxide (1 mM for 1 h) or exposed to hyperthermic treatment (43 degrees C for 1 h followed by 2 h of recovery)." | ( Dini, L, 2005) |
| "Treatment of several prostate cancer (CaP) cell lines (PC-3, CL-1, and DU-145) with the nitric oxide (NO) donor DETA/NONOate upregulated Fas expression and sensitized the CaP cells to the Fas ligand CH-11 agonist monoclonal antibody-induced apoptosis." | ( Bonavida, B; Garban, H; Hongo, F; Huerta-Yepez, S; Jazirehi, AR; Miki, T; Mizutani, Y; Vega, M, 2005) |
| "The ongoing Early Prostate Cancer (EPC) programme is assessing bicalutamide ('Casodex') 150 mg, either alone or as adjuvant to treatment of curative intent, in patients with localised or locally advanced prostate cancer (n=8113)." | ( Armstrong, J; Iversen, P; McLeod, DG; Morris, C; Payne, H; See, WA; Tyrrell, CJ; Wirth, MP, 2005) |
| "1370 patients with T1-4, MO, any N prostate cancer received bicalutamide 150 mg or placebo adjuvant to radiotherapy of curative intent." | ( Armstrong, J; Iversen, P; McLeod, DG; Morris, C; Payne, H; See, WA; Tyrrell, CJ; Wirth, MP, 2005) |
| "Men with histologically confirmed prostate cancer not amenable to curative surgery or radiation therapy were eligible for the study if they had radiographic or PSA progression on at least one antiandrogen (not nilutamide) despite continued androgen suppression and standard antiandrogen withdrawal periods." | ( Davis, NB; Ryan, CW; Stadler, WM; Vogelzang, NJ, 2005) |
| "Endocrine therapy of prostate cancer has mostly been reserved to patients with advanced stages of the disease." | ( Damber, JE, 2005) |
| "We have been treating localized prostate cancer with high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiation therapy (EBRT) at our institution." | ( Akimoto, T; Ito, K; Kashiwagi, B; Katoh, H; Nakano, T; Noda, SE; Yamamoto, T, 2005) |
| "Among the patients with localized prostate cancer who were treated by 192-iridium HDR brachytherapy combined with hypofractionated EBRT at Gunma University Hospital between August 2000 and November 2004, we analyzed 67 patients who were treated by HDR brachytherapy with the fractionation schema of 9 Gy x two times combined with hypofractionated EBRT." | ( Akimoto, T; Ito, K; Kashiwagi, B; Katoh, H; Nakano, T; Noda, SE; Yamamoto, T, 2005) |
| "In patients with advanced prostate cancer who use leuprorelin, monitoring of serum testosterone is necessary, with onset no later than 12 weeks after start of treatment." | ( Fosså, SD, 2005) |
| "Twenty prostate cancer patients were treated supine with definitive external radiotherapy according to an on-line target localization protocol using three or four intraprostatic gold fiducial markers and an electronic portal imaging device." | ( Herman, MG; Kruse, JJ; Pisansky, TM; Schallenkamp, JM, 2005) |
| "Treatment of PC-3 human prostate cancer cells with MSA was found to induce a number of signature ER stress markers: (a) the survival/rescue molecules such as phosphorylated protein kinase-like ER-resident kinase (phospho-PERK), phosphorylated eukaryotic initiation factor-2alpha (phospho-eIF2alpha), glucose-regulated protein (GRP)-78, and GRP94; and (b) the apoptotic molecules such as caspase-12, caspase-7, and CAAT/enhancer binding protein homologous protein or growth arrest DNA damage-inducible gene 153 (CHOP/GADD153)." | ( Dong, Y; Ip, C; Park, YM; Wu, Y; Zhang, H, 2005) |
| "In patients with advanced forms of prostate cancer bilateral orchiectomy was associated with the lowest incidence of gynecomastia, followed by nonsteroidal antiandrogen therapy, diethylstilbestrol and estrogen in rank order." | ( Darkes, MJ; Dobs, A, 2005) |
| "A total of 80 advanced prostate cancer patients with bladder outlet obstruction were treated by transurethral electrovaporization of the prostate (TVP), plus castration and antiandrogen therapy." | ( Chen, JH; Kong, L; Sheng, XJ; Ye, M; Zhang, L; Zhu, YJ, 2005) |
| "Since CT/CTR expression in prostate cancers increases with tumor progression, the suppression of "CT System" may enhance the effectiveness of chemotherapy." | ( Shah, G; Thomas, S, 2005) |
| "Cultured androgen-sensitive LNCaP prostate cancer cells were treated with tectorigenin of 100 microM for 24 hours." | ( Ringert, RH; Seidlová-Wuttke, D; Seseke, F; Thelen, P; Wuttke, W, 2006) |
| "Human prostate cancer cells PC3 were repeatedly treated in culture with paclitaxel, doxorubicin, or cisplatin with or without bexarotene for 3 months." | ( Lamph, WW; Yen, WC, 2006) |
| "placebo) in the treatment of prostate cancer, both at a late stage of disease following bone metastasis (over 5-month delay of first skeletal event and 36% reduction in global risk of skeletal complications) and at bone demineralization in subjects receiving androgenic depletion (overall improvement of 8% in bone mineral density)." | ( Conti, G, 2005) |
| "Patients with prostate cancer that was progressing despite androgen ablation therapy were treated with i." | ( Habuchi, T; Higashi, S; Ito, A; Ito, N; Kamoto, T; Kinoshita, H; Kunishima, Y; Nakamura, E; Nishiyama, H; Ogawa, O; Segawa, T; Takahashi, T; Yamamoto, S; Yoshimura, K, 2005) |
| "818 men with locally advanced prostate cancer were randomly assigned to: no androgen deprivation (ie, radiotherapy alone: 66 Gy in 33 fractions of 2 Gy per day over 6." | ( Atkinson, C; Christie, D; D'Este, C; Denham, JW; Duchesne, G; Franklin, I; Joseph, D; Kovacev, O; Lamb, DS; Mameghan, H; Matthews, J; North, J; Poulsen, M; Spry, NA; Steigler, A; Tai, KH; Turner, S; Wynne, C, 2005) |
| "In patients with locally advanced prostatic cancer, PEP therapy is associated with a statistically significantly higher risk of CV complications compared to OE." | ( Aro, J; Mikkola, A; Oksanen, H; Rannikko, S; Ruutu, M, 2005) |
| "Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer." | ( Gould, DC; Kirby, RS, 2006) |
| "The onset of the androgen-independent prostate cancer is often associated with up-regulation of the androgen receptor that can cause antagonists to exhibit agonistic activity, which could lead to the failure of androgen ablation therapy." | ( Hernandez, G; Hsieh, JT; Huang, CL; Tseng, CP; Tu, SW; Zhoul, J, 2005) |
| "Anti-androgenic therapy for prostate cancer is associated with an increased risk of osteoporosis and of fracture." | ( Rizzoli, R; Uebelhart, B, 2005) |
| "Mortality from prostate cancer remains a significant problem with current treatment(s), with an expected 30 350 deaths from prostate cancer in 2005." | ( Alli, AA; Gower, WR; Sanchez-Ramos, J; Song, SJ; Vesely, BA; Vesely, DL, 2005) |
| "Androgen deprivation therapy (ADT) for prostate cancer is now used in earlier disease stages and as adjuvant treatment." | ( Beer, TM; Bland, LB; Brunzell, JD; Garzotto, M; Lemmon, D; Purnell, JQ; Ryan, CW; Wersinger, EM, 2006) |
| "Current treatments for prostate cancer are effective in many patients with locally advanced disease, but many of these patients eventually have recurrence." | ( Davis, JJ; Dong, F; Fang, B; Guo, W; Inoue, S; Teraishi, F; Wu, S; Zhang, L, 2006) |
| "Although the overwhelming majority of prostate cancer patients during treatment of LHRH analogue achieve serum testosterone values within the castration range, individual patients may fail to reach this therapeutic goal, probably more often during treatment with leuprolide acetate than with goserelin acetate." | ( Bjoro, T; Fossa, SD; Yri, OE, 2006) |
| "We report a rare case of PRCA in a prostate cancer patient treated with combined androgen blockade (CAB) consisted of leuprolide acetate as a luteinizing hormone-releasing hormone agonist and chlormadinone acetate as an antiandrogen." | ( Kobayashi, M; Morita, T; Nukui, A, 2005) |
| "Metastatic prostate cancer, while initially responsive to androgen ablation, eventually becomes hormone-refractory and resistant to many treatments." | ( Isaacs, JT, 2005) |
| "Of men with metastatic prostate cancer who undergo androgen ablation, 70-80% respond rapidly to therapy, as manifested by a reduction in prostate cancer-related symptoms and declines in serum prostate-specific antigen (PSA) level." | ( Petrylak, D, 2005) |
| "Among prostate cancer patients who were treated with combination of radiation and hormone therapy from 1992, 42 patients who were measured with time in the concentration of testosterone after withdrawal of androgen ablation were selected." | ( Azuma, K; Hashine, K; Numata, K; Sumiyoshi, Y, 2005) |
| "Among prostate cancer patients treated with combination of radiation and hormone therapy, PSA is went up in some of them with recovery of testosterone after withdrawal androgen ablation." | ( Azuma, K; Hashine, K; Numata, K; Sumiyoshi, Y, 2005) |
| "Advanced prostate cancer is often treated with chemotherapy and most of these drugs exert their function by generating genotoxic stress such as DNA damage." | ( Garrett, MD; Mantoni, TS; Reid, G, 2006) |
| "Twenty-six men (15 newly diagnosed with prostate cancer, 2 with recurrent prostate cancer, 6 with no evidence of prostate cancer recurrence after treatment, and 3 with no history of prostate cancer) underwent dual-phase PET consisting of initial whole-body PET starting 7 min after injection of 3." | ( Coel, MN; Kwee, SA; Sesterhenn, I; Wei, H; Yun, D, 2006) |
| "We used the Montreal Prostate Cancer Model, a validated Markov model of prostate cancer progression, to compare the forecasted survival in treated and untreated men." | ( Coupal, L; Grover, S; Hajek, D; Lowensteyn, I; Marchand, S; Trachtenberg, J, 2006) |
| "In hormone-refractory prostate cancer, docetaxel has been studied as both a single agent and in combination with estramustine, and in different treatment schedules, with demonstrated efficacy." | ( Mackler, NJ; Pienta, KJ, 2005) |
| "The limitations of current forms of prostate cancer therapy have driven researchers to search for new alternatives." | ( Aguilar-Cordova, E; Ayala, G; Butler, EB; Frolov, A; Gdor, Y; Kadmon, D; Li, R; Miles, BJ; Rauen, K; Satoh, T; Shalev, M; Teh, BS; Thompson, TC; Wheeler, TM, 2006) |
| "Androgen treatment of AR-positive prostate cancer cells induced dose-dependent GREB1 expression, which was blocked by anti-androgens." | ( Cordero, KE; Gottardis, MM; Johnson, MD; Larios, JM; Lippman, ME; Pienta, KJ; Rae, JM; Scheys, JO, 2006) |
| "We treated several human prostate cancer cell lines with the HDACI trichostatin A and found that trichostatin A induced cell death in androgen receptor (AR)-positive cell lines to higher extent compared with AR-negative cell lines." | ( Cohen, MB; Glover, RB; Guseva, NV; Kohlgraf, KG; Rokhlin, OW; Taghiyev, AF, 2006) |
| "Specifically, no increased risk of prostate cancer was noted in 1) clinical trials of testosterone supplementation, 2) longitudinal population-based studies, or 3) in a high-risk population of hypogonadal men receiving testosterone treatment." | ( Morgentaler, A, 2006) |
| "Under a diagnosis of stage D2 prostate cancer, we initiated endocrine therapy (luteinizing hormone-releasing hormone analogue depot every 4 weeks and bicalutamide)." | ( Abe, H; Katsuoka, Y; Nishida, T; Segawa, N, 2006) |
| "During anti-hormonal therapy for prostate cancer, a major clinical problem is the development of androgen-independent disease." | ( Abdulkadir, SA; Eltoum, IA; Yang, SZ, 2006) |
| "Patients with recurrent prostate cancer may be treated with androgen deprivation strategies; however, most patients will develop androgen-independent prostate cancer." | ( Arlen, PM; Gulley, JL, 2005) |
| "immunotherapy) of prostate cancer is essential." | ( Carlsson, L; Larsson, A; Nilsson, S; Ronquist, G; Ronquist, KG, 2006) |
| "Locally recurrent prostate cancer after treatment with radiation therapy is a clinical problem with few acceptable treatments." | ( Busch, TM; Dimofte, A; Finlay, J; Glatstein, E; Hahn, SM; Malkowicz, S; Mick, R; Smith, D; Stripp, DC; Tochner, ZA; Verigos, K; Whittington, R; Zhu, TC, 2006) |
| "The androgen dependent prostate cancer cell line LNCaP was cultured in RPMI 1640 medium and treated with different concentrations of DHT(2, 10, 50 nmol/L) and flutamide (100 nmol/L)." | ( Gu, RG; Ma, QZ; Zhou, CW, 2006) |
| "In placebo treated men without prostate cancer there was an 8." | ( Andriole, GL; Marberger, M; Roehrborn, CG, 2006) |
| "Men with prostate cancer treated intermittently with TIP benefit from improved quality of life when TOP with recovered testosterone is prolonged." | ( Guess, BW; Jennrich, RI; Johnson, HJ; Lam, RY; Scholz, MC; Strum, SB, 2006) |
| "We demonstrate that treatment of human prostate cancer cell lines with zinc reduces expression of VEGF, IL-6, IL-8 and MMP-9." | ( Crispen, PL; Golovine, K; Horwitz, EM; Kolenko, VM; Makhov, P; Uzzo, RG, 2006) |
| "Men with androgen-independent prostate cancer were randomly assigned to either docetaxel/estramustine (D/E) or mitoxantrone/prednisone (M/P) treatment on Southwest Oncology Group Protocol 99-16." | ( Ankerst, DP; Benson, MC; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, JA; Kohli, M; Lara, PN; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME, 2006) |
| "Advanced prostate cancer has significant long-term morbidity, and there is a growing interest in alternative and complimentary forms of therapy that will improve the outcomes of patients who have recurrent or advanced prostate cancer while obviating the need for more toxic forms of therapy." | ( Clark, PE; Hall, MC; Rackley, JD, 2006) |
| "Fifty prostate cancer patients with elevated/increasing serum prostate-specific antigen levels after radical therapy underwent whole-body AC PET." | ( Becherer, A; Djavan, B; Dobrozemsky, G; Dudczak, R; Kletter, K; Kurtaran, A; Li, S; Mitterhauser, M; Pötter, R; Tomek, S; Wachter, S; Wachter-Gerstner, N, 2006) |
| "In a 72-year-old hormone refractory prostate cancer patient on hemodialysis for diabetic nephropathy for 3 years, a first dose (35 mg/m(2) iv) of docetaxel was completed 30 min before starting dialysis, while a second dose was administered 30 min after completion of a different hemodialysis session." | ( Ghio, R; Mencoboni, M; Olivieri, R; Schettini, G; Vannozzi, MO; Viazzi, F, 2006) |
| "We report a case of prostate cancer in which this treatment led to severe symptoms of intracranial hypertension due to the concomitant presence of an asymptomatic functional pituitary adenoma." | ( Daumont, M; Lopez, JG; Massoud, W; Paparel, P; Perrin, P; Ruffion, A, 2006) |
| "Using TSA treatment in prostate cancer cells, a requirement of PI-3K activity in mediating TSA function is demonstrated and a novel role for NF-kappaB in the regulation of FGF8 expression is uncovered." | ( Armstrong, K; Leung, HY; Robson, CN, 2006) |
| "Advanced prostate cancer is not curable by current treatment strategies indicating a significant need for new chemotherapeutic options." | ( Fitzpatrick, JM; Gill, C; O'Connor, K; Rehmann, FJ; Strohfeldt, K; Sweeney, N; Tacke, M; Watson, RW, 2006) |
| "Twenty patients with advanced prostate cancer underwent three consecutive prostate biopsies during the first cycle, namely at the beginning of androgen deprivation, 8 months after continuous therapy and at the time of prostate-specific antigen (PSA) progression above 20 ng/ml." | ( Augustin, H; Bayer, L; Freibauer, C; Kuber, W; Lunglmayr, G; Pummer, K; Tschurlovich, F, 2006) |
| "A 73-year-old man with localized prostate cancer was treated with androgen deprivation and radiation therapy." | ( Brown, MW; Singh, AK, 2006) |
| "Treatment of DU 145 prostate cancer cells with 500 nmol/L flavopiridol and 10 nmol/L docetaxel inhibited apoptosis probably because of their opposing effects on cyclin B1-dependent kinase activity." | ( de Las Pozas, A; Gomez, LA; Perez-Stable, C, 2006) |
| "Radiation treatment for localized prostate cancer has become a prominent choice of monotherapy, and carbon ion beam is a powerful means for this purpose." | ( Akakura, K; Harada, M; Ichikawa, T; Ishikawa, H; Shimazaki, J; Suzuki, H; Tsuji, H; Tsujii, H, 2006) |
| "In total, 37 patients with localized prostate cancer were treated by monotherapy with carbon ion radiation and the outcome, more than 4 years later, was followed." | ( Akakura, K; Harada, M; Ichikawa, T; Ishikawa, H; Shimazaki, J; Suzuki, H; Tsuji, H; Tsujii, H, 2006) |
| "Patients with androgen-dependent prostate cancer who had received prior definitive therapy with nonmetastatic, recurrent disease as manifested by a rising PSA of between 0." | ( Conry, S; Fong, L; Hershberg, RM; Rini, BI; Small, EJ; Weinberg, V, 2006) |
| "Human prostate cancer LNCaP cells in culture were treated with TPA alone or in combination with paclitaxel." | ( Avila, GE; Chang, RL; Conney, AH; Cui, XX; Garzotto, M; Hebbar, V; Kong, AN; Lin, Y; Lu, SE; Rabson, AB; Shih, WJ; Zheng, X, 2006) |
| "Late-stage prostate cancer patients are refractory to hormone therapy and exhibit a high propensity to develop skeletal metastasis." | ( Aprikian, A; Chen, G; Goltzman, D; Potti, A; Rabbani, SA; Sircar, K, 2006) |
| "To evaluate on 201 locally advanced prostatic cancers prospectively treated in a phase II trial, the efficacy of a combination of external beam radiotherapy (39." | ( Coppens, L; de Leval, J; Deneufbourg, JM; Jansen, N; Nickers, P, 2006) |
| "Men with prostate cancer, who had had definitive local therapy, with nonmetastatic recurrent disease as manifested by a rising PSA level, were enrolled on this phase II trial." | ( Fong, K; Fong, L; Lin, AM; Rini, BI; Rosenberg, JE; Ryan, CJ; Small, EJ; Weinberg, V, 2006) |
| "Treatment of hormone-refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases." | ( Bloomfield, D; James, ND; Luscombe, C, 2006) |
| "DU-145 prostate cancer cells were treated with either soluble laminin-5 (20 ng/ml) or laminin-10 (1 microg/ml) for 6, 24, and 48 hr." | ( Bair, EL; Beck, SK; Calaluce, R; Greer, KA; Hoying, AM; Hoying, JB; Mount, DW; Nagle, RB; Pandey, R, 2006) |
| "Involution and epithelial shrinkage of prostate cancer and HGPIN were evident after neoadjuvant treatment with bicalutamide 150 mg." | ( Freschi, M; Losa, A; Mazzucchelli, R; Montironi, R; Montorsi, F; Nava, L; Pappagallo, G; Rigatti, P; Scarpa, RM; Scattoni, V; Terrone, C, 2006) |
| "The study population comprised 32 prostate cancer patients with early evidence of relapse after initial radiotherapy (group A) or radical surgery (group B)." | ( Albrecht, S; Bischof Delaloye, A; Buchegger, F; Keller, A; Khan, HG; Miralbell, R; Ratib, O; Soloviev, D; Vees, H; Zaidi, H, 2007) |
| "Thirty-five patients with prostate cancer had gold marker seeds implanted transrectally and were treated with fractionated radiotherapy." | ( Buskirk, SJ; Earle, JD; Gale, AA; Igel, TC; Serago, CF; Serago, NE, 2006) |
| "The majority of prostate cancers (PCa) that relapse after androgen deprivation therapy (androgen-independent PCa) continue to express androgen receptor (AR)." | ( Balk, SP; Barua, M; Borgesi, RA; Bubley, GJ; Li, T; Lu, ML; Wang, H; Yuan, X; Zhang, T, 2006) |
| "A patient with prostate cancer had been treated with luteinizing hormone-releasing hormone and EMP." | ( Fujimoto, N; Kobayashi, M; Kuramoto, H; Ota, J, 2006) |
| "In this series high-risk prostate cancer was defined as clinical stage T2c or T3, pretreatment serum prostate-specific antigen (PSA) >20 ng/ml and/or a biopsy Gleason score of 8-10." | ( Fujisawa, M; Hara, I; Inoue, TA; Miyake, H; Sakai, I, 2006) |
| "Ultimately, patients with metastatic prostate cancer progress on androgen ablation therapy." | ( Borden, LS; Clark, PE; Hall, MC; Harmon, M; Lovato, J; M Mohler, R; Stindt, D; Torti, FM, 2006) |
| "Patients with prostate cancer without bone metastases who had received androgen deprivation therapy for 12 months or less were randomized to 4 mg zoledronic acid or placebo intravenously every 3 months for 1 year." | ( Beer, TM; Demers, LM; Huo, D; Lacerna, LV; Ryan, CW, 2006) |
| "In light of the significant sequelae of prostate cancer treatment, prevention is desirable, and men with HGPIN would be suitable, high-risk subjects." | ( Alberts, D; Berry, D; Coltman, C; Crawford, ED; Greenwald, P; Jarrard, D; Lieberman, R; Lippman, SM; Marshall, JR; Minasian, L; Parker, F; Sakr, W; Tangen, C; Thompson, I; Wood, D, 2006) |
| "Given the natural history of treated prostate cancer, implementation of chemoprevention would require an inexpensive medication with substantial cancer risk reduction to be cost effective." | ( Lee, JJ; Lippman, SM; Lotan, Y; Roehrborn, CG; Svatek, RS, 2006) |
| "The subset of patients within the early prostate cancer (EPC) program who received radiotherapy with curative intent (n = 1,370) were included in the analysis." | ( See, WA; Tyrrell, CJ, 2006) |
| "As for treatment of prostate cancer with metastases, a palliative treatment is common in the clinical scene." | ( Kakehi, Y; Sugimoto, M, 2006) |
| "Most of the prostate cancer cells that survived after prior hormonal treatment also expressed both kinases." | ( Inoue, T; Kamoto, T; Kobayashi, T; Nakamura, E; Ogawa, O; Segawa, T; Shimizu, Y; Toda, Y; Yamasaki, T; Yoshida, T, 2006) |
| "Improving prostate cancer survival with statins could have important treatment implications and could potentially limit or even improve the role of supplemental therapies." | ( Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE, 2006) |
| "28 patients diagnosed of localized prostate cancer and referred to our departments for radiation therapy with radical intention, in the period ranging between April 2002 and October 2003, were included prospectively." | ( López Carrizosa, MC; Melchor Iñiguez, M; Pérez Casas, A; Pérez Vara, C; Rubio Rodríguez, MC; Samper, PM; Vallejo, C, 2006) |
| "Highly invasive human prostate cancer cells PC-3 were treated with either the methyl donor S-adenosylmethionine (SAM) or methyl DNA-binding domain protein 2 antisense oligonucleotide (MBD2-AS)." | ( Chen, G; Pakneshan, P; Rabbani, SA; Shukeir, N; Szyf, M, 2006) |
| "Serum HER2 levels were assessed in the prostate cancer patients prior to treatment as well as in a control group of 100 patients with histologically confirmed non-cancer." | ( Higashihara, E; Kinjo, M; Nutahara, K; Okegawa, T, 2006) |
| "Twenty-one patients with prostate cancer progressing on gonadotropin-releasing hormone agonist therapy discontinued the gonadotropin-releasing hormone agonist and received abarelix-depot 100 mg by intramuscular injection every 2 weeks for up to 12 weeks." | ( Beer, TM; Bhat, G; Garnick, M; Ryan, C, 2006) |
| "Using cells and prostate cancer xenograft mouse models, we demonstrate in this study that a combination treatment using the PPARgamma agonist pioglitazone and the histone deacetylase inhibitor valproic acid is more efficient at inhibiting prostate tumor growth than each individual therapy." | ( Abella, A; Annicotte, JS; Berthe, ML; Culine, S; Dubus, P; Fajas, L; Fritz, V; Iankova, I; Iborra, F; Maudelonde, T; Miard, S; Noël, D; Pillon, A; Sarruf, D, 2006) |
| "When prostate cancer cells were treated for a longer time with valproic acid, we detected an enhancement of Fas-dependent apoptosis associated with an overexpression in Fas and Fas ligand." | ( Angelucci, A; Bernardini, S; Bologna, M; Dolo, V; Federici, G; Gravina, GL; Miano, R; Millimaggi, D; Valentini, A; Vicentini, C, 2006) |
| "Outcome after permanent BT for prostatic cancer relates to tumor stage, Gleason score, pretreatment PSA, BT year, and post-BT dosimetric quality." | ( Beyer, DC; Blasko, JC; Ciezki, JP; Elshaikh, M; Horwitz, EM; Kuban, DA; Levy, LB; Moran, BJ; Pisansky, TM; Potters, L; Zelefsky, MJ; Zietman, AL, 2007) |
| "The patients were treated for prostate cancer with 18 MV IMRT at institutions using different therapy machines and treatment planning systems." | ( Myrianthopoulos, L; Reft, CS; Runkel-Muller, R, 2006) |
| "DU-145 human prostate cancer cells were transfected+/-a dominant-negative mutant Akt, treated+/-SF and analysed for gene expression using Affymetrix arrays." | ( Abounader, R; Fan, S; Gao, M; Goldberg, ID; Laterra, JJ; Meng, Q; Ressom, H; Rosen, EM; Xu, J, 2007) |
| "In androgen-responsive, LNCaP prostate cancer cells, hormone treatment enhanced WT1-mediated activation of the VEGF promoter constructs." | ( Fraizer, G; Gorman, J; Hanson, J; Reese, J, 2007) |
| "The Early Prostate Cancer (EPC) programme is evaluating the efficacy and tolerability of bicalutamide following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with localized (T1-2, N0/Nx) or locally advanced (T3-4, any N; or any T, N + ) non-metastatic prostate cancer." | ( Armstrong, J; Iversen, P; Johansson, JE; Klarskov, P; Kylmälä, T; Lodding, P; Lundmo, P; Morris, T; Tammela, TL; Tasdemir, I, 2006) |
| "The histological diagnosis of prostate cancer treated with hormonal agents is often difficult because of various morphological changes induced by androgen ablation." | ( Azumi, M; Hashimoto, H; Kakizaki, H; Saga, Y, 2006) |
| "No genome alterations were seen in prostate cancer cell lines by comparative genomic hybridization together with a lack of systemic toxicity, making it a unique cancer cell-type-specific drug that needs further clinical evaluation for toxicity and synergy in combination chemotherapy regimens." | ( Ashok, BT; Banerjee, D; Chen, Y; Garikapaty, VP; Huang, Q; Konopa, J; Tadi, K; Tiwari, RK, 2007) |
| "Limitations of prostate cancer therapy may be overcome by combinations of chemotherapeutic agents with gene therapy directed against specific proteins critical for disease progression." | ( Atweh, GF; Mistry, SJ, 2006) |
| "Chemotherapy of prostate cancer targets androgen receptor (AR) by androgen ablation or antiandrogens, but unfortunately, it is not curative." | ( Barrack, ER; Chinnakannu, K; Dou, QP; Menon, M; Murthy, S; Pelley, RP; Reddy, GP; Strickland, FM, 2006) |
| "To determine: (1) the correlation of prostate cancer incidence and mortality with groundwater boron and selenium concentrations; and (2) the impact of boron on prostate cancer cell proliferation during co-treatment with alternative chemo-preventative agents, along with boron pre-treatment effects on cell sensitivity to ionizing radiation." | ( Barranco, WT; Eckhert, CD; Hudak, PF, 2007) |
| "VES and TOB were used to treat prostate cancer LNCaP, PC3, and 22Rv1 cells and primary-cultured prostate fibroblasts." | ( Chang, E; Chang, P; Chemler, SR; James, NS; Lin, CC; Ni, J; Yeh, S; Yin, Y, 2007) |
| "Patients with advanced prostate cancer eventually cease to respond to hormonal therapy and thus progress to hormone refractory prostate cancer (HRPC)." | ( Chi, KN; Heng, DY, 2006) |
| "Present management of metastatic prostate cancer, which includes hormonal therapy, chemotherapy, and radiotherapy, are frequently palliative." | ( Benita, S; Gofrit, O; Goldstein, D; Nyska, A, 2007) |
| "Growth of prostate cancer cells is initially dependent on androgens, and androgen ablation therapy is used to control tumor growth." | ( Bianco-Miotto, T; Butler, LM; Evdokiou, A; Marks, PA; Marrocco, DL; Richon, VM; Rifkind, RA; Scher, HI; Tilley, WD, 2007) |
| "We treated CWR22Rv1 and LNCaP prostate cancer cells with an mTOR inhibitor, rapamycin, alone, or in combination with either of two receptor protein kinase (RTK) inhibitors." | ( Balk, SP; Bubley, GJ; Masiello, D; McKnight, NC; Mohi, MG; Neel, BG; Smith, B, 2007) |
| "High-risk prostate cancer can be defined as a cancer that, although clinically localized, will not be cured by monotherapy, whether surgery or radiation, and as a result will require some form of multimodal therapy, which will normally include luteinizing hormone-releasing hormone agonists." | ( Boccon-Gibod, L, 2007) |
| "Patients with advanced prostate cancer now have many treatment options available including first- and second-line hormonal therapy, radiotherapy, bisphosphonate therapy with zoledronic acid, and taxane-based chemotherapy." | ( Gleave, ME; So, AI; Sowery, RD, 2007) |
| "Forty-two men with biopsy-proven prostate cancer were recruited of whom 24 had radical prostatectomy (RP), 12 other treatments and 6 had no treatment." | ( Blann, AD; Caine, GJ; Lip, GY; Ryan, P, 2007) |
| "Interestingly, different prostate cancer cells have different sensitivity to alpha-Vit E or VES treatment." | ( Ni, J; Pang, ST; Yeh, S, 2007) |
| "The images in this study are all from prostate cancer patients treated with radiotherapy in a previous study." | ( Carl, J; Larsen, EH; Lund, B; Nielsen, H; Nielsen, J, 2006) |
| "Patients with unresected prostate cancer prospectively underwent trans-rectal biopsy of primary tumor (before starting gefitinib treatment)." | ( Curigliano, G; de Braud, F; De Cobelli, O; De Pas, T; Manzotti, M; Pelosi, G; Renne, G; Spitaleri, G, 2007) |
| "Hormone refractory metastatic prostate cancer is a deadly disease that currently lacks curative treatments." | ( Ala-Opas, MY; Alfthan, H; Desmond, RA; Hakkarainen, T; Hemminki, A; Kanerva, A; Kangasniemi, L; Rajecki, M; Rintala, E; Sankila, A; Särkioja, M; Stenman, UH; Tenhunen, M, 2007) |
| "Human prostate cancer cells LNCaP, PC-3, and CWR22Rnu1 were treated with EGCG and NS398 alone and in combination, and their effect on growth and apoptosis was evaluated." | ( Adhami, VM; Afaq, F; Malik, A; Mukhtar, H; Pasha, FS; Saleem, M; Sarfaraz, S; Siddiqui, IA; Syed, DN; Zaman, N, 2007) |
| "Gene therapy shows promise for treating prostate cancer and has been evaluated in several clinical trials." | ( Kodibagkar, VD; Liu, L; Mason, RP; Yu, JX, 2007) |
| "Hormone refractory prostate cancer was not found 1 year after the start of treatment." | ( Hasegawa, Y; Masue, N, 2007) |
| "Hormonotherapy with bicalutamide for prostate cancer is one of the causes of gynecomastia." | ( Abdah-Bortnyak, R; Bernstein, Z; Kuten, A; Ramon, N; Shnaider, J; Zalman, D, 2007) |
| "In hormone refractory prostate cancer, estramustine may be administered as an estrogen effect is expected." | ( Soga, N; Sugimura, Y, 2007) |
| "Androgen antagonists are used in prostate cancer therapy to inactivate the transcriptional activity of the human androgen receptor (hAR) and to inhibit the proliferation of prostate cancer." | ( Baniahmad, A; Hong, W; Moehren, U; Papaioannou, M; Reeb, CA, 2007) |
| "The Early Prostate Cancer (EPC) Program consists of three randomised, double blind, placebo-controlled trials that assess bicalutamide either as adjuvant to treatment of curative intent or alone (radical prostatectomy, radiotherapy or watchful waiting) in patients with non-metastatic prostate cancer." | ( Fourcade, RO, 2006) |
| "Tasquinimod's anti-prostate cancer efficacy is enhanced when combined with androgen ablation and this enhancement was observed even when androgen ablation was either subsequent to or proceeded by tasquinimod treatment." | ( Becker, RE; Dalrymple, SL; Isaacs, JT, 2007) |
| "TRAMP mice with established prostate cancers were treated with 5-aza, castration, castration + 5-aza, or vehicle control (PBS)." | ( Day, ML; Gschwend, JE; Kuefer, R; McCabe, MT; Wojno, KJ; Zorn, CS, 2007) |
| "Even though hormone-refractory prostate cancer is still incurable, it is not untreatable." | ( Gleave, ME; Hadaschik, BA; Sowery, RD, 2007) |
| "Treatment of prostate cancer (CaP) patients frequently involves androgen ablation, but resistance often develops and androgen-insensitive tumors emerge." | ( Carey, AM; Dew, TK; Martin, FL; Morris, JD; Muir, GH; Nicholson, LJ; Pramanik, R, 2007) |
| "Treatment of prostate cancer cells with PGE2 (1 nM-10 microM) increased both VEGF secretion and cyclic adenosine monophosphate (cAMP) production." | ( Klein, RD; Wang, X, 2007) |
| "For advanced prostate cancer patients who progressed on first-line MAB with bicalutamide, flutamide administration as a second-line antiandrogen was found to be relatively effective, especially for those who showed a longer duration of response to the first-line MAB." | ( Arichi, N; Ichikawa, Y; Kishikawa, H; Nishimura, K; Tokugawa, S; Yoshioka, I, 2007) |
| "LNCaP human prostate cancer cells were treated with 0." | ( Christensen, MJ; Eggett, DL; Parker, TL, 2007) |
| "Seven patients died, including 4 of prostate cancer, 1 with intra-abdominal bleeding during treatment and 2 of pneumonia and sudden cardiac death, respectively, following treatment." | ( Beer, TM; Benson, MC; Chatta, GS; Cookson, MS; DiPaola, RS; Dreicer, R; Eisenberger, MA; Garrett-Mayer, E; Jarrard, DF; Kattan, MW; Kibel, AS; Klein, EA; Nelson, JB; Partin, AW; Petrylak, DP; Picus, J; Rosenbaum, E; Roth, BJ; Ryan, CW; Wilding, G, 2007) |
| "Multiple prostate cancer cell lines were treated with lithium chloride (LiCl)." | ( Li, B; Shanmugam, I; Song, J; Sun, A; Terranova, PF; Thrasher, JB, 2007) |
| "A prospective evaluation of prostate cancer risk with testosterone replacement therapy has not been conducted." | ( Brand, TC; Canby-Hagino, E; Thompson, IM, 2007) |
| "A new diagnosis of prostate cancer presents to both the patient and physician questions regarding the best approach for further assessing the extent of disease prior to selecting a treatment strategy." | ( Hernandez, J; Lacy, GL; Soderdahl, DW, 2007) |
| "Our previous studies on clinical prostate cancer specimens indicated that ErbB-2 expression was increased in patients undergoing hormone ablation therapy." | ( Albanese, C; Aventian, M; Casimiro, M; Chen, M; Cote, R; Cromelin, C; Datar, R; Diba, F; Ferzli, G; Fricke, S; Hung, MC; Johnson, K; Kallakury, B; Lushina, N; Ohanyerenwa, C; Ostrowski, M; Pestell, R; Pootrakul, L; Rabbani, SA; Rodriguez, O, 2007) |
| "One hundred eight prostate cancer patients who underwent brachytherapy using either an (125)I implant, a (103)Pd implant, or the combination of external beam radiotherapy with a (103)Pd implant and had a minimum of 1 year follow-up were screened for DNA sequence variations in the 62 coding exons of the ATM gene using denaturing high-performance liquid chromatography." | ( Atencio, DP; Burri, RJ; Cesaretti, JA; Peters, CA; Peters, SA; Rosenstein, BS; Stock, RG; Stone, NN, 2007) |
| "Most prostate cancers are androgen-dependent, meaning that they respond to androgen-ablation therapy." | ( Beke, D; Kudlacek, S; Meran, JG, 2007) |
| "Most patients with stage T3-T4 prostate cancer experience disease relapse despite radiation and/or hormonal therapy, and their management remains controversial." | ( Francini, E; Francini, G; Manganelli, A; Paolelli, L; Pascucci, A; Petrioli, R; Salvestrini, F, 2008) |
| "LNCaP and PC-3 prostate cancer cells stably overexpressing cyclin B1 are more sensitive to apoptosis induced by chemotherapy." | ( Burnstein, K; de Las Pozas, A; Gomez, LA; Perez-Stable, C; Reiner, T, 2007) |
| "The time from diagnosis of prostate cancer to first hormonal treatment, and from first hormonal treatment to VTE, was compared for different treatments." | ( de Vries, CS; Farmer, RD; Langley, SE; Seaman, HE, 2007) |
| "Patients with hormone-refractory prostate cancer and bone pain needing external-beam radiotherapy were assigned to four intravenous injections of (223)Ra (50 kBq/kg, 33 patients) or placebo (31 patients), given every 4 weeks." | ( Blom, R; Bolstad, B; Bruland, OS; Franzén, L; Garkavij, M; Harmenberg, J; Johannessen, DC; Lennernäs, B; Nilsson, S; Parker, C; Petersson, U; Pigott, K; Sokal, M; Strang, P; Tennvall, J; Tyrrell, C; Yachnin, J, 2007) |
| "A total of 263 low-risk prostate cancer patients randomized to Pd-103 versus I-125 were implanted with a brachytherapy target volume consisting of the prostate with a 5-mm periprostatic margin." | ( Adamovich, E; Allen, ZA; Anderson, RL; Butler, WM; Galbreath, RW; Grammer, R; Kurko, B; Merrick, GS; True, L; Wallner, KE, 2007) |
| "Treatment of human prostate cancer cells viz." | ( Fu, P; Gupta, S; Hartman, DJ; Maclennan, GT; Resnick, MI; Shukla, S, 2007) |
| "Eligible patients included those with prostate cancer and on androgen-deprivation therapy for <12 months." | ( Bylow, K; Demers, LM; Henderson, TO; Huo, D; Ryan, CW; Stadler, WM; Vogelzang, NJ, 2007) |
| "Once prostate cancer has metastasized, current treatment methods are generally ineffective." | ( Ivanov, V; Kalinovsky, T; Niedzwiecki, A; Rath, M; Roomi, MW, 2004) |
| "50-90% of hormone-refractory prostate cancer cells show an overexpression of epidermal growth factor receptor (EGFR), which may contribute to uncontrolled proliferation and resistance to chemotherapy." | ( Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G, 2007) |
| "The rational use of melatonin in prostate cancer prevention, stabilization of clinically localized favourable-risk prostate cancer and palliative treatment of advanced or metastatic tumour is discussed within the context of the molecular pathogenesis of the disease." | ( Shiu, SY, 2007) |
| "Treatment of prostate cancer cells with resveratrol resulted in generation of reactive oxygen species (ROS), translocation of Bax to mitochondria and subsequent drop in mitochondrial membrane potential, release of mitochondrial proteins (cytochrome c, Smac/DIABLO, and AIF) to cytosol, activation of effector caspase-3 and caspase-9, and induction of apoptosis." | ( Shankar, S; Siddiqui, I; Srivastava, RK, 2007) |
| "Radiation therapy (RT) for prostate cancer has been developing dramatically during the past 10 years in Japan as well as in USA." | ( Chang, TC; Hanyu, N; Karasawa, K; Kuga, G; Yoshida, D, 2007) |
| "Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life." | ( Dewilde, S; Kleinman, L; Lloyd, A; Penson, D, 2008) |
| "Treatment of DU145 human prostate cancer cells with 10 and 20 micromol/L apigenin also increased protein levels of E-cadherin by 27% to 74%, inhibited nuclear translocation of beta-catenin and its retention in the cytoplasm, and decreased c-Myc and cyclin D1 levels, an effect similar to the exposure of cells to beta-catenin small interfering RNA." | ( Flask, CA; Fu, P; Gupta, S; MacLennan, GT; Mishra, A; Resnick, MI; Shukla, S, 2007) |
| "Eligible patients had metastatic prostate cancer and had received combined androgen blockade for 6-8 months with a > or = 80% decrease in prostate-specific antigen from pretreatment." | ( Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC, 2007) |
| "The response of hormone-refractory prostate cancer (HRPC) to chemotherapy remains modest, necessitating the search for new forms of treatment to improve the prognosis." | ( Biroccio, A; D'Angelo, C; Leonetti, C; Scarsella, M; Semple, SC; Zupi, G, 2007) |
| "A total of 120 patients with prostate cancer and without bone metastases who had been treated with ADT for less than 12 months were enrolled in a clinical trial of zoledronic acid versus placebo." | ( Beer, TM; Davis, RL; Huo, D; McWhorter, LT; Ryan, CW; Stallings, JW, 2007) |
| "Hormone-refractory prostate cancer (HRPC) is a progressive chemotherapy-resistant disease that remains a challenge to manage." | ( Dawson, NA, 2007) |
| "Eligible patients had progressive prostate cancer during androgen deprivation therapy (with documented castrate levels of testosterone); an Eastern Cooperative Oncology Group performance status of 0 to 2; and adequate hematologic, renal, and hepatic function." | ( Halabi, S; Ou, SS; Small, EJ; Vogelzang, NJ, 2007) |
| "Patients with prostate cancer underwent fiducial marker implantation and computed tomography simulation for radiotherapy planning." | ( Brock, KK; Chung, PW; Haider, MA; Hensel, JM; Kirilova, A; Ménard, C; Milosevic, MF; Moseley, JL, 2007) |
| "Relapse of prostate cancer after androgen ablation therapy is hormone-refractory, with continued tumor growth being dependent on the androgen receptor (AR)." | ( Chen, D; Chinnakannu, K; Dou, QP; Kaseb, AO; Menon, M; Reddy, GP; Sivanandam, A; Tejwani, S, 2007) |
| "Twenty-five patients were treated for prostate cancer with Pd-103 implantation." | ( Arthurs, S; Cho, PS; Kim, Y; Merrick, G; Narayanan, S; Orio, PF; Tutar, IB; Wallner, KE, 2007) |
| "Because prostate cancer is often treated with radiotherapy, and 2ME2 has shown efficacy as a single agent against human prostate carcinoma, we evaluated 2ME2 as a potential radiosensitizer in prostate cancer models." | ( Amorino, GP; Casarez, EV; Conaway, MR; Dunlap-Brown, ME, 2007) |
| "In all, 50 patients with prostate cancer who had had initial therapy (radical prostatectomy in 40, external beam radiation in three and interstitial brachytherapy in seven) had PET/CT using [(11)C]-choline in the presence of an increased or increasing prostate-specific antigen (PSA) level." | ( Blumstein, NM; Gschwend, JE; Hautmann, RE; Hohl, K; Kuefer, R; Möller, P; Mottaghy, FM; Reske, SN; Rinnab, L; Wiegel, T, 2007) |
| "Patients with localized prostate cancer received amifostine as a rectal suspension 30-45 minutes before daily three-dimensional conformal radiation therapy." | ( Albert, PS; Camphausen, K; Coleman, CN; Cooley-Zgela, T; Crouse, NS; Godette, D; Guion, P; Ménard, C; Sciuto, LC; Simone, NL; Singh, AK; Smith, S; Soule, BP, 2008) |
| "Despite a 25% reduction of prostate cancers in the treatment arm the results were discussed controversially." | ( Bismarck, E; Dörsam, HJ; Fischer, C; Lümmen, G; Schmitz-Dräger, BJ, 2007) |
| "Human prostate cancer PC-3 cells in culture were treated with atorvastatin and celecoxib alone or in combination." | ( Avila, GE; Conney, AH; Cui, XX; Huang, MT; Kong, AN; Lin, Y; Liu, Y; Patel, J; Paulino, R; Rabson, AB; Reddy, BS; Shih, WJ; Zheng, X, 2007) |
| "Estrogen analogs have been used for prostate cancer therapy for years presumably by inhibiting testosterone biosyntheses, but with considerable adverse events due to their classic estrogenic activity." | ( Cai, LQ; Imperato-McGinley, JL; Qiao, Y; Tan, C; Zhang, ZK; Zhu, YS, 2007) |
| "Patients with prostate cancer who had rising PSA levels after radical prostatectomy and/or radiation therapy were given combined androgen ablation for 3 months." | ( Bouchillon, K; Brown, MA; Carter, CM; Daliani, DD; Do, KA; Kim, J; Logothetis, CJ; Mao, S; Perez, CA; Thall, PF; Wang, X, 2007) |
| "Selective targeting of prostate cancer cells with the activated beta-catenin pathway may be a novel and effective therapy in prostate cancer." | ( Arber, N; Dvory-Sobol, H; Giladi, N; Kazanov, D; Liberman, E; Sagiv, E, 2007) |
| "Chemotherapeutics used to treat prostate cancer are often from a class of drugs that target microtubule networks, such as paclitaxel." | ( Downing, KH; Killilea, AN; Killilea, DW, 2007) |
| "LNCaP prostate cancer cells were treated with 5 mmol/L VPA or 100 micromol/L tectorigenin and transfected with small interfering RNA (siRNA) against ERbeta." | ( Burfeind, P; Kaulfuss, S; Ringert, RH; Schweyer, S; Stettner, M; Strauss, A; Thelen, P, 2007) |
| "Forty prostate cancer patients were treated with external radiotherapy according to an online localization protocol using four intraprostatic gold seeds and electronic portal images (EPIs)." | ( Beltran, C; Davis, BJ; Herman, MG, 2008) |
| "Chemotherapy in prostate cancer (CaP) even as an adjunct has not been a success." | ( Ashok, BT; Banerjee, D; Chen, Y; Darzynkiewicz, Z; Konopa, J; Tadi, K; Tiwari, RK; Wysocka-Skrzela, B, 2007) |
| "To be eligible for the study, men with prostate cancer had to have rising serum PSA following local therapy or while on hormone therapy." | ( Banerjee, M; Cher, ML; Fontana, J; Forman, JD; Hussain, M; Kucuk, O; Pontes, JE; Powell, I; Sarkar, FH; Seren, S; Vaishampayan, U, 2007) |
| "In patients with castration-refractory prostate cancer, addition of estramustine to chemotherapy increases time to PSA progression and overall survival compared with chemotherapy without estramustine." | ( Berry, WR; Eymard, JC; Fizazi, K; Hudes, G; Kelly, WK; Le Maitre, A; Logothetis, CJ; Michiels, S; Pignon, JP, 2007) |
| "Standard therapy in local confined prostate cancer with curative intent is a radical ablation of the gland." | ( Börgermann, C; Jäger, T; Rübben, H, 2007) |
| "We reviewed 241 patients with Stage IV prostate cancer, who were treated in Niigata Cancer Center Hospital from 1992 to 2004." | ( Hara, N; Kitamura, Y; Komatsubara, S; Saito, T, 2007) |
| "One of the major obstacles in curing prostate cancer is the development of drug resistance to docetaxel, which is the gold standard for the treatment of this disease." | ( Chen, X; Djeu, JY; Gilvary, DL; Sallman, DA; Wei, S; Zhong, B; Zhou, J, 2007) |
| "Androgen deprivation therapy of prostate cancer with luteinizing hormone releasing hormone agonists may result in loss of bone mass, changes in body composition and a deterioration of arterial stiffness." | ( Haidar, A; Saad, F; Shabsigh, R; Yassin, A, 2007) |
| "Androgen-deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture." | ( Ishizaka, K; Kanbe, N; Kitahara, S; Kobayashi, S; Machida, T; Yoshida, K, 2007) |
| "Sixty-one prostate cancer patients with a mean age (+/- SD) of 79 +/- 6 years who had received androgen deprivation therapy for 42 +/- 29 months were enrolled, and were treated with 2." | ( Ishizaka, K; Kanbe, N; Kitahara, S; Kobayashi, S; Machida, T; Yoshida, K, 2007) |
| "The subjects were 20 patients with prostate cancer diagnosed between January 1992 and December 2005 whose PSA level was not lowered below 10 ng/ml after initial endocrine therapy with MAB or estrogenic drugs." | ( Furuya, Y; Hasumi, M; Nakano, K; Nakata, S; Takahashi, H, 2007) |
| "Metastatic prostate cancer (PC) is incurable by androgen deprivation therapy alone, due to the presence of androgen-independent/supersensitive cells in hormone-naive PC." | ( Hiraoka, T; Honda, S; Igawa, M; Inoue, S; Ishikawa, N; Shiina, H; Sumura, M; Urakami, S; Wake, K, 2008) |
| "LNCaP, DU-145, and PC-3 prostate cancer cells were co-treated with a DNMT inhibitor, 5'-aza-2'-deoxycytidine (5-AZAC), and an HDAC inhibitor, trichostatin A (TSA)." | ( Bishop, MC; Li, G; McArdle, SE; Rees, RC; Seth, R; Walton, TJ, 2008) |
| "We tested two hypotheses in human prostate cancer cells grown in vitro and in a xenograft model: (1) treatment of androgen-sensitive cells with DHT increases levels of oxidative DNA adduct levels; (2) flutamide, a competitive androgen receptor antagonist, prevents DHT-induced changes." | ( Farmer, PB; Gescher, AJ; Greaves, P; Mellon, JK; Pathak, S; Sharma, RA; Singh, R; Steward, WP; Verschoyle, RD, 2008) |
| "Patients with hormone-refractory prostate cancer were treated with 18." | ( Dahmane, A; de Klerk, JM; Lam, MG; Stevens, WH; van Rijk, PP; Zonnenberg, BA, 2008) |
| "The treatment was effective for prostate cancer cells independently on their androgen sensitiveness." | ( Bellezza, I; Bracarda, S; Conte, C; Culig, Z; Minelli, A; Tucci, A, 2008) |
| "In all, 232 patients with prostate cancer, whose serum testosterone levels were measured before and during treatment using a 1- or 3-monthly formulation of leuprolide or goserelin, were enrolled in a retrospective study." | ( Fujii, Y; Fukui, I; Kawakami, S; Okubo, Y; Yamamoto, S; Yonese, J, 2008) |
| "Because prostate cancer is, in its early stages, an androgen-dependent pathology, treatments aiming at decreasing testosterone plasma concentration have been developed for many years now." | ( Bavencoffe, A; Bidaux, G; Delcourt, P; Dewailly, E; Gackière, F; Katsogiannou, M; Mariot, P; Mauroy, B; Prevarskaya, N; Van Chuoï-Mariot, MT; Van Coppenolle, F, 2008) |
| "LNCaP prostate cancer cells were treated with 1,25-VD, followed by analysis of cell surface PSMA expression." | ( Bisoffi, M; Ji, M; Omdahl, JL; Serda, RE; Sillerud, LO; Thompson, TA, 2008) |
| "A promising agent for use in prostate cancer therapy is the Hedgehog (Hh) signaling pathway inhibitor, cyclopamine." | ( Anchoori, RK; Beachy, PA; Fazli, S; Khan, SR; Kumar, SK; Maitra, A; Roy, I, 2008) |
| "These results demonstrate that, in prostate cancer cells, the efficacy of chemotherapy may be limited by its effects on the intracellular signaling pathways found within the cell." | ( Chappell, WH; Lee, JT; McCubrey, JA; Steelman, LS, 2008) |
| "The treatment of human prostate cancer cells (PC-3) with berberine induced dose-dependent apoptosis but this effect of berberine was not seen in non-neoplastic human prostate epithelial cells (PWR-1E)." | ( Katiyar, S; Katiyar, SK; Meeran, SM, 2008) |
| "LNCaP and PC3 prostate cancer cells were cultured and treated with the following: 0-100 nM leptin; 0-100 nM fAd +/- 100 nM leptin; 0-100 nM gAd +/- 100 nM leptin." | ( Desai, KM; Digby, JE; Mistry, T; Randeva, HS, 2008) |
| "In patients with low-risk prostate cancer, HIFU monotherapy resulted in comparable immediate cancer control with other modalities." | ( Horie, S; Ide, H; Kamiyama, Y; Muto, S; Saito, K; Yoshii, T, 2008) |
| "In hormone-sensitive metastatic prostate cancer, androgen deprivation represents the first-line treatment." | ( Chaladaj, A; Droz, JP, 2008) |
| "The human prostate cancer cell line PC-3 was repeatedly exposed to docetaxel chemotherapy in vitro, and a docetaxel-resistant cell subline (PC-3dR) was developed and analysed." | ( Fazli, L; Gleave, ME; Hadaschik, BA; Hurtado-Coll, A; So, AI; Sowery, RD; Zoubeidi, A, 2008) |
| "Hormone refractory, metastatic prostate cancer patients initiated on docetaxel chemotherapy between September 2004 and February 2007 within the Alberta Cancer Board." | ( Chambers, C; Cusano, F; Howard, DN, 2008) |
| "Two human prostate cancer cell lines, DU145 and PC-3, were treated with leptin (5-100 ng/mL) for up to 48 h." | ( Hoda, MR; Popken, G, 2008) |
| "Pretreatment SPECT/CT suggested prostate cancer metastasis (22), seminal vesicle extension (20) and organ confined disease (197)." | ( Bodner, D; Ellis, RJ; Faulhaber, PF; Fu, P; Kaminsky, DA; Resnick, MI; Sodee, DB; Zhou, EH, 2008) |
| "We allocated 983 patients with prostate cancer with high-risk features to receive 2 years of androgen-deprivation therapy (ADT) with or without six cycles of mitoxantrone (12 mg/m(2)) after prostatectomy." | ( Crawford, ED; Flaig, TW; Glodé, LM; Hussain, MH; Raghavan, D; Stadler, WM; Tangen, CM, 2008) |
| "Once prostate cancer has metastasized, there is currently no curative therapy available." | ( Cai, LQ; Chen, GQ; Imperato-McGinley, J; Qiao, Y; Tan, C; Wu, W; Zhu, YS, 2009) |
| "This suggests that HF promoted prostate cancer cell growth is COX-2 dependent and this HF-COX-2 activation pathway can account for one reason of CAB therapy failure." | ( Bao, BY; Cai, Y; Chang, C; Hsu, CL; Huang, J; Lee, YF; Li, G; Liu, S, 2008) |
| "Because of the low alpha/beta value of prostate cancer, a therapeutic gain may be possible with a hypofractionated radiation scheme, and this gain may be further increased with the adjunct of hormone therapy." | ( Bahary, JP; Fortin, B; Fortin, MA; Lambert, C; Van Nguyen, T; Yassa, M, 2008) |
| "Precise localization of prostate cancer and the drainage lymph nodes is mandatory to define an accurate clinical target volume for conformal radiotherapy." | ( Harisinghani, MG; John, SS; Shipley, WU; Zietman, AL, 2008) |
| "Residual or recurrent prostate cancer after treatment was defined as local tumor progression if the biopsy results showed cancer foci." | ( Kim, CK; Kim, E; Kim, SS; Lee, HM; Park, BK, 2008) |
| "The PCPT (Prostate Cancer Prevention Trial) trial which compared 5 mg/d of finastéride to placebo in men over 55 years old showed that active treatment reduced the incidence of prostate cancer from 24." | ( Allory, Y; Molinié, V, 2008) |
| "Finasteride significantly reduced prostate cancer risk regardless of the level of this risk, estimated either by multivariable risk or by PSA stratum; this suggests that finasteride exerts both treatment and preventive effects." | ( Coltman, CA; Lippman, SM; Parnes, HL; Tangen, CM; Thompson, IM, 2008) |
| "Although prostate cancer in TRAMP mice shares some metabolic features with that in humans, it differs with respect to choline phospholipid metabolism, which could impact upon the interpretation of results from biomarker or chemotherapy/chemoprevention studies." | ( Edwards, RE; Farmer, PB; Gant, TW; Gescher, AJ; Greaves, P; Jones, DJ; Keun, HC; Steward, WP; Teahan, O; Teichert, F; Verschoyle, RD; Wilson, ID, 2008) |
| "PC-3-Bcl-2 and PC-3-Neo human prostate cancer cells treated with DCA in addition to irradiation were analyzed in vitro for changes in proliferation, clonogenic survival, apoptosis, cell cycle phase distribution, mitochondrial membrane potential, and expression of Bcl-2, Bcl-xL, Bax, or Bak proteins." | ( Cao, W; Namiki, K; Porvasnik, S; Rosser, CJ; Sakai, Y; Shiverick, KT; Urbanek, C; Yacoub, S, 2008) |
| "that androgens are essential for prostate cancer (PC) growth and progression, and there has been about 30 years experience using ketoconazole for PC therapy." | ( Moreira, VM; Njar, VC; Salvador, JA; Vasaitis, TS, 2008) |
| "Patients with untreated stage C/D prostate cancer were randomized to MAB with bicalutamide plus a luteinizing hormone-releasing hormone agonist (LHRHa) or LHRHa monotherapy." | ( Akaza, H; Arai, Y; Deguchi, T; Fujisawa, M; Hayashi, M; Hirao, Y; Kanetake, H; Naito, S; Namiki, M; Ohashi, Y; Tachibana, M; Usami, M, 2008) |
| "Further analysis of "prostate cancer-specific issues" revealed that, compared with monotherapy, MAB provided a greater improvement in "micturition disorder"-related QOL." | ( Akaza, H; Arai, Y; Deguchi, T; Fujisawa, M; Hayashi, M; Hirao, Y; Kanetake, H; Naito, S; Namiki, M; Ohashi, Y; Tachibana, M; Usami, M, 2008) |
| "Recurrent prostate cancer (PC) is usually treated with androgen deprivation therapy, which, despite initial success, eventually fails due to the development of androgen-independent PC." | ( Bedolla, R; Ghosh, PM; Kreisberg, JI; Lu, XH; Mikhailova, M; Wang, Y, 2008) |
| "Growth stimulation of prostate cancer cells with 5alpha-dihydrotestosterone (DHT) is accompanied by increased p66Shc level and ROS production, which is abolished by antioxidant treatments." | ( Lin, FF; Lin, MF; Veeramani, S; Yuan, TC, 2008) |
| "SCID mice bearing DU145 or PC-3 human prostate cancer xenografts were treated with either 20 or 30 mg/kg 10058-F4 on a qdx5 schedule for 2 weeks for efficacy studies." | ( Egorin, MJ; Eiseman, JL; Guo, J; Joseph, E; Lazo, JS; Parise, RA; Prochownik, EV, 2009) |
| "Historical data on 24 patients with prostate cancer who received ADT without bisphosphonate administration were studied as controls (control group)." | ( Kawahara, T; Kobayashi, T; Kobori, G; Mitsumori, K; Nishizawa, K; Ogura, K, 2008) |
| "Most prostate cancer patients develop resistance to androgen deprivation treatment, resulting in hormone resistance." | ( Calais-da-Silva, F; Cardoso, D; Fraga, A; Lobo, F; Medeiros, R; Pina, F; Pinto, D; Ribeiro, R; Teixeira, AL, 2008) |
| "We conducted a case-control study in prostate cancer patients treated with ABT (n = 123) and in healthy controls without evidence of cancer (n = 152)." | ( Calais-da-Silva, F; Cardoso, D; Fraga, A; Lobo, F; Medeiros, R; Pina, F; Pinto, D; Ribeiro, R; Teixeira, AL, 2008) |
| "To determine if patients with advanced prostate cancer carrying a polymorphism that codes for a more active testosterone transporter have less durable responses to androgen-deprivation therapy (ADT) than patients not carrying this polymorphism." | ( Baum, C; Dahut, WL; Danesi, R; Figg, WD; Gulley, JL; Hamada, A; Price, DK; Sharifi, N; Sissung, T; Venzon, D, 2008) |
| "The Bicalutamide Early Prostate Cancer Program, the largest ongoing prostate cancer trial in the world, investigates the effect of early treatment with 150 mg bicalutamide compared with placebo as monotherapy or adjuvant treatment after radical prostatectomy or external beam radiotherapy." | ( Froehner, M; Hakenberg, OW; Wirth, MP, 2008) |
| "Most prostate cancers escape endocrine therapy by diverse mechanisms." | ( André, J; Baille, ML; Benahmed, M; Chantepie, J; Joly-Pharaboz, MO; Kalach, JJ; Nicolas, B; Pharaboz, J; Ruffion, A, 2008) |
| "One man had metastatic prostate cancer treated with zoledronic acid." | ( Kogan, R; Lehrer, S; Montazem, A; Pessin-Minsley, M; Pfail, J; Ramanathan, L; Stock, RG, 2008) |
| "We report a case of hormone-refractory prostate cancer (HRPC) treated with oxaliplatin plus gemcitabine in a third-line schedule after liver progression, with an excellent clinical, biochemical and radiological response and with an acceptable tolerance." | ( Ceballos, J; García-Foncillas, J; Pérez-Gracia, JL; Santisteban, M; Vivas, I, 2008) |
| "Men with localized but unfavorable-risk prostate cancer who were treated with RT and 6 months of planned combined AST appear to have an increased risk of recurrence when treated with less than as compared with 6 months of the antiandrogen." | ( Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, B; Renshaw, AA, 2008) |
| "PC-3-Bcl-2 and PC-3-Neo human prostate cancer cells treated with docetaxel and/or bortezomib in addition to irradiation were analyzed in vitro for proliferation, clonogenic survival, cell cycle phase distribution, and expression of Bcl-2 and Bcl-xL proteins." | ( Cao, W; Namiki, K; Porvasnik, S; Rosser, CJ; Sakai, Y; Shiverick, KT; Urbanek, C, 2008) |
| "Hormone-refractory prostate cancer (HRPC) is a rapidly progressive disease which produces considerable morbidity and involves mostly men over 70, often comorbid and with poor tolerance to chemotherapy." | ( Adamo, V; Buda, C; Caristi, N; Iorfida, M; Lupo, G; Maisano, R; Scimone, A; Scisca, C, 2008) |
| "Advanced hormone-refractory prostate cancer (HRPC) is characterized by prevalently osteoblastic bone metastases which are what mostly affect these patients' quality of life and make the assessment of response to treatment particularly difficult by commonly used criteria." | ( Fiaschi, AI; Francini, E; Francini, G; Pascucci, A; Petrioli, R, 2008) |
| "Patients with androgen-independent prostate cancer treated with docetaxel alone (n = 23) or docetaxel and thalidomide (n = 50) were genotyped for the ABCB1 1236C>T, 2677 G>T/A, and 3435 C>T alleles by direct sequencing, and diplotypes were constructed using an EM algorithm." | ( Aragon-Ching, J; Baum, CE; Dahut, W; Deeken, J; Figg, WD; Price, DK; Sissung, TM; Sparreboom, A; Steinberg, SM, 2008) |
| "Patients with the most advanced prostate cancer and poorest prognosis do not show adequate biochemical prostate specific antigen response to androgen deprivation therapy but should be assessed for eligibility to receive nonendocrine treatment." | ( Ala-Opas, M; Lundstedt, S; Salonen, AJ; Taari, K; Tammela, TL; Viitanen, J, 2008) |
| "Here, different human colon and prostate cancer cell lines, expressing (HCT-116, PC-3 cells) or not (Caco-2, LNCaP cells) cav-1, were treated with varying concentrations of beta-carotene (0." | ( Lanza, P; Monego, G; Palozza, P; Picci, N; Ranelletti, FO; Sestito, R, 2008) |
| "We have previously reported that, in prostate cancer, inhibition of the oncogenic sphingosine kinase-1/sphingosine 1-phosphate (SphK1/S1P) pathway is a key element in chemotherapy-induced apoptosis." | ( Cuvillier, O; Doumerc, N; Golzio, M; Kohama, T; Malavaud, B; Naymark, M; Pchejetski, D; Teissié, J; Waxman, J, 2008) |
| "Chemotherapy-naïve men (n = 21) who had prostate cancer that was resistant to multiple hormonal therapies were treated in this phase I study of once-daily, continuous abiraterone acetate, which escalated through five doses (250 to 2,000 mg) in three-patient cohorts." | ( Attard, G; Barrett, M; Clark, J; Cooper, CS; de Bono, JS; Dearnaley, D; Dowsett, M; Folkerd, E; Kaye, SB; Lee, G; Martins, V; Parker, C; Raynaud, F; Reid, AH; Settatree, S; Yap, TA, 2008) |
| "Men with TDS after EBRT for localised prostate cancer are candidates for testosterone therapy." | ( Black, AM; Emerson, LE; Morales, A, 2009) |
| "Effective treatments for advanced prostate cancer are much needed." | ( Cheng, JQ; Chu, B; Djeu, J; Mohapatra, S; Pledger, WJ; Zhao, X, 2009) |
| "A total of 153 patients with pT3N0M0 prostate cancer or positive margins after radical prostatectomy, or with prostate specific antigen relapse were treated with radiation to the prostate bed plus 2 years of androgen suppression as per a phase II study." | ( Cheung, P; Choo, R; Danjoux, C; Gardner, SL; Morton, G; Yoon, FH, 2008) |
| "Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures." | ( Greenspan, SL; Miller, ME; Nelson, JB; Perera, S; Resnick, NM; Trump, DL; Wagner, JM, 2008) |
| "A total of 112 men with nonmetastatic prostate cancer receiving ADT were randomly assigned to alendronate 70 mg once weekly or placebo in a double-blind, partial-crossover trial with a second random assignment at year 2 for those who initially received active therapy." | ( Greenspan, SL; Miller, ME; Nelson, JB; Perera, S; Resnick, NM; Trump, DL; Wagner, JM, 2008) |
| "Advanced prostate cancer is first treated with androgen deprivation therapy." | ( Farrar, WL; Hurt, EM; Sharifi, N; Thomas, SB, 2008) |
| "Human PC3 prostate cancer cells were treated with high and low concentrations of simvastatin for different time periods." | ( Aberg, M; Johnell, M; Siegbahn, A; Wickström, M; Widunder, A, 2008) |
| "In vivo, prostate cancer deposits are found in a hypoxic environment which induces resistance to chemotherapy." | ( Brown, DJ; Habib, FK; Nanda, J; Riddick, AC; Ross, JA; Stewart, GD, 2009) |
| "135 stage IV prostate cancer cases were reviewed for treatment type; haemoglobin values before and after treatment; and symptoms of anaemia." | ( Adam, TJ; Chen, SC; Curtis, KK; Gornet, MK; Pruthi, RK, 2008) |
| "Osteoporosis is common in prostate cancer (CaP) patients both before and after institution of androgen deprivation therapy and is associated with significant morbidity." | ( Acharya, NC; Agarwal, MM; Khandelwal, N; Kumar, S; Malhotra, S; Mandal, AK; Rana, SV; Singh, SK, 2008) |
| "A decreased risk of prostate cancer among men treated with finasteride, a 5 alpha-reductase inhibitor which reduces levels of dihydrotestosterone, was observed in the Prostate Cancer Prevention Trial (PCPT), a large clinical trial." | ( Stattin, P; Wirén, S, 2008) |
| "Patients with localized high-risk prostate cancer were treated with 4 cycles (16 weeks) of continuous weekly paclitaxel at 80 mg/m(2) intravenously with estramustine at 280 mg orally 3 times a day for 5 days a week and carboplatin (area under the curve of 6) on Day 1 of every cycle followed by 3-dimensional conformal or intensity-modulated radiotherapy (total dose of 77." | ( Bogart, J; Elfiky, A; Halabi, S; Kelly, WK; Ou, SS; Small, E; Zelefsky, M, 2008) |
| "Interestingly, the treatment of those prostate cancer cells did not increase phosphorylation of STAT3." | ( Bektic, J; Cavarretta, IT; Culig, Z; Dietrich, H; Fuchs, D; Hobisch, A; Malinowska, K; Moser, PL; Neuwirt, H; Steiner, H, 2009) |
| "We also investigated the incidence of prostate cancer after antibiotic treatment by performing prostate biopsies in all patients regardless of posttreatment prostate specific antigen." | ( Baltaci, S; Bedük, Y; Elhan, AH; Gokce, MI; Haliloğlu, AH; Süer, E, 2009) |
| "Men with high risk localized prostate cancer were treated with platelet derived growth factor receptor inhibitor therapy, docetaxel and hormone ablation in the preoperative setting, and clinicopathological outcomes were evaluated." | ( Fidler, IJ; Horne, E; Langley, R; Mathew, P; Oborn, CJ; Papadopoulos, JN; Pettaway, CA; Pisters, LL; Thall, PF; Wen, S; Williams, DL; Wood, CG, 2009) |
| "Eight patients with prostate cancer had gold markers implanted transrectally and seven were treated with (neo) adjuvant androgen deprivation therapy." | ( Budiharto, T; Depuydt, T; Haustermans, K; Hermans, J; Heuvel, FV; Maes, F; Oyen, R; Slagmolen, P; Verstraete, J, 2009) |
| "The anti-prostate cancer effects of pHyde in conjunction with chemotherapy agent were analyzed by in vitro and in vivo assays using adenoviral vector expressing pHyde (AdRSVpHyde) in combination with DNA damaging chemotherapeutic agent, cisplatin, and docetaxel, respectively." | ( Beheshti, B; Lu, Y; Zhang, J; Zhang, X, 2009) |
| "Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy." | ( Brown, MA; Do, KA; Logothetis, CJ; Millikan, RE; Moomey, B; Pagliaro, LC; Wen, S, 2008) |
| "A total of 151 patients with prostate cancer, who were enrolled into this study from May 2001 to June 2003, were randomized to receive CAB therapy using a luteinizing hormone-releasing hormone agonist (leuprorelin) combined with a steroidal antiandrogen (chlormadinone) or a nonsteroidal antiandrogen (bicalutamide)." | ( Hakariya, H; Hara, T; Hayashi, M; Igawa, T; Iwasaki, S; Kanetake, H; Kusaba, Y; Sakai, H; Tsurusaki, T; Yura, M, 2009) |
| "Patients with localized prostate cancer may benefit from high-dose-rate brachytherapy, which may be used alone in certain circumstances or in combination with external-beam radiotherapy in other settings." | ( Choo, R; Furutani, KM; Gold, DG; Hebl, JR; Macdonald, OK; McLaren, RH; Mynderse, LA; Pisansky, TM; Wilson, TM, 2008) |
| "Castration-resistant prostate cancer (CRPC) is an incurable disease with limited treatment options." | ( Chaudhary, U; Turner, J, 2009) |
| "Treatment of advanced prostate cancer with androgen deprivation therapy inevitably renders the tumors castration-resistant and incurable." | ( Borowsky, AD; Busby, JE; Evans, CP; Kung, HJ; Ok, JH; Yang, JC, 2009) |
| "Results showed that prostate cancer patients receiving brachytherapy with volume-reducing hormone therapy also experienced lower treatment-related functions and lower sexual function." | ( Dankaart, B; Hendrikx, A; Houterman, S; Mols, F; Stijns, P; Vingerhoets, A, 2009) |
| "For predicting locally recurrent prostate cancer after radiation therapy, our preliminary results suggest that the use of either DWI or DCEI is superior to the use of T2WI." | ( Kim, CK; Kim, SS; Park, BK; Park, W, 2010) |
| "Thirty-one patients with high-risk prostate cancer were treated with docetaxel and gefitinib for 2 months before RP." | ( Corman, J; Isacson, C; Kozlowski, P; Picozzi, V; Porter, C; Vaughan, M; Vuky, J, 2009) |
| "LAPC-4 prostate cancer cells were grown in coculture with prostate stromal cells (6S) and treated with DHEA +/- TGFbeta1 or interleukin-6." | ( Arnold, JT; Blackman, MR; Choi, R; Gray, NE; Liu, X, 2009) |
| "One hundred seventeen prostate cancer patients with bone metastases and treated with zoledronic acid (4 mg every 4 weeks) were examined." | ( Haus, U; Jung, K; Lein, M; May, C; Miller, K; Schmidt, K; Schrader, M; Weissbach, L; Wirth, M, 2009) |
| "HCT-116 (colorectal cancer), PC-3 (prostate cancer) and MCF-7 (breast adenocarcinoma) cell lines were treated with insulin, IGF-I or insulin analogues, and proliferation and protection from apoptosis were measured by cell counting and fluorescent-activated cell sorter (FACS) analysis, respectively." | ( Laron, Z; Simon, M; Weinstein, D; Werner, H; Yehezkel, E, 2009) |
| "Treatment of androgen-independent prostate cancer (AIPC) remains unsatisfactory." | ( Ai, CZ; Li, W; Liu, HX; Liu, Y; Xiang, N; Yang, L; Zhang, JW, 2009) |
| "Brachytherapy to treat prostate cancer uses transrectal ultrasound to guide implantation of titanium-shelled radioactive seeds." | ( Feleppa, EJ; Mamou, J; Ramachandran, S, 2008) |
| "Although prostate cancer-specific survival was not statistically significantly different between treatment arms at 5 years (P = ." | ( Bae, K; Hanks, GE; Hussain, MH; Ray, ME; Sandler, HM; Shipley, WU, 2009) |
| "We observed that treatment of prostate cancer cells for 24 h with magnolol, a phenolic component extracted from the root and stem bark of the oriental herb Magnolia officinalis, induced apoptotic cell death in a dose- and time-dependent manner." | ( Lee, DH; Lee, YJ; Szczepanski, MJ, 2009) |
| "A total of 100 Japanese men with prostate cancer underwent (192)Ir HDR brachytherapy combined with hypofractionated EBRT." | ( Baba, S; Hayakawa, K; Ishiyama, H; Kitano, M; Kotani, S; Matsumoto, K; Okusa, H; Satoh, T; Tabata, K; Uemae, M, 2009) |
| "Thirty-nine men with prostate cancer were randomly assigned to treatment with 200 microg of selenium, 400 IU of vitamin E, both, or placebo." | ( Do, KA; Efstathiou, E; Kim, J; Lippman, SM; Logothetis, CJ; McDonnell, TJ; Menter, DG; Pettaway, CA; Pisters, LL; Stephens, C; Taylor, R; Thall, PF; Troncoso, P; Tsavachidou, D; Vakar-Lopez, F; Wang, X; Wen, S; Wood, CG, 2009) |
| "Most types of prostate cancer (PCa) are usually initially responsive to androgenic regulation and, therefore, to androgen ablation therapy." | ( Belfiore, A; Frasca, F; Genua, M; Pandini, G; Vigneri, R, 2009) |
| "We present two prostate cancer patients, including one with a castration-resistant cancer whose rising serum prostate-specific antigen (PSA) levels showed a remarkable drop after a reactivated varicella-zoster virus infection treated with valaciclovir." | ( Jurhill, RR; van der Veen, H; van Leenders, GJ; Verhagen, PC, 2009) |
| "Androgen treatment for prostate cancer can adversely affect functional domains of quality of life." | ( Damber, JE; Fosså, S; Fransson, P; Klepp, O; Lund, JA; Widmark, A; Wiklund, F, 2009) |
| "The diagnosis and treatment of prostate cancer place a substantial physical and emotional burden on patients and their families, and have considerable financial implications for healthcare providers and society." | ( Fitzpatrick, JM; Schröder, FH; Schulman, C; Zlotta, AR, 2009) |
| "To date, the Prostate Cancer Prevention trial (PCPT) is the only reported phase III randomized clinical trial to evaluate the role of 5-alpha reductase inhibitors in the prevention and treatment of prostate cancer." | ( Parekh, DJ; Reed, AB, 2009) |
| "Patients with hormone-refractory prostate cancer were treated with capecitabine for 14 days (oral twice daily in a dose escalation regimen with steps of 1/3 of 2,500 mg/m(2) per day in cohorts of three to six patients, depending on toxicity)." | ( Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009) |
| "In a large proportion of advanced prostate cancer patients treated with androgen deprivation therapy, progression of the disease occurs despite low levels of testosterone, termed castration-resistant prostate cancer." | ( Ryan, CJ; Van Allen, EM, 2009) |
| "Hormonal therapy in advanced prostate cancer is rapidly evolving to more effectively target disease processes underlying prostate cancer, with multiple promising agents on the horizon." | ( Ryan, CJ; Van Allen, EM, 2009) |
| "Androgen-dependent prostate cancer typically progresses to castration-resistant prostate cancer (CRPC) after the androgen deprivation therapy." | ( Balk, S; Brown, M; Kantoff, P; Lee, GS; Sun, T; Wang, Q, 2009) |
| "Patients with locally advanced prostate cancer have a high risk of progression after RP as single therapy." | ( Aus, G; Klintenberg, C; Madsen, M; Mäkelä, E; Palmqvist, E; Schelin, S, 2009) |
| "Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor." | ( Arora, V; Beer, TM; Chen, CD; Chen, Y; Clegg, NJ; Higano, CS; Hung, DT; Jung, ME; Kwon, A; Ouk, S; Sawyers, CL; Scher, HI; Smith-Jones, PM; Tran, C; Wasielewska, T; Watson, PA; Welsbie, D; Wongvipat, J; Yoo, D, 2009) |
| "Furthermore, in vivo growth of prostate cancer in nude mice treated with PAK6-siRNA alone or in combination with docetaxel was examined." | ( Gao, X; Li, X; Liao, B; Liu, Y; Ouyang, B; Sun, Q; Wen, X; Wu, J; Yuan, X, 2009) |
| "Further investigation of AT-101 in prostate cancer is warranted and trials combining AT-101 with androgen deprivation, as well as with docetaxel chemotherapy are ongoing." | ( Brill, K; Kelly, WK; Leopold, L; Liu, G; Somer, B; Wilding, G, 2009) |
| "In an in vivo xenograft model of prostate cancer, low level exposure of BPA was sufficient to reduce the efficacy of treatment." | ( Hess-Wilson, JK, 2009) |
| "In vitro and in vivo VPA treatment of prostate cancer cell lines results in significant dose- and time-dependent changes in nuclear structure." | ( Carducci, MA; Chowdhury, WH; Isharwal, S; Kortenhorst, MS; Marlow, C; Rodriguez, R; van Diest, PJ; Veltri, RW, 2009) |
| "Here we describe a case of a prostate cancer patient who underwent radiation treatment and had an FACBC scan obtained as part of a pilot study." | ( Fox, TH; Jani, AB; Schuster, DM; Whitaker, D, 2009) |
| "Besides, patients with advanced prostate cancer are at risk of skeletal complications and bisphosphonates are used in treatment." | ( Balbay, MD; Serefoglu, EC, 2009) |
| "This indirect inhibition of prostate cancer cells via bone cells could be beneficial in treating prostate cancer patients with bone metastases." | ( Kawashima, H; Kuratsukuri, K; Matsumura, K; Matsuyama, M; Nakatani, T; Ohnishi, K; Tanaka, T; Yoshimura, R, 2009) |
| "In fact, the incidence of prostate cancer in primary or secondary testosterone treated hypogonadal men is lower than the incidence observed in the untreated eugonadal population." | ( Raynaud, JP, 2009) |
| "Imaging in prostate cancer can be used in the initial diagnosis of the primary tumor, to determine the occurrence and extent of any extracapsular spread, for guidance in delivery and evaluation of local therapy in organ-confined disease, in locoregional lymph node staging, to detect locally recurrent and metastatic disease in biochemical relapse, to predict and assess tumor response to systemic therapy or salvage therapy, and in disease prognostication (in terms of the length of time taken for castrate-sensitive disease to become refractory to hormones and overall patient survival)." | ( Jadvar, H, 2009) |
| "Sixteen patients with relapsed prostate cancer after treatment with CAB, including surgical or medical castration and nonsteroidal antiandrogens, 80 mg bicalutamide daily or 375 mg flutamide daily, were enrolled." | ( Deguchi, T; Ehara, H; Fujihiro, S; Fujimoto, Y; Hagiwara, N; Kamei, S; Kanimoto, Y; Katoh, S; Katoh, T; Kojima, K; Nakane, K; Takada, T; Takahashi, Y; Yuhara, K, 2009) |
| "The hypothesis that early prostate cancer cells with differing biological potential may respond differently to finasteride treatment is worth testing." | ( Kim, J; Li, J, 2009) |
| "107 patients with localized prostate cancer treated in our institution from October 2004 to December 2007 with TR-HIFU procedure received a subarachnoidal anaesthesia with combined administration of 0." | ( Citro, R; Collura, D; D'Urso, L; Grassano, MT; Grosso, P; Guglielminotti, E; Guglielmotti, E; Macchiarulo, R; Muto, G; Rivalta, L; Valz, C, 2009) |
| "In men with localized but high-risk prostate cancer treated with external beam radiotherapy and brachytherapy, short-course AST with an LHRH agonist plus an antiandrogen is associated with a decreased risk of PCSM when compared with monotherapy with an LHRH agonist." | ( Braccioforte, MH; Chen, MH; D'Amico, AV; Dosoretz, D; Katin, M; Moran, BJ; Nanda, A; Ross, R; Salenius, S, 2010) |
| "We selected 61 patients with prostate cancer treated with ADT; 31 were treated with oral alendronate 70 mg once-weekly and a control group of 30 were not." | ( Cecchini, L; Encabo, G; Morote, J; Orsola, A; Placer, J; Planas, J; Raventós, C; Salvador, C; Trilla, E, 2009) |
| "In MSP-treated and KMSB-treated prostate cancer cell lines, acetylated histone 3 levels increased within 5 hours, and returned to essentially baseline levels by 24 hours, suggesting a rapid, transient induction of histone acetylation." | ( Bisson, WH; Cooper, AJ; Dai, J; Dashwood, RH; Lee, JI; Nian, H; Pinto, JT; Sinha, R, 2009) |
| "Once prostate cancers become androgen-independent, treatment options become limited." | ( Bhatia, V; Bi, LX; Falzon, M; Qiu, S; Saini, MK; Shen, X; Weigel, NL, 2009) |
| "In cultured prostate cancer LNCaP and PC-3 cells, R-568 treatment significantly reduced cellular survival in a dose- and time-dependent manner." | ( Cheng, G; Li, B; Li, H; Li, Z; Liu, Z; Ruan, G; Zhan, M; Zheng, H; Zheng, X, 2009) |
| "The standard systemic treatment for prostate cancer patients is androgen deprivation therapy." | ( Chun, JY; Dutt, S; Evans, CP; Gao, AC; Kung, HJ; Lou, W; Nadiminty, N; Yang, JC, 2009) |
| "Eleven prostate cancer patients undergoing IMRT were treated in prone position with a vacuum cushion." | ( Cheng, JC; Hsueh Liu, YW; Jeng, SC; Lee, KW; Wu, JK, 2009) |
| "Treatment of LNCaP prostate cancer cells with phorbol 12-myristate 13-acetate (PMA) causes a strong and sustained activation of RhoA and its downstream effector ROCK (Rho kinase) as well as the formation of stress fibers." | ( Eto, M; Kazanietz, MG; Xiao, L, 2009) |
| "The high incidence of prostate cancer and lack of an effective, long-term treatment for metastatic disease highlights the need for more potent non-calcemic vitamin D analogs as potential alternative or combinational prostate cancer therapies." | ( Chen, TC; Chiang, KC; Flanagan, JN; Holick, MF; Kittaka, A; Mathieu, JS; Nakabayashi, S; Persons, KS; Sakaki, T; Spanjaard, RA; Zhao, X; Zheng, S, 2009) |
| "Human prostate cancer PC-3 and LnCaP, and human breast cancer MDA-468 cells and xenografts were treated with chemotherapy (docetaxel and 5-fluorouracil, respectively) and temsirolimus, using concurrent and sequential treatment schedules." | ( Fung, AS; Tannock, IF; Wu, L, 2009) |
| "Hormone-refractory prostate cancer (HRPC) is characterized by poor response to chemotherapy and high mortality, particularly among African American men when compared to other racial/ethnic groups." | ( Almaguel, F; Casiano, CA; Daniels, TR; De Leon, M; Leoh, LS; Lilly, MB; Mediavilla-Varela, M; Pacheco, FJ; Padilla, A; Perez, J; Sahakian, E; Wall, NR, 2009) |
| "PC3, DU145 and LNCaP prostate cancer cells were treated with zoledronic acid or doxorubicin alone, in sequence or in combination, and apoptosis was measured by evaluation of nuclear morphology following staining with Hoechst and PI." | ( Clyburn, RD; Evans, CA; Holen, I; Lefley, DV; Reid, P, 2010) |
| "In castrate-resistant prostate cancer, beyond chemotherapy, existing guidelines suggest only supportive care." | ( Josephson, DY; Pal, SK; Twardowski, P, 2009) |
| "In elderly men with intermediate-risk prostate cancer, CVD status is a negative predictor of PCSM and affects the prognostic capacity of pretreatment PSA level." | ( Braccioforte, MH; Chen, MH; D'Amico, AV; Dosoretz, D; Katin, M; Moran, BJ; Nanda, A; Ross, R; Salenius, S, 2010) |
| "Patients with castration-resistant prostate cancer with no previous chemotherapy were enrolled in this study." | ( Ahlgren, G; Björk, A; Bratt, O; Damber, JE; Häggman, M; Nordle, O, 2009) |
| "The low probability of curing high-risk prostate cancer (PC) with local therapy suggests the need to study modality of therapeutic approaches." | ( Alcaraz, A; Aparicio, LA; Areal, J; Fernandez, PL; Font, A; Gallardo, E; Gascon, P; Hannaoui, N; Lorenzo, JR; Mellado, B; Sousa, A; Veiga, FJ, 2009) |
| "Androgen deprivation therapy for prostate cancer is associated with osteoporosis and increased fracture risk." | ( Arcenas, AG; Bhoopalam, N; Broderick, WR; Campbell, SC; Friedman, N; Garewal, H; Iyer, P; Moritz, T; Reda, D; Van Veldhuizen, PJ; Warren, S, 2009) |
| "We treated prostate cancer cells with the CK2 inhibitor TBB and determined its effect on CK2 activity by an in vitro phosphorylation assay and its effect on viability by an MTT assay." | ( Götz, C; Hessenauer, A; Montenarh, M; Schneider, CC, 2010) |
| "Xenografts of VIP-treated PC3 prostate cancer cells in nude mice gave tumors that grew significantly faster than those in the untreated group." | ( Bajo, AM; Carmena, MJ; Fernández-Martínez, AB; Isabel Arenas, M; Prieto, JC; Sánchez-Chapado, M; Valdehita, A, 2009) |
| "Pretreatment of mice bearing prostate cancer xenografts with acriflavine prevented tumor growth and treatment of mice bearing established tumors resulted in growth arrest." | ( Lee, K; Liu, JO; Qian, DZ; Rey, S; Semenza, GL; Zhang, H, 2009) |
| "AR is the central signaling pathway in prostate cancer, and its inhibition is used for both prevention and treatment of this disease." | ( Alumkal, J; Deng, V; Gibbs, A; Schwartzman, J, 2009) |
| "Treatment of prostate cancer cells with SGI-1776 resulted in a dose-dependent reduction in phosphorylation of known Pim kinase substrates that are involved in cell cycle progression and apoptosis (p21(Cip1/WAF1) and Bad)." | ( Agus, DB; Bearss, D; Berk, G; Hodge, A; Jain, A; Kanekal, S; Mumenthaler, SM; Ng, PY; Redkar, S; Taverna, P, 2009) |
| "Twenty patients with hormone refractory prostate cancer (HRPC) were administered a treatment regimen consisting of docetaxel 75 mg/m(2) once every 3 or 4 weeks and prednisolone 5 mg twice daily at our institution between 2006 and 2008." | ( Ide, H; Kikuchi, E; Kono, H; Miyajima, A; Nagata, H; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M, 2010) |
| "Daily treatment of prostate cancer xenograft-bearing mice with low-dose anthracycline (doxorubicin or daunorubicin) chemotherapy inhibits HIF-1 DNA-binding activity, HIF-1-dependent expression of angiogenic growth factors, mobilization of circulating angiogenic cells, and tumor vascularization, thereby arresting tumor growth." | ( Semenza, GL, 2009) |
| "Even for castration-resistant prostate cancer the therapeutic option of docetaxel-based chemotherapy is well studied and defined." | ( Finter, F; Gust, K; Küfer, R; Rinnab, L, 2009) |
| "However, in prostate cancer (PCa), TNF-mediated prosurvival signaling is the predominant pathway that leads to cell survival and resistance to therapy." | ( Chandramouli, A; Damodaran, C; Koduru, S; Kumar, R; Srinivasan, S, 2010) |
| "Treatment of LAPC4 prostate cancer cells with 10microg/ml POMx, a highly potent pomegranate extract prepared from skin and arils minus seeds and standardized to ellagitannin content (37% punicalagins by HPLC), resulted in inhibition of cell proliferation and induction of apoptosis." | ( Cobb, LJ; Cohen, P; Heber, D; Koyama, S; Mehta, HH; Pantuck, AJ; Seeram, NP, 2010) |
| "Between 1999 and 2004, 162 high-risk prostate cancer patients were treated with radiotherapy combined with long-term androgen deprivation therapy (L-ADT)." | ( Antczak, A; Baczyk, M; Kwias, Z; Martenka, P; Milecki, P; Skowronek, J, 2009) |
| "Metastatic prostate cancer is either inherently resistant to chemotherapy or rapidly acquires this phenotype after chemotherapy exposure." | ( Beer, TM; Garzotto, M; Higano, CS; Huang, CY; Myrthue, A; Nelson, PS; Pittsenbarger, J; Qian, DZ; Rademacher, BL, 2010) |
| "Treatments for advanced prostate cancer (CaP) typically involve androgen deprivation therapy." | ( Coleman, I; Corey, E; Koreckij, TD; Montgomery, RB; Nelson, PS; Nguyen, H; Pitts, TE; Reading, CL; Trauger, RJ; Vessella, RL, 2009) |
| "92 consecutive prostate cancer patients in biochemical progression following radical surgery (63) or radiation treatment (29) were studied with positron emission tomography (PET)." | ( Berián Polo, JM; Martínez-Monge, R; Richter, JA; Rincón Mayans, A; Rioja Zuazu, J; Rodríguez, M; Sansi, AS; Zudaire Bergera, JJ, 2009) |
| "PET is a useful tool for diagnosing prostate cancer recurrence after a curative attempt using radical treatment." | ( Berián Polo, JM; Martínez-Monge, R; Richter, JA; Rincón Mayans, A; Rioja Zuazu, J; Rodríguez, M; Sansi, AS; Zudaire Bergera, JJ, 2009) |
| "Androgen-deprivation therapy (ADT) for prostate cancer is associated with osteoporosis and fragility fractures." | ( Saylor, PJ; Smith, MR, 2010) |
| "Androgen-dependent prostate cancer LNCaP cells were treated with bicalutamide under an androgen-depleted condition to obtain refractory cells." | ( Aoki, Y; Ishii, N; Ishikura, N; Kawata, H; Nakamura, R; Nishimoto, A, 2010) |
| "We observed that human prostate cancer cells treated with MK591 undergo apoptosis within hours of treatment." | ( Ghosh, J; Myers, CE; Sarveswaran, S, 2010) |
| "To describe the clinical outcomes of prostate cancer survivors who were treated with high-dose testosterone-replacement therapy (TRT) for the relief of hypogonadal symptoms." | ( Dorff, TB; Leibowitz, RL; Symanowski, J; Tucker, S; Vogelzang, NJ, 2010) |
| "Hormone refractory prostate cancer poses a huge problem and standard of care chemotherapy has not been very successful." | ( Amin, S; Desai, D; King, T; Null, K; Sinha, I; Sinha, R; Suckow, MA; Wolter, W, 2010) |
| "If metastatic prostate cancer gets resistant to antiandrogen therapy, there are few treatment options, because prostate cancer is not very sensitive to cytostatic agents." | ( Braun, K; Didinger, B; Ehemann, V; Mueller, G; Pipkorn, R; Waldeck, W; Wiessler, M, 2009) |
| "Androgens regulate prostate cancer cell proliferation, and androgen deprivation therapy is the standard of care in the management of patients with advanced disease." | ( Brizuela, L; Cuvillier, O; Dayon, A; Doumerc, N; Golzio, M; Malavaud, B; Martin, C; Mazerolles, C; Nogueira, L; Pirot, N; Rischmann, P; Serre, G; Teissié, J, 2009) |
| "Of 1566 metastatic prostate cancer patients treated with LHRH agonists, 1245 (79." | ( Keating, NL; Lamont, EB; Landrum, MB; McNeil, BJ; Oh, WK, 2010) |
| "These results indicate that prostate cancer immunotherapy trials will be more successful if conducted in patients with less advanced disease." | ( de la Luz Garcia-Hernandez, M; Gray, A; Hubby, B; Kanodia, S; Kast, WM; van West, M, 2009) |
| "Despite that greater knowledge of prostate cancer biology has led to the isolation of many new and promising targets, treatment of metastatic prostate cancer is still challenging." | ( Albiges, L; Blesius, A; de La Motte Rouge, T; Escudier, B; Fizazi, K; Gross-Goupil, M; Loriot, Y; Massard, C, 2010) |
| "Men with prostate cancer initiating androgen-deprivation therapy (ADT) may have multiple factors that threaten their skeletal health, including increased fracture risk from bone loss during ADT and the propensity to develop bone metastases, which may lead to skeletal-related events (SREs)." | ( Abrahamsson, PA; Miller, K; Saad, F, 2009) |
| "TGF-beta signalling in prostate cancer is a valid target for the treatment of this disease; however any therapeutic regimen will require an understanding of all aspects of the TGF-beta-signalling nexus, otherwise by the very pleiotrophic nature of TGF-beta, limited clinical benefits may result." | ( Buchanan, G; Diener, KR; Hayball, JD; Need, EF, 2010) |
| "Androgen-deprivation therapy for prostate cancer (PC) eventually leads to castration-resistant PC (CRPC)." | ( de Jong, FH; Dits, NF; Hofland, J; Jenster, G; Schröder, FH; Steenbergen, J; van Leenders, GJ; van Weerden, WM, 2010) |
| "The treatment of advanced prostate cancer (CaP) with androgen deprivation therapy inevitably renders the tumours castration resistant and incurable." | ( Baldi, E; Forti, G; Gelmini, S; Maggi, M; Marchiani, S; Nesi, G; Orlando, C; Paglierani, M; Tamburrino, L, 2010) |
| "Twenty-nine patients with biopsy-proven prostate cancer underwent a DCE-CT exam prior to radiotherapy." | ( Groenendaal, G; Korporaal, JG; Moman, MR; van den Berg, CA; van der Heide, UA; van Vulpen, M, 2010) |
| "Here we report that treatment of prostate cancer cells with antibody directed against the carboxyl terminal domain of GRP78 inhibits alpha2M*-induced activation of NF-kappaB2 by approximately 50% while exerting a lesser effect of approximately 20% on NF-kappaB1 activation." | ( Kaczowka, S; Misra, UK; Pizzo, SV, 2010) |
| "Sensitivity of ovarian and prostate cancer cells toward these treatments was evaluated using the MTS assay." | ( Basu, A; Jain, D; Patel, N; Roque, R; Shelton, M; Siede, W, 2010) |
| "PATIENTS AND METHODS Raw data from the Prostate Cancer Prevention Trial were used to model chemopreventive treatment strategies: treat all men, treat no men, or treat a high-risk subgroup based on PSA level." | ( Lilja, H; Savage, CJ; Vickers, AJ, 2010) |
| "Our data reveal the endogenous need of prostate cancer cells for modified KLK5 expression to cope with the administration of chemotherapeutic drugs." | ( Mavridis, K; Scorilas, A; Talieri, M, 2010) |
| "These data suggest that prostate cancer cells could be effectively inhibited by combination treatment of cholesterol-lowering strategies and genistein." | ( Hong, SJ; Leem, J; Oh, HY; Yoon, S; Yoon, SJ, 2010) |
| "Patients with metastatic prostate cancer resistant to hormones and docetaxel were treated with vinflunine (320 mg/m(2) every 21 days), a new vinca alkaloid with improved preclinical activity." | ( Burris, HA; Crane, EJ; Gandhi, JG; Greco, FA; Hainsworth, JD; Lane, CM; Meluch, AA; Spigel, DR; Stipanov, MA, 2010) |
| "Androgen-independent prostate cancer (AIPCA) is a difficult disease to treat." | ( Blesa, JM; Candel, VA, 2010) |
| "A 79-year-old metastatic prostate cancer patient with AIPCA was treated with fulvestrant acetate with a loading dose strategy." | ( Blesa, JM; Candel, VA, 2010) |
| "Forty-three patients with disseminated prostate cancer, resistant to orchidectomy or hormone therapy with estramustine were treated." | ( Ackland, S; Grygiel, J; Raghavan, D; Rosenthal, MA; Stuart-Harris, R, 1992) |
| "PC-3 prostate cancer xenograft model was utilized to determine in vivo efficacy of the PEITC and/or Docetaxel treatments." | ( Singh, SV; Xiao, D, 2010) |
| "Reanalysis of the Prostate Cancer Prevention Trial (PCPT) suggests that high-grade cancer is not associated with finasteride therapy." | ( Andriole, GL; Strope, SA, 2010) |
| "Patients with localized prostate cancer can usually achieve initial response to conventional treatment." | ( Chen, X; Leng, F; Li, ZY; Ma, TT; Mao, YQ; Pan, L; Peng, XC; Shan, Y; Wang, CT; Wei, YQ; Wen, Y; Xiao, WJ; Yang, HS; Yang, L; Yu, DD; Yuan, QZ, 2011) |
| "A human prostate cancer (PC3) xenograft model was established which reflects acquired in vivo resistance towards metronomic cyclophosphamide (CPA) treatment." | ( Arnold, GJ; Guenther, M; Hoehn, M; Kashirin, R; Ogris, M; Thoenes, L; Wagner, E, 2010) |
| "It is believed that men diagnosed with prostate cancer and a low baseline serum testosterone (BST) may have more aggressive disease, and it is frequently recommended they forego testosterone replacement therapy." | ( Bae, K; Donnelly, BJ; Grignon, D; Hanks, GE; Lawton, C; Lepor, H; Porter, A; Roach, M; Sandler, H; Venketesan, V, 2010) |
| "Most untreated prostate cancers retain some dependence upon the AR and respond, at least transiently, to androgen ablation therapy." | ( Eikenberry, SE; Kuang, Y; Nagy, JD, 2010) |
| "On the other hand, the patients with prostate cancer had a reduced risk for hypocalcemia after ZDA administration (odds ratio 0." | ( Hanamura, M; Iwamoto, T; Okuda, M; Soga, N; Sugimura, Y, 2010) |
| "Men with BR of prostate cancer after radical prostatectomy (RP) or radiation (RT) were treated with androgen deprivation therapy (ADT) comprised of leuprolide and flutamide." | ( Etzioni, RD; Gulati, R; Higano, CS; Jiang, P; Nelson, PS; Russell, KJ; Tam, S; Telesca, D; Yu, EY, 2010) |
| "Treatment of highly invasive human prostate cancer cells PC-3 and DU-145 with different doses of SKI-606 decreased Src activation, cell proliferation, migration, and invasion as determined by Matrigel Boyden chamber invasion assay." | ( Ali, S; Arakelian, A; Boschelli, F; Rabbani, SA; Valentino, ML, 2010) |
| "Since majority of the early-stage human prostate cancers bear functional p53 gene (p53+/+), our findings indicate that the anticancer action of selenium may involve transactivation of p53 as a potential mechanism, and suggest that selenite may be useful not only for prevention but also for treatment of human prostate cancer." | ( Ghosh, J; Liroff, J; Nikitin, AY; Sarveswaran, S; Zhou, Z, 2010) |
| "Patients with prostate cancer who, in the judgment of the investigators, could benefit from androgen deprivation therapy received 6 monthly intramuscular injections of leuprolide acetate 3." | ( Germa, JR; Kaisary, AV; Karlin, GS; Leuratti, C; Marberger, M; Mis, R; Savulsky, C; Shore, ND, 2010) |
| "Two human androgen-resistant prostate cancer cell lines and one androgen-sensitive human prostate adenocarcinoma cell line were treated with leptin (5-100 ng / mL) for up to 48 hours." | ( Fischer, K; Fornara, P; Hamza, A; Heynemann, H; Hoda, MR; Schneider, J; Wagner, S, 2010) |
| "Human androgen-independent PC-3 prostate cancer cells were treated with sorafenib." | ( Chen, N; Chen, XQ; Huang, R; Huang, Y; Zeng, H, 2010) |
| "Using the prostate cancer cell line PPC-1, which is relatively resistant to cell death by doxorubicin (40-50% cytotoxicity), we first report that a combination treatment with cathepsin E can overcome resistance of the cells to this agent." | ( Kawakubo, T; Nakamura, S; Yamamoto, K; Yasukochi, A, 2010) |
| "Patients with prostate cancer who have progression of their disease while on androgen deprivation therapy have limited therapeutic options." | ( Dreicer, R; Shepard, DR, 2010) |
| "Administration of (153)Sm to prostate cancer patients with painful bone metastases offered clinical relevant pain relief with tolerable hematological toxicity." | ( Abrahamsen, J; Jakobsen, M; Jønler, M; Lund, L; Petersen, LJ, 2010) |
| "Advanced prostate cancer responds well to endocrine therapy initially, but soon becomes refractory and has a poor prognosis." | ( Miyazawa, Y; Nakano, K; Nakata, S; Sasaki, Y; Takahashi, H, 2010) |
| "Of all cancers, prostate cancer is the most sensitive to hormones: it is thus very important to take advantage of this unique property and to always use optimal androgen blockade when hormone therapy is the appropriate treatment." | ( Labrie, F, 2010) |
| "Almost all prostate cancers recur during androgen deprivation therapy, and new evidence suggests that androgen receptor activation persists despite castrate levels of circulating androgens." | ( Lih, FB; Mohler, JL; Titus, MA; Tomer, KB, 2010) |
| "Androgen-independent prostate cancer usually develops as a relapse following androgen ablation therapy." | ( Chhipa, RR; Ip, C; Mohler, JL; Wu, Y, 2010) |
| "As the mainstay treatment for advanced prostate cancer, androgen deprivation therapy (ADT) targets the action of androgen receptor (AR) by reducing androgen level and/or by using anti-androgen to compete with androgens for binding to AR." | ( Cheng, H; Dong, Y; Duplessis, T; Ge, Y; Horikawa, I; Ip, C; Liu, S; Lustig, AJ; Qi, Y; Rennie, PS; Rowan, BG; Yu, Q; Zhang, H, 2010) |
| "Twenty patients with prostate cancer underwent paired scans before and after androgen deprivation therapy." | ( Alonzi, R; Collins, DJ; d'Arcy, JA; Hoskin, PJ; Padhani, AR; Saunders, MI; Stirling, JJ; Taylor, NJ, 2010) |
| "Human prostate cancer PC3 cells are insensitive to calcitriol treatment." | ( Engler, KL; Johnson, CS; Kong, RX; Ma, Y; Muindi, JR; Trump, DL; Yu, WD, 2010) |
| "In men with metastatic or recurrent prostate cancer, androgen deprivation therapy (ADT) is the standard of care." | ( Freedland, SJ; Kim, HS, 2010) |
| "The Scandinavian Prostate Cancer Group-7 randomized trial demonstrated a survival benefit of combined endocrine therapy and external-beam radiotherapy over endocrine therapy alone in patients with high-risk prostate cancer." | ( Ahlgren, G; Angelsen, A; Bergh, A; Haugen, OA; Solberg, A; Tasdemir, I; Viset, T; Widmark, A, 2011) |
| "We evaluated patients with prostate cancer undergoing long-acting LH-RH agonist hormone therapy to determine the length of time that serum testosterone remains at castration level." | ( Kawamura, K, 2010) |
| "Treatment of hormone-refractory prostate cancer remains a source of debate." | ( Drouin, SJ; Houédé, N; Rouprêt, M; Wallerand, H, 2010) |
| "There is evidence that prostate cancer cells lacking functional retinoblastoma protein (Rb), a negative regulator of E2F activity, are poorly responsive to 1,25D treatment." | ( Kim, JS; Washington, MN; Weigel, NL, 2011) |
| "Using siRNA, Rb was reduced in C4-2 prostate cancer cells, and the response of cells to 1,25D treatment or depletion of c-myc measured by [(3)H]-thymidine incorporation and flow cytometry." | ( Kim, JS; Washington, MN; Weigel, NL, 2011) |
| "Upon brachytherapy of prostate cancer by implanting 192Ir into the prostate gland (the source organ), the absorbed dose of the prostate gland and surrounding organs and the expected dose of people within the vicinity were assessed." | ( Kim, CS; Kim, JH; Whang, JH, 2010) |
| "A total of 20 consecutive prostate cancer patients, treated with curative external beam radiotherapy, were included." | ( Assendelft, E; de Reijke, TM; Haverkort, MA; Koning, CC; Lensing, AL; Pieters, BR; Stoker, J; van de Kamer, JB; van Herk, M; van Tienhoven, G, 2011) |
| "Initially, most cases of prostate cancer respond well to hormone therapy; however, resistance often develops rapidly, leading to castration-resistant prostate cancer (CRPC)." | ( Hara, T; Kusaka, M; Yamaoka, M, 2010) |
| "While locally advanced prostate cancer is initially treatable with androgen ablation, eventually cells develop a castrate-resistant phenotype." | ( Carty, MP; Claffey, J; Cuffe, S; Dowling, CM; Fitzpatrick, JM; Hogan, M; Pampillón, C; Tacke, M; Watson, RW, 2011) |
| "Androgen deprivation therapy for prostate cancer leads to a significant increase of high-density lipoprotein (HDL), which is generally viewed as beneficial, particularly for cardiovascular disease, but the effect of HDL on prostate cancer is unknown." | ( Demosky, SJ; Furuya, Y; Koike, H; Remaley, AT; Sekine, Y; Stonik, JA; Suzuki, K, 2010) |
| "Advanced prostate cancer (CaP) is often treated with androgen deprivation therapy (ADT)." | ( Leon, CG; Twiddy, AL; Wasan, KM, 2011) |
| "Patients with hormone-refractory prostate cancer are treated with taxane drugs, but eventually become drug resistant." | ( Deguchi, T; Fujita, Y; Ito, M; Kojima, K; Nozawa, Y, 2010) |
| "Even though patients with prostate cancer commonly respond to endocrine treatment, in most cases the disease progresses to castration resistant prostate cancer (CRPC)." | ( Mulders, PF; Pfeiffer, MJ; Schalken, JA, 2010) |
| "Treatment of prostate cancer patients with docetaxel led to a significant translocation of AR." | ( Beer, TM; Garzotto, M; Horbinski, CM; Kyprianou, N; Qian, DZ; Zhu, ML, 2010) |
| "We stably expressed cdk2ap1 in prostate cancer cell lines using lentiviral vectors, as well as several different co-culture assays to quantify cellular invasion, migration, and the effect of the treatments on interaction with the bone microenvironment." | ( Figueiredo, ML; Zolochevska, O, 2011) |
| "A total of 72 patients with localized prostate cancer were prospectively studied based on blood samples before and after androgen deprivation therapy for 6 months." | ( Hara, N; Hoshii, T; Isahaya, E; Nishiyama, T; Takahashi, K; Takizawa, I, 2010) |
| "Patients were undergoing treatment for prostate cancer consisting of a standard daily dose of 50 mg bicalutamide, a fast acting non-steroidal anti-androgen with action comparable to other anti-androgen drugs but with reportedly fewer sexual side effects." | ( Kreienkamp, D; Motofei, IG; Paunica, S; Popa, F; Rowland, DL, 2011) |
| "In human prostate cancer cells, treatment with the PXR agonist rifampicin (RIF) inhibited androgen-dependent proliferation of LAPC-4 cells but had little effect on the growth of the androgen-independent isogenic LA99 cells." | ( Cheng, Q; Huang, M; Kochhar, U; Lee, JH; Ou, Z; Pflug, BR; Ren, S; Xie, W; Xu, M; Zhang, B, 2010) |
| "Advanced hormone-refractory prostate cancer is associated with poor prognosis and limited treatment options." | ( Campiani, G; Cloonan, SM; Lawler, M; Nathwani, SM; Stronach, M; Williams, DC; Zisterer, DM, 2010) |
| "Patients with prostate cancer on androgen deprivation therapy with luteinizing hormone-releasing hormone agonists experience deleterious side effects, including sexual dysfunction, hot flashes and osteoporosis." | ( Schellhammer, P; Wassersug, RJ; Wibowo, E, 2011) |
| "Thus, patients with prostate cancer should be informed about the pros and cons of estrogen therapy before starting androgen deprivation therapy." | ( Schellhammer, P; Wassersug, RJ; Wibowo, E, 2011) |
| "Thus, clinical trials enrolling prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens." | ( Bachmann, M; Füssel, S; Jähnisch, H; Kiessling, A; Rieber, EP; Schmitz, M; Wehner, R; Wirth, MP; Zastrow, S, 2010) |
| "PC3 and LNCaP prostate cancer cells were also sensitive to treatment with the PI3K inhibitor LY294002." | ( Belka, C; Eibl, HJ; Handrick, R; Jendrossek, V; Rudner, J; Ruiner, CE, 2010) |
| "A standard treatment for advanced prostate cancer is androgen deprivation by surgical or medical castration." | ( Akaza, H, 2011) |
| "We evaluated 1617 patients with prostate cancer who received LHRH-agonist monotherapy in the Kaiser Permanente Southern California Cancer Registry between January 2003 and December 2006." | ( Blumberg, JM; Cheetham, TC; Chien, GW; Kwon, EO; Loo, RK; Niu, F; Pacificar, J; Shapiro, CE; Williams, SG, 2011) |
| "Androgen deprivation therapy (ADT) for prostate cancer is associated with increases in fat mass and risk of type 2 diabetes; however, the relationship between sex steroid deficiency and abdominal fat distribution remains controversial." | ( Bolton, D; Gianatti, E; Grossmann, M; Hamilton, EJ; Lim-Joon, D; Strauss, BJ; Wentworth, J; Zajac, JD, 2011) |
| "Androgen deprivation treatment in prostate cancer patients is well established; however, resistance to such treatment manifests itself by progression to castration-resistant prostate cancer (CRPC)." | ( Casey, R; Casey, RG; Gleave, ME; Koupparis, A; Robinson, M, 2010) |
| "The levels of adrenal androgens in prostate cancer tissues after ADT were similar to those in untreated PCa." | ( Arai, S; Honma, S; Kobayashi, M; Miyashiro, Y; Shibata, Y; Suzuki, K; Tomaru, Y, 2011) |
| "The androgen-sensitive prostate cancer cell line LNCaP and androgen-insensitive prostate cancer cell line C4-2 both AR-positive, and androgen-insensitive DU145 and PC3 prostate cancer cell lines were treated with two HDACIs, sodium butyrate (NaB) and/or trichostatin A (TSA)." | ( Kolář, Z; Matiješčuková, N; Pašková, L; Trtková, K, 2010) |
| "For head-and-neck cancer and prostate cancer, the fraction of tumor clonogens killed over a full treatment course decreases by up to a factor of ∼10(3) as the dose per fraction is increased from 2 to 24 Gy and from 2 to 18 Gy, respectively." | ( Brown, JM; Carlson, DJ; Chen, ZJ; Keall, PJ; Loo, BW, 2011) |
| "Androgen-independent DU145 prostate cancer cells were treated with lycopene, apo-8'-lycopenal, or apo-12'-lycopenal." | ( Elsen, AC; Erdman, JW; Ford, NA; Lindshield, BL; Zuniga, K, 2011) |
| "Advanced prostate cancer is initially sensitive to androgen deprivation therapy, but usually progresses to the castration-resistant state." | ( De-Bono, J; Massard, C; Zivi, A, 2010) |
| "Treatment options of T3 prostate cancer were discussed, including the results of the Tap 032 study." | ( Descazeaud, A; Piéchaud, T; Rischmann, P; Roupret, M, 2011) |
| "Men with castrate resistant prostate cancer have limited treatment options." | ( Barkin, J; Bell, D; Fernandes, K; Fleshner, N; Lawrentschuk, N, 2011) |
| "Recurrent prostate cancer presents a challenge to conventional treatment, particularly so to address micrometastatic and small-volume disease." | ( Boisclair, J; Bruchertseifer, F; Frischknecht, M; Maecke, HR; Morgenstern, A; Provencher-Bolliger, A; Reubi, JC; Wild, D; Zhang, H, 2011) |
| "Human breast and prostate cancer cell lines were also treated with different doses of triptolide for different times, followed by measurement of proteasome inhibition (levels of the chymotrypsin-like activity, ubiquitinated proteins and three well-known proteasome target proteins, p27, IκB-α and Bax) and apoptosis induction (caspase-3 activity and PARP cleavage)." | ( Cui, QC; Dou, QP; Kanwar, J; Lu, L; Schmitt, S; Zhang, C; Zhao, C, 2011) |
| "Castration-refractory prostate cancer remains a therapeutic challenge even after introduction of docetaxel as first-line treatment." | ( Filleur, S; Nelius, T; Rinard, K, 2011) |
| "The co-treatment of prostate cancer cells with 100 ng/ml TRAIL and 50 µg/ml EEP increased the percentage of apoptotic cells to 65." | ( Dobosz, C; Janoszka, B; Kowalczyk-Ziomek, G; Krol, W; Szliszka, E; Zydowicz, G, 2011) |
| "Therapy for advanced prostate cancer is only palliative and its improvement could be achieved by sensitization to pro-apoptotic agents to which resveratrol belongs." | ( Culig, Z; Horndasch, M, 2011) |
| "Bicalutamide (BIC) is widely used in prostate cancer therapy." | ( Balbi, C; Barboro, P; Boccardo, F; Ferrari, N; Repaci, E; Rubagotti, A, 2011) |
| "A history of prostate cancer has been a longstanding contraindication to the use of testosterone therapy due to the belief that higher serum testosterone causes more rapid prostate cancer growth." | ( Avila, D; Bennett, R; Khera, M; Lipshultz, LI; Morgentaler, A; Sweeney, M, 2011) |
| "Twenty-eight patients referred for HIFU prostate cancer ablation underwent contrast-enhanced prostate US before treatment, gadolinium-enhanced magnetic resonance (MR) imaging and repeat contrast-enhanced US 1-3 days after treatment, and contrast-enhanced US-guided biopsy 30-45 days after treatment." | ( Chapelon, JY; Dantony, E; Gelet, A; Girouin, N; Glas, L; Lyonnet, D; Mège-Lechevallier, F; Rabilloud, M; Rouvière, O, 2011) |
| "Thus, a paradigm shift for treating prostate cancer is suggested whereby a combination of a non-toxic anti-Gal-3 drug together with a toxic chemotherapeutic agent could serve as a novel therapeutic modality for chemoresistant prostate cancers." | ( Balan, V; Hogan, V; Nangia-Makker, P; Raz, A; Wang, Y, 2010) |
| "Advanced prostate cancers are known to acquire not only invasive capabilities but also significant resistance to chemotherapy-induced apoptosis." | ( Bhatnagar, N; Guo, B; Li, X; Padi, SK; Tang, MS; Zhang, Q, 2010) |
| "Records of consecutive prostate cancer patients with coexisting diabetes mellitus type 2 who were treated at the study institution between 15 July 1999 and 31 December 2008 were reviewed." | ( He, XX; Lee, MH; Tu, SM; Yeung, SJ, 2011) |
| "Androgen deprivation therapy (ADT) for prostate cancer treatment induces a metabolic syndrome, which may contribute to non-cancer-related morbidity and mortality." | ( Ali, SS; Clements, A; Gao, B; Gurney, H; Wong, MKY; Yeap, SHO, 2011) |
| "Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss." | ( Izumi, K; Kitagawa, Y; Koh, E; Mizokami, A; Namiki, M; Narimoto, K; Sugimoto, K, 2011) |
| "Furthermore, treatment of human prostate cancer cells (PC-3) with ACA resulted in decreased cell viability and suppression of angiogenic factor production by interference with dual Src/FAK kinases." | ( Aggarwal, BB; Chen, J; Lai, L; Liu, M; Pang, X; Qu, W; Wu, Y; Yi, Z; Zhang, J; Zhang, L, 2011) |
| "Newly diagnosed prostate cancer patients with low risk disease either with symptomatic benign prostatic hypertrophy or deemed to require pre-brachytherapy androgen suppression therapy were eligible." | ( Chung, HT; Kurhanewicz, J; Noworolski, SM; Roach Iii, M; Weinberg, V, 2011) |
| "Current therapies to treat prostate cancer are often limited." | ( Frey, BM; Frey, FJ; Gazdhar, A; Goepfert, C, 2011) |
| "Seventy-one patients with localized prostate cancer, who received ADT with GnRHa, were prospectively studied based on their blood samples before treatment and after ADT for 6 months." | ( Hara, N; Hoshii, T; Isahaya, E; Ishizaki, F; Nishiyama, T; Takahashi, K; Takizawa, I, 2012) |
| "This approach could make prostate cancer treatments more effective." | ( Guan, Y; Jing, N; Qin, G; Reddy, KR; Zhou, Z, 2011) |
| "Human prostate cancer cell line, CWR22RV1, was treated with perifosine, radiation, or CTPR." | ( Brinkman, KL; Butler, EB; Floryk, D; Gao, Y; Huang, Y; Ishiyama, H; Ittmann, M; Mai, W; Sun, M; Teh, BS; Thompson, TC; Wang, X; Xu, B; Zhu, J, 2011) |
| "Treatment of metastatic rat and human prostate cancer cell lines with MSeA decreased hypoxia-inducible factor-1α (HIF-1α) levels in a dose-dependent manner." | ( King, T; Null, K; Pinto, JT; Sinha, I; Sinha, R; Suckow, MA; Wolter, W, 2012) |
| "Metastatic prostate cancer to the orbit is diagnosed, and the treatment with IMRT and hormone ablation is explored." | ( Heintz, J; Kahn, B; Kramer, A, 2011) |
| "Whereas the treatment of prostate cancer cells individually with anti-CaM drug or calcimycin, which increases intracellular Ca(++) and activates Cpn, led to minimal AR breakdown, combined treatment led to a precipitous decrease in AR protein levels." | ( Bai, VU; Barrack, ER; Chinnakannu, K; Kim, SH; Menon, M; Murthy, S; Reddy, GP; Sivanandam, A, 2011) |
| "One of the most troublesome aspects of prostate cancer is that androgen dependent prostate cancer inevitably progresses to highly aggressive, life threatening castration resistant prostate cancer after androgen ablation therapy." | ( Kikuchi, E; Kosaka, T; Miyajima, A; Oya, M; Shirotake, S; Suzuki, E, 2011) |
| "Since hormone refractory prostate cancer with bone metastasis is difficult to treat, it is crucial to investigate how androgen independent (AI) human prostate cancer cells communicate with their associated stroma." | ( Chung, LW; Fujisawa, M; Gotoh, A; Huang, WC; Li, X; Marshall, FF; Shigemura, K; Xie, J; Zhau, HE; Zhu, G, 2011) |
| "We diagnosed prostate cancer without a biopsy, and then maximally blockaded androgens by castration and bicalutamide administration." | ( Masago, T; Motoda, K; Nemoto, R; Watanabe, T, 2011) |
| "Treatment of highly aggressive human prostate cancer PC-3 cells with α-tomatine resulted in a concentration-dependent inhibition of cell growth with a half-maximal efficient concentration (EC(50)) value of 1." | ( Cheah, SC; Lee, ST; Mustafa, MR; Wong, PF, 2011) |
| "Although advanced prostate cancer patients respond very well to front-line androgen deprivation, failure to hormonal therapy most often occurs after a median time of 18-24 months." | ( Asmane, I; Barthélémy, P; Bergerat, JP; Céraline, J; Duclos, B; Dufour, P; Kurtz, JE; Litique, V; Rob, L, 2011) |
| "In all, 30 patients with prostate cancer with bone metastasis were treated with zoledronic acid infusion every 4 weeks." | ( Itai, S; Izumi, K; Koh, E; Konaka, H; Maeda, Y; Miwa, S; Mizokami, A; Namiki, M; Shigehara, K; Shima, T, 2012) |
| "Despite multiple advances in prostate cancer therapy, treatment options for castration resistant disease are very limited." | ( Espinosa, E; González, R; Merino, M; Pinto, A, 2011) |
| "A cohort of 538 patients with prostate cancer treated with ADT was genotyped for SLCO2B1 and SLCO1B3 single nucleotide polymorphisms (SNP)." | ( Balk, S; Brown, M; Figg, WD; Freedman, M; Kantoff, PW; Lee, GS; Mostaghel, E; Nakabayashi, M; Oh, WK; Pomerantz, M; Regan, M; Ross, R; Sharifi, N; Sun, T; Taplin, ME; Werner, L; Xie, W; Yang, M, 2011) |
| "Fifty-five patients with prostate cancer (T1-2 stage, Gleason score <7 and prostate specific antigen (PSA) <10 ng/ml) were treated with localized conformal 4-field radiotherapy to the prostate and seminal vesicles: 51 Gy were delivered (3." | ( Giatromanolaki, A; Kalogeris, K; Koukourakis, MI; Kyrgias, G; Mavropoulou, S; Milioudis, N; Nassos, P; Panteliadou, M; Papadopoulou, A; Sivridis, E; Touloupidis, S, 2011) |
| "Current treatments for prostate cancer consist of reducing androgen levels by chemical or surgical castration or pure antiandrogen therapy that directly targets the androgen receptor (AR)." | ( Nacusi, LP; Tindall, DJ, 2011) |
| "Radiotherapy is used to treat localized prostate cancer." | ( Bahl, A; Holly, JM; Perks, CM; Persad, R; Thomas, F, 2011) |
| "Androgen deprivation therapy for prostate cancer causes accelerated loss of bone mineral density and is associated with increased fracture risk." | ( Barnette, KG; Hancock, ML; Morton, RA; Saylor, PJ; Smith, MR; Steiner, MS, 2011) |
| "Although treatment for prostate cancer has improved over the past several years, taxanes remain the only form of chemotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC)." | ( Dahut, WL; Madan, RA; Pal, SK; Sartor, O, 2011) |
| "Conventional therapies to treat prostate cancer (CaP) of androgen-dependent phenotype (ADPC) and castration-resistant phenotype (CRPC) are deficient in outcome which has necessitated a need to identify those agents that could target AR for both disease types." | ( Karnes, RJ; Mishra, SK; Saleem, M; Siddique, HR, 2011) |
| "Treating LNCaP prostate cancer cells with carbidopa in transcriptional assays suppressed the enhanced AR transactivation seen with DDC overexpression and decreased prostate-specific antigen (PSA) mRNA levels." | ( Cheng, H; Cox, ME; Fazli, L; Fukumoto, T; Ghaidi, F; Gleave, ME; Plaa, N; Rennie, PS; Wafa, LA, 2012) |
| "Although localized prostate cancer can be effectively treated via surgery or radiation, metastatic disease is usually lethal." | ( Huang, Y; Khor, TO; Kong, AN; Lee, J; Shu, L; Wu, TY, 2011) |
| "Patients with high risk prostate cancer (prostate specific antigen greater than 20 ng/ml, Gleason score greater than 7, or clinical stage T2b or greater) have been shown to have a 30% to 40% biochemical recurrence rate after definitive local therapy." | ( Holzbeierlein, JM; Nisbet, AA; Reed, GA; Thrasher, JB; VanVeldhuizen, PJ; Womble, PR, 2011) |
| "In the majority of cases, advanced prostate cancer responds initially to androgen deprivation therapy by depletion of gonadal testosterone." | ( Auchus, RJ; Chang, KH; Li, R; Papari-Zareei, M; Sharifi, N; Watumull, L; Zhao, YD, 2011) |
| "For patients who still have prostate cancer which has not yet been treated or not yet cured decisions on whether the benefit of the testosterone replacement is greater than the potential risk of a progress of the disease have to be made on an individual case-specific basis." | ( Kaminsky, A; Sperling, H, 2011) |
| "Biochemically-recurrent prostate cancer patients with prostate specific antigen doubling times (PSADT) < 12 months, no radiographic evidence of metastasis, and no hormonal therapy within 6 months (with serum testosterone levels > 150 ng/dl) were eligible." | ( Antonarakis, ES; Beer, TM; Callahan, JA; Carducci, MA; Gordon, G; Lin, J; Mathew, P; Morris, M; Reich, SD; Ryan, CJ; Wilding, G; Zahurak, M, 2013) |
| "Men with advanced prostate cancer and a clinical response to 52 weeks of treatment with the histrelin implant." | ( Cookson, MS; Gittelman, MC; Shore, N, 2012) |
| "Relapse of castration-resistant prostate cancer (CRPC) that occurs after androgen deprivation therapy of primary prostate cancer can be mediated by reactivation of the androgen receptor (AR)." | ( Balk, SP; Bubley, GJ; Cai, C; Chen, S; Marck, B; Matsumoto, AM; Mostaghel, EA; Nelson, PS; Ng, P; Simon, NI; Wang, H, 2011) |
| "The threat of prostate cancer and the significant and often negative impact of its treatment underscore the importance of prevention." | ( Alberts, DS; Berry, DL; Crawford, ED; Davis, W; Ely, B; Gaziano, JM; Jarrard, DF; Klein, EA; Lee, WR; Lippman, SM; Marshall, JR; Minasian, LM; Parnes, HL; Ray, M; Sakr, WA; Tangen, CM; Thompson, IM; Wood, DP, 2011) |
| "Androgen deprivation therapy (ADT) for prostate cancer increases fracture risk, decreases bone mineral density, and increases bone turnover markers (BTMs) including serum type 1 C-telopeptide (sCTX), tartrate-resistant alkaline phosphatase 5b (TRAP-5b), and procollagen-1 N-terminal telopeptide (P1NP)." | ( Egerdie, B; Goessl, C; Ke, C; Leder, BZ; Saad, F; Sieber, P; Smith, MR; Tammela, TLj, 2011) |
| "Recent studies using prostate cancer cell and mouse models demonstrate a significant potential for SK1-targeting therapies to synergize with the effects of docetaxel chemotherapy and radiotherapy." | ( Böhler, T; Pchejetski, D; Stebbing, J; Waxman, J, 2011) |
| "The main therapy for metastatic prostate cancer (MPC) includes androgen manipulation, chemotherapy, and radiotherapy and/or radioisotopes." | ( Bui, NT; Ha, TV; Hoang, BX; Hoang, C; Le, BT; Pham, CQ; Pham, TD; Shaw, DG; Tran, DM; Tran, HD; Tran, HQ, 2011) |
| "Eighty-seven patients with prostate cancer underwent dynamic gadolinium-enhanced MRI before robotic stereotactic body radiation therapy, and prostate volume was calculated." | ( Fuller, DB; Low, RN; Muradyan, N, 2011) |
| "In men with prostate cancer observed rates of cardiovascular disease events were similar before and after degarelix treatment." | ( Colli, E; Klotz, L; Smith, MR; Tankó, LB; van der Meulen, E, 2011) |
| "We collected the data of 45 advanced prostate cancer patients complicated with lower urinary tract symptoms who were treated by MAB." | ( Gui, M; He, L; Li, W; Long, Z; Zhong, K, 2011) |
| "MAB for patients with advanced prostate cancer can improve their lower urinary tract symptoms, whose main effect is presented in the 3rd months after the androgen deprivation therapy." | ( Gui, M; He, L; Li, W; Long, Z; Zhong, K, 2011) |
| "Androgen administration can cause prostate cancer progression, and androgen deprivation therapy is a commonly used therapeutic modality in the treatment of prostate cancer." | ( Aylwin, S; Hughes, S; Landau, D; Tsakok, T, 2012) |
| "LNCaP prostate cancer cells were treated with 5-aza-2'-deoxycytidine (5-aza-CdR) either with a single high dose (5-20 µM), every alternate day (0." | ( Bianco-Miotto, T; Butler, LM; Centenera, MM; Chiam, K; Tilley, WD, 2011) |
| "In the prostate cancer setting, antiresorptive therapy was reported to delay the development of overt bone metastases." | ( Clézardin, P; Gnant, M, 2012) |
| "Castrate-resistant prostate cancer (CRPC) is a challenging aspect in the treatment of prostate cancer." | ( Redding, MB; Surati, M, 2011) |
| "Radio-resistant or recurrent prostate cancer represents a serious health risk for approximately 20%-30% of patients treated with primary radiation therapy for clinically localized prostate cancer." | ( He, Z; Mehta, SK; Pierson, DL; Rohde, LH; Wu, H; Zhang, Y, 2011) |
| "The influence of ERα on prostate cancer progression was studied in intact male rats treated with testosterone in combination with the ERα agonist, ERA-45 for either a long-term (20-week) period or a shorter term (6-week) period." | ( Attia, DM; Ederveen, AG, 2012) |
| "Advanced prostate cancer is typically sensitive to androgen-deprivation therapy, but invariably progresses to the castration-resistant state." | ( de Bono, JS; Massard, C; Michels, RM; Sartor, O, 2011) |
| "Patients with castration-resistant prostate cancer (CRPC) that progresses after docetaxel may benefit from receiving further chemotherapy." | ( Borsellino, N; Gebbia, V; Serretta, V; Valerio, MR, 2011) |
| "A cohort of 1,060 prostate cancer patients treated with radical radiotherapy was divided into nine subgroups based on National Comprehensive Cancer Network risk category and estimated 10-year overall survival (eOS 10y) derived from the age adjusted Charlson Comorbidity Index." | ( Herbert, C; Joffres, M; Khaira, M; Kwan, W; Liu, M; Moiseenko, V; Morris, WJ; Pickles, T; Tyldesley, S, 2012) |
| "This study unexpectedly shows that prostate cancer patients who develop ≥ Grade 2 RTOG acute toxicity during radiotherapy are less likely to remain BFF at 5 years." | ( Bayley, A; Bristow, RG; Catton, C; Chung, P; Gospodarowicz, M; Jacks, L; Lockwood, G; Ménard, C; Milosevic, M; Nichol, A; Rosewall, T; Skala, M; Vesprini, D; Warde, P, 2012) |
| "Twenty-three consecutive patients with prostate cancer treated by primary ADT were included." | ( Barrett, T; Gill, AB; Gnanapragasam, VJ; Graves, MJ; Griffiths, JR; Joubert, I; Kataoka, MY; Lomas, DJ; McLean, MA; Neal, D; Priest, AN; Sala, E; Stearn, S, 2012) |
| "Improved treatments for prostate cancer are in great need to overcome lethal recurrence and metastasis." | ( Kopeček, J; Yang, J; Zhou, Y, 2012) |
| "Advanced castration-resistant prostate cancer has high mortality rates and limited treatment options." | ( Lu, H; Martzen, MR; Slaton, JW; Verneris, MR; Wang, H; Wenner, CA, 2012) |
| "Advanced prostate cancer is currently treated with androgen deprivation therapy (ADT)." | ( Ai, J; Langmann, G; O'Malley, KJ; Ramos-Garcia, R; Vessella, RL; Wang, Z, 2012) |
| "The treatment for prostate cancer patients with biochemical failure after local therapy remains controversial." | ( Ahles, T; Gu, L; Halabi, S; Hussain, A; Kaplan, E; Kelly, WK; Monk, JP; Philips, G; Picus, J; Small, EJ; Vogelzang, N, 2012) |
| "HCT116 colorectal or PPC1 prostate cancer cells were treated with quercetin and the drugs." | ( Fadlalla, K; Katkoori, V; Manne, U; Mosley, L; Samuel, T; Turner, T, 2012) |
| "Primary prevention of prostate cancer remains an attractive goal because of its prevalence and treatment-related morbidity." | ( Klein, EA; Thompson, IM, 2012) |
| "The lack of response of WPE1-NA22 prostate cancer cells to androgen treatment may explain the inadequate tumor growth observed." | ( Lindshield, BL; Nelsen, MK; Opoku-Acheampong, AB; Unis, D, 2012) |
| "If MRSI is to be used in targeting prostate cancer and therapy assessment, the impact of gold seeds on MRSI must be investigated." | ( Buyyounouski, MK; Chen, L; Hossain, M; Ma, CM; Richardson, T; Schirmer, T, 2012) |
| "AKR1C3 is upregulated in prostate cancer (PCa) and castrate resistant prostate cancer (CRPC) that develops after androgen deprivation therapy." | ( Byrns, MC; Duan, L; Mindnich, R; Penning, TM, 2012) |
| "Altogether, these data suggest that as prostate cancer cells alter glucose and glutamine levels, O-GlcNAc modifications and OGT levels become elevated and are required for regulation of malignant properties, implicating OGT as a novel therapeutic target in the treatment of cancer." | ( Ferrer, CM; Jackson, SR; Lynch, TP; Reginato, MJ; Shahriari, KS; Vosseller, K, 2012) |
| "The primary endpoint was time to prostate cancer progression, defined as the number of days between the start of study treatment and the earlier of either pathological progression (in patients with ≥1 biopsy assessment after baseline) or therapeutic progression (start of medical therapy)." | ( Aaron, L; Black, L; Egerdie, B; Eure, G; Fleshner, NE; Lucia, MS; Nandy, I; Rittmaster, RS, 2012) |
| "Treatment of high-risk localized prostate cancer remains inadequate." | ( Barry, M; Bhatt, RS; Choueiri, TK; Febbo, P; Fennessy, FM; Galsky, MD; Hayes, J; Kantoff, PW; Oh, WK; Richie, JP; Ross, RW; Taplin, ME; Tempany, CM; Xie, W, 2012) |
| "The role of neoadjuvant chemotherapy in prostate cancer, and perioperative antiangiogenic therapy in general, requires further elucidation through ongoing and planned trials." | ( Barry, M; Bhatt, RS; Choueiri, TK; Febbo, P; Fennessy, FM; Galsky, MD; Hayes, J; Kantoff, PW; Oh, WK; Richie, JP; Ross, RW; Taplin, ME; Tempany, CM; Xie, W, 2012) |
| "In 14 patients with locally advanced prostate cancer, six to 12 prostatic needle core biopsy specimens were taken prior to castration therapy." | ( Al-Ubaidi, FL; Egevad, L; Granfors, T; Helleday, T; Schultz, N, 2012) |
| "The treatment of advanced-stage prostate cancer has been androgen deprivation." | ( Rehman, Y; Rosenberg, JE, 2012) |
| "New treatments for prostate cancer that improve patient outcomes without the serious estrogen deficiency-related toxicities associated with ADT using LHRH analogs are needed." | ( Barrett, CM; Coss, CC; Dalton, JT; Jones, A; Kearbey, JD; Miller, DD; Morton, RA; Narayanan, R; Parke, DN; Steiner, MS; Veverka, KA, 2012) |
| "Androgen deprivation therapy (ADT) for prostate cancer causes drastic hormonal changes that alter both disease and host factors." | ( Ancukiewicz, MA; Duda, DG; Efstathiou, JA; Jain, RK; Kozak, KR; Saylor, PJ; Smith, MR; Zietman, AL, 2012) |
| "The contemporary problem of prostate cancer overtreatment can be partially attributed to the diagnosis of potentially indolent prostate cancers that pose low risk to aged men, and lack of sufficiently accurate risk stratification methods to reliably seek out men with indolent diseases." | ( De Marzo, AM; Dunn, TA; Fedor, HL; Luo, J, 2012) |
| "Thirty-six men with untreated prostate cancer and negative for metastatic disease on pelvic CT and bone scan were prospectively enrolled." | ( Alanen, K; Aronen, HJ; Arponen, E; Borra, R; Dean, K; Jambor, I; Kemppainen, J; Lepomäki, V; Minn, H; Nurmi, M; Parkkola, R, 2012) |
| "The study included 25 prostate cancer patients with severe side effects (S) and 25 patients without severe side effects (0) after radiotherapy as well as 23 male healthy age-matched donors." | ( Brzozowska, K; Eble, MJ; Kriehuber, R; Müller, WU; Pinkawa, M; Schmitz, S; Wojcik, A, 2012) |
| "Fifty-six patients with advanced prostate cancer, who were refractory to both initial castration monotherapy and subsequent deferred CAB, received oestrogen therapy (estramustine phosphate 140 or 280 mg/day in 50 patients, diethylstilbestrol diphosphate 100 mg/day orally in six patients)." | ( Fujii, Y; Ishioka, J; Kawakami, S; Kihara, K; Kijima, T; Koga, F; Masuda, H; Matsuoka, Y; Numao, N; Saito, K; Yokoyama, M, 2012) |
| "The progression of prostate cancers (PCs) to locally invasive, androgen-independent and metastatic disease states is generally associated with treatment resistance and disease relapse." | ( Batra, SK; Johansson, SL; Mimeault, M, 2012) |
| "Following treatment of DU145 human prostate cancer cells with 10, 25 and 50 μg ml⁻¹ of WCE, respectively for 6 h, WCE significantly decreased the cellular viability of DU145 cells." | ( Catalli, A; Déziel, B; Gottschall-Pass, K; Hurta, R; Kulka, M; MacPhee, J; Neto, C; Patel, K, 2012) |
| "LNCap prostate cancer cells were treated with fucoxanthin and the effects were evaluated in relation to cell proliferation, cell cycle, expression of growth arrest, DNA damage-inducible protein (GADD45) genes, and phosphorylation status of mitogen-activated protein kinases." | ( Satomi, Y, 2012) |
| "Over-diagnosis and treatment of prostate cancer has been a major problem in prostate cancer care and management." | ( Decker, DA; Hallquist, H; Huo, Q; Litherland, SA; Rivera-Ramirez, I; Sullivan, S, 2012) |
| "We show that treatment of PC-3 prostate cancer and MDA-MB-231 breast cancer cells with these membrane-permeable Zn-chelators with different Zn affinities results in varying degrees of XIAP depletion." | ( Bi, C; Dou, QP; Fan, Y; Kodanko, JJ; Prakash, J; Schmitt, SM; Zhang, Z; Zuo, J, 2012) |
| "Patients with prostate cancer progressing after androgen ablation therapy and chemotherapy were treated with transdermal estradiol patches (0." | ( DiPaola, RS; Doyle-Lindrud, S; Eddy, S; Goodin, S; Kane, M; Metzger, D; Shih, W; Silberberg, J; Stein, M, 2012) |
| "The basis for endocrine treatment of prostate cancer is to deprive the cancer cells of androgens." | ( Tammela, TL, 2012) |
| "Two human prostate cancer cell lines, PC-3 and LNCaP, were treated with BP, and subsequently evaluated for their viability and cell cycle profiles." | ( Chen, SP; Chiu, SC; Harn, HJ; Huang, SY; Lin, SZ; Pang, CY; Wang, MJ, 2012) |
| "PC-3, DU-145, or LNCaP prostate cancer cells were treated with VPA (1 mM), IFNa (200 U/ml), or with the VPA-IFNa combination." | ( Bartsch, G; Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Makarević, J; Tezeeh, P; Tsaur, I; Wedel, S; Wiesner, C, 2012) |
| "Men with prostate cancer who lacked radiographically detectable metastases were treated in a prospective trial of IAD." | ( Chen, S; Gambol, TE; Gulati, R; Hall, SP; Higano, CS; Jiang, PY; Kuo, KF; Pitzel, P; Yu, EY, 2012) |
| "Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen." | ( Beatty, J; Bell, R; Miller, M; Mohammed, A; Rawlinson, A, 2012) |
| "One hundred seventy-six patients with prostate cancer (PC) who were candidates for bicalutamide monotherapy were randomized to receive TAM 20 mg daily orally within 1 month from the onset of BEs (arm A) vs." | ( Allegro, R; Altieri, V; De Grande, G; Ferraù, F; Gebbia, V; Mazza, R; Melloni, D; Morgia, G; Nicolosi, F; Serretta, V, 2012) |
| "Patients with prostate cancer with prostate specific antigen (PSA) levels between 20 and 99 ng/mL and/or Gleason score 8-10 tumours, planned for treatment with curative intent based on routine staging with a negative or inconclusive bone scan, were further investigated with a (18)F-fluorocholine and a (18)F-fluoride PET/CT." | ( Ahlgren, G; Almquist, H; Bratt, O; Kjölhede, H; Liedberg, F; Lyttkens, K; Ohlsson, T, 2012) |
| "Castration-resistant prostate cancer, defined when there is progression of disease despite low levels of testosterone, requires specialized care, and improved communication between medical and urologic oncologists has been identified as a key component in delivering effective therapy." | ( Herchenhorn, D; Maluf, FC; Smaletz, O, 2012) |
| "Understanding the molecular basis of prostate cancer progression can serve as a tool for early diagnosis and development of novel treatment strategies for this disease." | ( Chauhan, SC; Ebeling, M; Jaggi, M; Sundram, V, 2012) |
| "Prostatic acid phosphatase (PAP) is a prostate cancer tumor antigen and is an immunological target in several active immunotherapy clinical trials for the treatment of prostate cancer." | ( Johnson, LE; McNeel, DG, 2012) |
| "• All men treated for prostate cancer between 1998 and 2007 with curative radiation in the province of British Columbia, Canada were potentially eligible (n= 11752)." | ( Hamm, J; Morris, WJ; Pickles, T; Schreiber, WE; Tyldesley, S, 2012) |
| "Treatment of prostate cancer cells with α-santalol resulted in induction of apoptosis as evidenced by DNA fragmentation and nuclear staining of apoptotic cells by DAPI." | ( Bommareddy, A; Dwivedi, C; Rule, B; Santha, S; VanWert, AL, 2012) |
| "Patients with high risk prostate cancer with pT3 tumor and positive surgical margins have a high risk of biochemical failure after radical prostatectomy and adjuvant androgen deprivation therapy." | ( Bader, P; Briganti, A; Capitanio, U; Gontero, P; Joniau, S; Karnes, JR; Kneitz, B; Montorsi, F; Scholz, CJ; Schubert, M; Spahn, M; van Poppel, H, 2012) |
| "typhimurium) to treat prostate cancer in vitro and in vivo." | ( Gao, LF; Guo, BF; Guo, YX; Liu, XC; Liu, YB; Xu, DQ; Zhang, L; Zhao, LJ; Zhao, XJ, 2012) |
| "To develop a relevant mouse model for prostate cancer prevention research, we administered a dietary carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), to CYP1A-humanized mice." | ( Bosland, MC; Cheung, C; Li, G; Liu, AB; Reuhl, KR; Wang, H; Yang, CS, 2012) |
| "Androgen deprivation therapy (ADT) for prostate cancer causes an increase in fasting insulin and adverse changes in body composition and serum lipid profile." | ( Karoly, ED; Saylor, PJ; Smith, MR, 2012) |
| "Although most prostate cancers regress after androgen deprivation therapy is given at diagnosis, they eventually regrow in a castration resistant manner, spread systemically and end fatally." | ( Kashiwagi, E; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A, 2012) |
| "Human LNCaP prostate cancer cells were injected into the flank of athymic mice and tumors were treated with Ang-(1-7) for 54 days." | ( Gallagher, PE; Krishnan, B; Tallant, EA; Torti, FM, 2013) |
| "Human PC3 prostate cancer cells were injected into the aortic arch via the carotid artery of SCID mice pre-treated with Ang-(1-7) or injected into the tibia of athymic mice, administered Ang-(1-7) for 5 weeks beginning 2 weeks post-injection." | ( Dubey, P; Gallagher, PE; Krishnan, B; Smith, TL; Tallant, EA; Torti, FM; Willingham, MC; Zapadka, ME, 2013) |
| "At earlier stages, most diagnosed prostate cancers are responsive to androgen depletion treatment, yet, nearly all patients will eventually progress to metastatic androgen-independent prostate cancer (AIPC), which still has no effective therapeutic method or drug to deal with." | ( Ni, Y; Shi, G; Shi, Y; Yang, H; Zhang, Y, 2012) |
| "In many patients with prostate cancer, androgen deprivation therapy (ADT) is administered over prolonged periods of time." | ( Aapro, M; Irani, J; Schulman, C, 2012) |
| "A total of 320 localized prostate cancer patients including 272 at low-risk and 48 at intermediate-risk were treated with permanent iodine-125 seed implants." | ( Hashida, I; Hosaka, N; Iijima, K; Kamigaito, T; Nishizawa, S; Okaneya, T; Yamagishi, T, 2012) |
| "The major obstacles in human prostate cancer (PCA) treatment are the development of resistance to androgen ablation therapy leading to hormone-refractory state and the toxicity associated with chemotherapeutic drugs." | ( Agarwal, C; Agarwal, R; Amiranashvili, L; Barbakadze, V; Gagan, D; Gogilashvili, L; Merlani, M; Mulkijanyan, K; Papadopoulos, K; Raina, K; Ramasamy, K; Shrotriya, S, 2012) |
| "Bone metastases in prostate cancer are often the cause of significant morbidity in patients with castrate-resistant disease, and several studies have shown significant pain palliation with systemic radionuclide treatment." | ( O'Sullivan, JM; Parker, CC; Vengalil, S, 2012) |
| "• In all, 1063 potent men with T1-T3 prostate cancer were treated from 1990 to 2007 with seed implantation alone ((103) Pd or (125) I) (69." | ( Buckstein, M; Snyder, KM; Stock, RG; Stone, NN, 2012) |
| "TRAIL-resistant LNCaP prostate cancer cells were treated with TRAIL and artepillin C." | ( Krol, W; Mizgala, E; Szliszka, E; Zydowicz, G, 2012) |
| "Additionally, in castrate-resistant prostate cancer, treatment with denosumab delays the development of bone metastases." | ( Clezardin, P; Coleman, R; Gnant, M; Morgan, G, 2012) |
| "Many prostate cancers relapse due to the generation of chemoresistance rendering first-line treatment drugs like paclitaxel (PTX) ineffective." | ( Behrman, SW; Chitkara, D; Mahato, RI; Mehrazin, R; Singh, S; Wake, RW, 2012) |
| "Despite advances in prostate cancer screening, more than a quarter of a million men die from the disease every year(1) due primarily to treatment-resistance and metastasis." | ( Austin, LA; Dreaden, EC; El-Sayed, MA; Gryder, BE; Hayden, SC; Oyelere, AK; Pi, M; Quarles, LD; Tene Defo, BA, 2012) |
| "Additionally, in castrate-resistant prostate cancer, treatment with denosumab delays the development of bone metastases." | ( Coleman, RE, 2012) |
| "Traditional treatments for prostate cancer have limited efficacy; therefore, new therapeutic strategies and/or new adjuvant drugs must be explored." | ( Chen, YL; Chiu, HW; Fang, WH; Ho, SY; Wang, YJ; Wu, MD; Yuan, GF, 2012) |
| "Transition of prostate cancer (PC) to the castration-resistant phenotype correlates with AR-V7 accumulation, suggesting that PC progression in patients refractory to conventional therapy is due to the activity of this AR isoform." | ( Hartig, SM; Hayes, TG; Mancini, MA; Marcelli, M; Mediwala, SN; Sonpavde, G; Sun, H; Szafran, AT; Thiagarajan, P, 2013) |
| "Antisurvival factor therapy for prostate cancer cells (ASF) in castration-resistant prostate cancer, is a hormonal manipulation consisting of a somatostatin analog, which reduces the growth hormone-dependent, systemic IGF-1 production and of oral dexamethasone, which supresses the urokinase type plasminogen activator -mediated "local" increase of IGF-1 bioavailability in the bone metastases, while the patients continue on a luteinizing hormone-releasing hormone analog therapy." | ( Goulis, DG; Koutsilieris, M; Msaouel, P; Toulis, KA, 2012) |
| "Treatment of castration-resistant prostate cancer (CRPC) remains a challenge considering that most patients are elderly men with significant comorbidities." | ( Marschner, N; Zaiss, M, 2012) |
| "The time to diagnosis of prostate cancer was compared between treatment groups using the Cox proportional hazards model." | ( Ahmann, FR; Algotar, AM; Clark, LC; Dalkin, BL; Graham, DL; Holmes, MA; Hsu, CH; Nagle, RB; Parnes, HL; Ranger-Moore, J; Sindhwani, P; Slate, E; Stratton, MS; Stratton, SP; Thompson, PA; Tuckey, JA, 2013) |
| "Furthermore, when RM-1 prostate cancer cells were co-injected with MSCs pretreated with IL-1α, tumor incidence significantly increased in allogeneic recipients." | ( Bai, X; Cheng, J; Li, L; Liu, Y; Wang, Z; Zhu, X, 2012) |
| "Androgen deprivation therapy (ADT) for prostate cancer (PCa) may increase peripheral insulin resistance, induce type 2 diabetes, change body composition, and alter lipoprotein profile." | ( Breza, J; Goncalves, FM; Ziaran, S, 2013) |
| "Treatment of prostate cancer cell lines with a C21-based peptide specifically increased the level of NKX3." | ( Bieberich, CJ; Guan, B; Mutton, LN; Rao, V, 2012) |
| "In KHC-4 treatments for 72 h on human prostate cancer PC3 cells, cytotoxic effects (IC(50) =0." | ( Chen, PY; Chen, YJ; Chou, LC; Huang, CY; Hwang, JM; Kuo, SC; Liu, CY; Ting, WJ; Tsai, FJ; Wu, HC, 2012) |
| "An elderly man had been treated for prostate cancer with radiation and neoadjuvant hormonal therapy." | ( Arola, J; Metso, S; Raade, M; Välimäki, M, 2012) |
| "We observed that treatment of prostate cancer cells with low micromolar doses of XN inhibits proliferation and modulates focal adhesion kinase (FAK) and AKT phosphorylation leading to reduced cell migration and invasion." | ( Astigiano, S; Benelli, R; Ferrari, N; Minghelli, S; Tosetti, F; Venè, R, 2012) |
| "The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy." | ( Armstrong, AJ; Bahnson, RR; Boston, B; Busby, JE; D'Amico, AV; Eastham, JA; Enke, CA; Farrington, T; Higano, CS; Ho, M; Horwitz, EM; Kantoff, PW; Kawachi, MH; Kuettel, M; Lee, RJ; MacVicar, GR; Malcolm, AW; Miller, D; Mohler, JL; Plimack, ER; Pow-Sang, JM; Roach, M; Rohren, E; Rosenfeld, S; Shead, DA; Srinivas, S; Strope, SA; Tward, J; Twardowski, P; Walsh, PC, 2012) |
| "Many prostate cancers demonstrate an increased expression of growth factor receptors such as vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) which have been correlated with increased resistance to radiotherapy and poor prognosis in other tumors." | ( Bridges, K; Brooks, C; Kuban, D; Mason, K; Mathew, P; Meyn, R; Sheu, T, 2012) |
| "Increased understanding of prostate cancer biology has led to new treatment strategies and promising new agents for treating prostate cancer, in particular peptide-based agonists and antagonists." | ( Jiang, YF; Wu, B; Xu, Y, 2012) |
| "Effective treatment of prostate cancer (PCa) remains a major challenge due to chemoresistance to drugs including tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)." | ( Arscott, WT; Dempsey, RJ; Folsom, JB; Plante, MK; Tighe, SW; Wesley, UV, 2013) |
| "Patients with castration-resistant prostate cancer (CRPC) and bone metastases have an unmet clinical need for effective treatments that improve quality of life and survival with a favorable safety profile." | ( Chodacki, A; Germá, JR; Haider, T; Hoskin, P; O'Bryan-Tear, CG; O'Sullivan, JM; Parker, CC; Pascoe, S, 2013) |
| "The landscape of treatment for advanced prostate cancer is continually evolving as new therapies are developed and guidelines are constantly updated." | ( Aapro, MS, 2012) |
| "But current standard RT for prostate cancer uses higher doses, and it is unclear if concurrent chemotherapy is safe with modern RT." | ( Chen, RC; Chiu, WK; Crane, JM; Godley, PA; Hoffman, LG; Kim, WY; Pruthi, RS; Rathmell, WK; Rosenman, JG; Wallen, EM; Wang, AZ; Whang, YE, 2012) |
| "• Patients with high-risk prostate cancer were treated with a luteinising hormone-releasing hormone agonist (starting 2-3 months before IMRT and lasting 2 years), IMRT of 78 Gy to the prostate and seminal vesicles, and weekly docetaxel during RT." | ( Chen, RC; Chiu, WK; Crane, JM; Godley, PA; Hoffman, LG; Kim, WY; Pruthi, RS; Rathmell, WK; Rosenman, JG; Wallen, EM; Wang, AZ; Whang, YE, 2012) |
| "Few new prostate cancers were detected during the 2-year followup period in either former treatment group." | ( Andriole, GL; Castro, R; Grubb, RL; Mahoney, C; Manyak, MJ; Somerville, MC, 2013) |
| "Hormone-refractory prostate cancer shows substantial resistance to most conventional therapies including radiotherapy, constitutes a key impediment to curing patients with the disease." | ( Gao, X; Li, X; Sun, S; Yu, H; Zhou, D, 2012) |
| "Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen." | ( Kunkler, R; Miller, M; Mohammed, A; Rawlinson, A, 2012) |
| "The role of denosumab in prostate cancer will continue to evolve either as monotherapy or in combination with other bone-targeting strategies." | ( Carducci, MA; Paller, CJ; Philips, GK, 2012) |
| "So far no effect on prostate cancer specific survival has been proven by 3 randomized controlled trials (RCTs) on adjuvant radiotherapy." | ( Breeuwsma, AJ; de Jong, IJ; Leliveld, AM; Pruim, J; Rybalov, M, 2012) |
| "Under this therapy, prostate cancer will inevitably progress to castration resistant prostate cancer (CRPC)." | ( Bijnsdorp, IV; Geldof, AA; Jacobs, JJ; Meuleman, EJ; Rozendaal, L; van der Sluis, TM; van Moorselaar, RJ; Vis, AN, 2013) |
| "Most patients with prostate cancer respond to initial androgen deprivation therapy but eventually progress to castration-resistant prostate cancer (CRPC)." | ( Gleave, ME; Loriot, Y; Zoubeidi, A, 2012) |
| "Androgen deprivation therapy of prostate cancer with estrogens shows significant cardiovascular side-effects." | ( Cai, J; Imperato-McGinley, J; Wen, J; Weng, C; Yang, K; Yuan, H; Zhu, YS, 2013) |
| "When the prostate cancer cells become unresponsive to androgen therapy, resistance to chemotherapy becomes imminent, resulting in high mortality." | ( Bishayee, K; Boujedaini, N; Chakraborty, D; Ghosh, S; Khuda-Bukhsh, AR, 2013) |
| "Advanced prostate cancer that progresses under androgen deprivation therapy has long been thought to be refractory to further hormonal treatment." | ( Kuczyk, MA; Merseburger, AS; Wolff, JM, 2013) |
| "The effectiveness of salvage therapy in prostate cancer is greater for low prostate specific antigen values." | ( Briganti, A; Garcia-Parra, R; Gianolli, L; Giovacchini, G; Mapelli, P; Messa, C; Montorsi, F; Picchio, M, 2013) |
| "We evaluated 170 prostate cancer patients, previously radically treated, that were referred for restaging with [18F]-Choline PET/CT." | ( Biti, G; Carini, M; Cassani, S; Ceroti, M; Cipressi, S; Detti, B; Franceschini, D; Gacci, M; Livi, L; Nicita, G; Pertici, M; Pupi, A; Saieva, C; Scoccianti, S; Vaggelli, L; Villari, D, 2013) |
| "To treat localized prostate cancer without substantial morbidity, an ideal treatment would be an effective local therapy with minimal morbidity." | ( Bhullar, JS; Chaudhary, S; Decker, M; Mittal, VK; Silberberg, B; Subhas, G; Tilak, J, 2013) |
| "We enrolled 40 men with prostate cancer treated by MAB for 7 to 12 months." | ( Li, NC; Na, YQ; Sun, GF; Yang, B; Zhu, H, 2012) |
| "A total of 319 patients with prostate cancer treated with luteinizing hormone-releasing hormone agonist plus bicalutamide were included in this analysis." | ( Akaza, H; Hinotsu, S; Kawaguchi, S; Kitagawa, Y; Mizokami, A; Nakashima, K; Namiki, M; Shigehara, K; Yaegashi, H, 2013) |
| "Brain metastases from prostate cancer (PC) seem to be more frequent than in the past, possibly because advances in the treatment of patients with castration-resistant PC have prolonged their survival." | ( Caffo, O; Galligioni, E; Russo, L; Veccia, A, 2012) |
| "Hormone-refractory prostate cancer remains hindered by inevitable progression of resistance to first-line treatment with docetaxel." | ( Corcoran, C; Crown, J; McDermott, R; O'Brien, K; O'Driscoll, L; O'Neill, A; Prencipe, M; Rani, S; Sheikh, R; Watson, W; Webb, G, 2012) |
| "Effective treatment of prostate cancer should be based on targeting interactions between tumour cell signalling pathways and key converging downstream effectors." | ( Assinder, SJ; Chen, Z; Dixon, KM; Dong, Q; Kovacevic, Z; Lui, GY; Richardson, DR; Yao, M; Zhang, D, 2013) |
| "Eligible patients had advanced prostate cancer (metastasis, a prostate-specific-antigen test result of more than 10·0 ng/mL, and WHO performance status score of 0-2), had received no chemotherapy (except with estramustine), had undergone surgical or chemical castration, and had been referred to a treatment centre in Finland, Ireland, or Sweden." | ( Asola, R; Ginman, C; Harmenberg, U; Hemminki, A; Hervonen, P; Joensuu, H; Joensuu, T; Keane, M; Kellokumpu-Lehtinen, PL; Laestadius, F; Lehtinen, I; Luukkaa, M; Luukkaala, T; McCaffrey, J; McDermott, R; Nilsson, S; Nyandoto, P; Sandberg, K; Tasmuth, T; Turpeenniemi-Hujanen, T, 2013) |
| "Treatment of metastatic prostate cancer (PCa) with single agents has shown only modest efficacy." | ( Carboni, JM; Chatterji, T; Dayyani, F; Gallick, GE; Gottardis, MM; Logothetis, CJ; Maity, SN; Moorthy, S; Parikh, NU; Song, JH; Varkaris, AS; Wolfe, AR, 2012) |
| "Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide." | ( George, S; Pili, R, 2013) |
| "We recently reported reduced prostate cancer (PCa)-specific mortality for β-blocker users among patients receiving androgen-deprivation therapy in a health survey cohort including 655 PCa patients." | ( Fagerland, MW; Fosså, SD; Grytli, HH; Taskén, KA, 2014) |
| "Outcomes for poor-risk localized prostate cancers treated with radiation are still insufficient." | ( Annadanam, A; Armour, E; Aziz, K; Cades, JA; Chettiar, ST; DeWeese, TL; Gajula, RP; Gandhi, N; Hales, RK; Herman, JM; Kato, Y; Schaeffer, EM; Song, D; Tran, PT; Wild, AT; Williams, RD; Zhang, Y, 2013) |
| "Bone metastases in prostate cancer constitute the most frequent cause of systemic failure in treatment, which results in numerous complications and finally leads to patient's death." | ( Antczak, A; Baczyk, M; Gut, P; Hrab, M; Milecki, P; Pisarek, M, 2013) |
| "The data suggest a role for BIRC6 in prostate cancer progression and treatment resistance, and indicate for the first time that the BIRC6 gene and its product are potentially valuable targets for treatment of prostate cancers." | ( Fazli, L; Gleave, M; Gout, PW; Lin, D; Low, CG; Luk, IS; Wang, Y; Xu, Y; Yang, K, 2013) |
| "However, the majority of prostate cancer patients receiving the androgen ablation therapy will ultimately develop recurrent castration-resistant tumors within 3 years." | ( Chuu, CP; Hsu, JM; Kuo, LK; Liu, CC, 2013) |
| "The diagnostic approach to prostate cancer is still a big challenge for the treating physician." | ( Graser, A; Kretschmer, A; Seitz, M; Stief, CG; Tilki, D, 2013) |
| "Androgen deprivation therapy (ADT) for prostate cancer (PCa) treatment causes sexual dysfunction." | ( Wassersug, RJ; Wibowo, E, 2013) |
| "Treatment of all stages of prostate cancer has changed considerably in recent years, as our understanding of its biochemical pathways has improved." | ( Crawford, ED; Rove, KO, 2013) |
| "Recently, novel therapies of prostate cancer, such as immunotherapy, endothelin receptor antagonists, novel androgen receptor antagonist and novel taxanes, and others have been introduced into clinical practice." | ( Ding, Y; Feng, NH; Jiang, WY; Qiao, D; Shao, N; Wang, JL; Wang, Y; Wu, Y; Zhang, SG; Zhang, XX, 2013) |
| "In a competing-risk analysis, prostate cancer-related deaths were also significantly reduced among patients with pre-radiation therapy PSA nadirs of <0." | ( Gomez, DR; Kollmeier, M; Pei, X; Polkinghorn, WR; Zelefsky, MJ, 2013) |
| "Nearly 30% of prostate cancer (PCa) patients treated with potentially curative doses relapse at the sites of irradiation." | ( Honn, KV; Kandouz, M; Kenessey, I; Lövey, J; Nie, D; Tímár, J; Tóvári, J, 2013) |
| "Treatment of advanced prostate cancer (PCa) relies on pharmacological or surgical androgen deprivation." | ( Boutin, B; Courtoy, PJ; Gailly, P; Mondin, L; Tajeddine, N; Tombal, B; Van Schoor, M; Vandersmissen, P; Zanou, N, 2013) |
| "The treatment of prostate cancer has been impeded by the lack of both clinically relevant disease models and metabolic markers that track tumor progression." | ( Keshari, KR; Kurhanewicz, J; Peehl, DM; Sriram, R; Van Criekinge, M; Vigneron, DB; Wang, ZJ; Wilson, DM, 2013) |
| "We hypothesized that, in metastatic prostate cancer, androgen deprivation therapy suppression of serum androgen to the castration level may also disrupt serum E2 level, and variation in serum E2 level might play a role in the development of castration-resistant prostate cancer." | ( Dai, B; Qin, X; Yao, X; Ye, D; Zhang, H; Zhang, S, 2013) |
| "Recurrent prostate cancer is usually treated by combining radiotherapy and androgen deprivation therapy." | ( Breeuwsma, AJ; de Jong, IJ; Dost, RJ; Glaudemans, AW, 2013) |
| "Conversely in the restaging of prostate cancer recurrence, choline PET/CT is a promising imaging modality for the detection of local regional and nodal recurrence with an impact on therapy management." | ( Gocke, Ch; Hildebrandt, G; Krause, BJ; Kuhnt, T; Kurth, J; Schwarzenböck, SM, 2013) |
| "In the absence of effective therapy for prostate cancer, there is an immense need for developing improved therapeutic options for the management of this disease." | ( Gong, S; Mukhtar, H; Nihal, M; Pilla, S; Rosenthal, K; Siddiqui, IA; Xu, W, 2013) |
| "If metastatic prostate cancer progresses despite androgen suppression, the two main options in 2012 are either: palliative treatment with corticosteroids and external beam radiation therapy or radioisotope infusion; or docetaxel followed by abiraterone, which slightly prolongs survival but at a cost of sometimes serious adverse effects." | ( , 2013) |
| "Separating indolent from aggressive prostate cancer is an important clinical challenge for identifying patients eligible for active surveillance, thereby reducing the risk of overtreatment." | ( Angelsen, A; Bathen, TF; Bertilsson, H; Giskeødegård, GF; Gribbestad, IS; Halgunset, J; Selnæs, KM; Tessem, MB; Viset, T; Wright, AJ, 2013) |
| "The patient was diagnosed as having prostate cancer (clinical stage : T3bN0M0) and received radiotherapy and hormonal therapy." | ( Arima, R; Fujita, M; Goto, T; Saiki, S; Uchida, K, 2013) |
| "LNCaP prostate cancer cells were treated with dietary-based ratios of omega-6 to omega-3 fatty acids under hormone-deprivation conditions, and effects on various cellular processes were determined." | ( Apte, SA; Cavazos, DA; Degraffenried, LA; Whelan, KA, 2013) |
| "Treatment of prostate cancer (PC3) and angiogenic endothelial (HMEC-1) cells with F3-targeted liposomes containing anti-PLK1 siRNA resulted in a significant decrease in cell viability, which was mediated by a marked PLK1 silencing, both at the mRNA and protein levels." | ( Gomes-da-Silva, LC; Moreira, JN; Pedroso de Lima, MC; Ramalho, JS; Simões, S, 2013) |
| "Treatment of prostate cancer cells with D-pinitol reduced mRNA and cell surface expression of αvβ3 integrin." | ( Chen, CC; Chen, WC; Hsieh, TF; Lee, SS; Lin, TH; Liu, HH; Tan, TW; Tang, CH; Tsai, TH, 2013) |
| "Advanced prostate cancer (PCa) is associated with skeletal complications, both as a result of bone metastases and because of fractures associated with fragility due to androgen-deprivation therapy (ADT)." | ( Coleman, RE; Fizazi, K; Galsky, MD; Gartrell, BA; Miller, K; Saad, F; Sternberg, CN, 2014) |
| "Since Benign Prostatic Hyperplasia and Prostate Cancer are two of the most diffuse diseases of aging male and considering that standard medical therapy is accompanied with different side effects, the emerging use of African plants may be justified." | ( Castelli, T; Cimino, S; Favilla, V; Madonia, M; Morgia, G; Russo, GI; Salamone, C, 2013) |
| "In image-guided radiotherapy of prostate cancer defining the clinical target volume often relies on magnetic resonance (MR)." | ( Carl, J; Korsager, AS; Østergaard, LR, 2013) |
| "During years 1999-2002, some 850 prostate cancer cases, including 371 new cases, treated in TMH were considered as eligible entrants for the study." | ( Balasubramaniam, G; Mahantshetty, U; Saoba, S; Shrivastava, S; Talole, S, 2013) |
| "Ten patients have been treated for a prostate cancer, using three implanted gold markers." | ( Chapet, O; Colombel, M; De Bari, B; Devonec, M; Jalade, P; Michel-Amadry, G; Rouvière, O; Ruffion, A; Udrescu, C, 2013) |
| "We showed that a set of prostate cancer secretory miRNAs (PCS-miRNAs) were spontaneously released in the growth medium by DU-145 prostate cancer cells and that the release was greater after treatment with the cytotoxic drug fludarabine." | ( Evangelista, M; Lucotti, S; Rainaldi, G; Rizzo, M, 2013) |
| "An MTT assay using DU-145 prostate cancer cells yielded a 95% cell viability 72 hours after choline-GNP administration." | ( Amanie, J; Bédard, EL; Moore, RB; Pervez, N; Razzak, R; Roa, WH; Shaw, A; Yang, X; Zhou, J, 2013) |
| "After intravenous administration into prostate cancer bearing rats for 28 days, FLT-loaded CAS micelles showed a higher antitumor efficacy as revealed by significantly higher reduction in PSA serum level (65." | ( Elgindy, NA; Elzoghby, AO; Helmy, MW; Samy, WM, 2013) |
| "GVAX for prostate cancer is a cellular immunotherapy, composed of PC-3 cells (CG1940) and LNCaP cells (CG8711)." | ( Auerbach, E; Corman, JM; Dahl, K; Olgac, S; Porter, C; Vuky, J, 2013) |
| "Men with metastatic castrate-resistant prostate cancer, adequate organ function, and no prior chemotherapy were treated with docetaxel (75 mg/m(2) intravenously every 3 weeks) and oral prednisone (5 mg twice daily) and randomly allocated (1:1) to receive aflibercept (6 mg/kg) or placebo, intravenously, every 3 weeks." | ( Arén, O; Bavbek, S; Birtle, A; Elliott, T; Fizazi, K; Fléchon, A; Gil, T; Gravis, G; Hatteville, L; Ivanov, S; Karlsson, CT; Karyakin, O; Magherini, E; Matveev, V; Orlandi, F; Petrylak, D; Rosenthal, M; Skoneczna, I; Tannock, IF; Tombal, B; Viana, L, 2013) |
| "Previous CRAds used in prostate cancer (PCa) gene therapy require androgens to activate prostate-specific promoters and induce viral replication." | ( Chowdhury, WH; Deweese, T; Höti, N; Johnson, TJ; Li, Y; Liu, C; Lupold, SE; Rodriguez, R; Zhang, Y, 2013) |
| "We report the case of an 84 years old prostate cancer patient with severe side effects after radiotherapy in 2006." | ( Eble, MJ; Kriehuber, R; Pinkawa, M; Schmitz, S, 2013) |
| "Men with high-risk prostate cancer are often thought to have very poor outcomes in terms of disease control and survival even after definitive treatment." | ( Choi, SS; Frank, SJ; Hoffman, K; Kuban, DA; Lee, AK; Levy, LB; McGuire, S; Nguyen, QN; Pugh, TJ, 2013) |
| "PC-3 prostate cancer cells were treated with IL-6 at 20 ng/ml for 5, 10, 20, 30 and 45 min." | ( Chu, L; Fang, JM; Han, H; Li, CY; Liu, X; Xu, Q; Zhang, X; Zhao, HX, 2013) |
| "After intravenous administration into prostate cancer-bearing rats for 28 days, FLT-loaded CAS nanoparticles showed a higher anti-tumor efficacy as revealed by a significantly higher % reduction in PSA serum level (75%) compared to free FLT (55%)." | ( Elgindy, NA; Elzoghby, AO; Helmy, MW; Saad, NI; Samy, WM, 2013) |
| "As in patients with breast and prostate cancer, Sr-89 chloride is a promising agent for the treatment of painful bone metastases in patients with various other malignancies." | ( Akimoto, T; Arahira, S; Kawashima, M; Kinoshita, H; Matsumoto, Y; Nakagami, Y; Satake, M; Toshima, M; Zenda, S, 2014) |
| "DMSO-treated prostate cancer cells were used as controls to study the effect of Plk1 and HDAC inhibition." | ( Carducci, MA; Gonzalez, M; Hammers, H; Kachhap, SK; Kaelber, NS; Kim, E; Kortenhorst, MS; Mendonca, J; van Diest, PJ; Wissing, MD, 2013) |
| "Eight patients with biopsy-proven prostate cancer who were scheduled for either radical prostatectomy or external beam radiotherapy underwent (99m)Tc-HABBN scintigraphy and SPECT/CT prior to treatment." | ( Ananias, HJ; Chen, X; de Jong, IJ; Dierckx, RA; Elsinga, PH; Helfrich, W; Hoving, HD; Lub-de Hooge, MN; Pruim, J; Rosati, S; Wang, F; Yan, Y; Yu, Z, 2013) |
| "Men with prostate cancer (PCa) frequently undergo androgen deprivation therapy (ADT), typically in the form of a depot injection of luteinizing hormone-releasing hormone agonists (LHRHa)." | ( Robinson, JW; Tran, S; Walker, LM, 2013) |
| "The drug treatment of prostate cancer was for many years based on androgen deprivation with luteinizing hormone-releasing hormone (LHRH) analogues." | ( Cathomas, R, 2013) |
| "Breast or prostate cancer patients were treated with zoledronate." | ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| "Androgen-independent prostate cancer PC-3 cells were treated with different concentrations of As2 O3 for 24, 48 and 72 hours." | ( Jiang, T; Li, QL; Peng, JQ; Su, XM; Sun, DC; Zhang, ZW; Zheng, L, 2013) |
| "Castration-resistant prostate cancer patients treated with abiraterone were identified." | ( Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Mukherji, D; Omlin, A; Parker, C; Pezaro, CJ; Sandhu, S; Van As, N; Zaidi, S, 2013) |
| "Treatment of mice with advanced prostate cancer with T cells genetically engineered to express a tumor-reactive TCR and a dominant-negative TGF-β receptor II induces complete and sustained tumor regression, enhances survival, and leads to restored differentiation of prostate epithelium." | ( Bendle, GM; Bies, L; Linnemann, C; Schumacher, TN; Song, JY, 2013) |
| "Reduced sensitivity of prostate cancer (PC) cells to radiation therapy poses a significant challenge in the clinic." | ( Fu, Q; Gao, JY; Lei, YH; Li, YM; Ma, JJ; Shao, C; Shi, CH; Wang, H; Wang, JY; Wang, Y; Xu, P; Xue, W; Yi, CG; Yuan, JL; Zhang, W; Zhang, YT; Zhu, GF, 2013) |
| "Using a model of castration-resistant prostate cancer, we show that second-generation antiandrogen therapy results in downregulation of DNA repair genes." | ( Arora, VK; Cai, L; Carver, BS; Chaudhuri, J; Chen, Y; Fujisawa, S; Goglia, AG; Gopalan, A; Hieronymus, H; Iaquinta, PJ; Jasin, M; Kass, EM; Lee, MX; Parker, JS; Polkinghorn, WR; Powell, SN; Sawyers, CL; Scardino, PT; Shah, NP; Spratt, DE; Watson, PA; Wongvipat, J; Yen, WF; Zelefsky, MJ; Zheng, D, 2013) |
| "Current treatments for prostate cancer are still not satisfactory, often resulting in tumor regrowth and metastasis." | ( Kopeček, J; Rhim, JS; Yang, J; Zhou, Y, 2013) |
| "In our opinion, low-intermediate risk prostate cancer patients treated with radiotherapy only, without evidence of residual or recurrent disease, are candidates for TRT if symptoms justify it, leaving a free period of never less than one year after nadir (or 24 months after the end of therapy) which guarantees, on the possible means, the absence of biochemical or clinical recurrence,with strict follow up of clinical and biochemical usual parameters (hematocrit, hemoglobin, DRE, PSA)." | ( Borque Fernando, A; Estrada Domínguez, F; Rodríguez Vela, L, 2013) |
| "Compound 1 induced G2/M arrest in both prostate cancer cell lines (PC-3 and DU-145) when treated for 48 h." | ( Damodaran, C; Das, TP; Luevano, JE; Roy, RV; Suman, S, 2013) |
| "Though prostate cancer (PCa) has slow progression, the hormone refractory (HRCP) and metastatic entities are substantially lethal and lack effective treatments." | ( Ding, G; Ding, Q; Feng, C; Jiang, H; Liu, J; Na, R; Xu, H; Zhang, L, 2013) |
| "Radioresistance is a major challenge in prostate cancer (CaP) radiotherapy (RT)." | ( Bucci, J; Chang, L; Cozzi, PJ; Graham, PH; Hao, J; Kearsley, JH; Li, Y; Ni, J, 2013) |
| "Treatment of prostate cancer, breast cancer and glioblastoma tumor cell lines with Y27632 following MV infection resulted in increased cytopathic effect, as assessed by trypan blue exclusion assays." | ( Allen, C; Galanis, E; Iankov, I; Msaouel, P; Opyrchal, M, 2013) |
| "Today, patients with prostate cancer must often make a difficult decision between multiple treatment modalities, each with the risk of permanent sequelae, without robust randomized data to compare every treatment option." | ( Ciezki, JP; Klein, EA; Tendulkar, RD; Ward, MC, 2014) |
| "Men undergoing SBRT monotherapy for prostate cancer report sexual outcomes comparable to those reported for conventional radiation modalities within the first 24 months after treatment." | ( Bandi, G; Batipps, GP; Bhagat, A; Chen, LN; Collins, BT; Collins, SP; Dritschilo, A; Kim, JS; Kowalczyk, K; Kumar, D; Lei, S; Lynch, JH; McGeagh, KG; Obayomi-Davies, O; Pahira, J; Suy, S; Uhm, S; Wright, HC; Yung, TM, 2013) |
| "The hormonal treatment of the prostate cancer grew rich of new therapeutic classes which are going to change the medical care of the prostate cancer in the coming years and the urologist must play its full part." | ( Bastide, C; Bruyère, F; Guy, L; Karsenty, G; Rozet, F, 2013) |
| "By analyzing PC-3 and C4-2 prostate cancer cells overexpressing dominant negative ATG4B(C74A)in vitro and in vivo, we show that the effects of ATG4B(C74A) are cell type, treatment, and context-dependent." | ( Blakely, K; Chow, A; Emmenegger, U; Goda, T; Hoang, VC; Liu, SK; Rocha, M; Taeb, S; Tran, E; Wong, A, 2013) |
| "Pretreatment of prostate cancer with B2 receptor antagonist or small interfering RNA (siRNA) reduced BK-mediated VEGF production." | ( Chang, AC; Lin, YM; Tai, HC; Tang, CH; Wang, SW; Yeh, HI; Yu, HS, 2014) |
| "The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide." | ( Arora, VK; Balbas, MD; Cai, L; Efstathiou, E; Logothetis, C; Murali, R; Sawyers, CL; Schenkein, E; Shah, N; Subudhi, SK; Wongvipat, J; Zheng, D, 2013) |
| "Thirteen prostatectomized prostate cancer patients, after implanting four gold seed fiducials into their prostate bed, were imaged daily using a pretreatment cone-beam computed tomography (CBCT)." | ( Ålander, E; Keyriläinen, J; Kouri, M; Saarilahti, K; Tenhunen, M; Visapää, H, 2014) |
| "The intervention of advanced prostate cancer (PCa) in patients has been commonly depending on androgen deprivation therapy." | ( Chen, Z; Li, B; Lu, W; Matusik, RJ; Yang, Q; Yu, X, 2014) |
| "Treatment of prostate cancer remains a challenge." | ( Aragon-Ching, JB; El-Bahesh, E; Elkon, J; Gupta, K, 2016) |
| "O-GlcNAc expression level in prostate cancer cells was determined by immunohistochemistry of prostate biopsy specimens obtained from 56 patients later treated with hormone deprivation therapy comparing with adjacent normal prostate glands in the same sections." | ( Kamigaito, T; Kawakubo, M; Nakayama, J; Nishizawa, O; Okaneya, T; Shimojo, H, 2014) |
| "Men with localized high-risk prostate cancer (HRPC) were treated with weekly docetaxel at 10 to 30 mg/m(2) concurrent with IMRT of 77." | ( Chaudhary, U; Golshayan, AR; Keane, TE; Kraft, AS; Marshall, DT; Ramey, S, 2014) |
| "This study included 93 cases of prostate cancer confirmed by transrectal ultrasound-guided biopsy, 22 treated by bilateral orchiectomy plus bicalutamide as a continuous androgen deprivation (CAD) therapy, and the other 71 by the intermittent androgen deprivation (IAD) therapy, the latter divided into a standard IAD group (n = 29) and a modified IAD group (n = 42) to be treated by maximum androgen blockage (MAB) until the serum PSA level decreased to less than 0." | ( Cao, WL; Huang, BX; Su, HC; Sun, FK, 2013) |
| "We used androgen sensitive prostate cancer cells that progressed to ADT and AR antagonist Casodex (CDX) resistance upon androgen withdrawal and treatment with CDX." | ( Chakrabarti, R; Lorch, R; Nguyen, C; Ottman, R, 2014) |
| "Advanced prostate cancers, initially sensitive to androgen deprivation therapy, frequently progress to the castration-resistant prostate cancer phenotype (CRPC) through mechanisms not yet fully understood." | ( Arienti, C; Casadio, V; Castoria, G; De Giorgi, U; Di Donato, M; Falconi, M; Gabucci, E; Pignatta, S; Silvestrini, R; Tesei, A; Zoli, W, 2014) |
| "Recurrence of prostate cancer (CaP) after androgen-deprivation therapy continues to have the greatest impact on patient survival." | ( Eng, KH; Gao, L; Gelman, IH; Gillard, B; Su, B, 2013) |
| "This case report, through metastatic prostate cancer in a 66-year-old man with bone metastasis being treated with a monoclonal antibody denosumab, proposes the mechanism of hypocalcaemic oedema as being akin to calcium deprivation such as those induced by calcium channel antagonism." | ( Hung, AK, 2014) |
| "The treatment of prostate cancer using a radiotherapeutic (90)Y labeled N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer can be enhanced with localized tumor hyperthermia." | ( Buckway, B; Frazier, N; Ghandehari, H; Gormley, AJ; Ray, A, 2014) |
| "The role of statin therapy in prostate cancer (PCa) prevention and treatment is plagued by controversy." | ( Brown, AJ; Gardiner, RA; Hill, MM; Moon, H; Roberts, MJ, 2014) |
| "Clinical management of prostate cancer increasingly aims to distinguish aggressive types that require immediate and radical treatment from indolent tumors that are candidates for watchful waiting." | ( Busse, H; Do, M; Franz, T; Garnov, N; Horn, LC; Kahn, T; Moche, M; Otto, J; Stolzenburg, JU; Thörmer, G, 2015) |
| "A total of 72 patients with nodal prostate cancer relapse after primary therapy underwent pelvic and/or retroperitoneal salvage lymph node dissection." | ( Drendel, V; Grosu, AL; Henne, K; Hölz, S; Jandausch, A; Jilg, CA; Krauss, T; Reske, SN; Rischke, HC; Schultze-Seemann, W; Vach, W; Weber, WA; Wieser, G, 2014) |
| "96 cases of advanced-stage prostate cancer were divided into observation group (44 cases received treatment) and control group (46 cases received treatment)." | ( Li, F; Song, L; Tang, L; Tian, F; Wang, Z; Yang, J; Yu, Z, 2014) |
| "Treatment and prognosis of prostate cancer necessitate management of long-term consequences of androgen deprivation therapy (ADT), including accelerated bone loss resulting in osteoporosis." | ( Abrahamsen, B; Brixen, K; Frost, M; Poulsen, MH; Walter, S, 2014) |
| "Reduction by Dutasteride of Prostate Cancer Events was a 4-yr, multicenter, randomized, double-blind, placebo-controlled trial to compare PCa after dutasteride administration (0." | ( Andriole, GL; Fowke, JH; Freedland, SJ; Howard, L, 2014) |
| "Metastatic prostate cancer is lethal and lacks effective strategies for prevention or treatment, requiring novel therapeutic approaches." | ( Abdulghani, J; Alanen, K; Gu, L; Hoang, DT; Huszar, D; Leiby, B; Liao, Z; Mirtti, T; Nevalainen, MT; Romero-Weaver, AL; Talati, P; Vogiatzi, P; Zinda, M, 2014) |
| "Men with castration-sensitive prostate cancer and bone metastases whose androgen-deprivation therapy was initiated within 6 months of study entry were randomly assigned in a blinded 1:1 ratio to receive zoledronic acid (4 mg intravenously every 4 weeks) or a placebo." | ( Bhoopalam, N; Halabi, S; Hauke, RJ; Hussain, A; Kelly, WK; Monk, JP; Morris, M; Ryan, CJ; Saad, F; Sanford, B; Saylor, P; Small, EJ; Smith, MR; Stadler, W; Vogelzang, N, 2014) |
| "In men with castration-sensitive prostate cancer and bone metastases, early treatment with zoledronic acid was not associated with lower risk for SREs." | ( Bhoopalam, N; Halabi, S; Hauke, RJ; Hussain, A; Kelly, WK; Monk, JP; Morris, M; Ryan, CJ; Saad, F; Sanford, B; Saylor, P; Small, EJ; Smith, MR; Stadler, W; Vogelzang, N, 2014) |
| "In Japan, prostate cancer is treated with non-steroidal anti-androgen (flutamide and bicalutamide)." | ( Ito, H; Kakehi, Y; Kitamura, Y; Manabe, Y; Masuda, N; Mishina, M; Okuno, H; Sakura, Y; Sugimoto, M; Taoka, R; Terai, A, 2014) |
| "An 80-year-old man with prostate cancer receiving hormone therapy presented with urinary retention." | ( Aoyama, T; Hamano, T; Hashimura, T; Kawai, J; Kimura, H; Uegaki, M, 2014) |
| "To evaluate, in prostate cancer (PCa) patients the potential of (11)C-choline PET/CT as a guide to helical tomotherapy (HTT) of lymph-node (LN) relapses with simultaneous integrated boost (SIB)." | ( Berardi, G; Busnardo, E; Crivellaro, C; Di Muzio, N; Fiorino, C; Fodor, A; Gianolli, L; Giovacchini, G; Incerti, E; Kirienko, M; Messa, C; Picchio, M, 2014) |
| "Ninety-seven prostate cancer patients treated with androgen deprivation therapy, and severe osteopenia or osteoporosis were retrospectively studied." | ( Carles Galceran, J; Celma Domenech, A; Lorente Garcia, D; Morote Robles, J; Placer Santos, J; Planas Morin, J; Regis, L; Salvador Lacambra, C; Trilla Herrera, E, 2014) |
| "Patients with prostate cancer were treated with intravenous docetaxel (60-75 mg/m(2)) every 3 weeks and oral atrasentan (10 mg) daily starting on day 3 of cycle 1 and then given continuously." | ( Armstrong, AJ; Bacon, K; Creel, P; George, DJ; Hobbs, G; Hurwitz, H; McManus, TJ; Peer, CJ; Petros, WP; Younis, IR; Yu, JJ, 2014) |
| "High-risk prostate cancer (PC) has poor outcomes due to therapeutic resistance to conventional treatments, which include prostatectomy, radiation, and hormone therapy." | ( Choe, KS; Chun, SG; Hannan, R; Jacobs, CD; Kim, DW; Lotan, Y; Pistenmaa, DA; Roehrborn, CG; Xie, XJ; Yan, J, 2014) |
| "When metastatic prostate cancer progresses despite androgen suppression but symptoms do not yet warrant cytotoxic therapy, abiraterone appears to prolong overall survival and to delay the onset of some cancer-related symptoms." | ( , 2014) |
| "Reliable biomarkers that predict prostate cancer outcomes are urgently needed to improve and personalize treatment approaches." | ( Audet-Walsh, E; Caron, P; Fradet, Y; Guillemette, C; Lacombe, L; Laverdière, I; Lévesque, E; Rouleau, M, 2014) |
| "Among men undergoing radiotherapy for prostate cancer, daily use of tadalafil compared with placebo did not result in improved erectile function." | ( Bruner, DW; Buyyounouski, MK; Greenberg, RE; Kachnic, LA; Mowat, RB; Pervez, N; Pisansky, TM; Pugh, SL; Raben, A; Reed, DR; Rosenthal, SA, 2014) |
| "Two patients with prostate cancer and pituitary tumors were treated with leuprolide and radiation therapy." | ( Babbo, A; Bajramovic, S; Chandler, JP; Garnett, J; Kalapurakal, GT; Kalapurakal, JA; Liu, B, 2014) |
| "Androgen blockade-naïve prostate cancer (PCa) develops into CRPC during androgen deprivation therapy (ADT) by various genetic actions." | ( Mizokami, A; Namiki, M, 2015) |
| "The pretherapeutic assessment of prostate cancer is challenging and still holds the risk of over- or undertreatment." | ( Bechtloff, W; Danz, B; Hacker, M; Hartenbach, M; Hartenbach, S; Klemenz, B; Kraft, K; Sparwasser, C, 2014) |
| "Patients with prostate cancer often receive androgen deprivation therapy (ADT) as part of their treatment regimen." | ( Alibhai, SM; Tsang, DS, 2014) |
| "DU-145 prostate cancer cells were treated with insulin-like growth factor (IGF) to activate the Akt-mTOR cascade or with the HDAC-inhibitor valproic acid (VPA) to induce histone H3 and H4 acetylation (aH3, aH4)." | ( Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Makarević, J; Mani, J; Reiter, M; Tawanaie, N; Tsaur, I, 2014) |
| "To test this hypothesis, LNCaP human prostate cancer cells were xenografted into seven-wk-old Foxn1nu/nu male mice that were treated with melatonin (18 i." | ( Bianciardi, P; Bonomini, F; Favero, G; Finati, E; Fraschini, F; Paroni, R; Reiter, RJ; Rezzani, R; Samaja, M; Terraneo, L; Virgili, E, 2014) |
| "To assess prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG scores in patients with advanced and metastatic prostate cancer at baseline and after 6 months of treatment with triptorelin 22." | ( Cabri, P; de la Taille, A; Maisonobe, P; Martínez-Piñeiro, L; Schalken, JA, 2014) |
| "Patients with prostate cancer treated with androgen deprivation therapy (ADT) eventually develop castrate-resistant prostate cancer (CRPC)." | ( Beumer, JH; Buchanan, G; DeFranco, DB; Heitzer, MD; Leach, DA; Liu, TT; Normolle, DP; Parise, RA; Solomon, JD, 2014) |
| "To identify the factors underlying prostate cancer (PCa) patients' depression-anxiety, sexual problems, urinary dysfunction and androgen deprivation therapy (ADT)-linked breast changes and hot flushes, and test these as predictors of loss of masculinity (LoM) over 36 months following diagnosis." | ( Birsika, V; Denham, JW; Sharpley, CF, 2014) |
| "Fifty-four patients with high-risk prostate cancer (stage ≥ T3a, or Gleason score ≥ 8, or prostate-specific antigen level ≥ 20 ng/mL) treated with radiation therapy from 2005 to 2012 at our institution were evaluated." | ( Bhuiyan, M; Hong, D; Hsieh, JT; Jacobs, C; Kapur, P; Kim, DW; Pistenmaa, D; Saha, D; Tumati, V; Xie, XJ; Yan, J; Yu, L, 2014) |
| "Together, shikonin inhibits aggressive prostate cancer cell migration and invasion by reducing MMP-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways and presents a potential novel alternative agent for the treatment of human prostate cancer." | ( Cao, X; Chen, F; Chen, Y; Liu, J; Lv, X; Zheng, L; Zhou, Z, 2014) |
| "Improved treatments for prostate cancer are critically needed in order to overcome metastasis and lethal recurrence." | ( Al Robaian, M; Blatchford, DR; Chiam, KY; Dufès, C, 2014) |
| "Guidelines for prostate cancer treatment suggest that intermittent androgen deprivation (IAD) can be considered for certain patients." | ( Albers, P; Boccon-Gibod, L; de la Rosette, J; Malmberg, A; Montorsi, F; Morote, J; Neijber, A; van Poppel, H; Villers, A, 2014) |
| "Guidelines for prostate cancer treatment suggest that intermittent androgen deprivation (IAD) can be considered for certain patients." | ( Albers, P; Boccon-Gibod, L; de la Rosette, J; Malmberg, A; Montorsi, F; Morote, J; Neijber, A; van Poppel, H; Villers, A, 2014) |
| "Treatment of prostate cancer cells with lupulone derivatives initiated two modes of cell death: apoptosis as a killing pathway and autophagy as a protection against cell death." | ( Charolidi, N; Colston, KW; Mouratidis, PX; Pirianov, G, 2014) |
| "We determined whether the incidence of prostate cancer is increased in hypogonadal men receiving long-term testosterone therapy." | ( Doros, G; Haider, A; Hammerer, P; Isbarn, H; Yassin, A; Zitzmann, M, 2015) |
| "CSCs have been identified in prostate cancer (PCa), one of the most diagnosed malignancies in men over the world, for which chemotherapy resistance is a major problem in the treatment of castration-resistant advanced stages." | ( Castellon, EA; Castillo, V; Contreras, HR; Huidobro, C; Valenzuela, R, 2014) |
| "Patients with suspected recurrence of prostate cancer undergoing [18F]fluoromethyl choline ([18F]FCH) PET/CT were retrospectively evaluated to investigate the influence of hormonal therapy (HT) in [18F]FCH uptake." | ( Aristei, C; Bellavita, R; Buresta, T; Ferretti, F; Fravolini, ML; Mearini, L; Palumbo, B; Palumbo, I; Pelliccia, G; Radicchia, V; Scialpi, M; Sivolella, S, 2016) |
| "Moreover, human prostate cancer PC3 cell lines were treated with bortezomib at different concentration gradients and then their proliferation at different time points, mRNA and protein levels were investigated." | ( Ding, Y; Guo, S; Li, X; Shan, B; Shi, P; Shu, X; Wang, J; Wang, Z; Xing, L; Zhang, Y, 2014) |
| "The treatment of castrate-resistant prostate cancer (CRPC) still remains as an important challenge of daily oncology practice." | ( Atmaca, H; Bozkurt, E; Dirican, A; Erten, C; Karaca, B; Uslu, R, 2015) |
| "Men with prostate cancer (PCa) currently on active surveillance or post-therapy, have traditionally been excluded from management paradigms given the decade-old concern that testosterone caused PCa growth." | ( Kovac, JR; Lamb, DJ; Lipshultz, LI; Pan, MM, 2014) |
| "For Gleason 8-10 prostate cancers, 25(OH)D concentrations were associated with a linear decrease in risk among combined treatment arms [quartile 4 vs." | ( Goodman, PJ; Kristal, AR; Neuhouser, ML; Peters, U; Schenk, JM; Song, X; Tangen, CM; Till, CA; Torkko, KC, 2014) |
| "Treatment for prostate cancer involves reducing androgen production or using anti-androgen drugs to block the interaction of hormones with the AR-LBD." | ( Ban, F; Cherkasov, A; Dalal, K; Dehm, S; Hessein, M; Hsing, M; LeBlanc, E; Li, H; Rennie, PS; Roshan-Moniri, M; Sharma, A; Singh, K; Tomlinson Guns, ES, 2014) |
| "The four prostate cancer cell lines also showed different sensitivity to taxol treatments; LNCaP and 22Rv1 cells were more resistant to paclitaxel than DU145 and PC3 cells." | ( Bevilacqua, A; Calastretti, A; Gatti, G; Quaresmini, C, 2014) |
| "Silencing Bcl-2 in PTEN-mutated prostate cancer cells enhances the apoptotic effects of combined starvation and taxol treatments, indicating that inhibition of Bcl-2 may be of significant value in PTEN-mutant tumor therapy." | ( Bevilacqua, A; Calastretti, A; Gatti, G; Quaresmini, C, 2014) |
| "In contrast to castration-resistant prostate cancer, in patients with bone metastases from bladder cancer such treatment may even improve survival." | ( Froehner, M; Hakenberg, OW; Hölscher, T; Wirth, MP, 2014) |
| "By using two prostate cancer cell lines with different responses to paclitaxel treatment, we have identified two situations in which PTTG1 influences cell fate differentially." | ( Castilla, C; Flores, ML; Japón, MA; Medina, R; Pérez-Valderrama, B; Romero, F; Sáez, C; Tortolero, M, 2014) |
| "In the present study, using both prostate cancer cell line and xenograft models, we seek to investigate the therapeutic potential of combining γ-T3 and PSP in the treatment of prostate cancer." | ( Chen, J; Lau, EY; Lee, TK; Ling, MT; Liu, J; Lo, J; Ng, IO; Tang, KD; Yong, J, 2014) |
| "One of the key mechanisms by which prostate cancer cells evade hormone therapy is through intratumor testosterone production." | ( Knudsen, KE, 2014) |
| "Bone is the most common site of prostate cancer (PCa) progression to a therapy-resistant, lethal phenotype." | ( Aparicio, A; Cao, X; Chinnaiyan, AM; Corn, PG; Efstathiou, E; Iyer, MK; Kundra, V; Li Ning Tapia, EM; Logothetis, CJ; McKeehan, W; Navone, NM; Palanisamy, N; Ravoori, MK; Robinson, DR; Starbuck, MW; Tapia, EM; Troncoso, P; Vazquez, ES; Wan, X; Wang, F; Wu, YM; Yang, J; Zurita, AJ, 2014) |
| "To identify molecular alterations in prostate cancers associating with relapse following neoadjuvant chemotherapy and radical prostatectomy patients with high-risk localized prostate cancer were enrolled into a phase I-II clinical trial of neoadjuvant chemotherapy with docetaxel and mitoxantrone followed by prostatectomy." | ( Beer, TM; Coleman, I; Garzotto, M; Gordon, RR; Gulati, R; Harris, WP; Higano, CS; Huang, CY; Lange, PH; Lucas, JM; Nelson, PS; Sim, HG; True, LD; Vessella, R; Wu, M, 2014) |
| "Ten patients with metastatic prostate cancer were treated for 4 weeks with fixed AA doses of 5, 30 and 60 g." | ( Andersen, JT; Højgaard, M; Lykkesfeldt, J; Mikines, KJ; Nielsen, TK; Poulsen, HE, 2015) |
| "Men with nonmetastatic prostate cancer were treated with 9 months of leuprolide and flutamide followed by a variable off-treatment interval; AD was resumed when prostate specific antigen (PSA) reached a prespecified value (1 ng/mL, radical prostatectomy; 4 ng/mL, intact prostate)." | ( Gambol, TE; Gulati, R; Hall, SP; Higano, CS; Hunter-Merrill, R; Kuo, KF; Yu, EY, 2015) |
| "Two human prostate cancer cell lines, 22Rv1 and LNCaP, and prostate epithelial cells procured from two patients undergoing radical prostatectomy were treated with α-Mangostin and evaluated by RT-PCR, Western blot, fluorescent microscopy and siRNA transfection to evaluate ER stress." | ( Johnson, JJ; Li, G; Nonn, L; Petiwala, SM, 2014) |
| "Novel biomarkers predicting prostate cancer (PCa) aggressiveness and docetaxel therapy response of PCa patients are needed." | ( Buijs, JT; De Krijger, RR; De Morrée, ES; Dezentjé, VO; Gelderblom, H; Smit, VT; van der Pluijm, G; Van Weerden, WM; Wissing, MD, 2014) |
| "PCSD1 is a new primary prostate cancer bone metastasis-derived xenograft model to study bone metastatic disease and for pre-clinical drug development of novel therapies for inhibiting therapy resistant prostate cancer growth in the bone-niche." | ( Cacalano, NA; Godebu, E; Hirata, T; Jamieson, CA; Kulidjian, AA; Liss, MA; Ma, W; Muldong, M; Park, SC; Raheem, O; Strasner, A; Woo, JR; Wu, CN, 2014) |
| "Benign prostatic hyperplasia and prostate cancer can be treated with the 5α-reductase inhibitors, finasteride and dutasteride, when pharmacodynamic biomarkers are useful in assessing response." | ( Andrew, R; Faqehi, AM; Homer, NZ; Hughes, KA; Naredo, G; Stewart, LH; Upreti, R; Walker, BR, 2015) |
| "Current practices for treatment of prostate cancer are less than satisfactory because of metastasis and recurrence, which are primarily attributed to angiogenesis." | ( Ji, H; Jiang, F; Li, Y; Shen, J; Wang, X; Yang, X; Zhang, J, 2014) |
| "Human prostate cancer cells PC-3 and DU145 were respectively treated with various concentrations of formononetin." | ( Huang, W; Li, T; Ling, Z; Mo, Z; Yan, H; Ye, Y; Zhao, X, 2014) |
| "The efficacy of prostate cancer chemotherapy is frequently impaired by drug resistance; however, the underlying mechanisms of this resistance remain elusive." | ( Chen, H; Cui, RJ; Li, D; Li, Y; Lin, F; Lin, P; Yu, XG; Zhao, LN; Zheng, XL; Zou, HF, 2014) |
| "Cure rates for localized high-risk prostate cancers (PCa) and some intermediate-risk PCa are frequently suboptimal with local therapy." | ( Balk, SP; Bubley, GJ; Dalkin, BL; Davis, JW; Haqq, CM; Jiang, Z; Kantoff, PW; Kheoh, T; Lis, RT; Loda, M; Logothetis, CJ; Marck, BT; Matsumoto, AM; Molina, A; Montgomery, B; Mostaghel, EA; Nelson, PS; Peng, W; Penning, TM; Richie, JP; Sanda, MG; Tamae, D; Taplin, ME; Tran, N; Troncoso, P; True, LD; Xie, W; Ye, H, 2014) |
| "Treatment of human prostate cancer cells with δ-T resulted in strong growth inhibition and apoptosis stimulation, while the effects of α-T were modest." | ( Conney, AH; Cui, XX; DiPaola, RS; Du, ZY; Goodin, S; He, Y; Huang, H; Li, D; Tony Kong, AN; Wang, H; Yang, CS; Zhang, K; Zheng, X, 2014) |
| "The in vitro cultured human prostate cancer cell lines RWPE-1, LNCaP, PC-3, and TSU-Pr1 were randomly divided into four groups: control group; negative control group (treated with dimethyl sulfoxide), high-dose group (treated with 150 Μl 0." | ( Di, YC; Jiang, LL; Yu, F, 2014) |
| "Four human prostate cancer cell lines (LNCaP, LNCaP95, VCaP and 22Rv1) with different genetic backgrounds were treated with five PI3K/AKT inhibitors (LY294002, Wortmannin, BKM120, AKTi and AZD5363) and or AKT siRNA." | ( Dong, X; Liu, L, 2014) |
| "Treatment of localized prostate cancer (PC) is controversial." | ( Albertsson, P; Brandberg, Y; Damber, JE; Damm, O; Holmberg, E; Isacsson, U; Lennernäs, B; Ljung, G; Majumder, K; Nilsson, S, 2015) |
| "Nine dogs with spontaneously occurring prostatic cancer were treated." | ( Axiak-Bechtel, SM; Boote, E; Bryan, JN; Bryan, ME; Cutler, CS; Henry, CJ; Kannan, R; Katti, KV; Kelsey, J; Lattimer, JC; Selting, KA; Tate, DJ; Upendran, A, 2014) |
| "Androgen-dependent LAPC-4 and LNCaP prostate cancer cells were treated with low doses of Arc and Q alone or in combination for 48 h." | ( Chung, S; Gordon, D; Henning, SM; Phan, T; Vadgama, JV; Wang, P, 2015) |
| "Finally, using orthotopic prostate cancer xenografts, we demonstrate that both resveratrol treatment and MTA1 knockdown enhance PTEN levels leading to a decreased p-Akt expression and proliferation index." | ( Dhar, S; Kumar, A; Levenson, AS; Li, K; Tzivion, G, 2015) |
| "Three hundred twenty-four consecutive prostate cancer patients were submitted to bisphosphonates therapy after antiandrogen treatment was started." | ( Hering, F; Imperio, M; Rodrigues, P, 2015) |
| "We evaluated data from 268 prostate cancer patients who underwent 3D conformal radiotherapy between 1999 and 2006 at a single tertiary academic center." | ( Gerger, A; Kapp, KS; Krenn-Pilko, S; Langsenlehner, T; Langsenlehner, U; Pichler, M; Stojakovic, T; Thurner, EM, 2015) |
| "Overall mortality (OM), prostate cancer-specific mortality (PCSM), and use of salvage androgen deprivation therapy (ADT)." | ( Hu, JC; Kaplan, AL; Lenis, AT; Rajfer, J; Shah, A, 2015) |
| "TRT following prostate cancer diagnosis and treatment does not increase mortality or the use of salvage ADT." | ( Hu, JC; Kaplan, AL; Lenis, AT; Rajfer, J; Shah, A, 2015) |
| "We identified 6561 metastatic prostate cancer patients; 1350 subsequently received chemotherapy." | ( Barlow, WE; Etzioni, RB; Hershman, DL; LeBlanc, M; Martin, D; Ramsey, SR; Unger, JM, 2015) |
| "Over 70% of cancer metastasis from prostate cancer develops bone metastases that are not sensitive to hormonal therapy, radiation therapy, or chemotherapy." | ( Huang, CC; Lai, IL; Lee, KH; Liu, CH; Sia, P; Tang, WC; Wu, MH; Yang, PM, 2015) |
| "Hormone-refractory prostate cancer (HRPC), which is resistant to hormone therapy, is a major obstacle in clinical treatment." | ( Guh, JH; Hsu, JL; Hsu, JT; Kudryavtsev, KV; Liu, SP; Yu, CC, 2015) |
| "PC3 human and RM‑1 mouse prostate cancer cells were treated with increasing concentrations of berberine, followed by analysis of the cell viability with an MTT assay." | ( Du, S; Lu, W; Wang, J, 2015) |
| "Progression of aggressive prostate cancers (PCa) with androgen receptor splice variants or neuroendrocrine features is currently untreatable in the clinic." | ( Azabdaftari, G; Dalimov, Z; Ellis, L; Hu, Q; Kirk, JS; Ku, S; Lasorsa, E; Pili, R; Ramakrishnan, S; Schaarschuch, K; Wang, J, 2015) |
| "Highly invasive human prostate cancer cells PC-3 and DU-145 were treated with vehicle alone, S-adenosylhomocysteine (SAH) or SAM and their effects on tumour cell proliferation, invasion, migration and colony formation were monitored." | ( Arakelian, A; Chik, F; Parashar, S; Rabbani, SA; Shukeir, N; Stefanska, B; Szyf, M, 2015) |
| "Increasingly, in castration-resistant prostate cancer, patients are often treated with docetaxel and the bisphosphonate zoledronic acid concurrently, yet there is still a paucity in the literature regarding the molecular basis of how this drug combination works." | ( Bertelli, G; Jones, RM; Morgan, C, 2015) |
| "Treatment of advanced prostate cancer has changed considerably in recent years, but the vast majority of advances have been made in patients with metastatic castration-resistant disease." | ( Liaw, BC; Oh, WK; Shevach, J, 2015) |
| "The optimal treatment for high-risk prostate cancer (Pca) remains to be established." | ( Arai, Y; Habuchi, T; Kaiho, Y; Kawamura, S; Koie, T; Mitsuzuka, K; Narita, S; Ohyama, C; Tobisawa, Y; Tochigi, T; Tsuchiya, N; Yoneyama, T, 2015) |
| "All patients had advanced prostate cancer with normal testosterone levels before treatment and indication for long term castration." | ( Cury, F; Faria, S; Souhami, L, 2015) |
| "α2M*-treated human prostate cancer cells exhibit a 2-3-fold increase in glucose uptake and lactate secretion, an effect similar to insulin treatment." | ( Misra, UK; Pizzo, SV, 2015) |
| "Du145 prostate cancer cells were treated with a low dose of cisplatin for 24 h and cell viability and number were determined by MTT assay and trypan blue exclusion assay, respectively." | ( Jiao, YL; Liu, N; Liu, YQ; Liu, Z; Wang, Y; Zhang, BC; Zhang, GA; Zhao, YR, 2015) |
| "Reference treatment of advanced prostate cancer (PCa) relies on pharmacological or surgical androgen deprivation therapy." | ( Boutin, B; Bultynck, G; Gailly, P; Molgo, J; Monaco, G; Parys, JB; Rider, M; Tajeddine, N; Vertommen, D, 2015) |
| "Primary therapies for prostate cancer were 19 radical prostatectomy, 18 radiotherapy, 13 radiotherapy with hormonal treatment, 3 brachytherapy." | ( Arnoux, V; Boillot, B; Carnicelli, D; Descotes, JL; Dubreuil, J; Fiard, G; Lanchon, C; Long, JA; Poncet, D; Rambeaud, JJ; Terrier, N; Verry, C, 2015) |
| "Castration-resistant progression of prostate cancer after androgen deprivation therapy remains a critical challenge in the clinical management of prostate cancer." | ( Dong, Y; Guo, Y; Liang, Z; Liu, X; Liu, Y; Lu, L; Sun, Y; Tian, Y; Zhang, H; Zhao, X, 2015) |
| "Nine male patients with prostate cancer and four female patients with breast carcinoma with multiple bone metastatic lesions were treated with 177Lu-EDTMP." | ( Andrea, P; Balter, H; Eugenia, de M; Graciela, R; Javier, G; Juan, H; Mariella, T; Patricia, O; Rodolfo, F; Victoria, T, 2016) |
| "Food and Drugs Administration for prostate cancer have paved the way for DC-based vaccines." | ( Fu, B; Li, Y; Liu, WP; Wang, GX; Xi, HB, 2015) |
| "The relationship between recurrent prostate cancer risk and testosterone replacement therapy (TRT) for hypogonadal men is explored." | ( Gray, H; Seltzer, J; Talbert, RL, 2015) |
| "Detecting metastatic prostate cancer earlier than is currently possible with standard imaging may help prevent unnecessary morbidity for patients and improve staging in an effort to more accurately select the appropriate therapy at an appropriate time." | ( Hughes, CT; Nix, JW, 2015) |
| "Thirty patients with localized prostate cancer underwent (18)F-choline PET/CT before treatment." | ( Hirata, E; Kuang, Y; Kwee, SA; Miyazaki, K; Sato, M; Wu, L, 2015) |
| "The morbidity and mortality of prostate cancer have been increasing recently, and the comprehensive treatment for prostate cancer is unable to achieve satisfactory outcomes." | ( Song, L; Wang, H; Wang, J; Xing, N; Xu, Z; Yang, F, 2015) |
| "Prevention and treatment of advanced prostate cancer (PCa) by a nontoxic agent can improve outcome, while maintaining quality of life." | ( Altman, N; Hoye, K; Jordan, A; Kallifatidis, G; Lokeshwar, SD; Lokeshwar, VB; Lopez, LE; Ortiz, N; Yates, TJ, 2015) |
| "In an orthotopic xenograft model of prostate cancer, we show that sphingomab reduces hypoxia and modifies vessel architecture within 5 days of treatment, leading to increased intratumoral blood perfusion." | ( Ader, I; Andrieu, G; Bouquerel, P; Cuvillier, O; Golzio, M; Gstalder, C; Malavaud, B; Richard, S; Sabbadini, RA; Zalvidea, S, 2015) |
| "Because castrate-resistant prostate cancer is refractory to most therapies, we examined B cell involvement in the acquisition of chemotherapy resistance." | ( Ammirante, M; Birner, P; Dhar, D; Di Caro, G; Font-Burgada, J; Hansel, DE; Jamieson, C; Kane, CJ; Karin, M; Kenner, L; Klatte, T; Sanchez-Lopez, E; Shalapour, S; Strasner, A; Willimsky, G; Zhong, Z, 2015) |
| "INK-128-induced prostate cancer cell apoptosis and cytotoxicity were alleviated upon pretreatment of cells with the pan-caspase inhibitor z-VAD-FMK or the specific caspase-3 inhibitor z-DVED-FMK." | ( Jiang, SJ; Wang, S, 2015) |
| "The potential of genistein in treating prostate cancer has also been displayed by in vitro cell-based and in vivo animal experiments." | ( Chen, QH; DeLa Torre, E; Leon, F; Wang, G; Wang, R; Xiong, P; Zhang, Q; Zhang, X; Zheng, S, 2015) |
| "TRAIL-induced apoptosis in prostate cancer cells pretreated with delphinidin was dependent on death receptor 5 (DR5) and downstream cleavage of histone deacetylase 3 (HDAC3)." | ( Choi, KC; Jeon, H; Jeong, MH; Kim, I; Ko, H; Lee, SW; So, Y; Son, J; Sung, GJ; Yoon, HG, 2015) |
| "Metastatic hormone-sensitive prostate cancer (mHSPC) is an incurable disease, and despite a high response rate to androgen-deprivation therapy (ADT), outcomes have not significantly changed for many decades." | ( Hernandez-Aya, LF; Hussain, M, 2015) |
| "Treatment for prostate cancer remains a significant social problem due to the continuing trend of growth of morbidity and mortality in Russia from this disease." | ( Garmash, SV; Isaev, TK; Kravtsov, IB; Panshin, GA; Pavlov, AY; Solodky, VA; Tsybulsky, AD, 2015) |
| "A subgroup of patients with prostate cancer with M1b disease and certain characteristics showed a positive long-term response to androgen-deprivation therapy with an acceptable QoL over a decade or more." | ( Berglund, A; Hedlund, PO; Jǿnler, M; Klaff, R; Sandblom, G; Varenhorst, E, 2016) |
| "Fifty patients radically treated for prostate cancer and presenting with rising prostate-specific antigen (PSA) levels were consecutively and prospectively enrolled." | ( Borghesi, M; Boschi, S; Brunocilla, E; Fanti, S; Martorana, G; Nanni, C; Pettinato, C; Schiavina, R; Zanoni, L, 2015) |
| "More aggressive prostate cancer cells (PCCs) are often resistant to chemotherapy." | ( Jankovich, AD; Lash, LH; Putt, DA, 2015) |
| "Many tumors including prostate cancer are maintained by cancer stem cells (CSCs), which might cause tumor relapse if not eradicated during the course of treatment." | ( Castro Nava, A; Cirillo, G; Cojoc, M; Dubrovska, A; Erdmann, K; Fuessel, S; Hampel, S; Kunhardt, D; Kurth, I; Peitzsch, C; Vittorio, O, 2015) |
| "Metastatic prostate cancer is an incurable disease that is treated with a variety of hormonal therapies targeting various nodes of the androgen receptor (AR) pathway." | ( Antonarakis, ES; Maughan, BL, 2015) |
| "Patients diagnosed with prostate cancer between 1961 and 1980 were generally treated with estrogen." | ( Lindblad, M; Ljung, R; Lu, Y; Martling, A, 2015) |
| "Patients with prostate cancer undergoing bilateral orchiectomy, prostatectomy, or other treatments, including antiandrogen therapy and radiation, may be at increased risk for colorectal adenocarcinoma." | ( Lindblad, M; Ljung, R; Lu, Y; Martling, A, 2015) |
| "Studies on genetic changes underlying prostate cancer and the possible signaling pathways are getting increased day by day, and new treatment methods are being searched for." | ( Bağcı, G; Dodurga, Y; Eroğlu, C; Seçme, M, 2015) |
| "One of the major challenges in prostate cancer therapy remains the development of effective treatments for castration-resistant prostate cancer (CRPC), as the underlying mechanisms for its progression remain elusive." | ( Cai, T; Chen, X; Gao, WQ; Niu, L; Shu, Q; Wei, S; Xie, Z; Xue, P; Yang, F; Zhang, Q; Zhu, HH; Zhu, N, 2015) |
| "Application of endocrinotherapy in prostate cancer can easily lead to occurrence of cardiovascular disease, but cardiovascular complications can be prevented by aspirin, without affecting the effect of endocrinotherapy." | ( Chen, YF; Li, XX; Shan, YH; Wang, D; Zhang, YG, 2015) |
| "However, advanced prostate cancer is more difficult to treat and if metastatic, is incurable." | ( Klotz, LH; Mayer, MJ; Venkateswaran, V, 2015) |
| "Improved localization of prostate cancer by MRI will allow better surgical planning, targeted biopsies and image-guided treatment therapies." | ( Bartsch, H; Bradley, WG; Choi, HW; Dale, AM; Huang, J; Kane, CJ; Karow, DS; Kuperman, JM; Liss, MA; Margolis, DJA; Marks, L; Parsons, JK; Rakow-Penner, RA; Raman, SS; Reiter, RE; Schenker-Ahmed, N; Shabaik, A; White, NS, 2015) |
| "Fisetin treatment of human prostate cancer cells resulted in robust up-regulation of microtubule associated proteins (MAP)-2 and -4." | ( Adhami, VM; Mukhtar, E; Mukhtar, H; Sechi, M, 2015) |
| "Four hundred seventy prostate cancer patients with metastatic bone pain who were suitable for local radiotherapy were randomly assigned to radiotherapy (single dose, 8 Gy) or intravenous infusion of ibandronate (6mg) in a noninferiority trial." | ( Bloomfield, D; Forsyth, S; Hackshaw, A; Hoskin, P; Jitlal, M; Kirkwood, A; Mithal, N; Reczko, K; Sizer, B; Stratford, M; Sundar, S; Upadhyay, S; Wilson, P, 2015) |
| "Almost all prostate cancer patients show disease progression while on primary hormone therapy, despite having testosterone concentrations at castration level; they are then said to have castration-resistant prostate cancer (CRPC)." | ( Benoist, GE; Gerritsen, WR; Kramers, C; Mulders, PF; Schers, HJ; van Erp, PH; Westdorp, H, 2015) |
| "Improvements in prostate cancer treatment have led to a longer survival of patients." | ( Bienz, M; Saad, F, 2015) |
| "The administration of BR-DIM to prostate cancer patients before prostatectomy yields detectable plasma levels but without consistent or significant tissue accumulation or biomarker modulation." | ( Bailey, HH; Gee, JR; Harris, L; Havighurst, TC; House, M; Huang, W; Jarrard, D; Kim, K; Kolesar, J; Messing, E; Parnes, H; Saltzstein, DR; Wollmer, BW, 2016) |
| "We firstly explored the destruction of prostate cancer in vitro by the combination of PTT and chemotherapy using DOX@MNCs." | ( Shen, S; Wang, X; Zhang, W; Zheng, X, 2015) |
| "A critical challenge in prostate cancer (PCa) clinical management is posed by the inadequacy of currently used biomarkers for disease screening, diagnosis, prognosis and treatment." | ( Bucay, N; Dahiya, R; Deng, G; Greene, K; Majid, S; Mitsui, Y; Saini, S; Shahryari, V; Tabatabai, ZL; Tanaka, Y; Yamamura, S, 2015) |
| "Human prostate cancer cells were treated with ABL-N of different concentrations (0, 5, 10, 20, 30 and 40 µmol/l)." | ( Cai, W; Li, W; Liu, K; Lu, B; Qi, J; Shi, C; Yin, Y; Zhang, Y, 2015) |
| "A cohort of 57 patients with prostate cancer scanned with (68)Ga-PSMA-11 PET/CT for radiotherapy planning was retrospectively reviewed; 15 patients were at initial diagnosis and 42 patients at time of biochemical recurrence." | ( Afshar-Oromieh, A; Debus, J; Fiedler, H; Giesel, FL; Haberkorn, U; Habl, G; Katayama, S; Kopka, K; Kratochwil, C; Sterzing, F, 2016) |
| "Treating prostate cancer cells with physapubescin B resulted in the accumulation of cells in the G2/M phase, which was associated with reduced Cdc25C levels and increased levels of CyclinB1, P21 as well as p-Cdk1 (Tyr15)." | ( Ding, W; Hu, Z; Ma, Q; Ma, Z; Tang, H; Zhang, Z, 2015) |
| "The early diagnosis of prostate cancer (PCa) appears to be of vital significance for the provision of appropriate treatment programs." | ( Duan, Z; Jiao, G; Lei, J; Ouyang, Q, 2016) |
| "Moreover, a pre-treatment of the prostate cancer cells with Efipladib during induction of cell cycle re-entry subsequently compromised their tumorigenic capacity in vivo." | ( Bao, S; Dong, Q; Harman, D; Holst, J; Kiang, MY; Sved, P; Teng, Y; Tiffen, J; Wang, Q; Witting, P; Xie, C; Yao, M, 2015) |
| "A brief general overview of focal prostate cancer therapy was provided, followed by a discussion of both basic and clinical research pertaining to prostate cancer VTP, with a focus on the palladium-based WST-09 and WST-11 photosensitisers." | ( Bugaj, AM; Kawczyk-Krupka, A; Musiol, SK; Potempa, M; Sieroń, A; Wawrzyniec, K, 2015) |
| "Literature on VTP for prostate cancer with the fallowing medical subject headings search terms: prostate cancer, photodynamic therapy, vascular targeted photodynamic therapy, bacteriopheophorbide were reviewed." | ( Bugaj, AM; Kawczyk-Krupka, A; Musiol, SK; Potempa, M; Sieroń, A; Wawrzyniec, K, 2015) |
| "Castration-resistant prostate cancer (CRPC) progression after androgen deprivation therapy shows upregulated expression of androgen receptor (AR) splice variants, induced epithelial-to-mesenchymal transition phenotypes and enhanced stem cell characteristics, all of which are associated with resistance to enzalutamide." | ( Li, Y; Sarkar, FH, 2016) |
| "Treatment of human prostate cancer cells (LNCaP and PC-3) with UA inhibited the proliferation and induced apoptosis in both cell lines as characterized by the increased Annexin V-binding." | ( Ge, N; Huang, J; Kong, F; Lin, ZM; Meng, Y; Zhang, DL, 2015) |
| "Human prostate cancer PC-3 cells and DU145 cells were treated with WZ35 for further proliferation, apoptosis, cell cycle, and mechanism analyses." | ( Chen, M; Chen, W; He, L; Ji, J; Kanchana, K; Liang, G; Weng, Q; Zhang, X; Zhong, P; Zhou, H; Zou, P, 2015) |
| "We treated DU145 prostate cancer cells with different concentrations of CPT for 24, 48, and 72 hours followed by evaluation of the proliferation and apoptosis of the cells by MTT assay and TUNEL, respectively." | ( Li, HZ; Lin, MC; Liu, CM; Qian, BJ; Yao, Y; Zhang, JB, 2015) |
| "The treatment of a human AR-positive prostate cancer cell line, LNCaP, with the AR-agonist dihydrotestosterone (DHT) repressed DEPTOR mRNA expression in a time-dependent manner." | ( Inouye, Y; Kanno, Y; Nemoto, K; Yamashita, N; Yanai, K; Zhao, S, 2015) |
| "PB treatment of localized prostate cancer is preferred for the preservation of sexual function." | ( Hashimoto, M; Hayashi, T; Kikuti, T; Minami, T; Nagai, Y; Nishimoto, M; Nozawa, M; Saitou, Y; Shimizu, N; Toyoda, S; Tsuji, H; Uemura, H; Yamamoto, Y; Yoshimura, K, 2015) |
| "Therapy resistance and poor outcome in prostate cancer is associated with increased expression of cyclin D1." | ( Casimiro, MC; Chen, K; Crosariol, M; Di Sante, G; Gormley, M; Ju, X; Li, Z; Lisanti, MP; Meng, H; Pestell, RG; Yaman, I, 2016) |
| "Targeting specifically primary prostate cancer (PCa) cells for immune therapy, gene therapy or molecular imaging is of high importance." | ( Fradet, Y; Jain, P; Neveu, B; Pouliot, F; Têtu, B; Wu, L, 2016) |
| "Treatment of different prostate cancer cells with curcumin or α-tomatine alone resulted in growth inhibition and apoptosis in a concentration-dependent manner." | ( Chen, X; DiPaola, R; Du, Z; Goodin, S; He, Y; Huang, H; Li, D; Li, Y; Zhang, K; Zheng, X, 2015) |
| "Metastatic prostate cancer causes significant morbidity and mortality and there is a critical unmet need for effective treatments." | ( Banerjee, SR; Bhujwalla, ZM; Chen, Z; Krishnamachary, B; Penet, MF; Pomper, MG, 2016) |
| "This study found that prostate cancer patients treated with transdermal oestradiol for hormonal therapy did not experience the loss in bone mineral density seen with luteinising hormone-releasing hormone agonists." | ( Abel, PD; Abel, RL; Alhasso, AA; Cafferty, F; Carpenter, R; Duong, T; Honeyfield, L; Jovic, G; Kynaston, HG; Langley, RE; Paez, EM; Parmar, MK; Robertson, A; Scrase, CD; Stone, M; Welland, A, 2016) |
| "Sixty-eight subjects with primary prostate cancer scheduled for radical prostatectomy or hormone therapy underwent whole-body positron emission tomography/computed tomography after injection of NMK36." | ( Fujimoto, H; Fukasawa, S; Inoue, T; Inoue, Y; Otaka, A; Saito, S; Suzuki, H; Tanabe, K; Ueno, M; Yonese, J, 2016) |
| "Biomarkers can improve prostate cancer diagnosis and treatment." | ( Autorino, R; Bottero, D; Buonerba, C; Coman, I; Cosimato, V; De Cobelli, O; De Placido, S; Deliu, VM; Di Lorenzo, G; Ditonno, P; Ferro, M; Lucarelli, G; Perdonà, S; Terracciano, D, 2016) |
| "Treatment of PC-3 prostate cancer cells with the most potent compound led to appreciable cell cycle arrest at a G1/G0 phase and cell apoptosis induction." | ( Chen, C; Chen, G; Chen, QH; Wang, G; Wang, R; Zhang, Q; Zhang, X; Zheng, S; Zhong, Q, 2016) |
| "Human prostate cancer (DU-145) and human non-malignant fibroblast cells (HFFF2) were treated with losartan at different concentrations (0." | ( Ghasemi, A; Hosseinimehr, SJ; Pourfallah, TA; Rafiei, A; Yazdannejat, H, 2016) |
| "The field of prostate cancer has witnessed incredible progress in the last decade, owing to the approval of multiple survival-prolonging treatments for metastatic castration-resistant prostate cancer (mCRPC)." | ( Bellmunt, J; Nadal, R, 2016) |
| "A 54-year-old man, a case of prostate cancer, underwent radical prostatectomy and hormone therapy." | ( Chao, IM; Chen, ML; Hsieh, PJ; Hsieh, TS; Su, HY, 2016) |
| "Androgen-independent prostate cancer has severe chemoresistance towards conventional chemotherapeutic agents, so a new treatment approach is required for curing such prostate cancer." | ( Sato, A; Sato, C; Shiozawa, S; Sugahara, R; Uchida, A; Virgona, N; Yano, T, 2015) |
| "These results suggest that AA sensitize prostate cancer cells to radiation therapy by repressing H2AX expression." | ( He, L; Jiang, X; Jiang, Z; Tan, J; Tang, Y; Yao, K; Yin, G; Zeng, Q, 2015) |
| "Function of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle." | ( Basu, S; Bhowal, A; Chatterji, U; Majumder, S; Mukherjee, P; Sengupta, S, 2016) |
| "Nine patients with a history of prostate cancer documented by histopathology and radiologic evidence of metastatic diseases underwent radioligand therapy with [(177)Lu]DKFZ-PSMA-617." | ( Dietlein, M; Drzezga, A; Eschner, W; Fischer, T; Hohberg, M; Kobe, C; Schmidt, M; Wild, M, 2016) |
| "After radiotherapy (RT) for prostate cancer (PCa), several patients reported lower urinary tract symptoms (LUTS) due to damage and discontinuation of the glycosaminoglycan layer of the bladder." | ( Carini, M; Chini, T; Della Camera, PA; Detti, B; Finazzi Agro, E; Gacci, M; Giannessi, C; Gravas, S; Li Marzi, V; Livi, L; Minervini, A; Oelke, M; Saleh, O; Serni, S, 2016) |
| "Castration therapy in advanced prostate cancer eventually fails and leads to the development of castration-resistant prostate cancer (CRPC), which has no cure." | ( Agoulnik, AI; Agoulnik, IU; Coarfa, C; Frolov, A; Gandarillas, GA; Ittmann, MM; Li, R; Lopez, SM; Peterson, LE; Rajapakshe, K; Suarez, E; Weigel, NL; Zhang, M, 2016) |
| "Here, we show that the prostate cancer stem cell (pCSC)-like traits, such as accelerated activity of aldehyde dehydrogenase 1 (ALDH1), enrichment of CD49f+ fraction, and sphere forming efficiency, are attenuated by SFN treatment." | ( Hahm, ER; Moura, MB; Singh, KB; Singh, SV; Vyas, AR, 2016) |
| "In high-risk prostate cancer (PCa), no study with observation times beyond 10 yr has demonstrated survival improvement after addition of prostatic radiotherapy (RAD) to endocrine treatment (ET) alone." | ( Angelsen, A; Damber, JE; Fosså, SD; Hoyer, M; Klepp, O; Solberg, A; Widmark, A; Wiklund, F, 2016) |
| "He was found to have prostate cancer, and he received hormonal therapy with a luteinizing hormone-releasing hormone (LHRH) agonist." | ( Fukui, I; Hayashi, Y; Ikeda, H; Miyashita, K; Mizokami, A; Nagatani, H; Nakada, M; Sabit, H; Tsutsui, T, 2016) |
| "Fifty-six patients undergoing RP for prostate cancer were randomised into four groups, and 53 completed the protocol: Group 1 - control (n = 11), Group 2 - group psychotherapy (n = 16), Group 3 - lodenafil 80 mg/one tablet per week (n = 12) and Group 4 - group psychotherapy + lodenafil 80 mg/one tablet per week (n = 14)." | ( Denardi, F; Ferreira, U; Naccarato, AM; Reis, LO, 2016) |
| "The primary treatments for prostate cancer (ie, surgery, radiation and androgen depletion) were found to be comparable in both the groups." | ( Chong, RW; Solomon, SS; Vasudevan, V; Zuber, J, 2016) |
| "Advanced-stage prostate cancer usually metastasizes to bone and is untreatable due to poor biodistribution of intravenously administered anticancer drugs to bone." | ( Adjei, IM; Labhasetwar, V; Peetla, C; Sharma, B, 2016) |
| "African-American (AA) patients with prostate cancer (PCa) respond poorly to current therapy compared with Caucasian American (CA) PCa patients." | ( Bhat, TA; Chandra, D; Chaudhary, AK; Dhar, S; Koochekpour, S; Kumar, A; Kumar, R; Kumar, S; Shourideh, M; Underwood, W; Yadav, N, 2016) |
| "Given prostate cancer is driven, in part, by its responsiveness to androgens, treatments historically employ methods for their removal from circulation." | ( Abbott, DH; Bird, IM, 2016) |
| "In image-guided radiotherapy (IGRT) of prostate cancer, delineation of the clini-cal target volume (CTV) often relies on magnetic resonance (MR) because of its good soft-tissue visualization." | ( Carl, J; Korsager, AS; Riis Østergaard, L, 2016) |
| "Patients with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them eventually develop drug resistance." | ( Fu, J; Keller, ET; Lu, Y; Mizokami, A; Wang, L; Yang, Y; Zhang, J, 2016) |
| "Castration-resistant prostate cancer cells often develop resistance to chemotherapy agents and the search for new therapeutic strategies is necessary." | ( Castilla, C; Flores, ML; Gasca, J; Japón, MA; Medina, R; Pérez-Valderrama, B; Romero, F; Sáez, C, 2016) |
| "Androgen deprivation therapy in prostate cancer is extremely effective; however, due to the continuous expression and/or mutagenesis of androgen receptor (AR), the resistance to antihormonal therapy is a natural progression." | ( Bosland, MC; Johnson, JJ; Lantvit, DD; Li, G; Petiwala, SM; Petukhov, PA, 2016) |
| "However, castrate resistant prostate cancer (CRPC) develops in many men within 18-36 months, rendering this treatment ineffective." | ( Camussi, G; Chatterjee, D; Chatterjee, DN; DeChalus, A; Keller, ET; Mendelsohn, AR; Mizokami, A; Quesenberry, PJ; Renzulli Ii, JF; Wang, JQ, 2015) |
| "In contrast, in androgen-independent prostate cancer cell lines, TROP2high cells did not exhibit a differential treatment response but were characterized by their high self-renewal ability." | ( Butler, L; Hollande, F; Mølck, C; Paquet-Fifield, S; Sloan, E; Ventura, S; Xie, J, 2016) |
| "On posttreatment biopsy residual prostate cancer was found in the treated lobe in 10 men, the untreated lobe in 4 and both lobes in 1." | ( Andriole, G; Azzouzi, AR; Bennett, J; Coleman, J; Emberton, M; Grubb, R; Marks, L; Reiter, RE; Taneja, SS, 2016) |
| "DU145 and P3 human prostate cancer cells were treated with TBMS1." | ( Gao, HW; He, YY; Khan, M; Li, YM; Ma, TH; Yang, JB; Yao, M, 2016) |
| "Docetaxel efficiency in the therapy of prostate cancer (PCa) patients is limited due to the development of chemoresistance." | ( Chen, H; Chen, Q; Li, H, 2016) |
| "In the Prostate Cancer Prevention Trial, finasteride selectively suppressed low-grade prostate cancer and significantly reduced the incidence of prostate cancer in men treated with finasteride compared with placebo." | ( Basler, JW; Brown, PH; Davis, JW; Do, KA; Efstathiou, E; Gorlov, IP; Hoque, AM; Kim, J; Klein, EA; Lee, JJ; Li Ning Tapia, EM; Lippman, SM; Logothetis, CJ; Lotan, Y; Magi-Galluzzi, C; Parnes, HL; Pettaway, CA; Pisters, LL; Prokhorova, IN; Stephenson, A; Thompson, IM; Troncoso, P; Vornik, LA; Wang, X; Ward, JF, 2016) |
| "For patients with locally advanced prostate cancer with a high Eastern Cooperative Oncology Group score, a Gleason score of >8 points, prostate-specific antigen levels of >20 ng/mL, and high education, attention should be paid to the interference of fatigue with quality of life, especially general level of activity, ability to concentrate, and mood, after radiotherapy combined with hormonal therapy." | ( Chen, QH; Cheng, HH; Feng, J; Fu, ZC; Lei, Y; Liao, SG; Lin, GS; Luo, HC; Wang, D; Xu, JF; Yin, Q; Zhu, JF, 2016) |
| "Two human prostate cancer cell lines, 22Rv1 and Du145, were treated with norcantharidin at concentrations ranging from 3 to 30μg/ml." | ( Chou, CY; Hu, DN; Kao, YH; Lin, IC; Wu, YC; Yang, PY, 2016) |
| "Castration-resistant prostate cancer is the lethal condition suffered by prostate cancer patients that become refractory to androgen deprivation therapy." | ( Bertoncini, CW; Buzón, V; de la Fuente, A; De Mol, E; Escobedo, A; Estébanez-Perpiñá, E; Fenwick, RB; García, J; McEwan, IJ; Phang, CT; Riera, A; Salvatella, X; Szulc, E, 2016) |
| "DU145 prostate cancer cells were exposed to chemotherapy (free and liposomal Sorafenib) and ablative HIFU, alone or in combination." | ( Arora, JS; Ashe, S; Halliburton, G; He, J; John, VT; Khismatullin, DB; Murad, HY; Yu, H, 2016) |
| "PET/CT could have an important role in prostate cancer staging before primary treatment; however, before imaging, hormonal therapy status should be carefully evaluated." | ( Basso, U; Evangelista, L; Guttilla, A; Zattoni, F, 2019) |
| "Treatment of aggressive prostate cancer remains a great challenge due to inadequate drug distribution into the cancerous lesions after administration." | ( Chen, Z; Gao, S; Gu, F; Hu, C; Tai, Z; Zhu, Q, 2016) |
| "A 64-year-old man with prostate cancer and an increasing prostate-specific antigen (PSA) level under therapy with abiraterone acetate underwent a therapy with Ra." | ( Ahmadzadehfar, H; Essler, M; Rogenhofer, S; Schlenkhoff, CD; Yordanova, A, 2016) |
| "Human prostate cancer LNCaP, DU145, and PC-3 cell lines were treated with heteronemin for 24 hr, then the cell viability was evaluated by MTT assay." | ( Chang, MC; Chou, YW; Hung, HC; Sung, PJ; Tai, MH; Wang, CT; Wen, ZH; Wu, DC; Wu, JC; Wu, WJ, 2016) |
| "Most prostate cancer patients also have comorbidities that are treated with both prescription and nonprescription medications; furthermore, many use dietary supplements." | ( Greenberg, AJ; Mucci, LA; Stopsack, KH, 2017) |
| "Molecular staging of prostate cancer is important factor in effective diagnosis, prognosis and therapy." | ( Agarwal, S; Chakravarthi, BV; Chandrashekar, DS; Chinnaiyan, AM; Dodson, M; Goswami, MT; Hodigere Balasubramanya, SA; Kunju, LP; Lonigro, RJ; Nepal, S; Palanisamy, N; Pathi, SS; Siddiqui, J; Varambally, S, 2017) |
| "One mechanism of resistance of prostate cancer (PCa) to enzalutamide (MDV3100) treatment is the increased expression of AR variants lacking the ligand binding-domain, the best characterized of which is AR-V7." | ( Abrahamsson, PA; Dizeyi, N; Gjörloff Wingren, A; Heery, DM; Johnsson, H; Luo, J; Miftakhova, R; Mongan, NP; Persson, JL; Robinson, B; Sarwar, M; Semenas, J; Simoulis, A, 2016) |
| "Management of recurrent prostate cancer (CaP) after radiotherapy (RT) is dependent on accurate localization of the site of recurrent disease." | ( Boorjian, SA; Choo, R; Davis, BJ; Evans, JD; Gettman, MT; Haloi, R; Harmsen, WS; Karnes, RJ; Kwon, ED; Lowe, VJ; Moreira, DM; Mynderse, LA; Nathan, MA; Olivier, KR; Park, SS; Parker, WP; Sobol, I; Tollefson, MK; Welch, TJ; Zaid, HB, 2017) |
| "A 72-year-old man, on treatment for prostate cancer, attended the emergency department with his 2nd episode of spontaneous extensive bruising and haematomas." | ( Keane, F; Khan, AZ; Murad, F; Okiro, JO, 2016) |
| "Here, we combined an engineered prostate cancer-specific targeting ligand, the A11 minibody, with a novel photothermal therapy agent, polypeptide-based gold nanoshells, which generate heat in response to near-infrared light." | ( Chen, KY; Deming, TJ; Dern, KR; Ding, K; Grundfest, WS; Kamei, DT; Knowles, S; Mayle, KM; Rodriguez, AR; Sung, S; Taylor, Z; Wong, VK; Wu, AM; Zhou, ZH, 2017) |
| "Recurrence of prostate cancer is suspected when an increase in the prostate-specific antigen level is detected after radical treatment; the recurrence could be local relapse, distant relapse, or both." | ( Castellucci, P; Ceci, F; Fanti, S; Incerti, E; Mapelli, P; Picchio, M, 2016) |
| "We treated 22Rv1 prostate cancer cells with fractionated 2 Gy radiation to a cumulative total dose of 60 Gy." | ( Barsoom, SH; Bowman, KJ; Hernandez, C; Hurley, S; Jones, GD; Lynam-Lennon, N; Marignol, L; Marples, B; McDermott, N; Meunier, A; Mooney, B; Nortey, G, 2016) |
| "Two search terms were used: 'metastatic prostate cancer' and 'treatment'." | ( Bolton, D; Corfield, J; Crozier, J; Joshua, AM; Lawrentschuk, N, 2016) |
| "Treatment of prostate cancer (PCa), a leading cause of cancer among males, lacks successful strategies especially in advanced, hormone-refractory stages." | ( Cepas, V; Gonzalez-Menendez, P; Gonzalez-Pola, I; Hevia, D; Mayo, JC; Quiros-Gonzalez, I; Rodriguez-Garcia, A; Sainz, RM, 2017) |
| "As a model, we treated C4-2 prostate cancer cells with MSKE and performed a quantitative Tandem Mass Tag Isobaric Labeling proteomic analysis." | ( Boukli, N; Burton, LJ; Cubano, L; Hawsawi, O; Hudson, T; Odero-Marah, V; Rivera, M; Wang, G; Zhang, Q; Zou, J, 2016) |
| "Although treatment of prostate cancer has improved over the past several years, taxanes, such as cabazitaxel, remain the only form of effective chemotherapy that improves survival in patients with metastatic castration-resistant prostate cancer." | ( Adhami, VM; Mukhtar, E; Mukhtar, H; Siddiqui, IA; Verma, AK, 2016) |
| "Hormone sensitive advanced prostate cancer (PCa) is an incurable disease that is treated with a variety of hormonal therapies targeting the androgen/androgen receptor signaling axis." | ( Cronauer, MV; Hoda, MR; Kramer, MW; Merseburger, AS, 2017) |
| "The treatment options for high-risk prostate cancer are either radical prostatectomy or radiotherapy/brachytherapy depending on the patients' prognosis." | ( Bucci, J; Chang, JI, 2016) |
| "As the fears concerning prostate cancer have subsided, a new controversy regarding use of testosterone therapy and increase in cardiovascular disease was introduced." | ( Traish, A, 2016) |
| "5-AzaC treatment of RM-1 prostate cancer cells upregulated the expression of all 13 CTA tested in a dose-dependent fashion." | ( Goliadze, E; Guruli, G; Manjili, MH; Petrossian, AA; Robinson, SP; Sulek, JE; Toor, A; Zhou, S, 2017) |
| "The optimal treatment for high-risk prostate cancer (Pca) remains to be established." | ( Arai, Y; Habuchi, T; Hatakeyama, S; Inoue, T; Kawamura, S; Koie, T; Mitsuzuka, K; Narita, S; Narita, T; Ohyama, C; Ookubo, T; Tochigi, T; Yamamoto, H, 2017) |
| "Patients with prostate cancer (PCa) were treated with goserelin and bicalutamide for 24 weeks." | ( Arai, Y; Hirai, M; Kobayashi, Y; Miyagawa, T; Saito, K; Washino, S, 2018) |
| "Nine patients with aggressive prostate cancer underwent metabolic assessments prior to treatment (baseline), 7 and 33 weeks post-baseline (post-treatment initiation)." | ( Bell, KE; Di Sebastiano, KM; Dubin, JA; Mitchell, AS; Mourtzakis, M; Quadrilatero, J, 2018) |
| "Men with low-risk, localised prostate cancer (Gleason pattern 3) who had received no previous treatment were randomly assigned (1:1) to vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously over 10 min and optical fibres inserted into the prostate to cover the desired treatment zone and subsequent activation by laser light 753 nm with a fixed power of 150 mW/cm for 22 min 15 s) or active surveillance." | ( Ahlgren, G; Alcaraz, A; Amzal, B; Azzouzi, AR; Barret, E; Benzaghou, F; Cicco, A; Debruyne, FM; Emberton, M; Fromont, G; Gaillac, B; Gomez-Veiga, F; Gratzke, C; Kleinclauss, F; Rassweiler, J; Rosario, DJ; Salomon, G; Solsona, E; Stief, CG; Tammela, TT; van der Poel, HG; Vincendeau, S, 2017) |
| "Immunotherapy is moving forward in prostate cancer." | ( Angelergues, A; Mejean, A; Michel, C; Oudard, S; Tartour, E; Thibault, C; Timsit, MO; Vano, Y, 2016) |
| "High global incidence of prostate cancer has led to a focus on prevention and treatment strategies to reduce the impact of this disease in public health." | ( Bando, Y; Golberg, D; Hanagata, N; Ito, A; Li, X; Wang, X; Weng, Q; Zhang, J, 2017) |
| "Magnolin may be a novel medicine for prostate cancer therapy." | ( Chen, M; Huang, Y; Wang, F; Xiao, J; Zhang, G; Zhang, X; Zhu, W; Zou, X, 2017) |
| "Studysubjects were ten patients with prostate cancer (localized prostate cancer ; n＝8, prostate cancer with bone metastasis ; n＝2), who had hormone monotherapyfor over seven years, showed no signs of recurrence, and maintained prostatic-specific antigen (PSA) levels of less than the detection sensitivitylimit (＜0." | ( Fujimoto, Y; Hattori, S; Kato, S; Masue, N; Uno, M, 2016) |
| "He was diagnosed to have prostate cancer, cT3aN0M1b, and was treated with combined androgen blockage (CAB)." | ( Asakura, T; Nin, M; Okada, T; Satoh, M; Tsujihata, M; Yumiba, S, 2016) |
| "In men with prostate cancer receiving androgen deprivation therapy, baseline bone mineral density testing is encouraged." | ( Alibhai, SMH; Emmenegger, U; Finelli, A; Hotte, SJ; Morgan, SC; Walker-Dilks, C; Winquist, E; Zukotynski, K, 2017) |
| "Men with biochemical recurrence of prostate cancer following local therapies often use natural supplements in an attempt to delay metastases and/or avoid the need for more aggressive treatments with undesirable side-effects." | ( Bone, KM; Emery, J; Lusk, E; Pirotta, MV; Taylor, JM; van Die, MD; Williams, SG, 2017) |
| "In order to treat prostate cancer, drug combinations are often applied." | ( Cheng, Y; Ding, X; Jia, X; Jiang, J; Li, Y; Sharma, A; Wang, G; Xie, G, 2017) |
| "Treatment failure of prostate cancer (PCa) is often due to bone metastasis." | ( Huang, S; Kuchta, K; Li, J; Lin, Z; Pan, T; Peng, X; Tang, Y; Wang, X; Xiang, Y; Xu, J; Zhu, Y, 2017) |
| "A 63-year-old man with a history of prostate cancer, treated with resection, radiation, and androgen-depriving therapy over 4 years, was referred to our department with suspicion of recurrence based on increased blood PSA levels (1." | ( Drzezga, A; Große Hokamp, N; Kobe, C; Linzenich, E; Maintz, D, 2017) |
| "Furthermore, treatment of both prostate cancer cells with BA decreased the phosphorylation of IκB kinase (IKK)α and I-kappa-B-alpha (IκBα) inhibiting the nuclear location of NF-κB/p65 causing cytosolic accumulation and resulting in its decreased nuclear binding." | ( Franco, D; Gupta, S; Shankar, E; Zhang, A, 2017) |
| "The optimal treatment for high-risk prostate cancer (Pca) remains to be established." | ( Hagiwara, K; Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T, 2017) |
| "In the patients with prostate cancer and androgen deprivation therapy, greater bone loss occurred during the first year." | ( Chesa, N; Déniz, F; Domínguez, C; Lara, PC; Lloret, M; Naranjo, A; Ojeda, S, 2017) |
| "This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelled PSMA peptides." | ( Blanksby, A; Emmett, L; Lee, J; Shin, J; Violet, J; Willowson, K, 2017) |
| "Men with metastatic prostate cancer who have a poor response to initial androgen-deprivation therapy (ADT), as reflected by a prostate-specific antigen (PSA) level higher than 4." | ( Agarwal, N; Deshpande, HA; Flaig, TW; Hussain, MHA; Mitsiades, N; Plets, M; Thompson, IM; Vaishampayan, UN, 2017) |
| "Only a part of prostate cancer (PCa) patients has aggressive malignancy requiring adjuvant treatment after radical prostatectomy (RP)." | ( Bakavicius, A; Daniunaite, K; Dubikaityte, M; Gibas, P; Jankevicius, F; Jarmalaite, S; Rimantas Lazutka, J; Ulys, A, 2017) |
| "Data from 175 patients treated for prostate cancer were retrospectively analyzed." | ( Dolek, Y; Onal, C; Ozdemir, Y, 2017) |
| "To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa." | ( Adolfsson, J; Crawley, D; Garmo, H; Holmberg, L; Rudman, S; Stattin, P; Van Hemelrijck, M; Zethelius, B, 2018) |
| "For high-dose radiation therapy (RT) of prostate cancer, image-guided (IGRT) and intensity-modulated RT (IMRT) approaches are standard." | ( Barelkowski, T; Beck, M; Böhmer, D; Budach, V; Ghadjar, P; Graf, R; Joswig, M; Wust, P, 2017) |
| "Using men with prostate cancer initiating androgen deprivation therapy (ADT), we tested the hypothesis that severe sex steroid deprivation would accelerate telomere shortening." | ( Beilby, JP; Cheung, AS; Grossmann, M; Hoermann, R; Hui, J; Yeap, BB, 2017) |
| "The optimal treatment for high-risk prostate cancer (PCa) remains to be established." | ( Fujita, N; Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Matsumoto, T; Ohyama, C; Soma, O; Tanaka, Y; Tobisawa, Y; Yamamoto, H; Yoneyama, T, 2017) |
| "Most prostate cancers initially respond to androgen deprivation therapy, but then progress from androgen-dependent to androgen-independent prostate cancers." | ( Kawamoto, T; Tanaka, Y; Uchiyama, N, 2017) |
| "A 72-year-old man with prostate cancer (stage T3b, Gleason score 7) treated by radical prostatectomy was found to have biochemical failure (prostate-specific antigen 8." | ( Abikhzer, GS; Chaussé, G; Niazi, T; Probst, SM, 2017) |
| "Many prostate cancers relapse after initial chemotherapy treatment." | ( Alshaker, H; Böhler, T; Chao, Y; Cooper, C; Pchejetski, D; Srivats, S; Wang, Q, 2017) |
| "Trials in castration-resistant prostate cancer (CRPC) treatment have shown improved outcomes, including survival." | ( Beerlage, HP; Bloemendal, HJ; Boerma, MO; Bos, MMEM; Coenen, JLLM; Cordia, I; de Vos, AI; de Wit, R; Geenen, MM; Gerritsen, WR; Hendriks, MP; Peters, FPJ; Polee, MB; Spermon, R; Tick, LW; Uyl-de Groot, CA; van de Wouw, AJ; van den Berg, P; van den Bergh, ACM; van den Bosch, J; van den Eertwegh, AJM; van Moorselaar, RJA; Westgeest, HM, 2018) |
| "Obesity and aggressive prostate cancer (PC) may be linked, but how local peri-prostatic fat relates to tumour response following androgen deprivation therapy (ADT) is unknown." | ( Ahmad, I; Hendry, J; Leung, HY; Nixon, C; Patel, A; Salji, M, 2018) |
| "Another web-based survey of prostate cancer patients, who had received treatment with leuprorelin acetate injections, was carried out to calibrate the results of the discrete choice experiment." | ( Goto, R; Hiroi, S; Iwasaki, K; Oya, M; Takashima, K; Uda, A, 2017) |
| "Metastatic prostate cancer is initially treated with androgen deprivation therapy (ADT)." | ( Brown, JS; Cunningham, JJ; Gatenby, RA; Staňková, K; Thuijsman, F; You, L; Zhang, J, 2017) |
| "Around 40% of high-risk prostate cancer patients who undergo radiotherapy (RT) will experience biochemical failure." | ( Boidot, R; Boudon, J; Chevrier, S; Collin, B; Créhange, G; Joy, PA; Loiseau, A; Martin, E; Millot, N; Mirjolet, C; Oudot, A, 2017) |
| "Human prostate cancer cell lines PC3 and DU145 were treated with fasudil at the concentrations of 5, 10, 20, 40, 80, and 160 μmol/L, respectively, and those as negative controls cultured in the Ham's-F12 medium, all for 24 hours." | ( Chen, H; Chen, Y; Dai, YT; Gao, QQ; Han, YF; Xu, ZP; Yu, W; Zhu, LL, 2016) |
| "Men currently treated with ADT for prostate cancer will be randomised to either a 52-week, community-based, exercise training and nutritional supplementation intervention (n = 51) or usual care control (n = 51)." | ( Dalla Via, J; Daly, RM; Fraser, SF; Livingston, PM; Millar, JL; Mundell, NL; Owen, PJ, 2017) |
| "An 84-year-old man with a history of prostate cancer, treated with radiotherapy, presented with an increase in PSA levels." | ( Efthymiadou, R; Malamitsi, J; Pipikos, T; Prassopoulos, V; Vlachou, F, 2017) |
| "Neuroendocrine prostate cancer (NEPC) mostly occurs as a treatment-emergent adaptive response under the pressure of intensive androgen deprivation treatment (t-NEPC)." | ( Erdelkamp, R; Hentrich, M; Stief, C; Tritschler, S, 2017) |
| "Current treatments for advanced prostate cancer focus on inhibition of the androgen receptor (AR) by androgen deprivation therapy (ADT)." | ( Nelson, CC; Ramm, GA; Rockstroh, A; Russell, PJ; Soekmadji, C, 2017) |
| "In tumor-bearing mice (prostatic cancer model), TPR-NPs treatment with RES saturation exhibited a superior antitumor efficacy to free TPR and TPR-NPs alone." | ( Hou, Y; Song, X; Wang, P; Yin, J; Yin, Y, 2017) |
| "Clarifying the mechanisms underlying prostate cancer (PC) progression and resistance to androgen deprivation therapy (ADT) is an urgent clinical issue." | ( Ando, T; Hara, N; Miyashiro, Y; Nishiyama, T; Takizawa, I; Tomita, Y, 2018) |
| "SNPs associated with prostate cancer risk differed by treatment arm." | ( Ambrosone, CB; Figg, WD; Goodman, PJ; Hsing, A; Lippman, SM; Neuhouser, ML; Platek, ME; Platz, EA; Reichardt, JKV; Santella, RM; Stanczyk, FZ; Tang, L; Tangen, CM; Thompson, IM; Till, C; Wu, Y; Yao, S, 2018) |
| "Treatment following early diagnosis of Prostate cancer (PCa) is increasingly successful, whilst the treatment of advanced and metastatic PCa remains challenging." | ( Chambers, KF; Clements, JA; Doran, MR; Futrega, K; Mosaad, EO, 2018) |
| "A 76-year-old man with metastatic prostate cancer and back pain was referred for palliative radiotherapy." | ( Alabed, YZ, 2018) |
| "Nonmetastatic castration-resistant prostate cancer (nmCRPC) presents a challenge to urologists as currently there are no Food and Drug Administration-approved therapies." | ( Cancian, M; Renzulli, JF, 2018) |
| "A new avenue towards the treatment of prostate cancer may be opened by the cell-specific cytotoxicity of KNbO3." | ( Chandrasekaran, G; Farooq, MU; Fisher, JG; Hwang, EC; Jung, YD; Lakshmanan, VK; Lee, JJ; Thuan, UT, 2018) |
| "Over expressed MiR-21 in prostate cancer is associated with metastasis and drug resistance to chemotherapy with Docetaxel." | ( Amini-Khoei, H; Ghasemi, S; Lorigooini, Z; Wibowo, J, 2019) |
| "A 58-year-old man with Gleason 4+3 prostate cancer was initially treated by radical prostatectomy followed by salvage radiotherapy to the prostate bed for postoperative biochemical failure." | ( Abikhzer, G; Chaussé, G; Probst, S, 2018) |
| "Five prostate cancer patients treated with IMRT (74 Gy/37 Fr) were studied." | ( Chiba, T; Dobashi, S; Hayashi, N; Ito, K; Jingu, K; Kadoya, N; Katsuta, Y; Kon, Y; Matsumoto, T; Takayama, Y; Takeda, K, 2018) |
| "PSMA PET/CT visualises prostate cancer residual disease or recurrence at lower PSA levels compared to conventional imaging and results in a change of treatment in a remarkable high number of patients." | ( Bartenstein, P; Belka, C; Buchner, A; Eze, C; Fendler, WP; Ganswindt, U; Herlemann, A; Ilhan, H; Li, M; Rogowski, P; Schmidt-Hegemann, NS; Stief, C, 2018) |
| "The treatment of metastatic prostate cancer has remained unchanged for more than 70 years, based on androgen deprivation therapy (ADT)." | ( Duarte Ojeda, J; García González, L; García Rojo, E; González Padilla, D; Justo Quintas, J; Miñana López, B; Rodríguez Antolín, A; Romero Otero, J; Sopeña Sutil, R, 2018) |
| "Time to castration-resistant prostate cancer (CRPC), treatment-related complications, prostate-specific antigen (PSA) response and the time to PSA nadir were assessed." | ( Chan, K; Chan, M; Chan, T; Lam, D; Law, K; Lee, EKC; Poon, DMC, 2018) |
| "Recurrence after primary treatment of prostate cancer is one of the major challenges facing urologists." | ( Bianchi, G; Coelho, RF; Davis, JW; Eissa, A; Elsherbiny, A; Micali, S; Patel, VR; Porpiglia, F; Prandini, N; Puliatti, S; Rassweiler, J; Rocco, B; Sighinolfi, MC, 2018) |
| "Treatment landscape in prostate cancer has changed dramatically with the emergence of new medicines in the past few years." | ( He, J; Li, T; Pan, F; Proskorovsky, I; Reifsnider, O; Sorensen, SV; Zheng, Y, 2018) |
| "A recent "hot topic" in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy." | ( Allavena, P; Avuzzi, B; Bedini, N; Campi, E; Cicchetti, A; Magnani, T; Morlino, S; Palorini, F; Pennati, M; Pesce, S; Rancati, T; Valdagni, R; Villa, S; Visentin, ME; Zaffaroni, N; Zuco, V, 2018) |
| "Men treated for prostate cancer completed the University of California-Los Angeles Prostate Cancer Index and provided saliva samples four times daily for cortisol assessment." | ( Gaffey, AE; Hoyt, MA; Lawsin, CJ; Litwin, MS; Wang, AW, 2020) |
| "Nine men with prostate cancer and a rising PSA (biochemical recurrence) without evidence of metastases were treated with intermittent ADT consisting of 9 months of complete androgen blockade achieved with combined leuprolide acetate and flutamide." | ( Cherrier, MM; Cross, DJ; Higano, CS; Minoshima, S, 2018) |
| "Patients with locally advanced prostate cancer are generally treated with radiotherapy (RT) which can be combined with hormonal therapy." | ( Fodor, C; Jereczek-Fossa, BA; Marvaso, G; Viola, A, 2018) |
| "We used data from prostate cancer cases (45% African American) diagnosed between 2004 and 2007 who participated in the Health Care Access and Prostate Cancer Treatment in North Carolina cohort (HCaP-NC)." | ( Allott, EH; Arab, L; Bensen, JT; Farnan, L; Fontham, ETH; Mohler, JL; Song, L; Steck, SE; Su, LJ, 2018) |
| "Oligorecurrent prostate cancer with exclusive nodal involvement represents a common state of disease, amenable to local therapy." | ( Castellucci, P; Ceci, F; Di Muzio, N; Fodor, A; Hoyer, M; Incerti, E; Ingrosso, G; Jereczek-Fossa, BA; Lancia, A; Ost, P; Picchio, M, 2019) |
| "An increased incidence of prostate cancer was observed in Parkinson's disease (PD) patients treated with entacapone during a pre-approval randomized clinical trial; the relation has not been robustly investigated in the U." | ( Bird, ST; By, K; Cunningham, F; Dong, D; Graham, DJ; Hur, K; Jiang, R; Keeton, S; Major, JM; Pinheiro, S; Podskalny, GD; Shih, DC; Wei, X, 2018) |
| "The treatment of prostate cancer cells with diosmetin set in motion an apoptotic machinery by inhibiting X-linked inhibitor of apoptosis (XIAP) and increasing cleaved PARP and cleaved caspase-3 expression levels." | ( Bhaskaran, N; Isali, I; Khalifa, AO; Oak, C; Shukla, S; Walker, E, 2018) |
| "A total of 38 patients diagnosed with prostate cancer in our hospital from June 2013 to June 2016 were divided into paclitaxel-resistant group (n=19) and non-resistant group (n=19) according to the follow-up treatment effects." | ( Cai, DW; Chen, D; Kong, GQ; Liu, F; Liu, ZJ; Sun, SP; Wu, PS; Xian, SZ, 2018) |
| "We diagnosed the patient with prostate cancer, and combined androgen blockade (CAB) was administered." | ( Fujikawa, S; Fujiwara, H; Kamiyama, Y; Kanaoka, T; Somiya, S; Tamaki, M; Yamada, Y, 2018) |
| "From 2013 to 2017, 100 patients with prostate cancer who were set to undergo a staging PLND before external beam radiotherapy (n = 50) or PLND concomitant with radical prostatectomy (RP) (n = 50) were prospectively randomized 1:1 between bilateral TachoSil placement or nonplacement." | ( Buelens, S; Decaestecker, K; Lumen, N; Poelaert, F; Van Huele, A; Van Praet, C, 2018) |
| "A 65-year-old man with prostate cancer surgically treated in June 2016 underwent F-choline PET/CT in April 2017 for a biochemical recurrence of disease." | ( Cuppari, L; Evangelista, L, 2018) |
| "Many cases of androgen-dependent prostate cancer develop resistance during treatment with bicalutamide." | ( Heun Cha, B; Kang, HG; Kim, D; Lee, J; Mun, S; Park, A, 2018) |
| "Radiosensitivity of prostate cancer (PCa) cells promotes the curative treatment for PCa." | ( Li, R; Ma, J; Sun, J; Tang, Q; Wang, H; Wang, L; Wang, Y; Yang, F; Yang, L; Zhang, W, 2018) |
| "Management of prostate cancer would benefit from a clearer understanding of the molecular mechanisms behind the transition to the lethal, late-stage forms of the disease, which could potentially yield new biomarkers for differential prognosis and treatment prioritization in addition to possible new therapeutic targets." | ( Hofmann, WA; Maly, IV, 2018) |
| "Twenty Japanese prostate cancer patients underwent 11C-choline and FDG PET/CT before (n=5) or after (n=15) treatment." | ( Fujiwara, M; Fukushima, K; Hashimoto, T; Kamikonya, N; Kanematsu, A; Kitajima, K; Kobayashi, K; Nakanishi, Y; Nojima, M; Odawara, S; Suzuki, T; Yamada, Y; Yamakado, K; Yamamoto, S, 2018) |
| "Despite advances in prostate cancer therapy, dissemination and growth of metastases results in shortened survival." | ( Cordes, N; Klebe, S; Morel, KL; Ormsby, RJ; Solly, EL; Sweeney, CJ; Sykes, PJ; Tran, LNK, 2018) |
| "Metformin use in veterans with prostate cancer who receive androgen deprivation therapy is associated with improved oncologic outcomes." | ( Abel, EJ; Cryns, VL; Downs, TM; Jarrard, DF; Liou, JI; Richards, KA, 2018) |
| "With many prostate cancer patients living longer, and hypogonadism having significant morbidity, much care must go into the decision to treat." | ( Khera, M; Pastuszak, AW; Rodriguez, KM, 2018) |
| "Remarkably, treatment of prostate cancer cells with well-studied antitumorigenic agent, 2-methoxyestradiol (2-ME₂), caused significant DNA methylation changes in 3255 genes including COBRA1." | ( Bedolla, R; Chiang, HC; Ghosh, R; Horning, A; Huang, TH; Kumar, AP; Li, R; Olumi, AF; Reddick, R; Yun, H, 2018) |
| "This facilitated lethal prostate cancer growth and development of resistance to androgen signaling deprivation therapy (ADT)." | ( Agarwal, P; Angara, B; Bhowmick, NA; Duong, F; Gottlieb, RA; Haldar, S; Liu, Z; Madhav, A; Mishra, R; Placencio, V; Posadas, EM; Rohena-Rivera, K; Tripathi, M; Wagner, S, 2018) |
| "Local treatment of metastatic prostate cancer and its impact on future disease course requires further assessment." | ( Abdel-Rahman, O; Cheung, WY, 2018) |
| "Treatment of high-risk prostate cancer (HRPCa) is challenging." | ( Has Simsek, D; Sanli, O; Sanli, Y; Subramaniam, RM, 2018) |
| "Androgen deprivation therapy (ADT) in prostate cancer is associated with the appearance of different adverse effects." | ( Arrabal-Martín, M; Arrabal-Polo, MÁ; Cózar-Olmo, JM; Díaz-Convalía, EJ; Miján-Ortiz, JL, 2018) |
| "A 69-year-old man with newly diagnosed prostate cancer PSA 274 ng/mL, Gleason 4+3, T-stage 3b) underwent Ga-PSMA PET/CT for staging with follow-up scans 6 and 13 weeks after androgen deprivation therapy (ADT) initiation." | ( Petersen, LJ; Zacho, HD, 2018) |
| ": New targets are required for treating prostate cancer, particularly castrate-resistant disease." | ( Carling, D; Graham, R; Kent, TR; Muckett, P; Nikitin, AY; Penfold, L; Pollard, A; Woods, A; Zhang, S, 2018) |
| "In metastatic castrate resistant prostate cancer (mCRPC), abiraterone is conventionally administered continuously at maximal tolerated dose until treatment failure." | ( Brown, JS; Cunningham, JJ; Gatenby, RA; Staňková, K, 2018) |
| "Up to 50% of patients diagnosed with prostate cancer will develop biochemical failure after initial therapy." | ( Banks, KP; McConathy, JE; Molchanova-Cook, OP; Parent, EE; Savir-Baruch, B; Schuster, DM; Subramaniam, RM; Takalkar, A; Tulchinsky, M; Yu, JQ, 2018) |
| "Patients with biochemically recurrent prostate cancer and short prostate-specific antigen doubling time (PSADT) are at risk for metastasis yet may wish to avoid androgen deprivation therapy." | ( Aggarwal, R; Fong, L; Friedlander, TW; Hong, H; Kim, W; Lee, M; Lin, AM; Miralda, B; Rodvelt, TJ; Ryan, CJ; Small, EJ; Stocksdale, B; Wei, XX; Zhang, L, 2019) |
| "However, in men with metastatic prostate cancer, 71% of the uro-oncologists measured testosterone before starting ADT and the majority continued testing during treatment." | ( Bahl, A; Greene, D; McMenemin, R; Payne, H; Staffurth, J, 2019) |
| "We identified consecutive localized prostate cancer patients treated with ADT-RT at 2 academic medical centers from January 2011 to October 2016 with documented baseline testosterone." | ( Hong, JC; Koontz, BF; Lee, WR; Oyekunle, T; Salama, JK; Spiegel, DY; Waters, L, 2019) |
| "Overtreatment of prostate cancer (PCa) is a healthcare issue." | ( Bartha, R; Bauman, G; Broeke, NC; Chin, J; Farag, A; Gaed, M; Gomez, JA; Lee, J; Martin, PR; Moussa, M; Pautler, SE; Peterson, J; Scholl, TJ; Ward, A, 2019) |
| "Determining the best treatment for prostate cancer patients with a newly diagnosed positive biopsy can be challenging." | ( Donovan, M; Fernandez, G; Khan, FM; Scott, R, 2018) |
| "This is in part because prostate cancers adaptively switch to the androgen/AR-independent pathway for survival and growth, thereby conferring therapy resistance." | ( Beer, TM; Chen, A; Chen, Y; Dai, MS; Dang, S; Geng, H; Hua, V; Kachhap, SK; Liu, Q; Mendonca, J; Pan, F; Qian, DZ; Qian, K; Reardon, PN; Sun, XX; Xue, C; Yuan, J, 2018) |
| "A 73-year-old man with a prostate cancer treated by radical prostatectomy in 2006." | ( Di Gregorio, F; Evangelista, L; Ferretti, G; Rensi, M, 2019) |
| "In vitro models of prostate cancer (PCa) are not always reliable to evaluate anticancer treatment efficacy." | ( de Ridder, CMA; Erkens-Schulze, S; Kanaar, R; Meijer, TG; Nonnekens, J; Schönfeld, E; van Gent, DC; van Weerden, WM; Zhang, W, 2019) |
| "Treatment of mice bearing human prostate cancer xenografts with IATL was also associated with induction of ER stress and inhibtion of STAT3." | ( Chen, W; Huang, H; Li, P; Liu, Y; Yang, Y; Ye, X; Zhang, F, 2018) |
| "Limited pelvic nodal relapse of prostatic cancer is a paramount challenge for locoregional salvage treatments." | ( Beckendorf, V; Buthaud, X; Campion, L; Créhange, G; De Laroche, G; Denis, F; Goineau, A; Hasbini, A; Lagrange, JL; Latorzeff, I; Loos, G; Palpacuer, C; Pasquier, D; Pommier, P; Rio, E; Sargos, P; Silva, M; Supiot, S; Vaugier, L, 2019) |
| "Lymph node detection in prostate cancer is challenging and critical to determine treatment policy." | ( Huang, SM; Li, YF; Lin, ZC; Yang, Y; Yin, L; Yue, JL, 2018) |
| "The androgen-directed treatment of prostate cancer (PCa) is fraught with the recurrent profile of failed treatment due to drug resistance and must be addressed if we are to provide an effective therapeutic option." | ( Beitel, LK; Chowdhury, S; Lumbroso, R; Paliouras, M; Purisima, EO; Trifiro, M, 2019) |
| "Metastatic castration-resistant prostate cancer is commonly treated with chemotherapy, whose effect is less than satisfactory." | ( Belluti, S; Ferrari, E; Imbriano, C; Orteca, G; Parenti, F; Rigillo, G; Semeghini, V, 2018) |
| "The primary endpoint was prostate cancer-specific mortality and was analysed according to intention-to-treat using competing-risks methods." | ( Atkinson, C; Attia, J; Christie, D; Delahunt, B; Denham, JW; Diamond, T; Duchesne, G; Gogna, NK; Joseph, D; Kenny, L; Lamb, DS; Matthews, J; Oldmeadow, C; Spry, NA; Steigler, A; Tai, KH; Turner, S, 2019) |
| "Twenty-four men with prostate cancer (14 untreated; 10 with biochemical recurrence following radiation therapy)." | ( Carlin, D; Collins, D; deSouza, NM; Orton, MR, 2019) |
| "With prostate cancer not observed in eunuchs and total androgen suppression by castration an effective first-line treatment for advanced prostate cancer, the dramatic regression seen in tumour symptoms after castration, lead to the theory that high levels of circulating androgens were a risk factor for prostate cancer." | ( Al Ansari, A; Alkadhi, S; AlRumaihi, K; Alzubaidi, R; Yassin, A, 2019) |
| "Neuroendocrine prostate cancer (NEPC), a lethal form of the disease, is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, which results in resistance to AR-targeted therapy." | ( Ahmed, M; Ba-Alawi, W; Beltran, H; Berlin, A; Boutros, PC; Bristow, RG; Chen, S; Ci, X; Ellis, L; Fazli, L; Feng, FY; Gleave, M; Guo, H; Haibe-Kains, B; He, HH; Hua, JT; Koritzinsky, M; Li, E; Liang, Y; Lin, D; Mahamud, O; Nguyen, T; Poirier, JT; Puca, L; Rudin, CM; Sheahan, AV; Soares, F; Su, P; Tsao, MS; van der Kwast, T; Vellanki, RN; Vosoughi, A; Wang, Y; Wouters, BG; Xu, J; Xu, X; Xue, H; Zhang, S; Zhang, Y; Zoubeidi, A, 2019) |
| "Castration-naïve patients with prostate cancer and a rising serum prostate-specific antigen after definitive local therapy were eligible." | ( Acon, P; Baker, C; Galsky, MD; Gimpel-Tetra, K; Holland, J; Jia, R; Leiter, A; Mehrazin, R; Oh, WK; Sablinski, T; Sfakianos, JP; Shaffer, DR; Shahin, M; Tsao, CK, 2017) |
| "Localized and locally advanced prostate cancer patients who elected to have radical prostatectomy without prior androgen deprivation therapy were included in the study." | ( Khongcharoensombat, W; Lumbiganon, S; Patcharatrakul, S; Sangkum, P, 2019) |
| "Although prostate cancer (PCa) screening is conducted before testosterone replacement therapy (TRT), clinically occult PCa cases may exist." | ( Haider, A; Haider, K; Saad, F; Xu, X; Zhang, X; Zhong, Y, 2019) |
| "Mechanistic analysis of metastatic prostate cancer (PCa) biology and therapy response critically depends upon clinically relevant three-dimensional (3D) bone-like, organotypic culture." | ( Dondossola, E; Friedl, P; Logothetis, CJ; Navone, N; Paindelli, C, 2019) |
| "Seventeen men with untreated, low-grade prostate cancer consumed 485 g rye whole grain and bran products (RP) per day or refined wheat products with added cellulose (WP) in a randomized crossover design." | ( Åman, P; Andersson, SO; Brunius, C; Hallmans, G; Johansson, JE; Landberg, R; Larsson, A; Mhd Omar, NA; Zamaratskaia, G, 2020) |
| "We will also find which measures of prostate cancer control and which cancer and patient characteristics can be used to shorten and improve trials of newer treatments." | ( Halabi, S; Parelukar, WR; Rydzewska, L; Tierney, JF; Vale, CL, 2019) |
| "Standard therapy for advanced Prostate Cancer (PCa) consists of antiandrogens, which provide respite from disease progression, but ultimately fail resulting in the incurable phase of the disease: mCRPC." | ( De Benedetti, A; Ghosh, I; Jaiswal, PK; Koul, HK; Singh, V; Yu, X, 2019) |
| "Glucocorticoids are used during prostate cancer (PCa) treatment." | ( Anselmino, N; Brandani, JN; Cotignola, J; Galigniana, M; Giudice, J; Gueron, G; Jaworski, FM; Leonardi, DB; Mazaira, G; Meiss, RP; Nemirovsky, SI; Nuñez, M; Páez, AV; Pecci, A; Vazquez, E, 2019) |
| "Primary prostate cancer cells frequently develop resistance toward chemotherapy as well as most chemotherapeutics have been reported to induce undesirable cytotoxicity in normal cells." | ( Cho, HD; Gu, IA; Moon, KD; Park, KH; Seo, KI; Won, YS, 2019) |
| "Reirradiation of patients with prostate cancer who underwent previous radiation therapy is a valuable option that can be safely considered to delay the beginning of hormonal treatment." | ( Clerici, E; D'Agostino, GR; Di Brina, L; Franceschini, D; Franzese, C; Iftode, C; Mancosu, P; Navarria, P; Scorsetti, M; Tozzi, A, 2019) |
| "For those with a diagnosis of prostate cancer that remains untreated, there is a sparsity of evidence and therefore clinicians are "pushing the limits" of safety when considering the commencement of testosterone replacement therapy." | ( Ahmed, HU; Gallagher, KA; Jayasena, CN; Miah, S; Minhas, S; Shah, TT; Tharakan, T; Winkler, M, 2019) |
| "In this study, we reconstruct a prostate cancer (PRAD)-specific GEM for exploring prostate cancer metabolism and also repurposing new therapeutic agents that can be used in development of effective cancer treatment." | ( Arga, KY; Benfeitas, R; Kim, W; Mardinoglu, A; Turanli, B; Uhlen, M; Zhang, C, 2019) |
| "Short term treatment of US men with prostate cancer (PCa) with genistein decreases MMP-2 in prostate tissue." | ( Bergan, R; Catalona, WJ; Ding, Y; Fowler, G; Gordon, R; Huang, X; Jiang, H; Jovanovic, B; Kelly, DL; Li, W; Pattanayak, A; Xu, L; Yang, X; Zhang, H; Zhang, L, 2019) |
| "Patients with newly-diagnosed M1a/b prostate cancer (PSMA PET/CT staging is permitted) and 1-5 radiographically visible metastases (excluding pelvic lymph nodes) are undergoing local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present." | ( Aronson, WJ; Bennett, CJ; Garraway, IP; Gin, GE; Huiza, C; Inouye, WS; Jafari, L; Jordan, ML; Kalpage, N; Kishan, AU; Lee, SP; Lewis, M; Nickols, NG; Parikh, NR; Patel, JS; Pitcher, S; Reiter, RE; Rettig, MB; Sadeghi, A; Sanati, H; Thein, M; Tsai, S, 2019) |
| "In this open-label, multicenter study, prostate cancer patients with indication for androgen ablation therapy received two subcutaneous injection of LMIS 50 mg 6 months apart and were followed for an additional 6 months." | ( Chien, B; DeGuenther, M; Hu, CH; Huang, ST; Jievaltas, M; Lee, Y; Li, Y; Mao, J; Mincik, I; Patockova, J; Shore, N; Simpson, K; Student, V, 2020) |
| "Breast and prostate cancers are frequently treated with chemotherapy." | ( Almeida Paz, FA; Bachari, K; Bentarzi, Y; Helguero, LA; Nedjar-Kolli, B; Rocha, DHA; Saidi, L; Silva, AMS; Talhi, O, 2019) |
| "The pooled HR of prostate cancer for metformin therapy was 0." | ( Bi, Y; Chen, T; Liu, X; Sun, Y; Tang, J; Wang, Y; Yan, P; Zhang, ZJ; Zhou, W, 2020) |
| "Three human prostate cancer cell lines were treated with 5-aza-2-deoxycytidine; the expression of CD146 and EMT-related factors was analyzed by RT-PCR and western Blot." | ( Dudzik, P; Dulińska-Litewka, J; Kocemba-Pilarczyk, KA; Laidler, P; Ostrowska, B; Trojan, SE; Zemanek, G, 2019) |
| "After treatment of prostate cancer cells (PC-3 and DU-145) with MEPL, lupeol and β-sitosterol; induction of apoptosis, decrease in cellular-viability and inhibition of cellular-migration were noticed." | ( Das, L; Deb, M; Dhiman, R; Kar, S; Kausar, C; Mawatwal, S; Parbin, S; Patra, SK; Pradhan, N; Sengupta, D, 2019) |
| "Forty-nine consecutive prostate cancer patients diagnosed with oligometastatic recurrence on Ch-PET have been prospectively treated." | ( Ahtamon, A; Bilbao, P; Cacicedo, J; Casquero Ocio, F; Fernandez, I; Garcia-Olaverri, J; Gomez-Iturriaga, A; Llarena, R; Ortiz de Zarate, R; Ost, P; Rodeño, E, 2019) |
| "MR images of a phantom and 18 prostate cancer patients imaging using the usual diagnostic set-up with a curved tabletop (DX-set-up) and using a radiotherapy set-up (RT-set-up) with a flat tabletop, were analysed retrospectively." | ( Andres, I; Arenas, M; Berenguer, R; Jimenez-Jimenez, E; Korte, E; Lozano-Setien, E; Pastor-Juan, MR; Rovirosa, A; Sabater, S; Sevillano, M; Tercero-Azorin, MI, 2019) |
| "The progression of castration-resistant prostate cancer (CRPC) still relies on the function of androgen receptor (AR), achieved by evolving mechanisms to reactivate AR signaling under hormonal therapy." | ( Chen, B; Hu, DP; Hu, WY; Li, Y; Muzzarelli, KM; Ou, S; Prins, GS; Qin, Z; Vander Griend, DJ; Xu, L; Yang, Z, 2019) |
| "Using prostate cancer cell lines with differing sensitivities to radiation treatment, we analysed the DNA methylation profiles prior to and following a single dose of radiotherapy (RT) using the Illumina Infinium HumanMethylation450 BeadChip platform." | ( Ambrose, M; Berry, R; Brettingham-Moore, KH; Holloway, AF; Jeffreys, SA; Joo, JE; Phillips, JL; Skala, M; Sutton, LP; Taberlay, PC; Young, A, 2019) |
| "The increasing incidence of prostate cancer (PCa) indicates an urgent need for the development of new effective drugs in PCa therapy." | ( Chen, L; Chen, M; Dong, F; Jiang, M; Sun, W; Wang, A; Wang, R; Yang, P; Zhang, C; Zhang, Y, 2019) |
| "New directions in research on prostate cancer are highlighted, reflecting the unique challenges of the disease profile and treatment resources in India." | ( Arunsingh, M; Gupta, P; Mallick, I; Murthy, V, 2019) |
| "Androgen receptor (AR) expressing prostate cancer cells (LNCaP) were treated for 7 to 14 days with vehicle control (0." | ( Burger, IA; Deberle, LM; Eberli, D; Hermanns, T; Kranzbühler, B; Müller, C; Salemi, S; Sulser, T; Umbricht, CA, 2019) |
| "The reoccurrence of androgen-dependent prostate cancer after anti-androgen therapy mainly depends on prostate cancer stem-like cells." | ( Kaneko, S; Kato, K; Kohno, K; Sato, A; Yamazaki, T; Yano, T, 2019) |
| "The clinical data of 191 prostate cancer patients treated with definitive intensity-modulated RT were retrospectively analyzed." | ( Akyol, F; Cağlar, M; Guler, OC; Hurmuz, P; Onal, C; Ozyigit, G; Reyhan, M; Torun, N; Yildirim, BA, 2019) |
| "Currently, antiprostate cancer (PCa) drugs, including androgen deprivation therapy (ADT), are initially effective; however, most patients with PCa who receive ADT eventually progress to deadly aggressiveness." | ( Hsieh, PF; Huang, GJ; Huang, SY; Huang, WC; Wu, HC, 2019) |
| "After treatment with AA or ENZ, elderly prostate cancer patients with pre-existing CVDs experienced higher short-term mortality than otherwise similar patients without CVDs." | ( Chapman, A; Cullen, J; Gandhi, K; Gomella, L; Hegarty, SE; Kantoff, PW; Keith, SW; Kelly, WK; Lu-Yao, G; Nightingale, G; Nikita, N; Rebbeck, TR, 2020) |
| "The response for the 8 prostate cancer-treatment courses was PMD, which correlated well with changes in serum prostatic specific antigen (PSA) (7 of 8 cases showed increased PSA)." | ( Fujiwara, M; Go, S; Hashimoto, T; Kaida, H; Kanda, T; Kanematsu, A; Kitajima, K; Nakanishi, Y; Nojima, M; Suzuki, T; Tamaki, Y; Tsurusaki, M; Yamada, Y; Yamakado, K; Yamamoto, S, 2019) |
| "The antiangiogenic therapy for prostate cancer with Nintedanib, a potent inhibitor of important growth factor receptors, has been proven to delay tumor progression and arrest tumor growth; thus, the aim herein is to evaluate Nintedanib effects on tumor cells, besides angiogenesis and apoptosis processes, metalloproteinases and hypoxia factor in an animal model." | ( Agarwal, R; Alves, LF; Banzato, TP; Cagnon, VHA; Carvalho, JE; da Silva, RF, 2020) |
| "Treatment of prostate cancer cells with enzalutamide enhances recruitment of pioneer factor GATA2, AR, Mediator subunits MED1 and MED14, and RNA Pol II to regulatory elements of enzalutamide-responsive genes." | ( Armstrong, AJ; Chen, Z; Hankey, W; Huang, J; Somarelli, J; Wang, H; Wang, Q; Wu, D; Yuan, F, 2019) |
| "Conventional treatment for prostate cancer is radiotherapy (RT); however, the following radiation-induced radioresistance often causes treatment failure." | ( Chuang, HY; Hwang, JJ; Lee, YP; Lin, WC; Lin, YH, 2019) |
| "Men with nonmetastatic prostate cancer who were being treated with a medicine that lowers testosterone, a chemical in the body that causes prostate cancer tumors to grow." | ( Borghesi, G; Fizazi, K; Fricke, R; Gieschen, H; Graudenz, K; Koskinen, M; Kuss, I; Moss, J; Petrenciuc, O; Ploeger, B; Prien, O; Shore, N; Smith, MR; Tammela, TL; Verholen, F; Zurth, C, 2019) |
| "Although the early diagnosis of prostate cancer (PCa) enhances life expectancy with a 5-year survival rate of 100 %, metastasized-PCa is the fundamental reason for death by PCa, hence requires an advanced and target-directed treatment strategy." | ( Cao, Q; Chen, FZ; Chen, HC; Khusbu, FY; Roy, M; Zhou, X, 2020) |
| "RESULTS Treatment of human prostate cancer cells with Eriocalyxin B resulted in apoptosis in a dose- and time-dependent manner." | ( Chen, Y; Liang, C; Yu, Z, 2019) |
| "In a xenograft model of prostate cancer, this nanotherapy shows a durable inhibition of tumor progression upon the administration of a tolerable dose." | ( Cen, B; Lian, X; Liu, J; Shuai, Q; Su, W; Wan, J; Wang, H; Zhang, W; Zhao, G, 2020) |
| "302 localized prostate cancer (PCa) patients were treated with CWT (implantation dose: 145 Gy) and 215 patients were treated with SIT, which applied reduced implantation dose of 123." | ( Oh, JJ; Park, DS; Shin, HS; Yu, YD, 2019) |
| "Docetaxel chemotherapy in prostate cancer has a modest impact on survival." | ( Dufès, C; Hewit, K; James, D; Leung, HY; Munnings-Tomes, S; Patel, R; Rushworth, LK; Shanks, E; Somani, S; Straube, A, 2020) |
| "In multiple human prostate cancer cell lines under hypoxia, taxol treatment induces the degradation of HIF1α, and this response is abrogated by knockdown of CHIP, but not by E3 ligase VHL or RACK1." | ( Biswas, K; Brautigan, DL; Larner, JM; Said, N; Sarkar, S, 2020) |
| "Knockdown of PlexinB1 in prostate cancer cells decreases the levels of glucocorticoid-responsive gene products and antagonizes the decrease in cell motility and cell area of prostate cancer cells upon dexamethasone treatment, demonstrating the functional significance of these findings." | ( Garg, R; Wells, CM; Williamson, M, 2019) |
| "MicroRNA expression is altered in prostate cancer and may promote therapy resistance." | ( Boutros, PC; Downes, M; Dura-Perez, L; Haughey, C; Hoey, C; Jain, S; Jeon, J; Liu, SK; McCabe, N; Mills, IG; Murphy, R; Ray, J, 2020) |
| "Bone-metastasis prostate cancer (BMPCa)-targeting gene therapy is gaining increasing concern in recent years." | ( Chen, H; Chen, J; Chen, X; Gu, Y; Huang, S; Wang, H; Wu, X; Xu, Y; Zhang, H; Zhang, Y, 2020) |
| "According to the various techniques of prostate cancer radiotherapy, the dose values scattered to the testicular tissues ranged from 0." | ( Farhood, B; Milajerdi, A; Mortezaee, K; Motallebzadeh, E; Najafi, M; Sahebkar, A, 2020) |
| "RAI16 expression was detected in prostate cancer cells with or without the AR agonist R1881 treatment by quantitative RT-PCR and Western blot." | ( Ding, CL; Qi, ZT; Qian, CL; Wang, W, 2020) |
| "Neuroendocrine prostate cancer (NEPC) can arise de novo, but much more commonly occurs as a consequence of a selective pressure from androgen deprivation therapy or androgen receptor antagonists used for prostate cancer (PCa) treatment." | ( Chiorino, G; Farsetti, A; Gregnanin, I; Guana, F; Jachetti, E; Mello-Grand, M; Ostano, P; Peraldo-Neia, C; Sesia, D, 2020) |
| "Progression of prostate cancer has been associated with EGFR and HER2 activation and to tumor-initiating cells contribution toward chemotherapy resistance." | ( Aiello, P; Balsari, A; Giussani, M; Regondi, V; Ripamonti, F; Rossini, A; Tagliabue, E; Triulzi, T, 2020) |
| "In total, 125 patients with prostate cancer received 6 months of neoadjuvant ADT (nADT) followed by low-dose rate (LDR) brachytherapy." | ( Izumi, K; Kadono, Y; Kato, Y; Kawaguchi, S; Mizokami, A; Shigehara, K, 2020) |
| "To evaluate risk of prostate cancer biochemical recurrence (BCR) after radical prostatectomy (RP) in men receiving vs not receiving testosterone replacement therapy (TRT)." | ( Ahlering, TE; El Khatib, FM; My Huynh, L; Osann, K; See, K; Towe, M; Tran, J; Yafi, FA, 2020) |
| "Treatment of prostate cancer cells with alpha-santalol (20, 40 μM) resulted in the down regulation of survivin and p-AKT (s-473) expression and statistically significant reduction in total survivin levels as evidenced by survivin ELISA assay." | ( Bommareddy, A; Dwivedi, C; Hong, KL; Lewis, M; Lockus, L; McGlynn, D; Seward, J; VanWert, AL, 2020) |
| "Castration-resistant prostate cancer (CRPC) is frequent among patients receiving 18-24 months of androgen deprivation therapy." | ( Chen, J; Gao, Y; Gong, C; Jiang, W; Wang, Y; Yuan, Y, 2020) |
| "During radiotherapy (RT) for prostate cancer (PCa), interfraction and intrafraction movements can lead to decreased target dose coverage and unnecessary over-exposure of organs at risk." | ( Bourbonne, V; Boussion, N; Chasseray, M; Dissaux, G; Goasduff, G; Lucia, F; Pradier, O; Schick, U, 2020) |
| "Metastatic prostate cancer (PCa) has high mortality and a poor 5-year survival rate primarily due to the lack of effective treatments." | ( Adil, MS; Alwhaibi, A; Artham, S; Cummings, BS; Somanath, PR; Verma, A, 2020) |
| "Human prostate cancer (DU145) cells were treated with neferine for 18 h, and subsequently treated with TRAIL for 2 h." | ( Nazim, UM; Park, SY; Yin, H, 2020) |
| "This was, in particular, applied to prostate cancer, where conventional wisdom since Huggins has considered it almost taboo for a patient being treated with cancer to receive testosterone replacement therapy (TRT)." | ( Kim, JW, 2020) |
| "Human prostate cancer LNCaP and DU145 cells treated with HDAC inhibitors, sodium butyrate, and trichostatin A, resulted in maspin re-expression." | ( Abbas, A; Candamo, M; Gupta, S; Kanwal, R; MacLennan, GT; Pandey, M; Shankar, E; Shukla, S; Verma, S, 2020) |
| "A 68-year-old man was diagnosed with prostate cancer (initial serum prostate specific antigen [PSA] 389 ng/ml, stage cT4N1M1c, Gleason score 5+4), and androgen deprivation therapy was initiated." | ( Iinuma, K; Kato, D; Koie, T; Kotaka, H; Nakane, K; Okamoto, K; Ozawa, K; Takai, M; Yuhara, K, 2020) |
| "Metastatic prostate cancer cell lines (PC-3 and LNCaP) were treated with Pd (II) complex, CQ, and their combination." | ( Akar, RO; Ari, F; Aydinlik, S; Aztopal, N; Celikler, S; Cevatemre, B; Erkisa, M; Ulukaya, E; Yilmaz, VT, 2020) |
| "As problems with the overuse of radical prostate cancer (PCa) treatment are increasingly exposed, focal therapy represents the direction of low- or intermediate-risk PCa management in the future." | ( Mao, R; Miao, X; Qiu, C; Ren, J; Tian, J; Wang, K; Yang, B; Yin, T; You, Y; Zhang, X; Zheng, R; Zhou, H, 2020) |
| "The majority of patients with prostate cancer treated with docetaxel develop resistance to it." | ( Dai, J; Jiang, H; Keller, ET; Mizokami, A; Schnepp, PM; Shelley, G; Wakim, N, 2020) |
| "F-Fluciclovine is the most recent prostate cancer (PCa)-directed PET radiotracer approved by the US Food and Drug Administration for detection of recurrent PCa." | ( Ballas, LK; Desai, B; England, JR; Hwang, L; Jadvar, H; Paluch, J, 2020) |
| "Oligorecurrent prostate cancer has historically been treated with indefinite androgen deprivation therapy (ADT), although many patients and providers opt to defer this treatment at the time of recurrence given quality-of-life and/or comorbidity considerations." | ( Chang, EM; Deville, C; Feng, FY; Kishan, AU; Koontz, BF; Nickols, NG; Ost, P; Parikh, NR; Phillips, R; Raldow, AC; Reiter, RE; Rettig, MB; Spratt, DE; Steinberg, ML; Tran, PT; Vapiwala, N, 2020) |
| "Patients with localized prostate cancer with Gleason score ≤7, clinical stage T1b to T3a, and prostate-specific antigen <30 ng/mL were randomized to neoadjuvant and concurrent ADT for 6 months starting 4 months before prostate radiation therapy (NHT arm) or concurrent and adjuvant ADT for 6 months starting simultaneously with radiation therapy (CAHT arm)." | ( Craig, J; Eapen, L; Grimes, S; Malone, J; Malone, S; Morgan, SC; Roy, S; Spratt, DE, 2020) |
| "CHK1 has been associated with prostate cancer (PCa) induction, progression, and lethality; hence, CHK1 inhibitors SCH900776 (also known as MK-8776) and the more effective SCH900776 analog MU380 may have clinical applications in the therapy of PCa." | ( Búzová, D; Červený, J; Culig, Z; Drápela, S; Fedr, R; Hampl, A; Khirsariya, P; Krejčí, L; Paruch, K; Puhr, M; Souček, K; Suchánková, T; van Weerden, WM; Watson, WR, 2020) |
| "In castration-resistant prostate cancer, PSMA-targeting radionuclide therapy is showing potential as a curative possibility (e." | ( Fanti, S; Farolfi, A; Koschel, S; Murphy, DG, 2020) |
| "Despite advances in the treatment of prostate cancer, side effects and the risks of developing drug resistance require new therapeutic agents." | ( Erdogan, S; Koroglu, C; Serttas, R, 2021) |
| "The development of prostate cancer (PCa) from androgen-deprivation therapy (ADT) sensitive to castration resistant (CRPC) seriously impacts life quality and survival of PCa patients." | ( Bian, X; Butler, W; Du, L; Fu, G; Huang, Y; Li, Y; Ren, S; Shi, G; Shi, X; Wang, J; Wu, T; Xiao, Y; Yao, M; Ye, D, 2020) |
| "After treatment, prostate cancer was detected in 15 cases by subsequent biopsy." | ( Mochida, J; Obinata, D; Suzuki, S; Takahashi, S; Yamaguchi, K; Yamanaka, Y; Yoshizawa, T, 2020) |
| "Here, we demonstrate prostate cancer-targeted gold nanoparticles (AuNPs) for MR-guided radiotherapy to improve the targeting precision and efficacy." | ( Basilion, JP; Burda, C; Erokwu, BO; Flask, CA; Johnson, A; Li, H; Lou, J; Luo, D; Meade, TJ; Ramamurthy, G; Springer, S; Wang, X, 2020) |
| "We also demonstrate, using a prostate cancer syngeneic RM-9 mouse model and established cell lines, that this Cav-1-sphingolipid program evidences a metabolic vulnerability that is targetable to induce lethal mitophagy as an anti-tumor therapy." | ( Basourakos, S; Creighton, CJ; Davis, JW; Dennison, JB; Fahrmann, JF; Fleury, A; Gregg, JR; Hanash, S; Irajizad, E; Kim, J; Mayo, J; Murage, E; Park, S; Paulucci-Holthauzen, A; Peterson, CB; Tang, Z; Thompson, TC; Vykoukal, J; Yang, G, 2020) |
| "For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT)." | ( Bilusic, M; Bright, JR; Carrabba, NV; Choyke, PL; Chun, G; Cordes, LM; Couvillon, A; Dahut, WL; Gulley, JL; Hankin, A; Harmon, SA; Karzai, F; Lis, RT; Madan, RA; Merino, MJ; Pinto, PA; Shih, JH; Sowalsky, AG; Terrigino, NT; Turkbey, B; VanderWeele, DJ; Walker, SM; Wilkinson, S; Williams, MN; Ye, H, 2021) |
| "Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit because of emerging resistance." | ( Bushell, M; Clark, W; Hall, H; Harle, V; Leung, HY; Patel, R; Repiscak, P; Rushworth, LK; Shaw, R, 2020) |
| "The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs and new treatment options." | ( Benelli, A; Campodonico, F; De Censi, A; Ennas, M; Foppiani, L; Grillo-Ruggieri, F; Introini, C; Piccardo, A; Schiavone, C; Squillace, L; Zanardi, S; Zigoura, E, 2021) |
| "Docetaxel-based chemotherapy for prostate cancer is the clinical standard of care." | ( Chen, ML; Huang, CM; Lai, CJ; Lin, YH; Lin, YN, 2020) |
| "We treated DU145 human prostate cancer cells with a range of ICA II doses and then assessed their proliferation via CCK-8 assay, while flow cytometry was used to monitor apoptosis and cell cycle progression." | ( Li, S; Liu, Y; Wang, Y; Xie, Y; Zhan, Y, 2020) |
| "Although the incidence of canine prostate cancer is low, several patients have resistance to androgen therapy and poor clinical prognosis." | ( Maeda, M; Michishita, M; Morimatsu, M; Ochiai, K; Omi, T; Onozawa, E; Sasaki, T; Sutijarit, S; Tanaka, Y; Uemura, M; Watanabe, M, 2021) |
| "Loss of PTEN and TIMP1 in prostate cancer is frequent and correlates with resistance to docetaxel and worst clinical outcomes in patients treated in an adjuvant setting." | ( Alajati, A; Alimonti, A; Antonarakis, ES; Attanasio, G; Borrelli, C; Brina, D; Colucci, M; D'Ambrosio, M; De Marzo, AM; Dettwiler, S; Egger, G; Elia, AR; Garcia-Escudero, R; Guccini, I; Losa, M; Moch, H; Moor, AE; Mosole, S; Pasquini, E; Pernigoni, N; Revandkar, A; Rinaldi, A; Rüschoff, JH; Sheibani-Tezerji, R; Troiani, M; Wild, P, 2021) |
| "A 74-year-old man with a history of prostate cancer with proven osseous metastatic disease underwent Ga-prostate-specific membrane antigen (PSMA) PET/CT under antiandrogen therapy." | ( Dietlein, M; Drzezga, A; Hucho, T; Kobe, C; Mettler, J, 2021) |
| "Mice vaccinated with RM-1 mouse prostate cancer cell line treated with BZM or MG132 in combination with MTX showed enhanced tumor growth, and shortened tumor-free, and worse overall survival compared with those treated with MTX alone." | ( Bao, R; Li, C; Li, H; Wang, G; Wei, W; Wu, K; Xia, Y; Zhang, G; Zhang, Y; Zheng, H, 2020) |
| "The local treatment of prostate cancer is mainly radical resection and radical radiotherapy, but they are not applicable to advanced prostate cancer." | ( Fan, Y; Li, H; Liu, J; Luo, C; Quan, Z; Sun, W; Wu, X; Xiao, F; Zheng, Y, 2021) |
| "Early-stage prostate cancer (PCa) is dependent on serum androgen levels, and androgen-deprivation therapy (ADT), based on GnRH agonists and antagonists, represents the standard therapeutic approach for PCa patients." | ( Fontana, F; Limonta, P; Marzagalli, M; Montagnani Marelli, M; Moretti, RM; Raimondi, M, 2020) |
| "We cultured prostate cancer PC-3 cells in vitro and treated them with 3-BrPA at different concentrations for 24, 48 and 72 hours." | ( Cao, FH; Hu, JY; Li, LK; Wang, LM; Zhang, XJ, 2020) |
| "Evidence suggests that patients with prostate cancer (PCPs) receiving androgen-deprivation therapy (ADT) are at risk for cognitive impairment." | ( Amidi, A; Buus, S; H Gravholt, C; Haldbo-Classen, L; Hosseini, SMH; R Buskbjerg, C; Zachariae, R, 2021) |
| "Human prostate cancer tumors were procured from the patients who underwent radical prostatectomy without any neoadjuvant therapy." | ( Adomat, H; Chin, MY; Deb, S; Gleave, ME; Hurtado-Coll, A; Pham, S; Tomlinson Guns, ES, 2021) |
| "Most patients with advanced prostate cancer (PCa) initially respond well to androgen deprivation therapy (ADT) with antiandrogens, but most of them eventually become resistant to ADT." | ( Chang, C; Huang, C; Sun, Y; Wu, D; Xiang, Z; You, B; You, X; Yu, J; Zhang, M, 2021) |
| "In the prostate cancer patients, the median values of serum troponin I before and after treatment were 0." | ( Ahmadzadehfar, H; Amini, AL; Assadi, M; Bagheri, D; Jafari, E, 2021) |
| "Testosterone Replacement Therapy After Prostate Cancer Treatment: A Review of Literature." | ( Baum, N; Carlos, C; Hong, J; Khera, M; Natale, C; Raheem, OA, 2021) |
| "Treatment of metastatic prostate cancer has evolved significantly over the past decade." | ( Grewal, K; Tabbara, IA, 2021) |
| "The human prostate cancer cell lines, Du-145 and PC-3, were treated with various concentrations of verbascoside (0." | ( Chen, CH; Hsieh, PF; Hung, CH; Kuo, WW; Lee, YH; Lin, VC; Wu, CH; Wu, RC; Yang, YL, 2021) |
| "A 77-year-old man with prostate cancer had prostatectomy and hormonal therapy and underwent pelvic MRI and 68Ga-PSMA-11 PET/CT during clinical follow-up." | ( Lu, Y; Xu, G, 2021) |
| "Immunotherapy in prostate cancer (PCa) lags behind the progresses obtained in other cancer types partially because of its limited immune infiltration." | ( Battaglia, S; Cortes Gomez, E; Gillard, B; Karasik, E; Koya, RC; Lugade, A; Matsuzaki, J; Odunsi, K; Singh, PK; Thorne, JL; Tsuji, T; Want, MY, 2021) |
| "Conventional prostate cancer treatment strategies, including chemotherapy and radiotherapy, cannot effectively eradicate prostate cancer, especially castration resistance prostate cancer." | ( Feng, L; Han, F; Lu, L; Meng, L; Min, P; Sheng, G; Wang, C; Wang, Y; Xu, H; Zhang, L; Zhang, Y, 2021) |
| "We exploited this time lag to sensitize prostate cancer cells to radiation through short-term treatment with ONC201." | ( Allen, JE; Amoroso, F; Butterworth, KT; Glass, K; Jain, S; Liberal, F; Maguire, S; Mills, IG; O'Sullivan, JM; Prise, K; Singh, R; Steele, RE; Tarapore, R; Van Schaeybroeck, S; Waugh, DJ, 2021) |
| "The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development." | ( Arranz, JA; Castro, E; Climent, MA; Gallardo, E; González Del Alba, A; Gonzalez-Billalabeitia, E; Lorente, D; Maroto, JP; Méndez-Vidal, MJ; Vazquez, S, 2021) |
| "Metastatic castration-resistant prostate cancer (mCRPC) is a malignant and lethal disease caused by relapse after androgen-deprivation (ADT) therapy." | ( Creighton, CJ; Hou, PC; Hu, CY; Huang, YC; Lee, HC; Lin, SC; Lin, YS; Ou, CH, 2021) |
| "PC3 human prostate cancer cells were treated in vitro at different doses and times with PTX, DTX, or their combination." | ( Bravo-Cuellar, A; Cancino-Marentes, ME; Cruz-Gálvez, CC; Hernández-Flores, G; Orozco-Alonso, E; Ortiz-Lazareno, PC; Sierra-Díaz, E; Solís-Martínez, RA; Villaseñor-García, MM, 2021) |
| "We found that PTX in PC3 human prostate cancer cells induces significant apoptosis per se and increases that generated by DTX, while at the same time it reduces the senescence caused by the chemotherapy and increases caspases-3,-8, and -9 activity in PTX + DTX-treated cells." | ( Bravo-Cuellar, A; Cancino-Marentes, ME; Cruz-Gálvez, CC; Hernández-Flores, G; Orozco-Alonso, E; Ortiz-Lazareno, PC; Sierra-Díaz, E; Solís-Martínez, RA; Villaseñor-García, MM, 2021) |
| "However, treatments for advanced prostate cancer like androgen deprivation therapy (ADT) can lead to significant symptom burden that may be further exacerbated by stress-induced inflammation and cortisol dysregulation." | ( Begale, MJ; Chatterton, RT; Estabrook, R; Flury, SC; Fox, RS; Kundu, SD; Miller, GE; Mohr, DC; Moreno, PI; Oswald, LB; Penedo, FJ; Perry, K; Walsh, EA; Yanez, B, 2021) |
| "This metabolic reprogramming supports prostate cancer cell proliferation and protects cells from chemotherapy-induced cell apoptosis." | ( Cao, Y; Cheng, J; Dong, B; He, J; Ji, Y; Li, W; Ma, Z; Pan, J; Shangguan, X; Shen, K; Wang, Q; Xin, Z; Xue, W; Yue, Z; Zhang, W; Zheng, Q, 2021) |
| "Docetaxel (DTX)-based chemotherapy of prostate cancer is still confronted with significant challenges due to insufficient drug accumulation at the tumor sites and the systemic side effects on normal cells and organs." | ( Huang, H; Jiang, D; Kang, Y; Li, L; Li, M; Li, Y; Pang, J; Xiong, H; Zhang, L; Zhang, S, 2021) |
| "Despite the reduction of prostate cancer in both the PCPT and REDUCE trials, each study showed an increased risk of prostate cancer in the treatment arms." | ( Loughlin, KR, 2021) |
| "Metastatic prostate cancer in bone is difficult to treat as the tumor cells are relatively resistant to hormonal or chemotherapies when compared to primary prostate cancer." | ( Damasco, JA; Heralde, FM; Lin, SC; Lin, SH; Melancon, MP; Novone, NM; Perez, JVD; Rojo, RD; Santos, EB; Yu, G, 2021) |
| "We employed castration-resistant prostate cancer (CRPC), neuroendocrine prostate cancer (NEPC), and chemotherapy-resistant prostate cancer datasets to screen for potential target genes." | ( Chen, H; Jiang, Z; Meng, R; Shi, S; Wang, Y; Wu, S; Xu, L, 2021) |
| "For targeted therapy of prostate cancer, anti-prostate-specific membrane antigen (PSMA) antibodies were conjugated onto PEGylated GNPs through 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) (EDC/NHS) chemistry." | ( Dogan, N; Ford, JC; Hara, D; Pollack, A; Pourmand, A; Shi, J; Tao, W; Totiger, TM, 2021) |
| "PATIENT SUMMARY: Many men present with prostate cancer that has spread to distant sites beyond the prostate gland years after their initial diagnosis and treatment, while others have distant spread at the time the cancer is diagnosed." | ( Begbie, S; Chi, KN; Chowdhury, S; Coskinas, X; Davis, ID; Frydenberg, M; Hague, WE; Horvath, LG; Joshua, AM; Lawrence, NJ; Martin, AJ; Marx, GM; McCaffrey, J; McDermott, R; McJannett, M; North, SA; Parnis, F; Parulekar, W; Pook, DW; Reaume, MN; Sandhu, SK; Stockler, MR; Sweeney, CJ; Tan, A; Tan, TH; Thomson, A; Tu, E; Vera-Badillo, F; Williams, SG; Yip, S; Zhang, AY; Zielinski, RR, 2021) |
| "We performed an exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer receiving apalutamide (240 mg/day) or placebo, with continuous androgen deprivation therapy (ADT), in the phase 3, randomized, double-blind, placebo controlled TITAN trial (NCT02489318)." | ( Agarwal, N; Basch, E; Bjartell, A; Chi, KN; Chowdhury, S; Chung, BH; Given, R; Juárez Soto, Á; Lopez-Gitlitz, A; McQuarrie, K; Merseburger, AS; Miladinovic, B; Özgüroğlu, M; Pereira de Santana Gomes, AJ; Uemura, H; Ye, D, 2021) |
| "Although new drugs for treating prostate cancer continue to emerge, the unclear mechanism underlying drug targets limits this therapy, thereby constraining identification of effective therapeutic targets." | ( Jia, H; Jiang, S; Li, R; Lin, P; Liu, C; Wang, N; Wang, W; Xie, H; Yu, X, 2021) |
| "Evidence suggests that prostate cancer (PC) patients undergoing androgen deprivation therapy (ADT) are at risk for cognitive decline (CD), but the underlying mechanisms are less clear." | ( Amidi, A; Buskbjerg, CR; Buus, S; Gravholt, CH; Hadi Hosseini, SM; Zachariae, R, 2022) |
| "Lineage plasticity in prostate cancer-most commonly exemplified by loss of androgen receptor (AR) signaling and a switch from a luminal to alternate differentiation program-is now recognized as a treatment resistance mechanism." | ( Abida, W; Aggarwal, R; Alumkal, JJ; Attwell, S; Bankhead, A; Beltran, H; Campeau, E; Coleman, DJ; Coleman, IM; Corey, E; Feng, FY; Gesner, EM; Guan, X; Handelman, SK; Jenkins, C; Kim, DH; Kumaraswamy, A; Labrecque, MP; Lakhotia, S; Lucas, JM; Morrissey, C; Nelson, PS; Rao, A; Rodansky, ES; Sampson, D; Schwartzman, JA; Sexton, JZ; Small, EJ; Spratt, DE; Storck, WK; Sun, D; Urrutia, JA; Welker Leng, K; Xia, Z; Yates, JA; Zhang, C, 2021) |
| "Biochemical recurrence of prostate cancer after radiation therapy occurs in 5 to 50% of cases depending on the radiation technique used." | ( Biscans, C; Chalhoub, K; Debiais-Delpech, C; Guérif, S; Ingrand, P; Raynaud, N; Vallée, M, 2021) |
| "We treated prostate cancer cell lines with potent, specific inhibitors of ATR kinase, as well as with PARP inhibitor, olaparib." | ( Broom, BM; Corn, PG; Geng, C; Manyam, GC; Park, S; Peng, G; Peng, S; Pilié, PG; Tang, Z; Thompson, TC; Wang, D; Wu, C; Yang, G; Yap, TA, 2021) |
| "Nearly all men with prostate cancer treated with androgen receptor (AR) signaling inhibitors (ARSIs) develop resistance via diverse mechanisms including constitutive activation of the AR pathway, driven by AR genomic structural alterations, expression of AR splice variants (AR-Vs), or loss of AR dependence and lineage plasticity termed neuroendocrine prostate cancer." | ( Armstrong, AJ; Bubley, G; Chen, XE; Choueiri, TK; Dehm, SM; Emamekhoo, H; Feng, FY; Gilsdorf, CS; Halabi, S; Kwak, L; Lang, JM; McKay, RR; Morris, MJ; Rathkopf, D; Scher, HI; Silver, R; Singh, A; Sperger, JM; Stahlfeld, CN; Taplin, ME; Wei, XX; Wolfe, SK; Wyatt, AW; Zhang, Z; Zhao, SG, 2021) |
| "In total, 474 samples from 72 prostate cancer patients in the Netherlands receiving either chemical castration (CAS) or castration plus enzalutamide (ENZA) treatment were selected for data analysis." | ( Bergman, AM; Heijboer, AC; Jonker, N; Lanfermeijer, M; van der Poel, HG; van Rossum, HH; van Tellingen, O; van Winden, LJ, 2021) |
| "In patients with prostate cancer (PCa), there is a high rate of overdiagnosis and frequent overtreatment." | ( Lin, B; Ren, G; Wang, L, 2021) |
| "Castration-resistant prostate cancer (CRPC) is a lethal stage of disease in which androgen receptor (AR) signaling is persistent despite androgen deprivation therapy (ADT)." | ( Abraham-Miranda, J; Awasthi, S; Dhillon, J; Dominguez-Viqueira, W; El-Kenawi, A; Gatenby, RA; Gillies, RJ; Keske, A; Koomen, JM; Liu, M; Noel, L; Ruffell, B; Serna, AN; Steiner, KK; Yamoah, K; Yu, X, 2021) |
| "Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States." | ( Chen, T; Eisenberg, ML; Li, S, 2021) |
| "Proton therapy of prostate cancer (PCPT) was linked with increased levels of gastrointestinal toxicity in its early use compared to intensity-modulated radiation therapy (IMRT)." | ( Ackermann, B; Brons, S; Freitas, H; Magalhaes Martins, P; Seco, J; Tessonnier, T, 2021) |
| "Men with castration-resistant prostate cancer (CRPC) face poor prognosis and increased risk of treatment-incurred adverse effects resulting in one of the highest mortalities among patient population globally." | ( Al-Yasiri, AY; Hans, CP; Katti, KK; Katti, KV; Khan, A; Khoobchandani, M; Lugão, AB; MohanDoss, DKD; Nicholl, MB; Thipe, VC, 2021) |
| "Some drug treatments for prostate cancer, such as gonadotropin-releasing hormone (GnRH) receptor agonists and antagonists, work to reduce the production of testosterone." | ( Dearnaley, DP; George, DJ, 2021) |
| "In men with biochemically recurrent prostate cancer following definitive treatment of the primary, finite duration treatment with ADT and Abi +P results in a significantly longer PSA relapse-free interval than treatment with ADT alone." | ( Alafis, I; Aparicio, A; Araujo, J; Boukovala, M; Chapin, BF; Corn, P; Davis, J; Efstathiou, E; Logothetis, CJ; Papadopoulos, J; Pruitt, L; Spetsieris, N; Subudhi, SK; Tu, SM; Wang, J; Wang, X; Weldon, JA; Zurita, A, 2021) |
| "Keywords used for research were: "prostate cancer"; "focal therapy"; "focal treatment"; "High-Intensity Focal Ultrasound"; "cryotherapy"; "photodynamic therapy"; "focal laser ablation"; "irreversible electroporation"; "focal brachytherapy" and "gold nanoparticle directed therapy"." | ( Abi Tayeh, G; Albisinni, S; Aoun, F; Chebel, R; Khalil, N; Lilly, E; Mjaess, G; Peltier, A; Roumeguère, T; Sarkis, J, 2021) |
| "Osteoporosis is common in prostate cancer patients undergoing androgen deprivation therapy; furthermore, its incidence increases depending on the duration of androgen deprivation therapy." | ( Hagiwara, K; Kanatani, A; Kaneko, T; Kimura, M; Nakagawa, T; Sakamoto, A; Sasaki, K; Takahashi, S; Yamada, Y, 2022) |
| "Although prostate cancer is a very common form of malignancy in men, the clinical significance of androgen deprivation therapy (ADT) with abiraterone acetate versus the nonsteroidal antiandrogen bicalutamide has not yet been verified in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)." | ( Egawa, S; Enei, Y; Fukuokaya, W; Hata, K; Iwamoto, Y; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Obayashi, K; Onuma, H; Otsuka, T; Sakanaka, K; Sano, T; Shimomura, T; Suzuki, H; Tsuzuki, S; Yanagisawa, T, 2022) |
| "During radiation therapy (RT) for prostate cancer, bladder filling helps exclude the organ from irradiation and reduces adverse effects." | ( Aizawa, T; Ishibashi, N; Maebayashi, T; Okada, M; Sakaguchi, M, 2022) |
| "Patients with prostate cancer (PCa) receiving docetaxel chemotherapy invariably develop chemoresistance." | ( Alkashgari, HR; Casiano, CA; Diaz Osterman, CJ; Elix, CC; Mahler, M; Martinez, SR; McMullen, JRW; Ochoa, PT; Ortiz-Hernandez, GL; Roy, S; Sanchez-Hernandez, ES; Soto, U, 2021) |
| "For advanced, high risk prostate cancer, androgen deprivation therapy (ADT) is the preferred treatment and can induce remission, but resistance to ADT brings biochemical recurrence and progression of cancer." | ( Glass, AD; Grossfeld, DJ; Katz, AE; Pinkhasov, A; Reiss, AB; Saeedullah, U, 2022) |
| "First-line therapy for prostate cancer includes androgen deprivation therapy (ADT), depriving both the normal and malignant prostate cells of androgens required for proliferation and survival." | ( Brady-Nicholls, R; Enderling, H; Gatenby, RA; Pasetto, S, 2021) |
| "Loss of prostate cancer differentiation or de-differentiation leads to an untreatable disease." | ( Liu, AY, 2021) |
| "Neuroendocrine (NE) prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (PCa) arising either de novo or from transdifferentiated prostate adenocarcinoma following androgen deprivation therapy (ADT)." | ( Aggarwal, R; Alshalalfa, M; Bearss, JJ; Beltran, H; Buttyan, R; Chakravarti, D; Collins, C; Davicioni, E; Feng, F; Gibb, EA; Gleave, M; Hanna, MM; Karnes, RJ; Kobelev, M; Kraft, AS; Lee, BR; McCarthy, D; Mukherjee, P; Nouri, M; Okumura, K; Olive, V; Padi, SKR; Pandey, R; Parker, JB; Ramnarine, VR; Rubin, M; Singh, N; Slack, FJ; Small, EJ; Song, JH; Sun, B; Wang, Y; Warfel, NA; Zhou, M; Zoubeidi, A, 2021) |
| "Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy." | ( Alzoueb, M; Amos, CL; Atako, N; Attard, G; Birtle, A; Bowen, J; Brawley, C; Brown, LC; Buckner, M; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; Das, P; de Bono, JS; Dearnaley, DP; Gale, J; Gilbert, D; Gillessen, S; Gilson, C; Gray, E; James, ND; Jones, RJ; Langley, RE; Lydon, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Murphy, L; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MKB; Pedley, I; Pugh, C; Robinson, A; Rush, H; Russell, JM; Srihari, N; Sydes, MR; Syndikus, I; Tanguay, J; Thalmann, G; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A, 2022) |
| "Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone." | ( Alzoueb, M; Amos, CL; Atako, N; Attard, G; Birtle, A; Bowen, J; Brawley, C; Brown, LC; Buckner, M; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; Das, P; de Bono, JS; Dearnaley, DP; Gale, J; Gilbert, D; Gillessen, S; Gilson, C; Gray, E; James, ND; Jones, RJ; Langley, RE; Lydon, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Murphy, L; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MKB; Pedley, I; Pugh, C; Robinson, A; Rush, H; Russell, JM; Srihari, N; Sydes, MR; Syndikus, I; Tanguay, J; Thalmann, G; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A, 2022) |
| "Neuroendocrine prostate cancer (NEPC) is an aggressive, androgen independent PCa and it is detected in patients undergoing androgen deprivation therapy (ADT)." | ( Asha, SM; Khilar, P; Lakshmi, PSV; Natani, S; Sruthi, KK; Ummanni, R, 2022) |
| "Patients with prostate cancer (PCa) treated with apalutamide frequently develop rash." | ( Dranitsaris, G; Kollmeier, MA; Kraehenbuehl, L; Lacouture, ME; McBride, SM; Moy, A; Pan, A; Rathkopf, DE; Reingold, RE; Scher, HI; Xiao, H; Zhao, JL, 2022) |
| "An 80-year-old man with a history of prostate cancer, treated with radical prostatectomy and bilateral obturator nodal dissection, underwent an 18F-choline PET/CT because of biochemical recurrence." | ( Bertagna, F; Bosio, G; Calabrò, A; Drera, E; Giubbini, R, 2022) |
| "Treatment-induced neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer." | ( Chakraborty, G; Chen, Y; Gutierrez, JA; Kalidindi, TM; Khitrov, S; Korsen, JA; Lewis, JS; Morris, MJ; Pillarsetty, N; Poirier, JT; Rudin, CM; Samuels, ZV, 2022) |
| "In men with prostate cancer, androgen deprivation therapy (gonadoliberin analogues) induces rapid bone loss and severe deterioration of bone microarchitecture." | ( Szulc, P, 2022) |
| "Neuroendocrine prostate cancer (NEPC) is often diagnosed as a sub-type from the castration-resistant prostate cancer (CRPC) recurred from the second generation of anti-androgen treatment and is a rapidly progressive fatal disease." | ( Chen, YA; Chung, LW; Hernandez, E; Hofstad, M; Hsieh, JT; Kapur, P; Lai, CH; Lee, CF; Lee, MS; Lin, H; Ma, S; Pong, RC; Raj, GV; Zhau, H, 2022) |
| "After performing SAM treatment on prostate cancer cell lines (PC-3 and DU145), a cell-cycle arrest during the S-phase, a downregulation of cyclin A protein levels and an upregulation of p21 cell cycle inhibitor were observed." | ( Schmidt, T, 2022) |
| "PARPi treatment in prostate cancer (PC) is currently used as a monotherapy or in combination with standard therapies (hormonotherapy) in clinical trials for patients with DNA damage response mutation." | ( Cahuzac, M; Fleury, H; Langlois, P; Mes-Masson, AM; Péant, B; Saad, F, 2022) |
| "The role of BTAs in prostate cancer is pivotal throughout many stages of the disease, but several toxicities should be quickly recognized and treated." | ( Errani, C; Marchetti, A; Massari, F; Mollica, V; Nigro, MC; Nuvola, G; Rizzo, A; Rosellini, M; Tassinari, E, 2022) |
| "Advanced prostate cancer (PCa) patients with bone metastases are treated with androgen pathway directed therapy (APDT)." | ( Arreola-Villanueva, C; Burner, DN; Cacalano, NA; Gaasterland, T; Greenburg, O; Jamieson, CAM; Jamieson, CHM; Kane, CJ; Kang, SG; Kim, HT; Koutouan, E; Kulidjian, AA; Lee, S; Lennon, KM; Mendoza, TR; Muldong, MT; Murtadha, J; Pham, H; Pineda, G; Pineda, N; Wu, CCN; Zhu, WY; Zuniga, A, 2022) |
| "Systemic treatments for prostate cancer (PC) have significant side effects." | ( Bussberg, V; Chen, EY; Chi, JT; Freedland, SJ; Greenwood, B; Howard, L; Kiebish, MA; Lin, PH; Narain, NR; Tolstikov, V, 2022) |
| "Patients with prostate cancer treated at the Portuguese Institute of Oncology of Porto (n = 366) were evaluated with the Montreal Cognitive Assessment (MoCA), before treatment and after 1 year." | ( Araújo, N; Braga, I; Carneiro, F; Costa, A; Cruz, VT; Ferreira, A; Lopes-Conceição, L; Lunet, N; Morais, S; Oliveira, J; Pacheco-Figueiredo, L; Pereira, S; Ruano, L, 2022) |
| "We gathered cases diagnosed with prostate cancer based on the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database from 2004 to 2020." | ( Chen, C; Li, J; Shen, P; Wu, B; Wu, F; Xu, T; Yin, X; Yu, L, 2023) |
| "Lung function of prostate cancer patients should be monitored when receiving the hormone therapy drugs mentioned above, especially for the first year post medication." | ( Chen, C; Li, J; Shen, P; Wu, B; Wu, F; Xu, T; Yin, X; Yu, L, 2023) |
| "The use of gene therapy to treat prostate cancer is hampered by the lack of effective nanocarriers that can selectively deliver therapeutic genes to cancer cells." | ( Almowalad, J; Dufès, C; Laskar, P; Meewan, J; Somani, S; Tate, RJ, 2022) |
| "Melatonin blocks the recurrence of prostate cancer as well as hormone-refractory effects during androgen deprivation therapy." | ( Samanta, S, 2021) |
| "Patients with prostate cancer were categorized into two groups according to whether they received GnRH analogue treatment (study group I) or not (study group II), and men without prostate cancer and with no GnRH analogue use were defined to comprise the comparison group after their ages and index years were matched with group II." | ( Keller, JJ; Lee, MY; Lin, HC; Lin, SF; Wang, LH, 2022) |
| "In advanced stages of prostate cancer, androgen deprivation therapy (ADT) is initiated." | ( Axcrona, K; Bjerknes, C; Currie, C; Framroze, B; Hermansen, E; Pettersen, CHH, 2022) |
| "Accumulating evidence supports that prostate cancer stem-like cells (PCSCs) play significant roles in therapy resistance and metastasis of prostate cancer." | ( Chan, AM; Chan, FL; Chiu, PK; Gao, W; Ma, T; Ng, CF; Wang, Y; Wang, Z; Wu, D; Yu, S, 2022) |
| "Hypoxia followed by reoxygenation in prostate cancer drives androgen deprivation therapy resistance via increasing the rate-limiting enzyme and cofactors for androgen synthesis, revealing HIF2α as a therapeutic target to subvert resistance." | ( Berk, M; Chakraborty, AA; Chung, YM; Klein, E; Naelitz, B; Qin, L; Sharifi, N; Zhu, Z, 2022) |
| "For primary prostate cancer staging, PSMA PET/CT seems crucial for primary therapy assessment, being able in some cases to detect lesions outside the surgical template, thus permitting a change in management." | ( Fanti, S; Farolfi, A; Mei, R; Morigi, JJ, 2022) |
| "Animal models of prostate cancer are essential to identify chemopreventive treatments against this major male malignancy." | ( Bosland, MC; Horton, L; McCormick, DL; Schlicht, MJ, 2022) |
| "Castration-resistant prostate cancer shows resistance to not only androgen deprivation therapy (ADT) but also X-ray therapy." | ( Iwanaga, M; Kawabata-Iwakawa, R; Kawamura, H; Kubo, N; Miyazawa, Y; Mizukami, T; Nakano, T; Nishiyama, M; Ohno, T; Oike, T; Sato, H; Sekine, Y, 2022) |
| "Bone metastatic prostate cancer (BM-PCa) remains one of the most difficult cancers to treat due to the complex interactions of cancer and stromal cells." | ( Abdalla, MY; Alsamraae, M; Case, AJ; Chatterjee, A; Cook, LM; Costanzo-Garvey, DL; Dutta, S; Kielian, T; Lindsey, ML; Oberley-Deegan, RE; Watson, GF, 2022) |
| "A 79-year-old man with metastatic prostate cancer underwent radical prostatectomy and bilateral lymph node dissection and received multiple lines of systematic treatment for his biopsy-proven peritoneal carcinomatosis." | ( Gao, M; Lu, Y, 2022) |
| "In observational studies, men with prostate cancer treated by androgen deprivation therapy had a higher risk of dementia." | ( Flicker, L; Yeap, BB, 2022) |
| "Accordingly, in vitro treatment of prostate cancer cells with cyclocreatine, a creatine analog, dramatically reduced intracellular levels of creatine and its derivatives phosphocreatine and creatinine and suppressed proliferation." | ( Fleming, J; Ford, CA; Leung, HY; Lynch, V; Mackay, G; Mui, E; Patel, R; Rodgers, L; Rushworth, LK; Sansom, OJ; Sumpton, D; Vande Voorde, J; Watson, D; Zhang, T, 2022) |
| "Enhanced creatine uptake drives prostate cancer progression and confers a metabolic vulnerability to treatment with the creatine analog cyclocreatine." | ( Fleming, J; Ford, CA; Leung, HY; Lynch, V; Mackay, G; Mui, E; Patel, R; Rodgers, L; Rushworth, LK; Sansom, OJ; Sumpton, D; Vande Voorde, J; Watson, D; Zhang, T, 2022) |
| "Since prostate cancer, renal cell carcinoma, and retroperitoneal sarcomas such as liposarcoma and leiomyosarcoma are known to be radioresistant tumors, carbon-ion radiotherapy, which provides the advantageous radiobiological properties such as an increasing relative biological effectiveness toward the Bragg peak, a reduced oxygen enhancement ratio, and a reduced dependence on fractionation and cell-cycle stage, has been tested for these urological tumors at the National Institute for Radiological Sciences since 1994." | ( Akakura, K; Hiroshima, Y; Ichikawa, T; Imai, R; Inaniwa, T; Ishikawa, H; Kanematsu, N; Shirai, T; Suzuki, H; Tsuji, H; Wakatsuki, M, 2022) |
| "We compared castration-resistant prostate cancer (CRPC)-free survival (FS) and overall survival (OS) between patients with androgen deprivation therapy (ADT) plus upfront intensive therapy (docetaxel [DTX] or abiraterone acetate [ABI] plus prednisolone) and conventional therapy (ADT monotherapy or ADT combined with bicalutamide)." | ( Egawa, S; Habuchi, T; Hata, K; Hatakeyama, S; Hoshi, S; Ishi, N; Ishidoya, S; Ito, A; Kawamura, S; Kimura, T; Mitsuzuka, K; Miura, Y; Narita, S; Ohyama, C; Tanaka, T; Tsuchiya, N; Yanagisawa, T, 2022) |
| "Metastatic prostate cancer in the bone induces bone-forming lesions that contribute to progression and therapy resistance." | ( Agarwal, SK; Corn, PG; Lee, YC; Lin, SC; Lin, SH; Logothetis, CJ; Pacifici, M; Pan, J; Panaretakis, T; Shen, P; Song, JH; Yu, G; Yu-Lee, LY, 2022) |
| "Patients with prostate cancer undergoing treatment with radical radiation therapy (RT) plus androgen deprivation therapy (ADT) experience a constellation of deleterious metabolic and anthropometric changes related to hypogonadism that are associated with increased morbidity and mortality." | ( Ahmed, S; Danielson, B; Dubey, A; Ghosh, S; Hunter, W; Kim, JO; Koul, R; McDonald, M; Ong, AD; Parliament, M; Quon, H; Rowe, L; Sanghera, KP; Sivananthan, G; Usmani, N; Yee, D, 2023) |
| "Compared to leuprorelin, degarelix for prostate cancer treatment is cost-effective." | ( Cheng, L; Ding, R; Li, C; Yan, J; Zhang, L; Zhang, X, 2022) |
| "Future immunotherapy strategies in prostate cancer should address these immune cell populations, which may play more important roles in the prostate cancer tumor microenvironment." | ( Chandran, E; Karzai, F; Madan, RA; Meininger, L, 2022) |
| "A 58-year-old man with metastatic prostate cancer was treated with prostatectomy, radiation therapy to bone metastasis, and androgen deprivation therapy plus abiraterone." | ( Bhosale, PR; Lu, Y; Nguyen, TT, 2023) |
| "As patients are now living with prostate cancer for longer, the long-term impact of hormonal treatment on bone health is an increasingly debated subject." | ( Antonelli, A; Berruti, A; Borghetti, P; Bresciani, R; Dalla Volta, A; Farina, D; Maffezzoni, F; Magrini, SM; Mazziotti, G; Palumbo, C; Rinaudo, L; Simeone, C; Triggiani, L; Valcamonico, F; Zamboni, S; Zamparini, M, 2022) |
| "To evaluate the prostate cancer therapy efficiency of the synergistic combination docetaxel (DTX) and formononetin (FMN) in one nano-sized drug delivery system." | ( Dong, Z; Guo, J; Pan, W; Tian, C; Wang, H; Wang, Y; Yan, J, 2022) |
| "The medical treatment of metastatic prostate cancer relies heavily on androgen deprivation." | ( Xu, Y; Ye, ZY; Zheng, J, 2022) |
| "The landscape of advanced prostate cancer treatment has evolved tremendously in past decades." | ( Azad, AA; Chen, K; Kostos, L, 2023) |
| "To identify prostate cancer (PCa) patients with a high risk of recurrence is critical before delivering adjuvant treatment." | ( Bian, Z; Chen, J; Liang, C; Liu, Y; Meng, J; Niu, Q; Zhang, L; Zhang, M; Zhou, J, 2022) |
| "The Surviving Prostate cancer while Improving quality of life through Rehabilitation with Testosterone Trial, a placebo-controlled, randomized trial, will determine whether testosterone replacement therapy is safe and efficacious in correcting symptoms of testosterone deficiency in prostate cancer survivors, and potentially inform clinical practice." | ( Bhasin, S; Burnett, AL; Dorff, T; Ghattas-Puylara, C; Holmberg, M; Huang, G; Kibel, AS; Latham, NK; Pencina, K; Privat, F; Reid, KF; Storer, TW; Valderrábano, RJ; Wilson, L, 2023) |
| "The treatments currently used for prostate cancer (PC) do not meet clinical needs, and thus, new therapies with greater effectiveness are urgently required." | ( Fang, F; Hu, C; Li, Z; Liu, D; Wang, L; Xu, H; Zhang, S, 2023) |
| "The history of prostate cancer treatment is filled with progress over the past 120 years." | ( Loughlin, KR, 2022) |
| "In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted therapies (ARATs) abiraterone, apalutamide, or enzalutamide to androgen deprivation therapy (ADT)." | ( Barbier, MC; Haile, SR; Menges, D; Puhan, MA; Schwenkglenks, M; Tomonaga, Y; Yebyo, HG, 2022) |
| "Based on the evidence that prostate cancer lesions before treatment are the most common sites of tumor residual or recurrence after treatment, simultaneous integrated boost radiation therapy for prostate cancer has been proven to have the advantage of improving efficacy without increasing toxicities." | ( Guo, X; Hong, Z; Hu, W; Li, P; Pei, Y; Zhang, Q; Zhang, Z, 2022) |
| "We identified 124 consecutive prostate cancer patients from 2008 to 2018 with a solitary oligorecurrent metastatic lesion on positron emission tomography imaging who were treated with metastasis-directed therapy without androgen deprivation therapy from the Mayo Clinic C-11 choline registry." | ( Ahmed, ME; Andrews, JR; Boorjian, SA; Britton, C; Joshi, VB; Karnes, RJ; Kendi, AT; Kwon, ED; Phillips, R; Sharma, V; Sood, A; Stish, B; Tollefson, MK, 2022) |
| "Men with high-risk, non-metastatic prostate cancer receive adjuvant androgen deprivation therapy (ADT) for at least 2 years according to Danish guidelines." | ( Abildgaard, J; Albrethsen, J; Brasso, K; Juul, A; Jørgensen, N; Kirstine Bang, A; Røder, A; Smedegaard Kruuse, L; Vincent Stroomberg, H, 2023) |
| "SR9009 treatment markedly inhibited prostate cancer subtype 1 (PCS1), the most lethal and aggressive PCa subtype, through FOXM1 pathway blockade, while it had no impacts on PCS2 and PCS3." | ( Ai, J; Li, H; Liao, D; Tan, P; Wang, Y; Wei, Q; Xiong, X; Xu, H; Yang, L; Yang, Y; Yi, X; Zhang, J; Zheng, X, 2022) |
| "To differentiate those patients with prostate cancer (PCa) whose androgen deprivation therapy (ADT) injection treatment can be postponed, we investigated the characteristics of testosterone (T) recovery in Japanese patients after they received combined ADT and radiation therapy (RT)." | ( Arai, M; Kosaka, T; Matsumoto, K; Oya, M; Takeda, T; Yasumizu, Y, 2023) |
| "Androgen deprivation therapy for prostate cancer can lead to osteoporosis and increased fracture risk." | ( Alexander, C; El-Sakka, AI; Hewitt, K; Lee, L; Sharqawi, A, 2022) |
| "In patients with non-metastatic prostate cancer, treated with radiation therapy and androgen deprivation therapy for 3 years and DMAB on average for 5 years, BMD was in the normal or osteopenic range." | ( Brockstedt, HK; Harsløf, T; Langdahl, B; Sølling, AS, 2023) |
| "Patients with prostate cancer receiving androgen deprivation therapy (ADT) are treated with denosumab (DMAB) to prevent fractures and preserve bone mass." | ( Brockstedt, HK; Harsløf, T; Langdahl, B; Sølling, AS, 2023) |
| "In patients with non-metastatic prostate cancer, treated with radiation therapy and androgen deprivation therapy for 3 years and DMAB on average for 5 years, BMD was in the normal or osteopenic range." | ( Brockstedt, HK; Harsløf, T; Langdahl, B; Sølling, AS, 2023) |
| "Patients with prostate cancer receiving androgen deprivation therapy (ADT) are treated with denosumab (DMAB) to prevent fractures and preserve bone mass." | ( Brockstedt, HK; Harsløf, T; Langdahl, B; Sølling, AS, 2023) |
| "In patients with non-metastatic prostate cancer, treated with radiation therapy and androgen deprivation therapy for 3 years and DMAB on average for 5 years, BMD was in the normal or osteopenic range." | ( Brockstedt, HK; Harsløf, T; Langdahl, B; Sølling, AS, 2023) |
| "Patients with prostate cancer receiving androgen deprivation therapy (ADT) are treated with denosumab (DMAB) to prevent fractures and preserve bone mass." | ( Brockstedt, HK; Harsløf, T; Langdahl, B; Sølling, AS, 2023) |
| "In this study, LNCaP prostate cancer cell line was used and after MTT test, concentrations of 40, 60 and 80 μg/mL EGCG were used for treatment." | ( Bakhshandeh, N; Damchi, M; Khodabandelu, S; Mohammadi, M; Mohammadi, P; Mokhtari, H; Nazari, E, 2023) |
| "In the case of prostate cancer, the regulation of one of these enzymatic steps occurs at least in part by way of a germline-encoded missense in 3β-hydroxysteroid dehydrogenase-1 (3βHSD1), which regulates potent androgen biosynthesis and clinical outcomes in men with advanced prostate cancer treated with gonadal T deprivation." | ( Brown, K; Michael, P; Roversi, G; Sharifi, N, 2023) |
| "Ten metastatic hormone-sensitive prostate cancer patients (mHSPC) were treated with [ 177 Lu]Lu-PSMA-617 and 10 advanced salivary gland cancer (SGC) patients were treated with [ 177 Lu]Lu-PSMA-I&T." | ( de Bakker, M; Gotthardt, M; Konijnenberg, MW; Nagarajah, J; Peters, SMB; Privé, BM; Uijen, MJM; van Gemert, WA; van Herpen, CML; Westdorp, H, 2023) |
| "In metastatic hormone sensitive prostate cancer (mHSPC), treatment intensification with either docetaxel or an androgen-receptor-axis targeted therapy (ARAT), added to androgen deprivation therapy (ADT) is the new standard of care." | ( Alimohamed, N; Hotte, SJ; Jiang, DM; Sridhar, SS; Stecca, CE; Veitch, Z; Wood, L, 2023) |
| "Black men have a higher risk of prostate cancer diagnosis and mortality but are less likely to receive definitive treatment." | ( Agochukwu-Mmonu, N; Caram, MV; Chapman, C; Hollenbeck, BK; Kaufman, S; Makarov, D; Oerline, M; Qin, Y; Ravenell, J; Skolarus, TA; Vince, R, 2023) |
| "Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer frequently seen after prolonged treatment of castration resistant prostate cancer (CRPC)." | ( Karnes, RJ; Kemble, J; Kwon, ED, 2023) |
| "A 79-year-old man with prostate cancer was evaluated with 68Ga-prostate-specific membrane antigen (PSMA), 68Ga-FAPI-04, and 18F-FDG PET/CT scans since a rise in prostate-specific antigen was seen at last control while receiving chemotherapy." | ( Arslan, E; Baloğlu, MC; Çermik, TF; Ergül, N; Tatar, G, 2023) |
| "As a widely used first-line agent for prostate cancer treatment, cisplatin is facing drug resistance which has resulted in chemotherapy failure in many prostate cancer patients, while the related molecular mechanisms remain unclear." | ( Cheng, Y; Han, D; Li, X, 2023) |
| "More than 50% of all prostate cancer (PCa) patients are treated by radiotherapy (RT)." | ( Aires, F; Correa-Duarte, MA; Faria, I; Fernandes, R; Guerreiro, SG; Monteiro, A; Pinto, G; Sales, MG; Soares, S, 2023) |
| "Stereotactic body radiotherapy for prostate cancer using CyberKnife with circular cone requires a long treatment time." | ( Akino, Y; Mabuchi, N; Masai, N; Ogawa, K; Oh, RJ; Shiomi, H, 2023) |
| "RS-IMRT plans were created for five prostate cancer patients treated with the Novalis system and parameters were compared to the Novalis treatment plans." | ( Akino, Y; Mabuchi, N; Masai, N; Ogawa, K; Oh, RJ; Shiomi, H, 2023) |
| "The prevalence of prostate cancer according to metformin administration and the risk according to the cumulative duration of metformin were analyzed." | ( Heo, Y; Jo, JK; Kim, MJ; Kim, YJ; Song, HK, 2023) |
| "This study confirmed that prostate cancer risk decreased with increasing duration of metformin administration." | ( Heo, Y; Jo, JK; Kim, MJ; Kim, YJ; Song, HK, 2023) |
| "The increasing incidence of prostate cancer worldwide has spurred research into novel therapeutics for its treatment and prevention." | ( Ahmad, I; Mordecai, J; Ullah, S, 2023) |
| "Neuroendocrine prostate cancer (NEPC), a highly aggressive subtype of prostate cancer displaying resistance to hormone therapy, presents a poor prognosis and limited therapeutic options." | ( Chen, L; Ji, Y; Li, A; Liu, B; Shen, K; Su, R; Wang, Q; Xue, W; Zhang, W; Zhu, Y, 2023) |
| "De novo neuroendocrine prostate cancer (NEPC) and treatment-emergent neuroendocrine prostate cancer (T-NEPC) are rare diseases with a poor prognosis." | ( Al-Saad, S; Boland, P; Bosse, D; Bryce, AH; Collier, K; Costello, BA; Eule, CJ; Hu, J; Lam, ET; Lewis, AR; McKay, RR; Mortazavi, A; Narayan, V; Rose, TL, 2023) |
| "Despite treating advanced prostate cancer (PCa) with androgen deprivation therapy, it eventually progresses to castration-resistant PCa." | ( Aoyama, S; Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kamijima, T; Kano, H; Mizokami, A; Naito, R; Nakagawa, R; Nakagawa-Goto, K; Nakata, H; Saito, Y; Shimada, T; Toriumi, R; Yaegashi, H, 2023) |
| "Patients with non-metastatic high-risk prostate cancer by bone and computerized tomography (CT) scan were randomly assigned to receive androgen deprivation therapy (ADT) and docetaxel plus estramustine or ADT alone." | ( Baciuchka, M; Berdah, JF; Beuzeboc, P; Brihoum, M; Chinet-Charrot, P; Cojean-Zelek, I; Culine, S; Davin, JL; Delva, R; Deplanque, G; Drubay, D; Faivre, L; Ferrero, JM; Fizazi, K; Fléchon, A; Gravis, G; Grosse-Goupil, M; Houede, N; Krakowski, I; Labourey, JL; Lagrange, JL; Laguerre, B; Lavaud, P; Legouffe, E; Lesaunier, F; Linassier, C; Martin, AL; Mourey, L; Orlando, V; Oudard, S; Priou, F; Rolland, F; Teuff, GL; Theodore, C, 2023) |
| "Men with apparently localized prostate cancer and a high baseline PSA value have a reasonable chance of being long-term disease-free when treated with curative intent combining systemic and local therapy." | ( Baciuchka, M; Berdah, JF; Beuzeboc, P; Brihoum, M; Chinet-Charrot, P; Cojean-Zelek, I; Culine, S; Davin, JL; Delva, R; Deplanque, G; Drubay, D; Faivre, L; Ferrero, JM; Fizazi, K; Fléchon, A; Gravis, G; Grosse-Goupil, M; Houede, N; Krakowski, I; Labourey, JL; Lagrange, JL; Laguerre, B; Lavaud, P; Legouffe, E; Lesaunier, F; Linassier, C; Martin, AL; Mourey, L; Orlando, V; Oudard, S; Priou, F; Rolland, F; Teuff, GL; Theodore, C, 2023) |
| "PC3, DU-145, and LNCaP human prostate cancer cells were exposed to Wnt/β-catenin pathway inhibitor CCT036477 (iWnt) with salinomycin for 48 h, followed by cabazitaxel treatment for 48 h." | ( Erdogan, S; Serttas, R, 2023) |
| "We investigated 173 patients with prostate cancer with bone metastases who were treated either with zoledronic acid or denosumab at our hospital between July 2006 and June 2020." | ( Iijima, H; Imamura, M; Ito, K; Kumagai, M; Muro, Y; Shiraishi, Y; Yabusaki, R; Yoshimura, K, 2023) |
| "To evaluate clinical outcomes for cN1M0 prostate cancer treated with varied modalities." | ( Bhana, R; Billy Graham Mariam, N; Choudhury, A; Elumalai, T; Hoskin, P; Hughes, S; Maitre, P; Mistry, H; Portner, R; Sabar, M; Thippu Jayaprakash, K; Wickramasinghe, K; Young, T, 2023) |
| "Men with radiological stage cN1M0 prostate cancer on conventional imaging, treated from 2011-2019 with various modalities across four centres in the UK were included." | ( Bhana, R; Billy Graham Mariam, N; Choudhury, A; Elumalai, T; Hoskin, P; Hughes, S; Maitre, P; Mistry, H; Portner, R; Sabar, M; Thippu Jayaprakash, K; Wickramasinghe, K; Young, T, 2023) |
| "Galeterone, a novel prostate cancer candidate treatment, was discontinued after a Phase III clinical trial due to lack of efficacy." | ( Davis, DA; Gala, U; Kucera, S; Miller, D; Thompson, SA; Williams, RO, 2023) |
| "In the treatment of prostate cancer, the limited therapeutic efficacy of the standard non-hormonal systemic therapy docetaxel (DTX) represents an important challenge." | ( Bai, L; Tao, N; Zhang, W, 2023) |
| "Between 144 and 196 men with prostate cancer who are currently receiving ADT and are experiencing problematic HFNS will be individually randomised in a 1:1 ratio in groups of 6-8 participants to either treatment as usual (TAU) or participation in the guided self-help CBT intervention plus TAU." | ( Bacon, R; Boxall, C; Crabb, S; Eminton, Z; Fenlon, D; Fleure, L; Griffiths, G; Hunter, MS; Martin, J; Morgan, A; Nuttall, J; O'Neill, A; Raftery, J; Richardson, A; Stefanopoulou, E; Tilt, E; Wilding, S, 2023) |
| "Current treatment for prostate cancer is dependent on the stages of the cancer, recurrence, and genetic factors." | ( Cacaccio, J; Camacho, S; Dukh, M; Durrani, FA; Fayazi, Z; Guru, K; Kauffman, E; Kumar, I; Pandey, RK; Sumlin, A, 2023) |
| "Patients with advanced prostate cancer (PCa) invariably develop resistance to anti-androgen therapy and taxane-based chemotherapy." | ( Alkashgari, HR; Casiano, CA; Chen, Z; Diaz Osterman, CJ; Kremsky, I; Martinez, SR; Ochoa, PT; Ortiz-Hernandez, GL; Sanchez-Hernandez, ES; Suzuki, T; Unternaehrer, JJ; Wang, C, 2023) |
| "Despite the fact that androgens drive prostate cancer, peripheral T has had no role in the clinical evaluation or treatment of men with localized prostate cancer." | ( Alyamani, M; Berk, M; Hettel, D; Klein, EA; Li, J; Lundy, SD; McKenney, JK; Michael, P; Patel, M; Rashidi, H; Sharifi, N; Thomas, L, 2023) |
| "Hormone therapy was initiated to treat prostate cancer, but he developed dyspnea and back pain." | ( Habuchi, T; Kashima, S; Kobayashi, M; Mori, M; Nanjo, H; Nara, T; Narita, S; Numakura, K; Saito, M; Sasagawa, H; Yamamoto, R, 2023) |
| "In HERO, 930 men with advanced prostate cancer (APC) were randomized 2:1 and treated with relugolix (120 mg orally once daily; after single 360 mg loading dose) or leuprolide (injections every 3 months) for 48 weeks." | ( Brown, B; Cookson, MS; Fallick, M; Hanson, S; Lu, S; Mehlhaff, BA; Saad, F; Saltzstein, DR; Shore, ND; Tutrone, R, 2023) |
| "For metastatic hormone naïve prostate cancer patients, androgen deprivation therapy (ADT) with escalation therapy including docetaxel and/or androgen targeting drugs is the standard therapy." | ( Bergh, A; Freyhult, E; Josefsson, A; Spyratou, V; Thellenberg-Karlsson, C; Welén, K; Wikström, P, 2023) |
| "Advances in prostate cancer treatment have significantly improved survival, but quality of life for survivors remains an under-studied area of research." | ( Chen, Y; Gelfond, J; Johnson-Pais, TL; Leach, RJ; Morilak, DA; Ramamurthy, C; Thompson, IM; Vaiana, AM, 2023) |
| "Although treatable when detected early, prostate cancer commonly transitions to an aggressive castration-resistant metastatic state." | ( Bialkowska, A; Gordon, C; Hillowe, A; Kaczocha, M; Ojima, I; Rizzo, RC; Trotman, LC; Wang, L, 2023) |
| "In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide was superior to leuprolide alone with respect to metastasis-free survival; enzalutamide monotherapy was also superior to leuprolide alone." | ( de Almeida Luz, M; De Giorgi, U; Freedland, SJ; Gleave, M; Gotto, GT; Haas, GP; Kim, CS; Pieczonka, CM; Ramirez-Backhaus, M; Rannikko, A; Shore, ND; Sridharan, S; Sugg, J; Tang, Y; Tarazi, J; Tutrone, RF; Venugopal, B; Villers, A; Woo, HH; Zohren, F, 2023) |
| "The treatment of advanced prostate cancer remains a formidable challenge due to the limited availability of effective treatment options." | ( Bae, SM; Cho, EA; Chun, JN; Jeon, JH; Kim, SY; Kim, YS; Lee, DY; Lee, S; Park, EJ; Park, HH; Park, S; So, I, 2023) |
| "Patients with high-grade prostate cancer with low levels of prostate-specific antigen (PSA; <4 ng/mL) are at high risk of mortality, necessitating an improved treatment paradigm." | ( Brihoum, M; D'Amico, AV; Eastham, JA; Feng, FY; Fizazi, K; James, ND; Kwak, L; Mahal, BA; Ravi, P; Sandler, HM; Sweeney, C; Xie, W, 2023) |
| "Simvastatin was administered to prostate cancer cell lines (PC-3, LNCaP-LA; cultured under androgen-depleted conditions, DU145, 22RV1), and the tumor proliferation inhibition was evaluated using the MTS assay and cell count." | ( Miyazawa, Y; Nakayama, H; Nakazawa, S; Oka, D; Sekine, Y; Suzuki, K; Tsuji, Y, 2023) |